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ABSTRACT
MOLECULAR STUDIES ON THE CONTROL OF THE 
EXPRESSION OF THE NPY-YI RECEPTOR GENE
JUAN CARLOS BOURNAT
The cDNA that encodes for the rat NPY-Y 1 receptor has been reported (Eva at ah, 1990) and 
predicts a classical G-protein coupled receptor. This receptor has been linked to important 
physiological process in the nervous system (Grundemar and Hakanson, 1994).
In this thesis the gene that encodes for the promoter of the rat NPY-Y 1 receptor was obtained 
by PGR subcloning.
(i) This region contains several consensus sequences for transcription factors: a "TATA-like" 
box, a "GAAT-like" box, an Spl site, an API site, two GRE elements, a non-palindromic ERE 
and four non-palindromic GRE.
(ii) This region has been attached to the reporter function, luciferase, so that the expression of 
this enzyme has been placed under the control of the promoter region of the NPY-Y 1 receptor 
(pYl-LUG).
(iii) The pYl-LUG has been transiently transfected into PG12 cells, a rat phaeochromocytoma 
cell line (Greene and Tischler, 1976), GTl-7 cells, a mouse hypothalamic cell line (Mellon et 
ah, 1990) and RINm5f cells, a rat p-pancreatic cell line (Poliak et ah, 1993) which express 
constitutive levels of the NPY-Yl receptor. It is thus possible to measure the basal 
transcriptional activity of this gene and study the factors which affect its transcriptional levels in 
these cells.
(iv) Differentiation of the cells into an adrenal chromaffin-like phenotype with dexamethasone 
and in a neuronal-like phenotype with NGF or PAGAP increased the transcriptional activity of 
the NPY-Yl gene in PG12 cells. Moreover, activation of PKA with DBG or forskolin, and 
activation of PKG with DHl or PMA also increased the expression of this gene in PG12 cells.
(v) The transcriptional response to NGF was dependent on trk A receptor and PKG activation 
but independent of ras -MAPK activation. Moreover, the effect of PAGAP-38 was dependent 
in both PKA and PKG activation, but is also independent in ras -MAPK activation.
Thus, the transcription of the NPY-Yl receptor its under tight regulation by the glucocorticoid 
receptor, PKA and PKG signalling in a sympatho-adrenal model system, PG12 cells.
CHAPTER 1 
GENERAL INTRODUCTION
1.1 THE NEURAL CREST CELLS
Generation of neuronal diversity in the nervous system remains one of the most complex and 
compelling puzzles in developmental biology. This neural development programme involves 
the co-ordination of numerous molecular events including cell birth and differentiation, cell 
migration and survival, direct neurite (axon and dendrite) outgrowth and growth cone targeting 
and finally synaptogenesis and selective cell death (Nichols, 1994). Differentiation is a 
complex process that begins early in embryonic development with the determination of cells in 
the ectoderm to become neuronal precursors; thus the cells begin to divide (proliferation stage) 
and then migrate after the neuronal cells have become post-mitotic. Neuronal differentiation 
culminates in the acquisition of a specific morphology and function that distinguishes this 
specific cell type (Nichols, 1994).
One of the best characterised systems of neural differentiation and development is the neural 
crest and its derivatives (Landis and Patterson, 1981; Anderson, 1989; Sieber-Bium, 1990). 
Epithelial cells that line the wall of the neural tube, the neuroepithelium, generate all the 
neurons and glial cells of the central nervous system (CNS) and peripheral nervous system 
(PNS). Other cells within this region give rise to a specialised group of migratory cells called 
the neural crest. Neural crest cells emerge from the dorsal region of the neural tube and most of 
these cells migrate to many peripheral locations where they coalesce. The ultimate result of 
neural crest cell migration and differentiation is a suiprising variety of cell types which includes 
neurons and cells of the autonomic and sensory nervous system.
The ultimate fate of these cells is critically controlled by the local environment through which 
they migrate. Restiictions in cell fate appear to occur during the process of cell migration since 
the developmental options of neural crest cells appear to be gradually restricted by changes in 
cellular environment as they migrate in the periphery of neural crest cells, cells of the 
sympatho-adrenal (SA) lineage, give rise to the sympathetic nervous system and the adrenal 
medulla (Anderson, 1993; Bronner-Fraser, 1994). This lineage comprises the major 
catecholaminergic descendents of the neural crest which are the sympathetic neurons, 
chromaffin cells and another group of cells found in sympathetic ganglia known as small 
intensely fluorescent (SIF) cells (Anderson, 1993). Precursors of these distinct cell classes can 
be isolated from the embryonic adrenal medulla or sympathetic ganglia. When grown in 
culture, it is possible to control the fate of these immature cells by varying culture conditions. It 
has been demonstrated that the differentiation of adrenal progenitor cells into clii'omaffin cells is 
dependent upon the presence of glucocorticoid hormones; indeed, these cells are exposed to 
high levels of such hormones upon migration to the adrenal gland since adrenal cortex 
synthesises high levels of glucocorticoids.
1
Neural crest cells destined to form sympathetic ganglia can become either; (i) SIF cells, which 
process may depend on the availability of low levels of glucocorticoids; or (ii) sympathetic 
neurons, which have been demonstrated to require nerve growth factor (NGF). It has also been 
shown that as progenitor cells differentiate into sympathetic neurons, they gradually lose 
sensitivity to glucocorticoids and acquire dependence on NGF for survival. Evidence thus 
suggests that a pluripotent SA progenitor exists which is capable of differentiation to a vaiiety 
of cell types and that the nature of the differentiation response is dependent on local 
environmental signals (Anderson, 1993).
Adrenal chromaffin cells are considered to be following stimulation, a modified form of 
postganglionic sympathetic neuron. Chromaffin cells release their transmitter stores to the 
circulation while postganglionic sympathetic neurons release transmitter locally to 
sympathetically-innervated target organs. Both cell types are innervated by cholinergic 
preganglionic sympathetic cells. Furthermore, these two cell types are both catecholaminergic 
(Langley and Grant, 1995). Thus, even though chromaffin cells exhibit a distinct morphology 
from sympathetic cells the common heritage of chromaffin cells and sympathetic neurons is 
reflected in certain functional similarities in these cell types. In addition, precursors of the SA 
lineage express peptidergic potential and this expression is more prolific, in terms of amount 
and diversity of peptides, than in the adult. Both neuropeptide (NPY) and vasoactive intestinal 
peptide (VIP) are expressed in embryonic superior cervical ganglion (SCG) (Tyrrell and 
Landis, 1994).
1.2 PC12 CELLS
P C I2 is a clonal cell line established from a solid tumour of an adrenal gland 
(phaeochromocytoma) of an irradiated New England Deaconess Hospital white rat by 
subcutaneous passage (Warren and Chute, 1972; DeLellis et ah, 1973). Under resting 
conditions, PC 12 cells proliferate and display a number of ultrastructural and biochemical 
characteristics of immature adrenal medullary chromaffin ceils which constitute their non- 
neoplasic counterpart (Tischler and Greene, 1975; Greene and Tischler, 1976). They have 
morphological features that more closely resemble those of chromaffin cells found in the late 
embryonic rat adrenal glands than those of adults. The cells have a round shape, tend to clump 
and protrude short processes. PC 12 cells synthesise catecholamines, and stores them in both 
large dense core vesicles (LDCVs) and small synaptic-like vesicles (SSVs) (Greene and Rein, 
1977a). PC I2 cells release both dopamine (DA) and noradrenaline (NA) in a Ca++ -dependent 
mechanism in response to depolarising concentrations of K+ or to nicotinic cholinergic 
stimulation and in response to veratridine, a voltage-gated Na++ channel activator (Greene and 
Rein, 1977a; Green and Rein, 1978; Ritchie, 1979).
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PC 12 cells, unlike many normal chromaffin cells or other phaeochromocytomas, lack 
phenylethanolamine-N-methyl transferase (PNMT) and thus do not synthesise adrenaline, and 
cannot be induced to do so by high concentrations of corticosteroids. Chromaffin cells also 
contain large amounts of opiate-like peptides but PC 12 cells do not (Guroff, 1985). Another 
characteristic of PC 12 cells which makes them different from normal chromaffin cells is that 
they have a saturable, high affinity uptake mechanism for noradrenaline (NA) which is 
characteristic of sympathetic neurons.
PC 12 cells have biochem ical markers not found in chromaffin cells or other 
phaeochromocytomas such as acetylcholine (ACh), endorphins, enkephalin, y-aminobutyric 
acid (GABA), somatostatin, substance P and receptors for ACh, substance P and GABA 
(Greene and Rein, 1977b). Intracellular recordings has shown that PC12 cells cannot generate 
action potentials in response to chemical or electrical stimulation in the absence of NGF, 
although they do possess voltage-gated Na’’”*' channels (Dichter et ah, 1977). Both chromaffin 
cells and phaeochromocytomas are excitable in the absence of NGF (Greene and Tischler, 
1982).
1.3 NERVE GROWTH FACTOR (NGF)
Growth factors in the nervous system include secreted and cell-bound proteins as well as 
steroid hormones. The established action of growth factors in the developing and adult nervous 
system is as retrograde, or target-derived signals (Curtis and DiStefano, 1994). Apart from 
their classical growth and survival activities, these factors are also used by neuronal targets to 
regulate the type and number of neurons that innervate them (Patterson and Nawa, 1993). 
Influences on phenotype include the nature of neurotransmitter and neuropeptide produced and 
the synaptic input received by the dendrites of the neuron (Landis, 1990). Differentiation 
factors can affect neuronal gene expression as well as neuronal phenotype without changing 
neuronal growth or survival. Thus, depending on the responsive cell population, the same 
factor can act both as a differentiation factor or as a growth factor (Landis, 1990; Patterson and 
Nawa, 1993).
NGF was the first neurotrophic agent to be identified and serves as the prototype for this class 
of polypeptide growth factors (Thoenen and Barde, 1980; Thoenen and Edgar, 1985; Thoenen,
1991). NGF is required for the maintenance of specific neuronal cell types, such as 
sympathetic postganglionic neurons. Response of explanted sympathetic neurons to this target- 
derived agent includes anabolic alterations, induction of neuronal morphology and increased 
survival of the cells (Levi-Montalcini et ah, 1987). Thus, markers of sympathetic neuronal 
differentiation are initiated by NGF.
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The biological activity of NGF can be divided into three: (i) trophic, (ii) tropic and (iii) 
differentiative. In relation to the trophic actions, in vivo experiments have revealed that 
developing sensory and sympathetic neurones depend on NGF for their survival. Sympathetic 
neurons continue to depend on NGF during maturation, whereas sensory neurons do not, 
although they seem to require NGF for normal biochemical and morphological homeostasis 
(Johnson et al., 1986). It has also been established that certain central neurons also respond to 
NGF, in particular the basal forebrain cholinergic system of rodent and human brains (Hefti et 
ah, 1986; Whittemore and Seiger, 1987). The tropic role of NGF is exemplified by the 
induction of neuronal sprouting of NGF-responsive neurons towards a source of NGF in 
culture (Gundersen and Barrett, 1979).
NGF is the best characterised member of a family of "neurotrophins" that includes brain 
derived neurotrophic factor (BDNF) (Barde et ah, 1982; Barde, 1988; 1989), neurotrophin-3 
(NT-3) (Maisonpierre et ah, 1990; Rosenthal et. al, 1990), neurotrophin-4/5 (NT-4/5) 
(Berkemeir et ah, 1991; Hallbook et ah, 1991) and neurotrophin-6 (NT-6) (McDonald and 
Chao, 1995). These molecules promote the differentiation, growth and survival of discrete, 
and sometimes overlapping neuronal cells through specific receptor tyrosine kinases (RTKs) 
similar to those used by "traditional" growth factors such as Epidermal Growth Factor (EGF), 
Fibroblast Growth Factor (FGF) and Platelet-derived Growth Factor (PDGF).
Neurotrophin receptors are encoded by a gene family, designated trk (tropomyosin receptor 
kinase), which includes three related loci: trk A, trk B and trk C (Chao, 1992 a,b; Ebendal, 
1992; Roback et ah, 1992; Chao and Hempstead, 1995). Neurotrophins are synthesised and 
released from target organs of neurotrophin-responsive nerve cells and exert their actions by 
binding to specific RTKs on the cell surface of responsive cells which lead to activation of 
specific intracellular signalling mechanisms (See NGF signalling pathway) and internalisation 
of the neurotrophin/receptor complex (desensitisation) and retrograde transport to the neuronal 
cell body.
NGF is required for differentiation and survival of sympathetic neurons and some sensory 
neurons in PNS and of selective basal forebrain cholinergic neurons in CNS. It also acts on 
cells of the adrenal medulla and on a number of tumour lines (Barde, 1988; 1989). Other 
cytokines known to influence neuronal gene expression include insulin and insulin-like growth 
factors (IGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived 
growth factor (PDGF) and transforming growth factor (TGF) (Walicke, 1989; Patterson and 
Nawa, 1993; Silos-Santiago et ah, 1995).
1.3.1 NGF BIOCHEMISTRY
A major contribution in the route to study NGF was the discovery that submaxillary glands of 
the male mouse produce and secrete large amounts of NGF (Cohen, 1960). The presence of 
large amounts of NGF in these tissues provided the basis for its purification and determination 
of amino acid sequence. Antibodies able to block biological activity were also developed using 
NGF from mouse submaxillary glands (Angeletti et ah, 1973).
NGF can be isolated as a 7 S, high-molecular weight (130 kDa) complex consisting of three 
subunits: a , p and y (Thoenen and Barde, 1980; Fahnestock, 1991; Bradshaw et ah, 1993). a 
and g subunits are thought to be accessory proteins not responsible for the growth-promoting 
actions of NGF while the 2.5S p subunit has been demonstrated to confer the neurotrophic 
responses associated with NGF in responsive cells.
The primary structure of NGF shows a high degree of conservation among different species. 
P-NGF is synthesised as a glycosylated precursor which is processed at amino- and caiboxy- 
terniinals to the mature protein of molecular weight 13.2 kDa. 2.5S P-NGF is present in the 7S 
complex as a noncovalently linked dimer of molecular weight 26 kDa. This dimer is composed 
of two identical units each of 118 amino acids; both monomers and dimers are biologically 
active. Three intrachain disulphide bonds are present in each monomer and disruption of these 
bonds completely abolishes biological activity of NGF. The crystal structure of NGF has been 
resolved to 2.3 angstroms (McDonald et ah, 1991). The protein function is a dimer which each 
monomer is a 130 kDa polypeptide complex containing three subunits (a, p, y) stabilised by 
zinc ions (Bradshaw et ah, 1993).
1.3.2 NGF RECEPTORS
The distribution of specific binding sites for NGF defines its responsiveness in the target 
tissues (Sutter et ah, 1991; Me akin and Shooter, 1992; Raffioni and Bradshaw, 1993; 
Barb acid, 1995). In PNS, NGF can bind to specific surface receptors of sympathetic neurons 
and subsets of dorsal root ganglion (DRG) cells, the latter being a subgroup of sensory 
neurons. NGF receptors are also found on neural cell precursors such as chromaffin cell 
precursors, neuroepithelial stem cells and sensory ganglia precursor cells. NGF receptors are 
also present in neuroblastoma cells and pheochromocytoma cells, such as PCI2 cells.
When NGF binds to its receptor on the cell membrane of the target cells, it triggers several 
signal transduction mechanisms involved in coordinating the multiple changes which lead to the 
response of PC12 cells to NGF. NGF interacts with two cell surface receptors in PC12 cells
and primary neuron cultures : (i) p7 5 ^^R  ^ a low affinity receptor (Kd = IQ-^-lO'^ M), is a cell 
surface glycoprotein of 75-80 kDa with a single cytoplasmic domain and lacks structural 
features known to mediate signal transduction in other receptors (Berg et ah, 1991a). (ii) 
p l 4 0 r^/c^  a high affinity receptor (Kd = IQ-^O-lQ-i  ^ M), is a tyrosine kinase receptor which 
either alone or in combination with p7 5 NTR binds NGF. This high affinity receptor mediates 
most of the known effects of NGF and is the product of the trk A proto-oncogene (pl40'‘''  ^) 
(Hempstead et ah, 1991; Klein et ah, 1991a; Martin-Zanca et ah, 1991).
1.3.2.1 LOW AFFINITY RECEPTOR (pTS^TR)
The p75^'r^ low affinity receptor is a type I integral membrane protein of 400 amino acids 
comprising a single tr ans membrane spanning region with four negatively-charged, cysteine- 
rich extracellular regions and a unique cytoplasmic domain which is conserved between 
species; a G protein binding site has been identified (Johnson et ah, 1986; Sutter et ah, 1991; 
Meakin and Shooter, 1992). p7 5 ^^ TR jg ^ member of a superfamily of cell surface proteins 
which includes the receptor for tumour necrosis factor (TNF). Interestingly, some of these 
receptors mediate cell death, suggesting that p7 5 NTR ^^ a^y play a role in determining neuronal 
cell survival. The p7 5 NTR bas a wide distribution compared with trk receptors and is expressed 
on a variety of cell types including Schwann cells, motor neurons and cerebellar Purkinje cells 
(Meakin and Shooter, 1992).
In contrast to the rather restricted binding of neurotrophins to their respective trk receptor, all 
neurotrophins bind this low affinity receptor (p75^^^). This receptor has been implicated in 
phospholipase (PLA2) activation (MacEwan, 1996) which itself is linked to the activation of 
the sphingomyelin cycle which results in the production of ceramides (Dobrowsky et ah, 
1995). Thus, p7 5 ^TR bas been suggested to play a role in apoptosis since ceramides have been 
implicated in this process (Chao, 1995) and introduction of p7 5^TR into immortalised neuronal 
cells induces this process (Rabizadeh et ah, 1993).
I .3.2.2 HIGH AFFINITY RECEPTOR (pl40<''* )
The p i40"* receptor shares a number of features with members of the RTKs family; they have
an extracellular binding domain, a transmembrane domain and a cytoplasmic tail with tyrosine 
kinase activity. The p i40^''^receptor consists of 790 aminoacids, has a molecular weight of 
135 kDa and is heavily glycosylated. Immunoglobulin G-C2 (IgG-C2) domains, and 
leucine/cysteine-rich repeats have been identified in the extracellular domain and the 
cytoplasmatic tail has a consensus tyrosine kinase domain (Sutter et ah, 1991; Meakin and 
Shooter, 1992).
Modification of Lys-32 residue on the p-NGF protein together with either Lys-34 or Glu-35 
results in loss of binding to p75^^^ without affecting binding to pldO'^^ '  ^(Ibanez et ah, 1992). 
This modified form of NGF is still able to bind pldO' '^'  ^with high affinity and retain biological 
activity as determined by neurite outgrowth in explanted chick embryonic sympathetic ganglia. 
Others have reported evidence that expression of p i40 '^'^ is sufficient to mediate mitogenic 
properties of NGF in heterologous cell systems, such as mouse fibroblast NIH 3T3 cells line 
(Cordon-Cardo et ah, 1991). Thus p 140^ '^^  interacts with overlapping but distinct populations 
of intracellular target proteins in different cell types to produce proliferative or differentiative 
responses (Hempstead et ah, 1992).
The p 140 '^'  ^receptor mediates NGF-responsiveness in neuroblastoma and PC I2 cells (Kaplan 
et ah, 1991a,b ; Klein et ah, 1991). Overexpression of pl40 '^'/"  ^accelerates NGF-induced 
differentiation pathways in PC 12 cells, including enhanced NGF-dependent pl40'^''^ 
autophosphorylation and phosphorylation of phospholipase C-yl (PLC-yl), phosphoinositol-3 
kinase (PI-3-K) and mitogen-activated protein kinase 1 (MAPK-1) (Hempstead et ah, 1992; 
Saltiel and Decker, 1994; Stephens et ah, 1994). The PC12-nnr5 cell subline, which express 
p7 5 NTR, but lacks measurable levels of p i40 '^'  ^receptor, fails to respond to physiological levels 
of NGF but introduction of pldO '^''^ receptor into these cells restores the NGF-dependent 
induction of neurite outgrowth (Loeb and Greene, 1993).
The pl40^'‘*^'^ high-affinity NGF receptor {trl<A ) belongs to a family of tyrosine kinase receptors 
which includes trk B (Klein et ah, 1989, 1991b, 1992) and trk C (Lamballe et ah, 1991) 
receptors. These trk receptors, however, are the products of separate genes and interact with 
specific neurotrophins (Chao, 1992 a, b; Ebendal, 1992; Roback et ah, 1992; Chao and 
Hempstead, 1995). The trk A receptor preferentially interacts with NGF, the trk B receptor 
interacts with BDNF and NT-4/5, and trk C receptor interacts with NT-3.
The identification of p i40^''^ as an NGF receptor was made after it was noted that the 
distribution of p i40 '^" ,^ first identified as an oncogene fusion protein with tropomyosin 
(tropomyosin receptor kinase or trk ) was restricted to a targets of NGF action in neural crest- 
derived sensory neurons (Martin-Zanca et ah, 1990). Indeed, pl40^^* receptor proved to be an 
high affinity NGF receptor whose tyrosine kinase activity and autophosphorylation is 
stimulated upon binding of NGF. Trk A receptor expression is restricted during development 
to those cell types defined to be NGF-responsive, including sensory and sympathetic neurons 
in PNS and a subsets of cholinergic neurons of the basal forebrain of CNS (Martin-Zanca et 
ah, 1990). PC12 cells do not respond to BDNF and NT-3 because they lack trk B and trk C 
receptors.
1.3.3 NGF ACTIONS ON NEURAL CREST CELLS
1.3.3.1 NGF ACTIONS ON ADRENAL CHROMAFFIN CELLS
Adrenal chromaffin cells, from which PC 12 cells derive, develop from neural crest cells that 
migrate ventrally from the apex of the neural tube to the dorsal aorta (Anderson, 1989, 1993). 
This SA cell type gives rise to sympathetic neurons, SIF cells and chromaffin cells. SA 
progenitor cells that migrate to the adrenal gland encounter high concentration of 
glucocorticoids, hormones which are synthesised in the adrenal cortex. The high level of 
glucocorticoids induce the SA cells to adopt a chromaffin phenotype by two different 
mechanisms. First, glucocorticoids upregulate genes whose products are abundant in 
chromaffin cells such as PNMT (Bohn et al., 1981) and second, inhibit neuronal differentiation 
induced by NGF (Unsicker et ah, 1978; Anderson, 1993). This inhibition is reciprocal as 
NGF can inhibit the ability of glucocorticoids to upregulate PNMT (Stein et ah, 1988). This 
antagonism probably reflects events related to the differentiation process of cells from the SA 
lineage (Seeley et ah, 1984).
Adrenal chromaffin cells are responsive to NGF at a defined stage in their ontology which is 
distinct from that of sympathetic neurons (Anderson, 1993). Neural crest cells retain plasticity 
as late as the neonatal stage, as shown by the ability of NGF to transform neonatal chromaffin 
cells into sympathetic neurons (Aloe and Levi-Montelcini, 1979; Douple et ah, 1985). This 
NGF dependent conversion is antagonised by dexamethasone, a synthetic glucocorticoid. 
Adrenal chromaffin cells appear to respond to NGF in two temporal components (Lillien and 
Claude, 1985; Tischler et ah, 1993). Early effects include an increase in proliferation and 
neuritogenesis. More delayed effects, seen after two weeks of NGF treatment include 
withdrawal from the mitotic cell cycle and development of more mature neuronal cell 
characteristics, as seen in NGF-treated P C I2 and sympathetic neurons. Functional aspects 
modified upon treatment with NGF of adrenal chromaffin cells include the induction of 
tyrosine hydroxylase (TH) and dopamine P-hydroxylase (DBH) activities (Acheson et ah, 
1984; Acheson and Thoenen, 1987).
1.3.3.2N G F ACTIONS ON SYMPATHETIC NEURONS
NGF effects are restricted to specific cell types in CNS and PNS (Barde, 1989; Martin-Zanca 
et ah, 1990). Primary sensory neurons are well known to be NGF-responsive. Recent 
evidence supports a role for NGF in CNS in a subset of cholinergic neurons of the forebrain. 
NGF has also a profound and universal influence on sympathetic neurons.
NGF acts as a survival factor for specific neurons during defined periods of their ontogenesis; 
the administration of NGF antibodies in the early post-natal period leads to the complete 
destruction of sympathetic ganglia (Levi-Montalcini and Angeletti, 1968). As a corollaiy, it has 
been demonstrated that exogenous NGF can reduce the level of naturally-occurring neuronal 
death in sympathetic ganglia (Oppenheim et ah, 1982). That existing developing neurons 
compete with each other for NGF for their survival is a generally accepted aspect in the model 
of nervous system development. This hypothesis is supported by the fact that NGF mRNA 
exists in target tissues of sympathetic neurons at very low and therefore limiting levels. In 
addition, a link between levels of NGF and density of sympathetic innervation, has been 
demonstrated (Barde, 1989).
NGF is thus described as a target-derived molecule that controls neuronal survival at the time 
of target innervation (Shelton and Reichardt, 1984; Heumann and Schwab, 1985). Recent data 
from both NGF and NGF receptor knockout mice confirm previous findings (Smeyne et ah, 
1994; Snider, 1994). Both knockout phenotypes have dramatically depleted populations of 
DRG neurons by birth and both have virtually absent sympathetic ganglia by 10 days of age; 
most animals die within the first month of life.
In addition to effects on survival and general growth of sympathetic neurons, NGF influences 
differentiation of these cells at both morphological and functional levels during defined periods 
of ontogenesis (Thoenen and Barde, 1980). Morphological effects include: (i) enhanced 
transformation of neuroblast into differentiated neurons; (ii) heightened development of Golgi 
cisternae; (iii) enhanced formation and ramification of neurofilaments and microtubules; and
(iv) promotion of fibre elongation as well as directional effects on neurite growth.
Differentiation and development of the sympathetic nervous system by NGF has been 
extensively studied using a variety of cellular models. In vivo , NGF is an absolute 
requirement for survival of sympathetic neurons. Primary culture of sympathetic neurons has 
allowed for the characterisation of many properties and response of these cells. Significant 
inherent disadvantages, however, in their use in dissecting the mechanism of NGF action lie in 
the fact that these cells require NGF for their survival and cannot be isolated in an NGF-naive 
state. The creation of an NGF-naive cell line, PC 12, which responds to NGF by differentiating 
to a sympathetic neuron-like phenotype but does not require the neurotrophin for survival, has 
proved an invaluable tool in the study of neuronal differentiation (Tischler and Greene, 1975; 
Greene and Tischler, 1976). Thus, the initial effects of NGF can be studied, in contrast to 
sympathetic neurons which, by necessity, will have been exposed to NGF before explantation. 
PC I2 cells can be also used to study NGF dependent regeneration of neurites as PC 12 cells 
previously treated with NGF will regenerate neurites only in the presence of NGF (Greene, 
1977).
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1.3.3.3 NGF ACTIONS ON PC12 CELLS
The discovery that an adrenal chromaffin cell line derived from a rat phaeochromocytoma 
responds to NGF by extending processes, provided a replicating cell model to study NGF 
induced differentiation (Tischler and Greene, 1975). As mentioned before, it is thought that 
these NGF effects are representative of the events that occur during neuronal differentiation, 
particularly for cells derived from the neural crest (Greene and Tischler, 1976, Tischler and 
Greene, 1978). Thus, PC 12 cells represent a model for the pluripotent progenitor SA cell; the 
differentiation response of which seems not to be restricted to either neural or non-neural types 
(Landis and Patterson, 1981; Anderson, 1989; Sieber-Blum, 1990).
The actions of NGF on PC 12 include the dramatic changes in morphological and functional 
characteristics very similar to those seen in sympathetic neuronal differentiation by NGF 
(Greene and Tischler, 1976; Guroff, 1985; Halegoua et ah, 1991). The overall effect of NGF 
on PC 12 cells is to convert them from a population of replicating adrenal chromaffin-like cells 
to a population of non-replicating post-ganglionic sympathetic neuron-like cells. PC 12 cells 
flatten down, decrease proliferative rate (cease mitosis), undergo cell hypertrophy, increase 
cell-substratum adhesiveness and extend long, branching neurites with prominent growth 
cones (Guroff, 1985).
NGF causes PC 12 cells to undergo a major reorganisation of their metabolic process. The 
differentiation process comprises a multiplicity of rapid and transient changes as well as 
delayed and prolonged alterations. Thus, NGF-mediated differentiation of the PC 12 cells can 
be separated into two types of events: (i) early events (generally occuring in minutes and 
transcriptional-independent) (ii) delayed events (generally occuring after 24-48 hours and 
transcriptional-dependent) (Burnstein and Greene, 1978; Greene, 1984).
1.3.3.3.1 Rapid Changes to PC12 Cells
NGF has rapid effects on PC 12 morphology, second messenger synthesis and transcription of 
immediate early genes (lEGs). Membrane structural changes, including ruffling of 
lamellopodia, take place in minutes (Connolly et ah, 1979, 1981, 1984). The cells become 
more adhesive to the culture dish, as well as to each other. NGF also triggers an increase in 
transport across the plasma membrane (Greene and Tischler, 1982). NGF increases calcium 
efflux and sodium influx by the stimulation of the activity of the Na+ -, K+ -pump (Greene and 
Tischler, 1982). The rate of amino acid uptake increases between 15 minutes and 24 hours 
after NGF treatment. These experiments, however, showed no increase in the uptake of 
nucleosides or noradrenaline (McGuire and Greene, 1979).
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Within minutes of adding NGF to PC I2 cells, it is possible to observe changes in the pattern of 
protein phosphorylation (Halegoua and Patrick, 1980) and breakdown of phosphatidyl inositol 
(PI) (Contreras and Guroff, 1987). Changes in phosphorylation have been correlated with 
either enhanced or reduced kinase activities as well as changes in phosphoprotein phosphatase 
activities (Halegoua et ah, 1991).
Most of the phosphorylation changes described occur on serine or threonine residues, but 
phosphorylation on tyrosine residues has also been described. Many phosphorylation events 
are rapid but in some instances can occur over a broad time range after NGF addition. Among 
those proteins phosphorylated are TH, ribosomal protein S6, histones H la  and H3, non­
histone chromosomal high mobility group protein HMG17, microtubule associated protein 
(MAP) 1,2, other MAPs which include char tins, a neuronal intermediate filament protein, 
called peripherin and synapsin (Halegoua and Patrick, 1980). Conversely, decreased 
phosphorylation of hi stone H2a and other proteins has been reported following NGF 
treatment. The correlation of phosphorylation changes with altered cellular activity has been 
demonstrated in some cases. For example, increased phosphorylation of TH as a result of 
NGF treatment of PC 12 cells leads to activation of the enzyme and increased catecholamine 
synthesis (Zigmond et ah, 1989).
Rapid changes to lEG expression also occurs within minutes after NGF treatment. Early 
responsive genes are characterized by mRNAs detectable within minutes of NGF stimulation. 
Their mRNAs normally have a relatively short half-live and their introduction is 
characteristically not dependent upon ongoing protein synthesis. PC 12 cells transiently express 
a number of lEGs such as c-fos, c-jim, jun-B and c-myc. (Greenberg et ah, 1985; Kiuijer et 
ah, 1985; Wu et ah, 1989). The products of these lEGs are involved in mediating late events in 
the response to NGF, since many of these genes encode transcription factors which control the 
expression of late response genes (Sheng and Greenberg, 1990; Morgan and Curran, 1991). 
Induction of these genes by NGF has been implicated in the more delayed gene transcription- 
dependent actions of NGF in PC 12 cells (McMahon and Monroe, 1992). Nicotine and 
potassium depolarisation can also induce expression of c-fos and /wnB, in NGF-differentiated 
PC 12 cells (Greenberg et ah, 1986).
1.3.3.3.2 Long-Term Changes to PC12 Cells
NGF also results in late long-term, translation-dependent alterations in PC 12 cells. Maximal 
accumulation of mRNAs of the late responsive genes occurs only after several hours of NGF 
treatment. Their induction can be blocked by pre-treatment with agents that inhibit translation 
such as cycloheximide, indicating a requirement for on-going protein synthesis.
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Less rapid responses of PC 12 cells to NGF include changes in the expression of several genes, 
such as neuropeptides, neurotransmitter synthesis enzymes, cytoskeletal and adhesion 
molecules, cell surface receptors and components of cell signalling machinery (Garrels and 
Shubert, 1979; Guroff, 1985; Halegoua et ah, 1991). Moreover, the presence of increased 
cellular concentrations of RNA and protein upon NGF-stimulation of PC 12 cells has been 
suggested to influence quantitative aspects of process growth (Gunning et ah, 1981).
Amongst the proteins induced by NGF are neuronal enzymes required for acetylcholine and 
catecholamine biosynthesis, such as choline acetyltransferase (CAT), acetylcholinesterase and 
TH (Schubert et ah, 1977; Goodman and Herschhman, 1978; Lucas et ah, 1980). Also up- 
regulated at the level of protein synthesis are the NGF-inducible large external glycoprotein 
(NILE) (McGuire et ah, 1978), neurofilament protein subunits (Lee and Page, 1984), growth 
associated protein (GAP-43) (Basi et ah, 1987; Costello et ah, 1990) and MAPs such as 
chartin, Tau proteins and tubulin (Black et ah, 1986). It has been suggested these microtubule 
and neurofilamental proteins are involved in the organisation of cytoskeletal proteins during 
growth of axons and have been implicated in neurite formation (McGuire et ah, 1978; Drubin 
et ah, 1985; Lee, 1985; Black et ah, 1986). NGF also induces the synthesis of neuron-specific 
enolase, synaptophysin, SCG-10, Thy-1 and VGF (Lee and Page, 1984; Guroff, 1985).
NGF induces the synthesis and storage of neurotransmitters, such as acetylcholine and 
catecholamines (DA and NA) and increases responsiveness to ACh (Dichter et ah, 1977; Levi 
and Alema, 1991). Other NGF-inducible proteins with important functional consequences 
include proteins involved in transmitter release, such as synapsin I and Ca++~channels (Garber 
et ah, 1989). PC12 cells also exhibit other characteristics associated with sympathetic neurones 
which include the acquisition of excitable Na++-based action potentials (Dichter et ah, 1977; 
O'Lague et ah, 1980, 1985; Rudy et ah, 1982, 1987). This functional change has been 
correlated with induction of voltage-sensitive type II sodium channels (Mandel et ah, 1988; 
Kalman, et ah, 1990; Pollock et ah, 1990; D'Arcangelo and Halegoua, 1993; Fanger et ah, 
1993).
NGF treatment is initially mitogenic to PC I2 cells but these cells cease to divide after 3-5 days 
(Burstein and Greene, 1982; Boonstra et ah, 1983; Peunoova and Enikolopov,1995). The 
mitogenic effect of NGF relates to its ability to act in PC12 cells in S and G2 phases to permit 
progression through the cell cycle before differentiation is initiated from G1 (Rudkin et ah, 
1989). In addition, DNA synthesis also increases, which has contributed to the proposal that 
NGF can also act as a mitogen in PC I2 cells (Burstein and Greene, 1982). Inhibition of cell 
cycle progression occurs during programmed events like senescence, programmed cell death, 
differentiation and neuronal cell development (Ross, 1996). Most neurons undergo their final
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division during embryogenesis and differentiation proceeds from arrest in G1 phase. Unlike 
other growth factors, NGF does not support multiple rounds of division of PC I2 cells. As 
with other inducers of differentiation, such as activators of adenylyl cyclase and cAMP 
analogues, NGF causes growth arrest and accumulation of PC12 cells in the G] phase of the 
cell cycle and this arrest is necessary before initiation of differentiation processes can occur 
(Rudkin et ah, 1989).
These changes are followed by outgrowth of neurite-like processes after several days (Greene 
and Tischler, 1976). By 24 hours, NGF-treated PC12 cells become increasingly neuronal in 
morphology, producing neurites that elongate an average of 30-50 pm/day. These neurites are 
long, thin (approximately 1 pm in diameter), branched and vesiculated and contain varicosities 
and prominent growth cones (Luckenbill-Edds et ah, 1979). Synaptic-like vesicles (20-60 nm) 
form in clusters at the ends of these varicosities (Roger-Jacobs and Stevens, 1986). Structural 
characterisation of growth cones has led to the identification of micro spikes, filopodia, actin 
and microtubules within these structures. Growth cones also appear to have components of 
transmitter release machinery: catecholamine-containing LDCVs, SSVs and Ca++-channels. 
Finally, these neurites are capable of forming functional synapses, as demonstrated in co­
culture with rat skeletal muscle cells, with which they form cholinergic synapses (Schubert et 
ah, 1977).
The NGF-induced phenotype is reversible meaning that removal of NGF leads to loss of 
differentiated traits and resumption of cell division (Greene and Tischler, 1982). Thus, 24 
hours after withdrawal of NGF most cells lose their processes and after three days most cells 
resume multiplication (Greene and Tischler, 1982). Priming was observed in experiments 
where cells exposed to an initial pre-treatment with NGF exhibited enhanced differentiation 
when re-exposed to NGF. This model suggests that a transcription-dependent slow 
accumulation of a set of proteins is a prerequisite for morphological differentiation. The 
accumulation of proteins primes the cells for rapid, transcription-independent, neurite 
outgrowth in the further presence of NGF.
PC I2 cells offer a window on a period in the natural history of sympathetic neurons that was 
previously unavailable. It is, in fact, largely due to the substantial work of NGF action on 
PC12 cells that a model has been developed of NGF differentiation in which a variety of 
cellular control mechanisms are co-ordinately recruited for this process. The NGF response is 
initiated by binding of NGF to its receptors resulting in the stimulation of multiple second 
messenger pathways, the activation of which causes a series of post-translational modifications 
to specific proteins leading to immediate changes in cellular phenotype as well as eliciting gene 
expression changes resulting in the more delayed alterations.
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1.4 NGF SIGNALLING PATHWAYS
1.4.1 PROTEIN PHOSPHORYLATION AND NEURONAL
FUNCTION
Phosphorylation is the major language used within the cells to communicate information from 
the environment. Covalent modification by phosphorylation serves to alter the structure and 
function of proteins involved in cellular structure, metabolism, cell growth and differentiation. 
Thus, it is not surprising that 30% of eukaryotic proteins are estimated to be phosphoproteins. 
It is estimated that there are over a thousand kinases, so that over 1% of the genes would be 
predicted to encode kinases. These kinases differ in their regulation, substrate-specificity and 
cellular localisation. Kinases with specificity for one substrate exist; other kinases, such as the 
second messenger-regulated kinases, cAMP-dependent protein kinase (PKA), Ca++/ 
phospholipid-dependent protein kinase (PKC) and Ca++/calmodulin-dependent protein kinase 
(CaM-K) phosphorylate a variety of substrates (Walaas and Greengard, 1991).
The eukaryotic protein kinases constitute one of the largest superfamilies of homologous 
proteins that are related by virtue of their catalytic domain. Most related protein kinases are 
specific for either serine/threonine and/or tyrosine phosphorylation. The common structure of 
these kinases is reflected in the conserved structure of the kinase domain: a core of 30-32 kDa 
comprised of 12 subdomains that is conserved tlri'oughout phytogeny (Hanks et ah, 1988).
Phosphorylation of protein kinases is now recognised to be essential for their regulation. For 
many kinases, this phosphorylation occurs on a loop termed the "activation loop" near the 
entrance to the catalytic core. Phosphorylation of this loop is thought to correctly align residues 
involved in catalysis. Kinases regulated by phosphorylation of their activation loop include 
PKA, PKC (Edwards and Newton, 1997) and CaM-K. Mutation of this activation loop, 
typically to glutamate, mimics the effect of the phosphate in allowing constitutive activation of 
the kinase (Newton, 1995). The activation of kinases by phosphorylation results in tight 
regulation of the kinase cascade within the cell. In most cases, kinases are held in an inactive 
state because an autoinhibitory domain occupies the substrate-binding cavity. These 
autoinhibitory domains are called "pseudosubstrates" because they contain a stretch of amino 
acids similar to those found in phosphorylation motifs of substrates. These autoinhibitory 
domains can be on a separate polypeptide, as in the case of the regulatory subunit of PKA, or 
be part of the same polypeptide as the kinase core, as in the PKC. Importantly, binding of 
cofactors to the regulatory domain causes a conformational change that releases the 
pseudosubstrate and allows access of substrates to the active site (Newton, 1995).
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The affinity of kinases for their substrates is dictated by residues surrounding the 
phosphorylation site of the substrate, so that "consensus" sequences can be defined. It is 
important to note that factors such as the secondary and tertiary structure of the protein, and 
accessibility of the sequence, also play major roles in determining whether a site will be 
phosphorylated (Newton, 1995). With the myriad of kinase families and isozymes within 
kinases families, it has been difficult to dissect the contribution of specific kinases in specific 
signalling pathways. To this end, recent advances using antisense DNA, expression of 
dominant negative mutant kinases or the use of cell-permeant activators or inhibitors has 
allowed much headway in understanding how signals are transduced. Inhibitors of kinases fall 
into two classes: those that inhibit the chemistry (e.g. competitively bind to the active site), and 
those that inhibit the regulation of the kinase (e.g. by binding to the regulatory domain and 
preventing the binding of cofactor) (Newton, 1995).
In the nervous system, reversible phosphorylation is involved in regulating processes as 
diverse as biosynthesis of neurotransmitter, activity of ion channels and cell differentiation 
(Walaas and Greengard, 1991). Phosphorylation can affect a protein's activity by changing its 
allosteric conformation (Sprang et ah, 1988) or by inducing electrostatic repulsion on its 
surface (Hurley et ah, 1990). These properties can be reversed by dephosphorylation of the 
protein by changing its properties back its original state. Reversible phosphorylation provides a 
flexible method of controlling protein activity. Some substrates can be phosphorylated by 
different protein kinases in different or the same region of the molecule, and each 
phosphorylation event can change the properties of the protein in a particular way as a substrate 
for other protein kinases (Hunter, 1995).
Protein phosphorylation is central to the process involved in regulation of gene transcription. 
Many transcription factors are activated by phosphorylation thus increasing transcription of 
specific genes. Phosphorylation of transcription factors can affect their activity at thi*ee different 
levels: (i) they can be prevented from entering the nucleus and coming in to contact with their 
target sequences, (ii) the affinity for their target sequence can be modified by phosphorylation 
and (iii) their ability to interact with the transcriptional machinery can be altered (Hunter and 
Karim, 1992).
1.4.2 NGF-MEDIATED TYROSINE PHOSPHORYLATION
NGF is internalised after binding to its receptor on the cell surface, but internalisation is not 
involved in its action on its target cells (Heumann et ah, 1981). Therefore, a mechanism able to 
transmit the signal must exist for the taiget cells to respond to NGF. Binding of NGF to PC I2
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cells results in activation of several protein kinase cascade systems through the intracellular 
tyrosine protein kinase domain of the high affinity NGF receptor (Halegoua et ah, 1991).
Protein tyrosine phosphorylation plays a role in regulating cellular processes including 
differentiation, proliferation and tumorigenesis (Brewster et ah, 1993). Phosphorylation at 
tyrosine residues occurs as a cellular response to a variety of stimuli including cytokines, 
hormones and growth factors. The initial event triggered by these stimuli is a process of 
activation, dimerization and autophosphorylation of RTKs. This in turn initiates an intracellulai' 
cascade which involves the phosphorylation of several proteins. The balance of tyrosine 
phosphorylation is controlled by the opposing activities of protein tyrosine kinases and protein 
tyrosine phosphatases (Walton et ah, 1993).
The binding of NGF to its receptors and their activation result in stimulation of a number of cell 
signalling systems in chromaffin cells, sympathetic neurons and PC I2 cells (Grimes et ah, 
1993; Szeberenyi and Erhardt, 1994; Greene and Kaplan, 1995). Indeed, work using PCI2 
cells has facilitated the identification of the involvement of these pathways. Second messenger 
systems activated by NGF activation include the MAPK, PLC-y and PI-3-K signalling 
pathways (Hempstead et ah, 1992; Saltiel and Decker, 1994; Stephens et ah, 1994).
Ligand binding to the extracellular domain of the receptor produces a conformational change in 
the cytosolic domain causing adjacent sections to phosphorylate each other and thereby enhance 
the kinase activity towards other substrates (Cantley et ah, 1991). Activation of trk A is 
followed by receptor dimerization or oligomerization and trans-autophosphorylation of five 
tyrosine residues on trk A : Tyr-490, Tyr-670, Tyr-674, Tyr-675 and Tyr-785 (Loeb et ah, 
1992, 1994). These phosphotyrosine residues act as docking sites for downstream effector 
substrates by specifically binding these substrates through a non-catalytic region of 100-110 
amino acid residues called src -homology 2 (SH2) domains (Sonyang and Cantley, 1995) or 
protein tyrosine binding (PTB) domains (Pawson, 1995). SH2 is a domain that recognises 
peptide motifs bearing phosphotyrosine (pTyr) on receptors and cytoplasmic proteins. trkA has 
multiple auto-phosphorylation sites, each of which is relatively specific for a particular SH2 
protein. Two of these phosphotyrosines Tyr-490 and Tyr-785 bind two proteins src 
-homology/collagen (She) and PLC-yl, respectively (Kaplan and Stephens, 1994; Loeb et ah, 
1994; Stephens et ah, 1994b). Two other proteins, p85 subunit of PI-3-K (Obermeir et ah,
1993) and MAPK-1 (Loeb et ah, 1992) also form complexes with tyrosine phosphorylated 
trkA in PC 12 cells.
The binding of substrates to trk A enhances their specific activity either through receptor- 
induced tyrosine phosphorylation or alterations of conformation, thereby initiating a cascade of 
signalling events that ultimately leads to neuronal differentiation. NGF stimulates the
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phosphorylation on tyrosine of PLC-yl (Vetter et ah, 1991), She (Ohmichi et ah, 1994) and 
the p85 regulatory subunit of PI-3-K (Soltoff et ah, 1992). The activities of PLC-yl and PI-3- 
K are also stimulated in response to NGF (Kim et ah, 1991; Soltoff et ah, 1992). PLC-yl 
tyrosine phosphorylation directly increases its catalytic activity. However, the regulatory 
subunit p85 of the PI-3-K does not possess a catalytic domain and its phosphorylation does not 
result in changes of activity. This protein serves as adaptor molecules to couple the activated 
receptor to other intermediates. Such proteins contain an additional src -homology 3 (SH3) 
domain.
SH3 domains are composed of approximately 60 amino acid residues containing a proline-rich 
sequence of 10 amino acids. NGF also stimulates an increase in the protein bound to
GTP mediated by adaptor molecules containing SH2 and SH3 domains, which are capable of 
binding to guanine nucleotide release factors (GNRFs) and stimulates the association with the 
MAPK-1 increasing its serine/threonine activity (Loeb et ah, 1992). Recently it has been 
shown that SH3 domains within proteins may also be involved in other aspects of function, 
particularly the targeting of molecules to specific subcellular locations. Indeed a number of 
cytoskeletal proteins, for example a-spectrin, contain SH3 domains, consistent with the idea 
that the SH3 domain is involved in membrane localization (Pawson, 1995).
Thus, NGF exert its actions in PC 12 cells through multiple protein tyrosine phosphorylation 
events. These initial phosphorylation events triggered by NGF are followed by activation of 
several protein serine/threonine kinases that include members of PKC, Raf, MAPKK, MAPK 
and ribosomal S6 kinase families (p90^'^^ ) or tyrosine kinases, such as ppbO*^ "^^  ^ kinase 
(Cantley et ah, 1991). Several PC 12 cellular proteins undergo increased phosphorylation 
including soluble proteins (tyrosine hydroxylase, ribosomal 86 protein), nuclear proteins 
(histone H3, H I7, HMG17) and cytoskeletal proteins (MAP 1.2, peripherin, chartins, 13- 
tubulin) (Halegoua and Patrick, 1980).
1.4.3 SECOND MESSENGER SYSTEMS IN NGF SIGNALLING
1.4.3.1 s r c  KINASE (pp60^-«'*^ )
belongs to a family of cytosolic protein tyrosine kinase which have been proposed 
to play a role in signal transduction (Cooper and Howell, 1993). The pp60 '^"- '^'^ family has 
five conserved regions of homology. At the amino terminal region of the protein, there is an 
extreme myristoylation signal responsible for the addition of myristic acid required for 
membrane localisation (Croos et ah, 1985). Adjacent to this region are the SH2 and SH3 
regions, the kinase domain and the noncatalytic tail (Cooper and Howell, 1993).
17
An inhibitory phosphorylation site, Tyr-527, in the non-catalytic cai'boxy-terminal tail has been 
identified and is conserved in the src family members (Cooper and Howell, 1993). A specific 
carboxy-terminal src kinase (Csk) has been isolated which phosphorylates on Tyr-
527, resulting in inhibition of activity. A tyrosine phosphorylation site (Tyr-416) is also 
present in the catalytic domain and autophosphorylation within this domain stimulates kinase 
activity. is activated by growth factors and other cellular activators even though they
lack extracellulai' domains. In some cases this activation may be mediated by G proteins and/or 
PKC activity (Cantley et ah, 1991), although in other cases ppbO'^"' '^ '^  has been shown to 
associate directly with the cytosolic domain of RTKs. ppbO^"'^^  ^ activates She, the universal 
tyrosine kinase substrate adaptor protein in the ternary complex, activating p2F'^‘^' (Hashimoto 
et ah, 1994). The mechanisms of pp60^"-^ '^  ^ activation are still unclear. In the inactivated state, 
the cai'boxy-terminal phosphorylated tyrosine (Tyr-527) binds to the SPI2 domain. Following 
receptor autophosphorylation, the receptor tyrosine kinase phosphopeptide sequence has higher 
affinity for the SH2 domain of pp60^“‘^ <^^  and displaces the carboxy-terminal inhibitory 
phosphotyrosine, initiating an allosteric change in the molecule and catalysing 
autophosphorylation at Tyr-416. Since phosphorylation is essential for carboxy-terminal-SH2 
interactions, it is likely that a receptor-associated protein tyrosine phosphatase is also involved 
(Cooper and Howell, 1993). Once ppdO^ '*^ ^^  ^ is activated, its SH3 domain plays a role in the 
recognition of proline-rich regions of the substrates.
ppbO^ --^ ’^ '^  involvement in NGF signalling is demonstrated by v-src mimicking NGF induction 
of differentiation and neurite outgrowth and other neuronal characteristics in P C I2 cells 
(Thomas et ah, 1991). Microinjection of ppbO^ '*^ ^^ '^  has shown that this protein is required for 
transduction of signals for phenotypic change in PC12 cells. Furthermore, sequential p2K^*^ 
and pp60(^"^''^ actions are required for NGF-induced signals to be transduced (IGemer et ah, 
1991; D'Arcangelo and Halegoua, 1993). In addition, microinjection of anti-jrc antibodies 
into PC 12 cells prevents NGF-induced but not p2H'^‘^ induced neurite outgrowth, while anti- 
ras antibodies block both NGF and pp60^"‘^ '^  ^effects, indicating that pp60‘^ "’^''<^  activation lies 
upstream of in the cascade of events mediating NGF effects (Kiemer et ah, 1991).
1.4.3.2 MAP KINASE CASCADE
The MAP kinase cascade has been extensively characterised in yeasts and mammals (Cobb and 
Goldsmith, 1995; Hunter, 1995; Marshall, 1995a). MAP kinase cascades are part of a three 
kinase pathway consisting of a MAP kinase kinase kinase (MAPKKK), a MAP kinase 
activator (MAPKK), and a MAP kinase (MAPK) which act sequentially (Cobb and Goldsmith, 
1995). MAPKK can be activated by one or two MAPKKK but reports strongly suggest that 
the MAP kinases are activated only by dedicated MAPK activators. In this cascade, activated
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MAPKs translocate to the nucleus and activate transcription by phosphorylation of transcription 
factors (Crowley et ah, 1994).
Proteins of the MAPK cascade ai’e involved in development and differentiation, proliferation 
and oncogenesis (Cobb and Goldsmith, 1995; Hunter, 1995; Marshall, 1995b). Oncogene 
products aie involved in every step of the MAPK cascade of events involved in mediating the 
response of PC 12 cells to NGF. Oncogenes encode for proteins that are either growth factors, 
growth factor receptors, transducers of growth factor responses or transcription factors 
(Cantley et ah, 1991). The transducers of the growth factor responses include several members 
of the MAPK cascade. Thus, overexpression of the pl40^^ and point mutations in can
render these upstream components transforming. At the level of the kinase cascade itself, rqf-1 
and mos are oncogenic proteins (Seger and Ki'ebs, 1995).
1.4.3.2.1 pZl^as p ro te in
The best understood means of activating the MAPK pathway is that used by RTKs which 
transduce their signals via a p2H'^^'^-dependent pathway (Marshall, 1995a) (Figure 1.1). 
belongs to a superfamily of small GTP binding proteins consisting of some 60 distinct 
manmialian proteins. The first members to be discovered were p2 1 ^"Ha-m.y and p21^"^"^^'^'^, 
the 21 kDa proteins encoded by the oncogenes of the Harvey and Kirsten rat sarcoma viruses. 
These proteins are responsible for the transforming ability of the retroviruses. A third, closely 
related transforming protein, p21^“ '^ ‘^^  , was later discovered as an oncogene product 
overexpressed in a neuroblastoma (Marshall, 1995b).
p2ira5 plays a critical role in mediating the mitogenic and differentiating actions of tyrosine 
kinase-coupled receptors (Downward, 1990; Bourne et al., 1991). p2 ira^  is a plasma 
membrane associated protein which is activated upon binding to GTP and becomes inactive 
after hydrolysis of GTP to GDP. GTPase activating protein (GAP) is a 120 kDa protein that 
interacts with p2H''^‘^ with low affinity to stimulate the otherwise slow intrinsic hydrolysis of 
GTP on normal p2H"'^ -^  (Trahey and McCormick, 1987). The release of bound GDP is 
stimulated by guanine nucleotide releasing proteins (GNRPs), such as Sos, Vav and Ras-GEF 
which promotes its replacement by GTP, therefore activating p21^#3 (Marshall, 1995b). 
GNRPs possess proline-rich regions which are probable motifs for protein-protein interactions 
involving SH3 domains. These exchange factors interact with adapter proteins, such as Ash, 
Grb-2, Nek and She via the SH3 domains and these adapter proteins, in turn, interact with the 
phosphorylated tyrosine residues of activated RTKs via SH2 domains. In this way, the 
receptors are coupled to downstream signalling mechanisms through p2ir#^ which can then 
result in the activation of lEGs and subsequent gene expression (Marshall, 1995b).
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FIGURE 1.1 AN OVERVIEW OF RAS SIGNALLING 
(Taken 1998 Signal Transduction Calbiochem catalog)
It has been demonstrated that NGF, FGF and interleukin-6 induce accumulation of the GTP- 
bound active form of in PC12 cells (Qui and Green, 1991, 1992; Nakafuku et al.,
1992; Ng and Shooter, 1993). Binding of NGF to the high affinity receptor results in 
autophosphorylation of pldO'^ ^^  ^ on tyrosine residues within 5 minutes and activation of p21''^*  ^
(Ras-GTP) within 20 minutes after NGF treatment by induced increase in GNRPs activity and 
reduced GAP activity. Thus, these factors, each of which can cause differentiation of PC I2 
cells induce increased levels of p21'"^ *^  activity.
RTKs use adapter proteins to couple p2F"‘^ -^  to autophosphoiylated receptors. In PC I2 cells, 
there is evidence to suggest that the She-Grb2-Sos ternary complex performs this role 
(Hashimoto et al., 1994). Autophosphorylation of trk A following binding of NGF and the 
resulting phosphotyrosine domains serve as docking sites to recruitment of two adapter 
proteins. She and growth factor receptor bound protein-2 (Grb-2). SH2 domains, which are 
present in both She and Grb-2, mediate high affinity binding to specific pTyr residues. The 
SH2-homology domains of She bind directly to ihttrk A receptor and the SH2-homology 
domains of Grb-2 then bind to She already phosphorylated on tyrosine residues (Hashimoto et 
al., 1994). In addition to its carboxy-terminal SH2 domain, She has a second structurally 
unrelated protein tyrosine binding (PTE) domain at its amino-terminus, which also dictates 
receptor-Shc interactions.
SH3 domains bind with high affinity to proline-rich regions of proteins. The SH3 domain of 
Grb-2 mediates its binding to the carboxy-terminus of Sos-1. The Grb-2 proline-rich SH3 
domain-binding sites facilitate the recruitment of Sos-1 to the membrane in proximity to the 
membrane-bound isoprenylated This recruitment of Sos-1 to the cytoplasmic surface of
the membrane activates p2H'^‘^ by catalyzing GDP for GTP exchange (Hashimoto et al.,
1994). Other components of the ternary complex, including Sos-1 and Ras-GAP, contain 
pleckstrin-homology (PH) domains, which have been shown to bind to both Gbg subunits and 
phospholipids (Pawson, 1995). Thus, Grb-2 is an adaptor protein that bridges She to Sos-1 
and then activates p2i^^^ (Kaplan and Stephens, 1994).
Thus, Sos-1 a member of the GNRPs family enhances the rate of GDP-GTP exchange on 
p2 irav, leading to p2V^'^' aetivation. The GTP-bound form of p2F'^‘^ then binds raf protein 
kinase, thereby targeting it to the membrane where c-raf activity is increased (Vojtek et al.,
1993). The direct binding of raf to p2K ^‘^ in vivo leads to translocation of the kinase to the 
plasma membrane. Activated raf kinase is therefore the first component of the now committed 
MAPK module and activation of the other kinases in the module follows, leading to the 
activation of the MAPK cascade. Activation of MAPKs causes hyperphosphorylation of Sos-1 
and results in its dissociation from Grb-2 and hence to the inactivation of p2V^^ (Kaplan and 
Stephens, 1994).
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Biochemical and genetic evidence indicates that functions downstream of the trk A
receptor and src -related protein tyrosine kinases and upstream of the serine/thi'eonine kinase c- 
raf (Kaplan and Stephens, 1994). Introduction of the oncogenic form of p2V^^^ into NGF- 
responsive cells by microinjection of the protein, transfection with the gene or infection with a 
virus carrying the gene can mimic the NGF-mediated differentiation effects, including neurite 
outgrowth (Bar-Sagi and Feramisco, 1985; Brightman et al., 1990; Kremer et al., 1991). 
Furthermore, microinjection of anti-ras antibodies or transfection with dominant negative 
interfering variants of p2V^^ (Asm 17) block NGF-induced neurite outgrowth in PC I2 cells 
(Hagag et al., 1986; Kiemer et al., 1991). Indeed, expression of a dominant inhibitory mutant 
of p2V^^^ is able to block the activation of raf-1, MAPKs and p90''‘^ ^by NGF and phorbol 
ester, while expression of an activated p2K ‘^ '^  variant leads to tyrosine phosphorylation and 
increase of MAPK activity (Thomas et al., 1992). These results support that p21T<3v jg central 
to NGF-induced intracellular signalling pathways in PC 12 cells (Szeberenyi et al., 1990; 
Robbins et al., 1992).
The p21^(^^ pathway, however, only appears to be responsible for some of the responses of 
PC12 cells to NGF (Borasio et al., 1993). Tyrosine phosphorylation of trk A or PLC-yl were 
not altered by the inhibition of p2V^ '^  ^ activity (Thomas et ak, 1992). p2F^ -^  ^ may not required 
for some of the early responses of cells to NGF (shape change, elaboration of short neurites). 
Futhermore, expression of the constitutively activated form of p2F''^^, raf-1 or mitogen- 
activated protein kinase/ERK kinase (MEK-1) in PC 12 cells cannot mimic the complete 
neuronal differentiation pattern seen with NGF (Crowley et al., 1994) nor induce the 
appareance of the differentiation-associated gene Thy-1 or of Na++-channel genes, an ultimate 
marker of acquisition of neuronal phenotype (D'arcangelo and Halegoua, 1993; Fanger et al.,
1993). Thus, other targets of NGF action might act in novel intracellular signalling pathways in 
PC12 cells.
p2tra5 has been shown to interact in vivo and in vitro with raf kinase (Moodie et al., 1993; 
Warne et al., 1993), This interaction is dependent on p2F '^ ‘^ being in the GTP bound 
(activated) state (Vojtek et al., 1993). Microinjection experiments with monoclonal anti-raA 
antibody inhibited raf signalling and provided direct evidence that raf kinase was downstream 
of p2V^^ in PC12 cells (Smith et al., 1986). Expression of activated forms of p2V'^^ in PC12 
cells is necessary and sufficient to activate both raf-1 and B-raf as well as the MAPKs 
(Troppmair et al., 1992; Wood et al., 1992) and dominant inhibitory p2E'<^‘^’blocks NGF- 
induced hyperphosphorylation and activation of raf-1 and MAPKs activation (Robbins et ak,
1992).
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1.4.3.2.2 r « /K in a se  (MAPKKK)
The MAPKKK are the first components in the signalling by MAPK modules and are divided 
into two groups, the raf kinases and the MEK kinases. The proto-oncogene raf-1 is well 
known to code for a cytosolic serine/threonine kinase of the pp60‘^ "‘^ ^^  ^family that consists of 
an amino-terminal negative regulatory domain containing a conserved region 1 (CRl) which 
includes a ras -binding domain (RED) and a cysteine-rich domain (CRD), a serine/threonine 
rich domain (CR2) and a carboxy-terminal kinase domain (CR3) (Warne et ak, 1993; Avruch 
et ak, 1994; Morrison and Cutler, 1997). This combination of functional domains is similar to 
that present in the PKC family of serine/threonine kinases.
Three isozymes of raf protein have been identified in mammalian tissues: (i) A-raf, (ii) B-raf 
and (iii) raf-1 (also known as c~raf) (Damn et ak, 1994). raf-1 protein is the best chaiacterised 
member of this family, because of its ubiquitous tissue distribution and its occurrence in many 
cells lines (Morrison and Cutler, 1997). raf-1 gets activated when it is translocated to the cell 
membrane after association with by a process that has not been fully elucidated but has
been reported to involve the members of the 14-3-3 proteins, a well-conserved family of 
proteins present in mammalian cells as well as flies, yeast, and plants that has been implicated 
in biochemical processes such as inhibition of PKC, activation of tyrosine and tryptophan 
hydroxylases, and stimulation of exocytosis from adrenal chromaffin cells (Aitken, 1995).
At the cell surface membrane, raf-1 may become fully activated by either autophosphorylation 
or by the action of either serine/threonine- or tyrosine-specific protein kinases (Daum et ak,
1994). raf-1 is phosphorylated at serine residues following stimulation of the NGF receptor. 
raf-1 also becomes phosphorylated on tyrosine residues by members of the src- family of 
kinases, and this phosphorylation is essential for its activation (Fabian et ak, 1993). Certain 
isoforms of PKC have been demonstrated to phosphorylate raf-1 (Kolch et ak, 1993). In 
fibroblasts, PKC-Ô activates the MAPK pathway in a manner independent of and
dependent on raf-1 phosphorylation (Ueda et ak, 1996). Thus, PKC activation may act 
synergistically with NGF-induced activation of raf-1 to increase raf-1 activity and subsequent 
MAPK activation. In contrast, the observations that activation of PKA inhibits raf-1 activity 
have suggested that PKA phosphorylation plays a role in suppressing raf-1 activity. The 
activation of PKA by cAMP has been implicated in the negative regulation of MAPK cascade in 
Rat-1 cells and PC 12 cells expressing PDGF receptor (Cook and McCormick, 1993; Wu et ak, 
1993; Vaillancourt et ak, 1994). PKA may inhibit the activity of raf-1 at two different levels, 
by regulating the affinity for ras -GTP binding through phosphorylation of raf-1 at Ser-43 and 
by regulation of its catalytic activity through phosphorylation of other residues (Hafner et ak,
1994).
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B-Raf protein, has a much more restricted distribution, being limited to brain, spinal cord, 
ovary and testis; reminiscent, of the distribution of the p i40^ '^^  receptor. B-raf protein can be 
expressed as either a 68- or 95- kDa polypeptide. Treatment of PC12 cells with NGF does not 
alter the levels of B-raf mRNA, but does induce rapid and transient phosphorylation of B-raf 
B-raf is phosphorylated exclusively on serine residues; no tyrosine phosphorylation is 
observed (Oshima et al., 1991; Jaiswal et al., 1994; Traverse and Cohen, 1994). Concomitant 
with the increase in serine phosphorylation, NGF treatment also increased the serine/thi'eonine 
kinase activity of B-raf within 1-2 minutes (Oshima et ak, 1991). Recently, it has been shown 
that cAMP can activate the MAPK cascade in PC12 cells through a B-raf dependent pathway 
and activation of the small G protein rap-1 (Vossler et ak, 1997). Thus, in B-raf expressing 
cells, such as PC 12 cells, activation of B-raf provides a mechanism for tissue-specific 
regulation of cell growth and differentiation via MAPK cascade.
1.4.3.2.3 MAPK kinase (MAPKK)
The MAPKs are phosphorylated at both threonine and tyrosine residues for a "dual specificity" 
enzyme, unique to each MAPK isoform termed MAP kinase kinase (MAPKK), also known as 
MAPÆr/c kinase (MEK) following treatment with various growth factors (Boulton et ak, 
1991; Gomez and Cohen, 1991; Ahn et ak, 1992; Crews et ak, 1992). These kinases 
phosphorylate TEY, TPY, or TGY motifs on each MAPK isotype (Cano and Mahadave,
1995). MEK-1 and MEK-2 phosphorylate MAPK-1 and MAPK-2 respectively (Kyriakis et 
ak, 1992; Dent et ak, 1992). MEKs are highly specific kinases that phosphorylate only 
MAPKs. Other kinases related to MAPK-1 and MAPK-2, despite possessing activating 
phosphorylation sites, are poor in vitro substrates for MEK-1 (Lin et ak, 1995). MEK-1 and 
MEK-2 ai'e "dual specificity" kinases activated by raf-1 thiough phosphorylation on two serine 
residues within the catalytic domain, Ser-217 and Ser-221 as well as tyrosine residues 
(Boulton et ak, 1991).
Constitutively activated mutants of MEK-1 stimulate PC 12 cells to undergo neuronal 
differentiation and dominant negative mutants of MEK-1 inhibit growth factor-induced PC 12 
differentiation (Crowley et ak, 1994). This indicates that activation of MEKs is necessary and 
sufficient for PC 12 differentiation. MEK activity is increased by NGF very rapidly (within 30 
seconds) and this activation always precedes the development of MAPK activity in PC 12 cells 
(Gomez and Cohen, 1991; Traverse et ak, 1992). The time course of MEK activity correlates 
with the time course of tyrosine phosphorylation of MAPKs in PC 12 cells. Sustained 
activation of MEKs is observed after NGF binding to the PC 12 cells whereas MEK is only 
transiently activated by EGF. This suggests that alterations in MEK activity dictate the 
sustained activation of MAPKs by NGF and transient activation of MAPKs by EGF (Traverse 
et ak, 1992).
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1.4.3.2.4 Mitogen-Activated Protein Kinases (MAPK)
Many cytokine receptors, RTKs and heterotrimeric G-protein coupled receptors (GPCRs) 
activate a class of intracellular protein serine/threonine kinases termed MAPKs, also know as 
extracellular-signal regulated kinases (ERKs) (Anderson and Mailer, 1990; Gomez and Cohen, 
1991; Pelech and Sanghera, 1992). These are considered to represent switch molecules as they 
can convert signals from receptor-associated tyrosine kinases into serine/threonine 
phosphorylation (Crews and Erikson, 1993). p42 (MAPK-2) and p44 (MAPK-1) kinase 
isoforms are the most well-studied members of the MAP kinase family and have been 
implicated in induction of cell cycle re-entry, differentiation, migration and apoptosis. They are 
activated when phosphorylated on both the threonine and the tyrosine residue (Sturgill et al., 
1988; Anderson and Mailer, 1990) within the threonine-glutamine-tyrosine (TEY) motif in 
domain VIII (Lloyd and Wooten, 1992; Peraldi et ak, 1993; Cano and Mahadevan, 1995).
A mechanism which gives the MAPK cascade specificity is the kinetics of MAPK activation. 
MAPK activation is associated with both cell proliferation and differentiation and it is the 
duration of MAPK activation that determines whether a stimulus elicits proliferation or 
differentiation. In PC 12 cells, sustained activation of this pathway leads to differentiation while 
transient activation leads to proliferation (Qiu and Green, 1992; Traverse et ak, 1992; Marshall,
1995). In particulai', the NGF stimulated MAPK activity is exceptionally robust in PC 12 cells 
(Tsao et ak, 1990). From a low basal level, MAPK activity is increased at least 10 fold and 
largely sustained for at least 90 minutes. The plateau phase of MAPK activation by NGF is 
particularly important since NGF, and bFGF, which induce neurite outgrowth in PC 12 cells, 
cause prolonged MAPK phosphorylation, whereas EGF, which does not induce neurite 
outgrowth in PC12 cells causes only transient MAPK phosphorylation (Traverse et ak, 1992).
Since EGF mediates its proliferative effects via the MAPK cascade but this activation is of a 
more transient nature than that elicited by NGF, it has been proposed that a minimum thieshold 
of MAPK activation is required to elicit activation of the differentiation response (Marshall,
1995). Specifically, transient activation is believed to be involved in the proliferative response 
induced by mitogenic growth factors while sustained MAPK activation is implicated in the 
differentiation response by such factors as NGF and bFGF. There are potentially many 
different pathways for receptors to signal transient, versus sustained MAPK activation: 
differences in ligand concentration and receptor number, rate of internalization and down- 
regulation of receptors and differential usage of signalling pathway downstream of receptor 
(Marshall, 1995).
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Stimulation with NGF causes a translocation of MAPKs from the cytosol to the nucleus. 
Nuclear transloeation of MAPKs does not occur after stimulation with EGF. These findings 
suggest that the sustained activation of the MAPKs is required for entry to the nucleus, thereby 
initiating gene transcription events required for neuronal differentiation of PC 12 cells. Thus, 
quantitative differences in MAPK activation are translated into a qualitative difference in 
transcription factor activation, indicating that the cellular response is determined by which 
transcription factors are present in the cell. Thus, sustained activation of MAPK is just a final 
switch determined by previous events that set which MAPK transcription factors are present in 
the cell (Marshall, 1995).
Following prolonged activation, MAPK translocates into the nucleus and phosphorylates 
nuelear targets such as c~myc, elk-1, c-jun and ATF-2. Translocation of both MAPK-1 and 
MAPK-2 kinases has been shown to occur after mitogen stimulation (Sanghera et ak, 1992) 
and MAPK-2 translocation has been shown to occur after exposure of PC 12 cells to NGF 
(Traverse et ak, 1992; Nguyen et ak, 1993). MAPKs phosphorylate the transcription factor 
elk-1 which leads to an increase in the formation of the ternaiy complex that binds the serum 
response element (SRE) (Gille et ak, 1992). Thus, these kinases phosphorylate elk-1 at a 
cluster of serines/threonines residues at its carboxy-terminus (particularly Ser-383) critical for 
transcriptional activation (Marais et ak, 1993).
Substrates of MAPKs can be also found on the cell surface and in the cytoplasm. On the cell 
surface, the NGF receptor, the EGF receptor and Sos-1 all serve as substrates for MAPKs. In 
the cytoplasm, one group of protein kinases that have been identified as MAPK substrates can 
be divided into two subgroups based on their location within the MAPK signalling pathway. 
The first subgroup includes the protein kinases that lead to MAPK activation, such as the 
MAPKKK {raf-1, MEKK-1) (Anderson et al.,1991; Lee et al.,1992) and the MAPKK 
(Matsuda et ak, 1993). This suggests that the MAPK cascade might be regulated by MAPK 
itself (Anderson et ak, 1991; Lee et ak, 1992). The second subgroup are the protein kinases 
that are downstream of MAPK. The ribosomal S6 kinase II (p90' '^^  ^) is phosphorylated and 
activated by MAPK (Sturgill et ak, 1988). Another substrate is the MAPKAPK-2 which 
phosphorylates glycogen synthase kinase-3 (GSK-3) (Stokoe et ak, 1992).
MAPK also phosphorylates cytoskeletal proteins, such as Tau and MAP 1, 2 and 4 proteins 
(Drewes et ak, 1992). This phosphorylation regulates cytoskeletal rearrangements and cellular 
morphology. Cytoplasmic PLA2 is another MAPK substrate and its phosphorylation on Ser- 
505 causes an increase in enzymatic activity resulting in increased arachidonic acid release and 
the formation of lysophospholipids from membrane phospholipids (Lin et ak, 1993). Thus, 
MAPKs mediate several actions of growth factors and cytokines on translation, transcription, 
cytoskeletal function and cell signalling.
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Certain dual specificity phosphatases selectively inactivate MAPK by dephosphorylating the 
two sites that are required to activate them, threonine and tyrosine residues (Hunter, 1995). In 
vitro experiments have demonstrated that these phosphatases are highly specific for MAPKs 
(Alessi et al., 1993; Zheng and Guan, 1993). The genes encoding these phosphatases are 
themselves inducible by growth factors and other stimuli that activate the MAPK. A number of 
genes have been cloned in different laboratories and include: 3CH134, CL 100, HVHl, PAC- 
1, and erp-I ( Alessi et al., 1993; Zheng and Guan, 1993).
1.4.3.3 MAPK SIGNALLING TO NUCLEUS
Intracellular mechanisms mediating the effect of growth factors on the nucleus may involve 
modification of proteins already present in the cytosol by processes such as enzymatic cleavage 
or phosphorylation (Hunter and Karin, 1992). Some effects, however, may require the 
synthesis of new proteins which in turn regulate expression of other genes. Based on the 
events required for a gene to be influenced by an extracellular factor, it is possible to identify 
two major groups of genes: (i) immediate early responsive genes (lEGs) in which specific 
transcription factors required for their transcription are already present in the cytoplasm and are 
activated directly, shortly after the binding of the ligand to its receptor, (ii) late responsive 
genes (LRGs) which are activated by transcription factors which required synthesis de novo . 
These transcription factors are usually codified by a subset of the lEGs, and their effects thus 
depend on fully active translation machinery.
Several intracellular mechanisms seem to be involved in transmitting the NGF signal to the 
nucleus. The intracellular organisation and hierarchy of these second messenger systems 
remains to be fully solved. Although activation of different second messenger systems can 
reproduce some of the observed responses of PC I2 cells to NGF, it is becoming evident that a 
complex pattern of multiple interconnected intracellular pathways is responsible for the 
observed effects of NGF in these cells.
I.4.3.3.1 AP I TRANSCRIPTION FACTOR
A class of cellular genes, lEGs, has been identified whose transcription is rapidly and 
transiently activated. Several members of the lEG family encode putative transcription factors, 
critical to the cell response to growth factors, c-fos and c-jun proto-oncogenes are the most 
extensively studied of these genes (Sheng and Greenberg, 1990).
c-jun , encodes a DNA-binding protein that is present in the transcription factor activation 
protein 1 (AP-1). c-jun binds to a TPA-responsive element (TRE) (5'-TGAGTCA-3') in a
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complex with the product of the c-fos proto-oncogene. As a heterodimer, Fos and Jun proteins 
bind to the AP-1 site with high affinity by interaction of their leucine zipper domains and 
thereby regulate transcription of genes. The Jun family members bind to DNA either as 
homodimers or as heterodimers with members of the Fos and activating transcription 
factor/cAMP responsive element binding protein (ATF/CREB). The Fos family bind to DNA 
as heterodimers with the Jun family and with selected members of the ATF/CREB family 
(Sheng and Greenberg, 1990).
AP-1 was first identified as a transcription factor extracted from HeLa cells that bound 
selectively to cis -elements of SV40 and human metallothionein IIA genes (Bohmann et al.,
1987). AP-1 was found to be a complex of related proteins encoded by different genes. This 
complex recognises and binds the consensus DNA sequence (TRE element) which has been 
shown to confer phorbol ester inducibility to the associated genes. AP-1 can function as an 
intermediate in signal transduction mediated by cell surface receptors, including growth factor 
receptors (Curran and Franza, 1988; Morgan and Curran, 1991).
The AP-1 family also includes other members belong either to the Fos {c-fos ,fo sB  , f r a l  , 
fra 2  ) and Jun (junB  and ju n D  ) (Curran and Franza, 1988). A functional DNA binding 
domain seems to require the formation of dimers between members of the AP-1 family. This 
dimer formation is dependent on a structural motif of leucine residues repeated every 7 amino 
acids capable of forming a bimolecular coiled structure know as a "leucine zipper" (Kerppola 
and Curran, 1991). The DNA binding region is a basic amino acid rich region immediately 
adjacent to the leucine zipper motif. It is thought that DNA binding is required but not sufficient 
for A P-1 induced transcriptional activation. Induction of c-jun by phorbol esters is thought to 
result from a positive autoregulatory mechanism and to involve dephosphorylation of a 
preexisting c-jun at inhibitory phosphorylation sites next to its DNA-binding domain (Boyle et 
al.,1991). Compai'isons between cellular and viral Jun protein suggest that a regulatory domain 
present in the carboxy-terminal region of c-jun  is responsible for the significantly lower 
transcriptional activity of c-jun compared with v-jun . This putative repressor domain may also 
play a role in the signal dependent induction of c-jun activity (Bohmann and Tjian, 1989).
These rapid changes activate gene expression, through modification and activation of pre­
existing transcription factors (Fu and Zhang, 1993). NGF produces a complete rearrangement 
of gene transcription and translation machinery by activation of multiple second messenger 
systems. NGF activates a number of genes in PC I2 cells. Several of these are activated within 
15 minutes and activation is transient. These include lEGs, such as c-fos , NGFI-A, NGFI-B, 
NGFI-C, c-jun  and ju n  B genes (Sheng and Greenberg, 1990). Other genes, including c-myc, 
are more slowly activated over 1-2 h. Still other late responsive genes are slowly and 
persistently activated by NGF over several hours or days (Halegoua et al., 1991).
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The c-fos mRNA induction is observed after 5 minutes of NGF addition and peaks within 15 
to 30 minutes (Greenberg et ak, 1985). This rise has been reported to be an early event in the 
NGF induced differentiation of PC I2 eells and indeed is thought to be required to mediate 
some of the late responses to NGF (Halegoua et ak, 1991). The proto-oneogene c-fos , is one 
of these lEG and its transient induction is an important step in evoking a normal response to 
NGF. Other factors known to induce c-fos  in PC 12 cells include fibroblast growth factor 
(FGF), interleukin 6 (IL-6), nicotine agonists, depolarising stimuli and cAMP analogues 
(Morgan and Curran, 1991).
1.4.3.3.2 API ACTIVATION
In most cell types, members of the c-fas and c-jun  gene families are expressed at relatively 
low levels, but they are induced transiently by a wide range of extracellular stimuli (Sheng and 
Greenberg, 1990). c-fos  has become a model gene for the study of inducible expression 
because c-fos activation occurs in a wide range of cell types in response to a diverse set of 
agents including specific polypeptide growth factors, serum, phorbol esters, neurotransmitters 
and agents that elevate intracellular Ca++ and cAMP (Angel and Karim, 1991).
Although the c-fos and c-jun genes exhibit cell type, stimulus and temporal specificity of the 
expression, a relatively large subset of these gene families can be co-expressed in any given 
situation. Therefore, mechanisms exist that permit the recognition and assembly of specific 
dimeric complexes with the appropriate DNA regulatory element (Sheen and Greenberg,
1990). The role of c-fos and c-jun  in gene transcription is complex and may be regulated in 
several ways including association with different dimerization partners, interaction with other 
transcription factors, effects on DNA topology, and reduction/oxidation of a conserved 
cysteine residue in the DNA binding domain. In addition, phosphorylation of c-fos and c-jun  
by several protein kinases is affected by dimerization and binding to DNA (Abate et ak, 1993).
1.4.3.3.2.1 c - fo s  activation
Activation of AP-1 transcription factor by NGF and PKC, has been well documented (Sheen 
and Greenberg, 1990). For instance, c-fos activation via the PKC pathway has been shown to 
be regulated by a serum responsive element (SRE) (Treisman, 1990, 1995). SRE is a 
significant component of the c~fos promoter that contributes to the mitogen-stimulated 
expression of the c-fos protein. The trans-acting factors that bind to this element to form a 
ternary complex include serum response factor (p67^^^) and ternary complex factor (p6 2TCF) 
(Treisman, 1990, 1995). Characterisation of p6 2 TCF protein indicates that this factor is 
represented by elk-1 , a member of the ets  (E-twenty-six) gene family (Treisman, 1990).
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Member of the E ts  gene family have a conserved DNA binding domain and regulate 
transcriptional initiation from a variety of cellular and viral genes and enhancer elements by 
binding to specific DNA sequences on the SRE (Macleod et a l, 1992).
The carboxy-terminal activation domain of elk-1 is phosphorylated by MAPKs (Marais et al.,
1993). Elk-1  is phosphorylated by MAPKs at a cluster of serine and threonine motifs at its 
carboxy-terminus, particularly at Ser-383/Ser-389. These phosphorylation events are critical 
for transcriptional activation of elk-1. p90''*^^ phosphorylates SRE at Ser-103. This 
phosphorylation facilitates the formation of the ternary complex factor (TCP) composed by elk- 
1, SRE and SRE, and stimulates its ability to activate transcription, without affecting its DNA 
binding properties (Edwards, 1994). p90^ ">^  ^ phosphorylates c-fos on the trans-repression 
domain at the carboxy-terminal region of c-fos (Ser-362) in close proximity to another MAPK 
site (Ser-374). These cooperative phosphorylations by two enzymes may play a role in the 
inactivation of c-fos , raising the posibility that the MAPK cascade not only activates AP-1 but 
may also participate in repression (Edwards, 1994). p90^'^^ phosphorylates glycogen synthase 
kinase-3 (GSK-3) on Ser-9 that leads to its inactivation. Because GSK-3 kinase seems to play 
a role in the negative regulation of c-jun  , the transient activation of GSK-3 kinase would 
enable rapid activation of the AP-1 activity that is normally repressed by this kinase.
1.4.3.3.2.2 c -ju n  a c tiv a tio n
c-jun is a component of the transcription factor AP-1 that binds and activates transcription at 
AP-1/TRE elements. The c-jun  promoter is somewhat simpler, and operates through one 
major cis -element, the c-jun TRE (Angel et al., 1988). This c-jun TRE sequence differs from 
the consensus TRE sequence by a 1-base pair insertion and due to this change is more 
efficiently recognized by c-jun/ATF-2  heterodimers (Karim, 1995). ATE is a family of at least 
ten different transcription factors encoded either by different genes or generated by differential 
splicing. These factors form homodimers or heterodimers with other members of the ATE 
family or Jun families which can bind to both the AP-1 or CRE/TRE responsive element 
(Karim, 1995).
Unlike c-fos , both c-jun and ATF-2 are constitutively present in the cell. Like the c-fos SRE, 
the c-jun  TRE is constitutively occupied in vivo (Karim, 1995). Following exposures to 
stimuli, such as inflammatory cytokines, UV irradiation, osmotic stress, both c-jun and ATF-2 
are rapidly phosphorylated and these phosphorylation stimulates their ability to aetivate 
transcription, thereby leading to induction of the gene expression (Karim, 1995). 
Phosphorylation of c-jun  at Ser-63 and Ser-73, located within its transactivation domain, 
potentiates its ability to activate transcription as either homodimer or a heterodimer with c-fos . 
Furthermore, mutation of Ser-63 and/or Ser-73 renders c-jun nonresponsive to mitogenic and
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stress-induced signalling pathways. Phosphorylation at these sites also may potentiate c-jun 
transcriptional activity through recruitment of CREB binding protein (CEP). CBP connected 
the phosphoiylated activation domains of CREB or c-jun to the basal transcriptional machinery 
(Karim, 1995). Thus, MAPK and p90^-^^ kinase activation by growth factors, such as NGF, 
leads to c-fos induction, which upon translocation to the nucleus combines with pre-existing c- 
jun  proteins to form AP-1 heterodimers that are more stable than those formed by c-jun 
proteins alone (Edwards, 1994). However, another part of the increase in AP-1 activity is due 
to c-jun and ATF-2 phosphorylation (Karim, 1995).
1.5 G-PROTEIN COUPLED RECEPTORS (GPCRs)
All biological systems have the ability to process and respond to enormous amounts of 
information. Much of this information is provided to individual cells in the form of changes in 
concentration of hormones, growth factors and neuromodulators. Several families of cell 
surface receptors have been characterized that are coupled to different mechanisms of signal 
transduction, one of these is coupled to heterotrimeric G-proteins, the G-protein coupled 
receptors (GPCRs) (Simon et ak, 1991). Comparison of the deduced amino acid sequences of 
GPCRs reveals a similar secondary structure: a single polypeptide chain containing an amino- 
terminal region, six relatively conserved hydrophobic domains plus a seventh region of lower 
hydrophobicity spanning the membrane (seven transmembrane region), and a carboxy terminal 
region (Savai’ese and Fraser, 1992).
The amino-terminal sequence of most GPCRs contains putative sites for N-linked 
glycosylation (Asn-Xaa-Ser/Thr) and is presumed to be located extracellulaiiy. The membrane- 
spanning regions of GPCRs contains acidic amino acids (aspartate and glutamate) and the 
putative second and third extracellular domains contain cysteine residues (disulphide bond) 
involved in ligand binding. Many neurotransmitters have a positive charge centre and many 
peptide hormones contain basic amino acids indispensable for biological activity. This raises 
the possibility that ligand binding may, in part, involve acidic amino acids. Conserved 
transmembrane aspartate residues and cytoplasmic domains (third cytoplasmic domain) are also 
involved in receptor activation by conformational change that facilitates receptor-G-protein 
interactions and G-protein activation (Savarese and Fraser, 1992). The carboxy-terminal 
sequence eontains putative phosphorylation sites and is also involved in homologous or 
heterologous desensitization and receptor down-regulation (Savarese and Fraser, 1992). Thus, 
strictly conserved amino acid residues may play a role in maintaining the structure of the 
receptor, perhaps by determining protein folding, whereas those residues conserved among 
major classes may play a role in defining their unique functional properties (Savarese and 
Fraser, 1992).
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FIGURE 1.2 AN OVERVIEW OF G-PROTEIN SIGNALLING 
(Taken from 1998 Signal Transduction Calbiochem catalog )
1.5.1 G-PROTEINS
Signal transduction G-proteins occur in two forms, (i) "small G proteins" that are generally 
found as single polypeptides composed of about 200 amino acids associated with growth factor 
receptors, such as RTKs and (ii) heterotrimeric G-proteins that are made up of a  (36-52 kDa), 
P (35-36 kDa), and y (8-10 kDa) subunits and are associated with GPCRs (Simon et ak, 
1991). The small G-proteins, such as the members of the family, function in regulating
cell growth, protein secretion and intracellular vesicular trafficking. The heterotrimeric G- 
proteins are generally associated with signal transduction by GPCRs.
Signal transduction by GPCRs is initiated by ligand binding which stabilizes an alternate 
conformational form of the receptor and thus transmits information across the cell membrane. 
The ligand-bound receptor initiates two processes: one leads to desensitization, and occurs 
through receptor modification, and the other is a signal-generating process that begins with the 
activation of the heterotrimeric G-protein (Simon et ak, 1991).
Interaction of the G-protein with the activated receptor promotes the exchange of guanosine 
diphosphate (GDP), bound to the a  subunit, for guanosine triphosphate (GTP) and the 
subsequent dissociation of the a-GTP complex from the bg heterodimer. The a  subunit with 
GTP bound and the free Py subunit may interact with effector proteins that further amplify the 
signal. Such effectors include ion channels and enzymes, such as adenylyl cyclases, guanylyl 
cyclases, phospholipases, and phosphodiesterases, that generate regulatory molecules or 
second messengers (Rens-Domiano and Hamm, 1995) (Figure 1.2).
Low molecular weight second messengers, such as cyclic adenosine monophosphate (cAMP), 
cyclic guanosine monophosphate (cGMP) or intracellular Ca++ in turn, generate dramatic 
changes including selective protein phosphorylation, activation of gene transcription, 
cytoskeletal reorganization, secretion and membrane depolarization (Simon et ak, 1991). 
Termination of the signal occurs when GTP bound by the a subunit of the G protein is 
hydrolyzed to GDP. The a subunit exhibits an intrinsic but slow GTPase activity. Hydrolysis 
of bound GTP leads to reassociation of the a  subunit with the py complex and stops further 
effector enzyme activation.
1.5.1.1 G a SUBUNITS
Four families of a subunits of G-proteins have been identified: Gs, Gi, Gq and G 12 (Rens- 
Domiano and Hamm, 1995). The Gs family includes Gs and Golf, and mediates the hormonal 
stimulation of adenylyl cyclase and closing of Ca++ channels. The Gi family includes Gi, Gt,
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Go, Ggust and Gz. Gi is generally involved in the inhibition of adenylyl cyclase and opening 
of K+ channels. Gt mediates the stimulation of cGMP phosphodiesterase and Go, primarily a 
neuronal G-protein, mediates Ca++ channel closure and inhibition of phosphoinositol (PI) 
turnover. Gq are generally coupled to the activation of phospholipase and stimulation of PI 
turnover. G12 and G13 compose the fourth class of G-proteins and their effectors systems are 
unclear (Rens-Domiano and Hamm, 1995).
The a  subunit consist of two domains; (i) a GTPase domain that contains the guanine 
nucleotide-binding pocket as well as sites for binding receptors, effectors and Py subunit, and 
(ii) a helical domain. The amino-terminus appears to be an important site of interaction with 
Gpy. The carboxy-terminus has an important role in defining the specificity of G-protein 
receptor interactions and is also involved in receptor desensitization (Rens-Damiano and 
Hamm, 1995).
The functional role of specific a  subunits is not obvious from their structural classification. 
Activated Gi subunits lower intracellular cAMP levels. However, Go has been implicated in 
increasing PI turnover. GTP dependent signalling pathways résistent to pertussis toxin (PTX) 
have also been described; all of these lack the cysteine residues four amino acids from the 
carboxy-terminal end that is the target for PTX-mediated adenosine diphosphate (ADP) 
ribosylation. They include two novel classes: GI 1 and Gq involved in PTX-resistant coupling 
to PLC activation (Rens-Damiano and Hamm, 1995).
1.5.1.2 GPy SUBUNITS
During the signalling process, py subunits act to coordinate cellular responses, py subunit 
increases the affinity of the a subunits for GDP and can facilitate deactivation of a  subunits, 
activities which promote the inactive state of the G-protein. However, they also have several 
additional functions, these include: (i) localizating a subunits in the membrane, (ii) stabilising 
the interaction of a subunits with receptors in a functional complex, (iii) modulating the effects 
of activated a subunits (Neer, 1994, 1995).
Thus, Py subunits act as a helper protein that facilitates activation-deactivation, localization and 
stability of a-subunits. However, bg subunits directly can be activated effector enzymes, such 
as p-adrenergic receptor kinase, PLA2, PLCP2, types II and IV adenylyl cyclases, phosducin, 
muscarinic K+ channels, PH domain-containing tyrosine kinases, PI-3-K and N-type Ca++ 
channels (Sternweis, 1994). The Py subunit may also act through to activate MAPK
pathway (Crespo et al., 1994).
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1.5.1.3 G-PROTEINS AS MITOGENS
Our current understanding of the process regulating cell growth, division, and differentiation 
has been derived from the study of transforming viral oncogenes and their cellular 
homologues, principally on the role of receptor and non-receptor tyrosine kinases as regulators 
of low molecular weight G-proteins, such as pZU'^-^ and its relatives. The low molecular 
weight G-proteins, like their heterotrimeric counterparts, are signalling intermediates whose 
activation is achieved by exchange of GDP for GTP, but unlike heterotrimerie G-proteins, the 
low molecular weight G-proteins lack the intrinsic ability to catalyze GDP release and GTP 
hydrolysis and are therefore dependent on exogenous proteins, guanine-nucleotide releasing 
proteins (GNRPs), GDP-dissociation inhibitors (GDIs) and GTPase activating protein (GAPs) 
for this regulation (Simon et ak, 1991).
Several ligands that signal via GPCRs have been shown to elicit mitogenic responses, 
including stimulation of DNA synthesis, expression of nuclear oncogenes and cell proliferation 
(Van Biesen et ak, 1996). Thus, the potential of GPCRs to act as proto-oncogenes has been 
suggested, indicating that GPCRs could play a important role in tumour induction or 
progression. Activation of MAPK cascade by GPCRs signalling via PTX-sensitive and 
insensitive G-proteins has been reported (Van Biesen et ak, 1996). GPCRs agonists, including 
angiotensin II, somatostatin, endothelin-1, interleukin-8, bombesin, oxytocin and vasopressin 
induce MAPK activation. The MAPK activation by GPCRs coupled to PTX-insensitive G- 
proteins occurs via two distinct signal pathways: (i) Gs-dependent and/or (ii) Gq-dependent 
(Van Biesen et ak, 1996).
The role of Gs in regulating cell growth is complex and apparently cell type-specific. cAMP 
was the first second messenger to be identified, and its role in regulating physiological 
processes is well established. Hormone receptors increase intracellular cAMP by increasing the 
amount of the free a subunit of the GTP binding protein which activates adenylyl cyclase 
(Simon et ak, 1991). cAMP inhibits the proliferation of many cell lines in the early Go to GI 
phase as well as mid-Gl phase and G2. In contrast, in some cells, such as Swiss 3T3 cells, 
cAMP is a mitogenic messenger and promotes the GI to S phase transition in the cell cycle. 
Lack of forskolin-mediated MAPK-1/2 inhibition in COS-7 and Swiss 3T3 cells and an 
activating role for cAMP on MAPK activation in PC12 cells (Frodin et ak,1994; Young et 
al.,1994) have been observed, suggesting a cAMP sensitive pathway in these cells. 
Furthermore, a eonstitutively activated Gs mutant and a cAMP analog increased MAPK-1 
activity in COS-7 cells (Faure et ak, 1994). Thus, these results indicate that Gs-coupled 
receptors stimulate the MAPK pathway by activating adenylyl cyclase and raising intracellular 
cAMP in these cell lines.
33
Gq activates PLC-p, resulting in the conversion of PI-4,5-P2 (PIP2) to inositol triphosphate 
(1P3) and diacylglycerol (DAG) (Simon et ah, 1991). An activated Gq mutant and activation of 
PLCP2 stimulate MAPKs (Hawes et al., 1995). Activation of MAPK by the PTX-insensitive 
Gq/11 has been reported in both ras -dependent (Eguchi et al., 1996) and ras -independent 
manners (Ueda et al., 1996). Treatment of the PC 12 cells with tumor-promoting phorbol esters 
that directly activate PKC results in the activation of MAPK in a ras -independent manner. 
Futhermore, the down-regulation of PKC activity in CHO and COS-7 cells by chronic 
exposure to phorbol esters blocks Gq-mediated mitogenic signals (Hawes et ak, 1995). Gq 
also activates a series of intracellular signals, which include Ca++/calmodulin and PKC 
activation of specific non-RTKs, such as PYK2, which in turn mediates ras -dependent MAPK 
activation of She and Shc-Grb2-Sos complex formation. These observations define a Gq- and 
Ca++ -mediated mitogenic pathway that requires the same intermediates as the RTK-mediated 
pathways (Van Biesen et ak, 1996).
MAPK-1/2 activation via GPCRs coupled to PTX-sensitive pathway occurs via G^y subunits. 
GPy subunits are capable of transmitting mitogenic signals in COS-7 cells and these signalling 
pathways appear to require the activity of RTKs and not PI turnover, supporting the hypothesis 
that Gi-receptors activate mitogenesis by elevating intracellular level of tyrosine 
phosphorylation of the RTKs and/or Shc-Grb2 adapter protein via a non-RTK, such as src 
-family kinases. Protein tyrosine phosphatases such as SHP2 may mediate dephosphorylation 
of the carboxy-terminal regulatoiy tyrosine residue of c-src family kinases, thereby stabilizing 
the kinase in the active state. Thus, GPCRs and RTKs can induce p2U'^'^ activation via 
convergent pathways (Van Biesen et ak, 1996).
1.5.2 GPCR SUBTYPES
GPCRs can be further classified into three subfamilies; (i) rhodopsin/p adrenergic, (ii) 
secretin/vasoactive intestinal peptide (VIP) and (iii) metabotropic glutamate (niGlu) receptor 
families (Strader et ak, 1995). The secretin/VIP family includes receptors for the peptides 
calcitonin, secretin, glucagon, glucagon-like peptide I, gastric inhibitory peptide, parathyroid 
hormone, vasoactive intestinal peptide (VIP), pituitary adenylyl cyclase activating peptide 
(PACAP) and growth hormone releasing hormone (Strader et ak, 1995). These receptors share 
25-50% amino acid identity among themselves and little primary sequence homology with the 
rhodopsin/b-adrenergic and metabotropic glutamate receptor families.
The secretin/VIP family of GPCRs all contain an amino-terminal hydrophobic domain, which 
is presumed to serve as signal sequence. Within this amino-terminal hydrophilic domain are a 
series of conserved cysteines presumed to play a role in determining the tertiary structure of
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this region. The sequence conservation in the amino-terminal region of these receptors suggest 
a role in mediating receptor-ligand interactions. All members of the secretin/VIP subfamily aie 
coupled to Gs and upon activation of intracellular cAMP (Strader et al., 1995). In addition to 
coupling to Gs, many of these receptors (e.g. calcitonin, glucagon, PACAP, VIP) have been 
reported to activate other G-proteins, leading to increases in intracellular Ca++ levels and PI 
hydrolysis. Thus, it appears that the potential to signal through multiple second messenger 
pathways may be a hallmark of this receptor subfamily (Strader et a l, 1995),
1.6 PITUITARY ADENYLYL CYCLASE 
ACTIVATING POLYPEPTIDE (PACAP)
PACAP is a polypeptide discovered as a consequence of a search for candidate novel 
hypothalamic-releasing hormones (Arimura, 1992a; Arimura and Shioda, 1995). The search 
strategy centred around the observations that releasing hormones, such as growth hormone- 
releasing hormone, luteinizing hormone releasing-hormone and corticotropin releasing 
hormone, increase cAMP as a common response parameter. The search for a candidate 
hormone that increases cAMP in pituitary cells resulted in the isolation of two substances from 
ovine hypothalamus which are now known as PACAP-27 and PACAP-38 (Miyata et ak, 
1989).
1.6.1 PACAP BIOCHEMISTRY
PACAP is synthesised from a single gene as a precursor protein of 176 amino acids (human) 
and 175 amino acids (rat), with a molecular weight of approximately 19.5 IcDa. The amino acid 
sequence corresponding to PACAP-38 is located between His-132 and Lys-169, which are 
flanked by sequences recognised in the post-translational proteolytic processing of various 
peptide hormone precursors (Steiner et ak, 1980). Contained within the PACAP-38 sequence 
is another consensus sequence for proteolytie processing which likely yields PACAP-27. 
Several lines of evidence support the hypothesis that PACAP-27 and PACAP-38 are generated 
from the same precursor polypeptide (Arimura, 1992a). PACAP has been shown to belong to 
the same polypeptide family as vasoactive intestinal peptide (VIP). Indeed, the amino-terminal 
28 amino acid residues of PACAP-38 show 6 8 % homology with vasoactive intestinal peptide 
(VIP) (Arimura, 1992a).
The cDNA for rat PACAP-38 was cloned and shown to be identical at the amino acid level to 
both human and ovine peptide (Kimura et ak, 1990; Ogi et ak, 1990). The human genomic 
clone has been isolated and reveals PACAP to be a gene of five exons and four introns 
(Hosoya et ak, 1992). PACAP-38 is encoded, however, by the single exon (number five); 
thus, PACAP-27 and PACAP-38 are not generated by alternative splicing. Southern blot
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analysis, even under low-stringency conditions, indicating that the PACAP-38 gene is 
probably unique (Arimura, 1992a).
Interestingly, the 5'-flanking promoter region of the human PACAP gene contains no apparent 
TATA, CAAT or GC boxes, which are sequences known to be required for accurate initiation 
of transcription. Several cyclic AMP responsive elements (CREs) and a TP A response element 
(TRE) have, however, been identified in the 5'-flanking region of the gene which may mediate 
transcriptional regulation by cAMP/PKA or PKC-dependent pathways (Ohkubo et al., 1994). 
PACAP expression can be induced by cAMP or phosphodiesterase inhibitors in IMR32 cells, a 
PACAP producing neuroblastoma cell line, and therefore it is possible that autocrine 
stimulation of PACAP expression occurs (Ohkubo et al., 1994). The PACAP gene is localised 
to chromosome IS p ll which has been associated with holoprosencephaly, or failure of the 
forebrain to divide into hemispheres; this finding provides supporting evidence for a role of 
PACAP in brain development (Arimura and Shioda, 1995).
1.6.2 PACAP DISTRIBUTION
A variety of studies have indicated that PACAP distribution in neurons is similar among 
mammalian species and has pleiotropic distribution (Arimura and Shioda, 1995). PACAP has 
been found to be abundant in CNS as well as in PNS such as adrenal gland (Arimura et ak, 
1991). The rat brain contains high levels in basal forebrain, hypothalamus and brainstem. 
Moderate concentrations of PACAP were found in cerebral cortex, hippocampus, thalamus, 
amygdala and locus coeruleus, brainstem, posterior pituitary and spinal cord, where many 
PACAP-immunoreactive (PACAP-IR) fibres and terminals were detected. PACAP-IR nerve 
cell bodies have also been demonstrated in the dorsal root and trigeminal ganglia (Arimura, 
1992a; Arimura and Shioda, 1995).
In the periphery, PACAP-IR nerve fibres occur in several organs, including the blood and 
lymphatic vascular systems, adrenal gland, skin, digestive, respiratory, urinary, and 
reproductive organs and the eye (Arimura and Shioda, 1995). PACAP and VIP have been 
found to coexist in nerve cell bodies and fibres in the gut of chickens and humans and in fibres 
in the gastric mucosa of mice, as well as in neurons in the human ovarian cortex. PACAP-IR 
has also been identified in both endocrine and exocrine parts of rat and mouse pancreas. In all 
other regions of the gut, many PACAP-IR and VIP-IR cell bodies and fibres were distinct. The 
demonstration of PACAP-IR in peripheral lymphoid tissues such as mesenteric lymph nodes 
(Gaytan et ak, 1994) suggests that PACAP may have a potential role in immune system 
communications and thus may serve to integrate communication between neuroendocrine and 
immune systems (Arimura and Shioda, 1995).
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1.6.3 PACAP RECEPTORS
Both PACAP and VIP have been demonstrated to target cells via cell-surface receptors which 
have been identified to belong to the subfamily of secretin/glucagon, seven-transmembrane 
spanning region, GPCRs superfamily (Strader et ah, 1995). Several receptors specific for 
PACAP or VIP have now been identified pharmacologically and the cDNAs encoding these 
receptors have been characterised. These defined receptors are distinct with regard to primary 
amino acid sequence and ligand affinity (Ishihaia et ai., 1992; Spengler et al., 1993).
Two distinct PACAP receptors, type I and type II, have been defined on the basis of 
pharmacology, signalling activation and distribution (Harmar and Lutz, 1994; Journot et ah, 
1994; Arimura and Shioda, 1995). The PACAP type I receptor has a high affinity for PACAP 
but much reduced affinity for other members of the secretin/glucagon/VIP subfamily, while the 
PACAP type II receptor, also known as the VIP type I receptor, can bind PACAP and VIP 
with similar affinities (Couvineau et al., 1994; Arimura and Shioda, 1995). Two isoforms for 
the type I receptor, designated type la and type Ib, on the basis of differential affinities for 
PACAP-27 and PACAP-38 have been proposed (Arimura, 1992b).
1.6.3.1 PACAP TYPE I RECEPTOR
The cloning of the rat and human PACAP type I receptors have been reported (Hashimoto et 
ah, 1993; Hosoya et al., 1993; Morrow et al., 1993; Pisegna and Wank, 1993; Spengler et ak,
1993). The PACAP type I receptor is encoded by an mRNA of between 7.5 and 9.5 kb and 
belongs to the GPCR superfamily with seven conserved transmembrane domains, containing 
many of the motifs expected for a G protein-coupled receptor. While the amino-terminal 
domains of the secretin/glucagon/VIP receptor family are highly divergent, substantial 
similarity at specific positions (including six cysteine residues, postulated to confer general 
conformation of the extracellular binding domain) is noted (Mayo, 1991). The PACAP type I 
receptor is most similar to that of the VIP type I receptor, with 51% homology. Homologies 
with other secretin/glucagon/VIP receptors lie between 47% for secretin receptor and 37% for 
parathyroid hormone and gastric inhibitory peptide.
Rat and human PACAP type I receptors share 92.5% amino acid homology and similar 
pharmacology (Ogi et ak, 1993); PACAP-27 (IC5o= 0.5-1.3 nM) and PACAP-38 (IC50 = 0.2- 
1.3 nM) are very much more potent than VIP (IC50 > IjLlM) in displacing the binding of [^251] 
PACAP-27 (Arimura and Shioda, 1995). As for the VIP type I receptor, the PACAP type I 
receptor is coupled positively to adenylyl cyclase and cAMP production. The relative 
effectiveness of these compounds in stimulating adenylyl cyclase activity for the PACAP type I
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receptor, however, is markedly different; half-maximal stimulation of cAMP production is 
achieved at 0.1 nM for PACAP-27, 0.4 nM for PACAP-38 or greater than 1000 nM for VIP 
(Journot et al., 1994).
The array of receptor types available to PACAP is further extended by the existence of a 
number of splice variants for the PACAP type I receptor (Spengler et ak, 1993). Unlike many 
GPCRs previously described, the PACAP type I receptor mRNA can be alternatively spliced 
resulting in the generation of multiple receptor variants. Variation resulting from alternate 
splicing of the PACAP type I receptor mRNA is localised to the third intracellular loop of the 
receptor, an area known to be required for the molecular coupling of receptors of this class 
with G-proteins and thus with the effector molecules (Savarese and Fraser, 1992).
Differential splice vai'iants aie generated by insertion in the third intracellular loop of either one 
and/or two cassettes of 28 amino acids ("Hip" and "Hop") (Spengler et ak, 1993). In addition, 
two variants of the Hop cassette exist; in the Hop-2 variant, the Ser-349 which is found within 
the Hop-1 species is deleted. Thus, the primary gene transcript of PACAP type I receptor is 
capable of alternative processing of these exon cassettes to yield mature mRNA containing any 
of the Hip, Hop-1 or Hop-2 insertions. Additionally, the generation of concatamers of the 
cassettes Hip or Hop during differential splicing results in mRNA containing both Hip-Hop 1 
or Hip-Hop2 (Journot et ak, 1994). Indeed, as many as five separate splice variants have been 
identified which are generated by the alternative splicing of an 84 base pair exon which encode 
the third intracellular loop of this receptor. This region of the receptor has previously been 
implicated in coupling with accessory signalling machinery, such as G-proteins (Savarese and 
Fraser, 1992).
The existence of multiple variants of the receptor at this site may reflect a mechanism for the 
coupling of PACAP to multiple signalling pathways. GPCRs have been directly and/or 
indirectly linked with multiple signalling pathways, including adenylyl cyclase, PLC, MAPK 
and PI-3-K (Hepler and Gliman, 1992; Exton, 1994; Neer, 1994; Gudermann et ak, 1996; 
Van biesen et ak, 1996). Furthermore, it has been demonstrated that the profile of expression 
of splice variants is tissue-dependent as well as perhaps developmentally regulated (Spengler et 
ak, 1993). Thus, ligands signalling through the PACAP type I receptor are potentially capable 
of signalling through a wide variety of pathways; moreover, the pathway of choice in any 
given instance, may be dependent upon the tissue involved and its physiological and/or 
developmental status.
The PACAP type I reeeptor has been localised to a variety of tissues on the basis of 
autoradiographic, binding strategies and/or in situ hybridisation (Arimura and Shioda, 1995). 
The PACAP type I receptor has a widespread distribution in CNS with highest levels in the
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olfactory bulb, the dentate gyrus of the hippocampus and cerebellum, and significant 
concentrations in hypothalamus, thalamus, brain stem, cerebral cortex, basal ganglia and 
anterior and intermediate lobes of the pituitaiy which is consistent with its role in the regulation 
of pituitary functions. At the periphery, the PACAP type I receptor is predominantly found in 
the adrenal gland and testis (Cauvin et al., 1991; Lam et al., 1990),
1.6.3.2 PACAP TYPE II RECEPTOR
The existence of a PACAP type II distinct from type I was initially chaiacterised on the basis of 
pharmacology by virtue of its similar affinities for PACAP or VIP (Harmar and Lutz, 1994). 
These peptides compete for a single binding site in lung, liver, intestine, ovary, thymus and 
splenocytes but these receptor sites are negligible in hypothalamus and pituitary. The 
distribution of type II PACAP receptor is shared with that for VIP receptor type I, which has 
also been demonstrated to exhibit similar affinities for PACAP and VIP. Thus, there is current 
consensus that the PACAP type II receptor is identical to the VIP type I receptor since their 
distribution, pharmacology and putative intracellular signalling coupling mechanisms appear to 
be the same.
1.6.4 PACAP-VIP BIOLOGICAL ACTIONS
PACAP has been shown to affect a wide variety of physiological processes in a large number 
of tissues and organs; these actions appear to be mediated via cAMP and PI turnover induced 
by activation of PACAP receptors (Arimura and Shioda, 1995). Specifically, PACAP has been 
demonstrated to serve as neurotransmitter and neuromodulator (Guo and Wakade, 1994), 
pituitary releasing hormone (Miyata et al., 1989), vasorelaxant dilator (Arimura, 1992a), 
secretagogue (Yada et al., 1994), mediator of neuroimmune communication (Gaytan et ak,
1994) and to play a role in reproductive activity (McArdle, 1994).
The high eoncentration of PACAP-38 in the adrenal gland in rat and other animals suggests an 
important functional role in adrenal chromaffin cells. PACAP-38 has been localised to 
adrenaline-containing cells of the adrenal medulla; no co-existence with vasoactive intestinal 
peptide (VIP) has been noted. Moreover, PACAP-IR fibres have also been identified in the 
adrenal medulla (Tabarin et ak, 1994). The PACAP type I receptor has been identified by 
autoradiography (Shivers et ak, 1991) and PACAP type I receptor mRNA is found in adrenal 
medulla tissue (Spengler et ak, 1993).
A role for VIP in trans-synaptic regulation of the TH activity has been implied by the finding 
that VIP-IR is present in cells of the intermediolateral column (IML) (Sasek and Zigmond, 
1989) and adrenal medulla (Yoshikawa et ak, 1990). VIP is also present in ACh positive nerve
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terminals of sympathetic ganglia and SIF cells (Lai’s-Gosta et al., 1993). VIP has been reported 
to be as potent as ACh in evoking the secretion of catecholamines in the adrenal gland 
(Malhotra et ak, 1987). VIP increases TH activity within SCG (Schwarzchild and Zigmond, 
1989) and adrenal gland (Malhotra and Wakade, 1987; Malhotra et ak, 1989). VIP also 
increased the activity of existing pools of TH (Roskoski et ak, 1989) and induced the 
expression of the TH gene in PC 12 cells (Wessels-Reiker et ak, 1991). Thus, trans-synaptic 
activation of TH in postganglionic sympathetic nerves via non cholinergic neuromodulators, 
such as VIP and PACAP present in pre-ganglionic nerve terminals is implicated in the 
restoration of synaptic stores of catecholamines. VIP and PACAP also stimulated 
transcriptional activation of the NPY gene in a PKA-dependent manner in PC 12 cells (Colbert 
et ak, 1994).
PACAP induces adenylyl cyclase activity and elevates cytosolic Ca++ levels in adrenal tissue 
(Watanabe et ak, 1992). Other cells of SA lineage are well known to be responsive to VIP in 
micromolar amounts but PACAP stimulates cAMP production more potently than VIP in these 
cases, generally at nanomolar concentrations. Moreover, both PACAP and VIP, at 0.1-1 nM 
and 0.1-1 pM, respectively, stimulate the phosphorylation of TH, the rate-limiting enzyme in 
the synthesis of catecholamines in PC 12 cells (Strong et ak, 1992). PACAP has been 
demonstrated to modulate catecholamine and NPY expression in PC 12 cells (Colbert et ak,
1994) and in rat superior cervical ganglion (SCG) (May and Braas, 1995). Stimulation of the 
splanchnic nerve induces PACAP levels in adrenal perfusates (Wakade et ak, 1992). Thus, like 
VIP, PACAP would appear to function as a physiological noncholinergic neurotransmitter in 
the rat SA system (Watanabe et ak, 1995).
In addition to these actions, PACAP and VIP aie involved in differentiation, neural growth and 
survival of specific rat neuronal cells, such as PC 12 cells (Deutsch and Sun, 1992; Colbert et 
ak, 1994; Okumura et ak, 1994; Hernandez et ak, 1995), sympathetic neuroblast (Dicicco- 
Blom and Deutsch, 1992), corticotrope cell line (Braas et ak, 1994) and neonatal chromaffin 
cells (Wolf and Krieglstein, 1995). The state of differentiation and secretory profile of 
mammalian cells of SA lineage are altered by the neuroendocrine peptide VIP but typically at 
micromolar or higher concentrations (Colbert et ak, 1994; Okumura et ak, 1994). Both, 
PACAP-27 and PACAP-38 are much more potent activators (typically at nanomolar 
concentrations) than VIP on signal transduction in cells of SA lineage (Deutsch and Sun, 1992; 
Colbert et ak, 1994; Hernandez et ak, 1995).
A trophic role for VIP through cAMP has been suggested using cultured sympathetic 
neuroblast (Pincus et ak, 1990). Incubation of the PC 12 cells with micromolar concentrations 
of VIP induces neurite extension (Colbert et ak, 1994; Okumura et ak, 1994). In response to 
VIP treatment over several days, PC 12 cells appeared to take on a neuronal morphology. Thus
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the cells flatten down and extend long, slender neurites with prominent growth cones (Colbert 
et a l, 1994; Okumura et al., 1994). However, a lack of neurotrophic effect of VIP on PC12 
cells over similar time courses even when compai able concentrations of the peptide were added 
to cell cultures under similar conditions to those described (Deutsch and Sun, 1992; Hernandez 
et al., 1995). The basis for these contradictory findings remains unclear but may again reflect 
inherent variability in the PC 12 cell population in different laboratories.
The effects of PACAP on morphological differentiation and growth of PC 12 cells are the same 
as those seen upon treatment with VIP. Several other reports describe the morphological effects 
of PACAP on this pheochi'omocytoma-derived cell line (Deutsch and Sun, 1992; Frodin et al., 
1994; Hernandez et al., 1995), Both the 27- and 38-amino acids forms of PACAP stimulate 
adenylyl cyclase and elevate cAMP levels in PC 12 cells with a EC50 at nanomolar levels 
(Deutsch and Sun, 1992). PACAP-38 additionally is a potent activator of the PI turnover in 
PC 12 cells, elevating the content of inositol phosphates by 8 -fold (EC50 = 7 xlO'^M) and is an 
effective inducer of neuronal morphology, whereas PACAP-27 is 200-fold less potent in 
activating the PI turnover and much less active in promoting neurite outgrowth (Deutsch and 
Sun, 1992). Moreover, the concentration of PACAP required to elicit a comparable 
differentiation response to that of VIP in PC 12 cells, is a thousand times lower. The 
pharmacology of these differences mirrors the peptide binding distinctiveness of the PACAP 
type I and PACAP type II/VIP type I receptors (Arimura, 1992b; Arimura and Shioda, 1995). 
Similar findings have been reported by a number of laboratories (Watanabe et ak, 1990; 
Colbert et ak, 1994; Okumura et ak, 1994). The differential sensitivity of PC 12 cells to 
PACAP and VIP may reflect signalling of these peptides through the PACAP type I receptor 
rather than the PACAP type BTVIP type I receptor.
The PACAP type I receptor is known to be coupled to cAMP production as well as PI turnover 
(Spengler et ak, 1993; Harmar and Lutz, 1994; Journot et ak, 1994). The precise molecular 
coupling machinery of the receptor to these pathways remains to be elucidated but is likely to 
involve the variable third intracellular loop which is the site of previously described alternate 
splicing. The Hop cassette encodes a consensus motif for phosphorylation by PKC and may 
thus possibly contribute to the specific fine-tuned regulation of PACAP receptor function 
(Harmar and Lutz, 1994; Journot et ak, 1994; Spengler et ak, 1993). The presence of the Hip 
cassette has been reported to impair adenylyl cyclase stimulation and abolish PLC stimulation 
(Spengler et ak, 1993). Expression of the Flip-Hop concatamer has been demonstrated to elicit 
intracellular signalling responses that aie intermediate between those of Hop and Hip isoforms. 
Ill the adrenal gland, the Hop variant has been reported to be almost exclusively expressed; no 
concatamer is detectable in this tissue (Spengler et ak, 1993).
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The PACAP type I receptor containing the Hip cassette identified in PC 12 cells plays a 
prominent role in VIP- or PACAP-induced neuronal differentiation in these cells. There is 
evidence that PACAP acts through the MAPK cascade in PC12 cells (Frodin et ah, 1994; 
Young et ah, 1994; Barrie et al., 1997). The mechanisms involved in such potential signalling 
pathway capability are not yet resolved but recruitment of molecules along these pathways also 
may well be influenced by the upstream PACAP receptor splice variants available.
The change to a neuronal pattern of morphology observed in PC 12 cells following the addition 
of PACAP or VIP suggests that these peptides may play a trophic role in the nervous system, 
in addition to the neurotransmitter function of PACAP and VIP in postganglionic sympathetic 
nerves. Thus, within preganglionic sympathetic nerves, the trophic role of these peptides may 
be their primary action in the developing nervous system, whereas their regulation of 
sympathetic nerve function may occur later once the specialised enviromeiit is achieved by high 
steroid input to the adrenal medulla and the establishment of NGF dependence in the 
sympathetic nervous system.
That such classical neuromodulators may have the novel capability to act as trans-synaptic or 
autocrine neurotrophins upon cells derived from the neural crest is supported by several lines 
of evidence. Firstly, VIP and PACAP-IR have been identified in cells or afferent fibres of 
sympathetic ganglia and chromaffin cells and, in some cases, in these cells themselves and thus 
may act through classical synaptic transmission mechanisms to mediate unorthodox action 
(Sasek and Zigmond, 1989; Tabarin et ah, 1994; Arimura and Shioda, 1995). Moreover, the 
time of expression initiation in vivo of these peptides co-incides with innervation and 
differentiation schedules in the ontology of sympathetic development; VIP expression appears 
one day after functional connections with preganglionic neurons are established (Tyrrell and 
Landis, 1994). Thus, it has been proposed that VIP and PACAP may serve as trophic agents in 
the development of SA cells at a time prior to, or overlapping with, that identified for the 
classic NGF action.
1.6.5 PACAP-VIP SIGNALLING PATHWAY
PACAP-27 and PACAP-38 increase adenylyl cyclase activity and elevate intracellular cAMP 
levels in PC I2 cells at nanomolar concentrations. PACAP-38 is a potent activator of PLC and 
PI turnover in PC 12 cells and is an effective inducer of neuronal morphology, whereas 
PACAP-27 is much less potent in activating PI turnover and in promoting neurite outgrowth 
(Deutsch and Sun, 1992; Hernandez et ah, 1995). Thus, PACAP-38 but not PACAP-27, 
results in a concentration-dependent increase in neurite outgrowth in PC 12 cells. PACAP-38 
result in a rapid but transient activation of MAPK-1 (Frodin et ah, 1994; Young et ah, 1994;
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Barrie et al., 1997) consistent with the binding to the PACAP type I receptor and the biological 
potency of PACAP-38 in PC 12 cells and chromaffin cells.
Forskolin, an adenylyl cyclase activator acted non-additively with PACAP-38 on MAPK-1 
activation indicating cAMP involvement in the PACAP-38 response in PC 12 cells (Frodin et 
al., 1994). PACAP-38 stimulation of MAPK-1 is inhibited following PKC downregulation 
with phorbol esters, suggesting PKC is also involved in the PACAP-38 response (Frodin et 
al., 1994). PACAP-38 potentiates the NGF-stimulated neurite outgrowth with a concominant 
potentiation of NGF-stimulated MAPK-1 activation (Frodin et ah, 1994). Taken together these 
observations with PACAP-38 in PC12 cells, suggest that the synergistic stimulation of 
MAPKs by cAMP/PKA and activators of PKC occur upstream in the MAPK cascade and this 
stimulation appear to be involved in the neuronal differentiation of PC 12 cells (Barrie et ah, 
1997).
1.7 cAMP IN SIGNALLING PATHWAY
1.7.1 ADENYLYL CYCLASE
Adenylyl cyclases comprise a heterogeneous multigene family, members of which are 
variously regulated by the G a and Gpy subunit of G-proteins, by Ca++ and by protein kinases 
(Mons and Cooper, 1994). All eight isoforms share a commom double motif with six 
membrane-spanning domains, and two large cytoplasmic segments. Based on sequence 
similaraties, the isoforms have been classified into three subfamilies : (i) the type I-like group 
(types I, II and VIII) are stimulated by Ca++ and Gs but not by G^y or PKC, (ii) the type II- 
like group (types II, IV and VII) are stimulated by Gs and Gpy but not by Ca++ and PKC, (iii) 
the type V-like group (types V and VI) are stimulated by Gs but not by GPy or PKC and ai*e 
inhibited by Ca++ (Mons and Cooper, 1994). Functional properties are shared within these 
subfamilies, although individual isoforms display unique responses. Broadly speaking, each 
adenylyl cyclase can be regulated by a subunits of a G-protein, although type I, in particular, is 
quite refractory to stimulation by Gs and the type Il-like group is refractory to inhibition by Gi. 
However, individual isoforms show a range of responses to factors such as Ca++, PKC and 
bg subunits of G-proteins (Mons and Cooper, 1994).
1.7.2 cAMP-DEPENDENT PROTEIN KINASE (PKA)
cAMP is one of the most ubiquitous regulatory molecules in biological systems. It controls a 
great variety of metabolic processes. Its role in regulating transcriptional activity is central to 
the role it plays in many systems. Several lines of evidence implicate the activation of PKA as 
an intermediate in the transcriptional activity of cAMP. Transfection of the somatostatin gene
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cAMP responsive element (CRE) in PC 12 cells deficient in type II cAMP dependent protein 
kinase showed that this element cannot respond to cAMP in these cells (Montminty et ah, 
1986). Furthermore, transfection of a DNA encoding an inhibitor of the catalytic domain of 
PKA blocks induction of genes which are upregulated by cAMP (Grove et ah, 1987). This 
protein kinase inhibitor (PKI) is a 77 amino acid (8 kDa) protein which binds and inhibits the 
PKA catalytic subunit in a potent (Ki = 0.098 nM) and highly specific manner.
Phosphodiesterase hydrolysis of cAMP leads to a reassociation of the catalytic and regulatory 
subunits regenerating the inactive holoenzyme and leading to cessation of cAMP effects in the 
cells (Walaas and Greengard, 1991). Five major classes of phosphodiesterases have been 
reported: (i) type I (CaM-dependent), (ii) type II (cGMP-stimulated), (iii) type III (cGMP- 
inhibited), (iv) type IV (cAMP-specific) and (v) type V (cGMP-specific). These isozymes 
exhibit sequence homology in their catalytic domain and are differentially expressed and 
regulated in different cells.
PKA consist of tetramers composed of two regulatory subunits and two catalytic subunits that, 
in the absence of cAMP, bind together to form an inactive complex. Molecular genetic studies 
have shown that there are multiple isoforms of catalytic and regulatory subunits which have 
distinct properties and tissue distribution (Walaas and Greengard, 1991). PKA is found in two 
classes or isoforms which differ in their regulatory subunits. PKA type I is soluble and widely 
expressed, whereas the PKA II isoforms, PKAIIa and PKAIIp, are membrane anchored and 
are particularly abundant in neuroendocrine cells, such as PC I2 cells. The regulatory units of 
PKA have two cooperative binding sites for cAMP which induce them to dissociate from the 
catalytic subunits, making them active. Thus, the free catalytic subunit translocates to the 
nucleus and phosphorylates different transcription factors (Cassano et ah, 1996).
Activation of PKA by cAMP causes phosphorylation of transcription factors which are 
responsible for the transcriptional activity of cAMP. Transcription factors under control of 
PKA include the activator protein 2 (AP-2) and CREB (Roesler et ah, 1988). The mechanisms 
by which phosphorylation of these transcription factors affects their transcriptional activity is 
not completely clear. Although phosphorylation does not seems to affect binding affinity of 
AP-2 or CREB to their DNA consensus sites, it is clear that phosphorylation is important for 
the increase in transcriptional activity suggesting that other mechanisms are involved in 
mediating cAMP-induced transcription (Roesler et ah, 1988).
1.7.3 cAMP RESPONSIVE ELEMENT (CRE)
cAMP functions to coordinate diverse metabolic processes ranging from the breakdown of 
glycogen to the synthesis of a number of specific enzymes. The mechanisms by which cAMP
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exerts these diverse effects are pleiotropic in nature altering numerous steps in a metabolic 
pathway. cAMP is also responsible for a very marked induction of gene expression in 
eukaryotes (Roesler et ah, 1988). The promoter-regulatory regions of these genes have been 
isolated and CRE characterized by functional analysis. There are two classes of genes which 
are transcriptionally induced by cAMP: (i) Group 1 genes aie those which are rapidly regulated 
by cAMP, usually within minutes and in a cycloheximide-insensitive manner, (ii) Group 2 
genes are those where the transcription is increased only after several hours of cAMP treatment 
and in a cycloheximide-sensitive manner. Since transcription of the genes in Group 1 seems to 
be insensitive to cycloheximide, in turn their responsiveness to cAMP most likely involves the 
rapid modification of a pre-existing protein to a more active form (Roesler et ah, 1988).
There are two classes of cis -acting elements identified in the c AMP-regulated genes of Group 
1. The 8 -bp palindromic sequence T(G/T)ACGTCA, originally termed a CRE, lie generally 
within the first 150 bp of the 5'-flanking region, and therefore available evidence supports a 
dual role for the CRE as both a basal and an inducible transcriptional enhancer element (Roesler 
et ah, 1988). Another regulatory consensus sequence CCCCNGGG, is bound by the AP-2 
and can be induced by treatment with either forskolin, which raises the eoncentration of cAMP 
and phorbol esters, which activates PKC. Considerable variation occurs on this palindromic 
consensus sequence as comparison of AP-2 binding sequences across different genes show 
variability in all 8 base pairs. This sequence also can act as a basal enhancer, increasing the rate 
of gene transcription in the absence of any hormonal stimulation (Roesler et ah, 1988).
1.7.4 cAMP RESPONSIVE BINDING PROTEIN (CREB)
Using DNA affinity chromatography a protein has been purified with a molecular mass of 43- 
kDa wich bound specifically to the CRE (Montminy and Bilezikjian, 1987). CREB is a 
transcription factor which binds the CRE and activates transcription in response to a Vciriety of 
extracellular signals including neurotransmitters, hormones, membrane depolarization and 
growth and neurotrophic factors. CREB protein is ubiquitious being distributed in a variety of 
tissues and its phosphorylation by PKA does not seem to increase the amount of CRE binding 
activity but is essential for transcriptional activation (Yamamoto et ah, 1988; Mellon et ah, 
1989). In addition, phosphorylated CREB can turn on transcription of the gene for another 
transcriptional activator, the proto-oncogene c-fos (Edwards, 1994). Thus, it is conceivable 
that these two transcription factors, AP-1 and CREB work cooperativily for the regulation of 
gene transcription in response to the same stimuli.
Thus, cAMP alters the transcriptional activities of these proteins independent of their binding to 
regulatory elements in the target gene. In the case of cAMP-regulated genes, transcription 
factors such as CREB appear to bind to the CRE sites in a cAMP-independent manner, and
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thus resemble basal transcription factors, which maintain a basal rate of gene transcription, 
which is dependent of their concentration in a specific tissue. Moreover, unlike transcription 
factors whose activity is regulated, at least in part, by subcellular localization, nuclear 
expression of CREB is constitutive (Roesler et ah, 1988), Rapid changes in the levels of 
cAMP activate PKA, resulting in the translocation of its catalytic subunit into the nucleus, 
leading to a PKA-mediated modification of the CREB proteins, already bound to their 
respective elements in the promoter-regulatory region of the gene. This modification in the 
binding protein alters transcription levels of these genes (Roesler et a l, 1988).
Phosphorylation of CREB by PKA appears to be necessaiy and sufficient for the activation of 
transcription by cAMP (Yamamoto et ah, 1988). In either of two forms of CREB (CREB-327 
and CREB-341) that result from alternative splicing, a mutation of the PKA phosphorylation 
site Ser-119/Ser-133 to an alanine or aspartic acid residue prevented activation by PKA in vitro 
and abolished the cAMP control of transcription in vivo . A phosphate group in the 
transactivating region, within a domain termed the P-box (a 46 amino-acid sequence, residues 
92-137 of CREB) is therefore essential for a transcriptionally active protein (Fiol et a l, 1994). 
This domain of CREB is serine rich and includes consensus phosphorylation sites for casein 
kinase II, CaM-K II, PKC and the well established PKA site (Dash et a l, 1991; Sheng et a l,
1991).
1.8 PHOSPHOLIPASE SIGNALLING PATHWAY
1.8.1 PHOSPHOLIPASES C (PLC)
Many growth factors, hormones and neurotransmitters effect intracellular regulation through 
activation of PI-PLC enzymes which hydrolyse the plasma membrane phospholipid, PI-4,5- 
bisphosphate (PIP2) and results in the production of inositol-1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG), which both can serve as second messengers. IP3 regulates the Ca++ 
release of intracellular stores, while Ca++ and DAG are activators of PKC (Rhee and Choi, 
1992; Divecha and Irvine, 1995; Lee and Rhee, 1995).
Thiee isotypes of PI-PLC have been identified in mammalian tissues either thiough purification 
of proteins or isolation of cDNAs that code for homologous proteins : PLC-|3 (4 isoforms), 
PLC-y (2 isoforms) and PLC-Ô (4 isoforms) (Lee and Rhee, 1995). The overall similarity is 
low except in two regions: 170 amino acids (60% homology) and Y= 260 amino acids
(40% homology). All PLCs have an amino terminal region of 300 amino acids before the X 
domain and a PH homology domain (100 amino acids) which is found in many signalling 
molecules as it is involved in complex formation recruitment to the plasma membrane (Toker 
and Cantley, 1997). PLC-(3 and PLC-ô have only 50-70 amino acids between X and Y. The
46
PLC-y family have 400 amino acids between X and Y and this region contains two SH2 and 
one SH3 domains involved in protein-protein interactions (Pawson, 1995).
The PLC-p isoform has been shown to be activated by a subunit of the heterotrimeric G- 
proteins which are members of the Gaq/n subunit class (Rens-Domiano and Hamm, 1995). 
The activation of PI-PLCs by G-protein is either sensitive or insensitive to inhibition by PTX 
depending on the cell type. Screening of cDNA libraries under low stringency conditions has 
resulted in the cloning of four subtypes of PLC-P: PLC-P 1, PLC-p2, PLC-p3 and PLC-P4 
(Smi'cka and Sternweis, 1993; Lee and Ree, 1995). PLC-Ps do not possess the SH2 domain, 
but all four subtypes are activated by purified Gaq/i i subunits with the following efficacy: 
PLC-P3 > PLC-P 1 »  PLC-P2/PLC-P4 (Smicka and Sternweis, 1993).
PI-PLC subtypes are activated by py subunits, generally in a PTX-sensitive manner. Py 
subunits stimulate PLC-p3 > PLC-P2 »  PLC-P 1. Py subunits do not stimulate PLC-P4 
(Smrcka and Sternweis, 1993; Sternweis, 1994). Py complexes required prénylation of the 
carboxy-terminal CAAX motif of the y subunit to regulate PLC-p indicating a possible role for 
bg complexes in PLC-P membrane recruitment/association. Mutational analysis suggests that 
the carboxy-terminal region of PLC-ps is the site of regulation by Gaq/i i subunits and py 
subunits interact with the PLC-ps at the amino-terminal domain which contains the PH 
homology domain upstream of the X region (Smi’cka and Sternweis, 1993; Sternweis, 1994). 
Thus, Got and Py subunits may act in a mutually reinforcing manner to activate PLC-ps 
consistent with the separate binding sites for Gaq/i i and Py subunits on PLC-p.
The most of the receptor-coupled PIP2 hydrolysis occurs at the cell membrane and is 
responsible for transducing many of the early events associated with cell activation. However, 
PIP2 also binds a number of proteins including profilin (actin monomer sequestering protein) 
and gelsolin (actin filament protein) and this binding favours actin polymerisation and inhibits 
PIP2 hydrolysis by all the PI-PLCs. Receptor activation of the PI-PLCs, PIP2 hydrolysis and 
subsequent Ca++ mobilisation leads to actin depolymerisation, increases cell motility and 
changes in cell structure. PIP2 is also hydrolysed in the nucleus in response to cell stimulation 
with mitogens and this correlates with a corresponding increase of DAG which precedes 
translocation to the nucleus and activation of PKC (Divecha and Irvine, 1995; Lee and Rhee, 
1995).
The hydrolysis of PIP2 by receptor activated PLC is considered to be an important signal
transduction mechanism for regulating the effect of extracellular signals such as growth factors,
hormones and neurotransmitters (Lee and Rhee, 1995, Spiegel et al., 1997). In the
un stimulated cell, more than 95% of PLC is present in the cytosol. Binding of NGF to pl40^''^
receptor, phosphorylates crosswise several tyrosine residues in the receptor carboxyl tail and
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thereby binds the SH2 domains of the PLC-y molecule. PLC-y is phosphorylated on tyrosine 
residues (771, 783, 1254) and is activated (Vetter et al., 1991). It is then thought that PLC 
dissociates from the receptor, binds to the membrane cytoskeleton and thus brings the catalytic 
domains of the enzyme to the plasma membrane where they hydrolyse inositol phospholipids 
(Rhee, 1991). As this phosphorylation has been shown to induce hydrolytic activity of PLC-y 
by the NGF receptor, it has been proposed that activation of PLC-y may constitute a link 
between NGF-dependent activation of pldO^''^ and the stimulation of intracellular second 
messenger pathways (Lee and Rhee, 1995; Spiegel et ah, 1997).
Among the metabolic changes in NGF-treated PC 12 cells that have been suggested to result 
from elevations of PLC-yl activity are changes in ion fluxes and intracellular pH, cytoskeletal 
rearrangements and induction of cellular genes (Stephens et al., 1994). An important role of 
PLC-yl in NGF signalling events is the stimulation of certain gene transcriptional events. 
Mutation of the site in trkA responsible for inducing the tyrosine phosphorylation, receptor 
association and activation of PLC-yl results in selective loss of the NGF-mediated increases of 
peripherin in PC 12 cells, a gene codifying an intermediate filament protein (Loeb et al., 1994).
Upon stimulation of cell surface receptors, DAG is immediately produced from from PIP2, as 
a result of PLC activation. This DAG molecule Is rapidly converted to phosphatidic acid (PA) 
by the action of DAG kinase, and further to PI, PIP and PIP2 (English et al., 1996). The level 
of DAG, however, often increases again with a relatively slow onset, and persists for minutes 
or hours. This sustained elevation of DAG is frequently observed in response to various long- 
acting signals such as cytokines, growth factors and phorbol esters. Sustained elevation of 
DAG levels for several hours is a prerequisite essential for long-term cellular responses such as 
growth and differentiation, although it is not known whether continuous PKC activation is 
needed during the cell cycle. This second wave of DAG results from the hydrolysis of 
phosphatidylcholine (PC) by PLA2 , PLC and PLD (Boarder, 1994; Morris et ah, 1996). The 
DAG produced from PC hydrolysis is slowly degraded by DAG lipase.
1.8.2 PHOSPHOLIPASE D (PLD)
PLD is a phosphodiesterase that catalyses the hydrolysis of glycerophospholipids to yield PA
or its analogues. The mammalian PLD also catalyses the transphosphatidylation reaction (base
exchange reaction) and incorporates choline, ethanolamine and serine into phospholipids
(Boarder, 1994; Morris et al., 1996). PLD generates a phosphatidyl moiety which uses water
as a nucleophilic acceptor. This base exchange reaction represents a minor pathway for the
synthesis of most phospholipids. There must be a phosphatidyl ~ enzyme intermediate,
preserving the high energy phosphate bond. This phosphoric group is transferred preferentially
to primary alcohols such as methanol, ethanol and n-butanol in aqueous medium to produce
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PA. Non-cytotoxic concentrations of butanol inhibit the PLD-catalysed production of PA by 
diverting the product to phosphatidyl-butanol, but do not affect the production of PA formed 
by the sequential actions of PLC and DAG kinase.
PLD hydrolyses PC and cleaves the phosphodiester bond distal to the glycerol backbone, 
resulting in the formation of choline and PA. PA and its metabolic product lysophosphatidic 
acid (LPA) are proposed to serve as a second messenger or mediator for mitogenic signals in 
certain cell types (English et al., 1996). This acidic lipid is suggested to be implicated in 
intracellular Ca++ mobilisation, direct activation of PKC and has also been shown to stimulate 
the GTP-bound PLCgl, PLD and PIP-kinase. In addition, the hydrolysis of the
steroyl arachinodil species of PA by PLA2 releases arachidonic acid (AA), another proposed 
second messenger (English et al., 1996).
PA produced from PC is hydrolysed to DAG by the action of phosphatidic acid 
phosphohydrolase (PPH), thereby activating PKC. Several lines of evidence show, at a later 
phase of cellular response, PLD plays a major role in the production of DAG from PC to 
prolong PKC activation. PLD activation is also involved in mitogenesis in some cell lines 
(Boarder et al., 1994). For example, PC12 cells divide in culture and show PLD responses to 
purinoceptor-mediated agonists and bradykinin, while adrenal chromaffin cells do not divide 
and exhibit no PLD responses. PLD enzymes may play a role in intracellulai' protein trafficking 
(vesicle transport and exocitosis) and mitogenic signalling (Boarder et ah, 1994).
Receptors are coupled to PLD by events that are either downstream of PLC activation or are 
independent of PLC (Boarder et al., 1994). The PLC-independent mechanisms have been 
described as those either directly coupling to a G-protein or those linked to a tyrosine protein 
kinase. However, the most commonly reported form of linkage of receptors to PLD involves 
an elevated intracellular Ca++ concentration and activation of PKC. This is consistent with the 
initial activation of PLC and consequent hydrolysis of PIP2 (Boarder et al, 1994). PLD 
receptors are also direct coupling to PLD via G-protein. However, in many cases there has 
been no adequate distinction between receptors that have a direct G-protein linkage and 
receptors that are dependent on G-proteins but via an intermediate PLC intermediate step. The 
stimulation of PLD by tyrosine kinase mechanisms involves either receptors or non-receptors 
of the intrinsic tyrosine kinase type or GPCRs where the tyrosine kinase activity is downstream 
of PLC. Agonists that enhance tyrosine phosphorylation via GPCRs stimulate both Ca++- and 
PKC- dependent activation of tyrosine kinases, phosphorylating both soluble and membrane 
bound proteins in association with PLD activation (Boaider et al, 1994).
PLD activity is stimulated by PKC activators such as phorbol esters and DAG analogues, 
sometimes synergistically with Ca++ ionophore, such as ionomycin (Boarder et al, 1994). It is
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also suggested that tyrosine phosphorylation takes part in the regulation of PLD, since 
pervanadate, a tyrosine phosphatase inhibitor, enhances PLD activity, whereas tyrosine kinase 
inhibitors prevent enzyme activation. In addition, an endogenous membrane constituent, 
sphingosine, stimulates both mitogenesis and PLD (Spiegel and Milstein, 1996). Sphingosine- 
1-phosphate (SPP), a metabolic product of sphingosine, is mitogenie and stimulates PLD 
activity. It elevates PA and intracellular Ca++ without the hydrolysis of PIP2 , and in some 
cases may provide the link in the chain between intrinsic tyrosine kinase receptors and PLD 
activation (Spiegel and Milstein, 1996).
1.9 PI-3-KINASE SIGNALLING PATHWAY
Activation of PI-3-K is a common response to stimulation of cells by numerous ligands, 
including those that signal through cytokine receptors, GPCRs and RTKs (Toker and Cantley, 
1997). The activation of PI-3-K by RTKs is mediated by the SH2 domains of the 85-kDa 
regulatory subunit (p85) and 110-kDa catalytic subunit (pi 10) (Kaplan et al., 1987). In 
addition, PI-3-K activity increases in response to ligands of GPCRs (Stephens et al., 1991). A 
PI-3-K isotype, p llO y is  activated in vitro by bg subunits of G-proteins and is sensitive to 
inhibition by wortmannin (Stoyanov et al., 1995). A potential PH domain is located near its 
amino terminus. This novel PI-3-Ky is activated by direct binding to a 101-kDa regulatory 
subunit (plOl) (Stephens et al., 1997).
In vitro , PI-3-K enzyme can phosphorylate PI, PI-4-P or PI-4,5-P2 to produce PI-3-P, PI- 
3,4-P2 and PI-3,4,5-P3 respectively (Toker and Cantley, 1997). PI-3-P is present in 
unstimulated cells and does not significantly increase in response to cell activators, however, 
PI-3,4 -P2 and PI-3,4,5-P3 are normally absent in unstimulated cells and appear within seconds 
to minutes of cell activation. The physiologically important product is PI-3,4,5-P3 which is 
formed by the action of the kinase on PI-4,5 -P2 . PI-3,4,5-P3 has been shown to bind 
specifically to the SH2 domains of c-src and the p85 regulatory subunit of PI-3-K (Toker and 
Cantley, 1997). The m vivo relevance of this result is supported by the observation that 
inhibition of PI-3,4,5-P3 production results in enhanced association of the p85 subunit of PÏ-3- 
K with tyrosine phosphorylated insulin reeeptor (Toker and Cantley, 1997). These results 
suggests that PI-3,4,5-P3 binds directly to the SH2 domains of p85 and causes dissociation of 
PI-3-K from tyrosine phosphorylated proteins. Similar interaction between PI-3,4,5-P3 and the 
c-src SH2 domain might activate c-src by displacing the interaction between the c~src SH2 
domain and its tyrosine-phosphorylated carboxy-terminus. This c-src activation also correlates 
with the reeruitment and binding of PI-3-K to the plasma membrane and in vivo PI-3-K 
activation (Varticovsky et al., 1991).
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P I-3 ,4 -P 2  and PI-3,4,5-P3 also may bind to the ami no-terminal PH domain of a 
serine/threonine kinase Akt/PKB (Tower and Cantley, 1997). This binding promotes 
dimerization and kinase autophosphorylation, resulting in activation of the protein kinase 
activity (Burgering and Coffer, 1995; Franke et al., 1995). Akt/PKB phosphorylate p7 0 S6K 
(Boudewijn et ah, 1995) and this latter kinase is implicated in mitotic proliferative events since 
phosphorylation of ribosomal protein S6 and increased protein synthesis during mitogenesis 
and meiotic maturation have been demonstrated to be correlated (Chou and Blenis, 1995).
Thus PH domains are a common structural motif used as universal membrane adapter and bind 
with high affinity to inositol phosphates such as PI-4,5-bisphosphate (PIP2) and PI-3,4,5- 
triphosphate (PIP3) (Pawson, 1995). This motif is found in over 100 proteins, including 
GNRFs such as Sos-1, GAPs proteins such as ras -GAP, PLC-ôl, cytoskeletal proteins, PI-3- 
K and protein tyrosine kinases (PTKs) (Tower and Cantley, 1997).
In PC 12 cells, NGF-dependent phosphorylation of p85 regulatory subunit of PI-3-K by 
ppl40^''^ is weak (Stephens and Kaplan, 1994). However, association of a phosphotyrosine- 
containing protein with molecular masses of 110 kDa with PI-3-K is detected in PC 12 cells. 
Elevation of PI-3,4-P2 and PI-3,4,5-P3 levels has been observed several minutes after NGF 
stimulation, returning to near normal levels after 10 minutes (Kimura et al., 1994). This 
response is totally inhibited by wortmannin. Moreover, NGF-induced neurite elongation of 
PC12 cells is suppressed by wortmannin (Kimura et ak, 1994).
Most mitogenic stimuli activate both p2H"'^‘^ and PI-3-K. This could reflect the fact that there 
are common components, such as tyrosine kinases, in the upstream regulatory pathways for 
both proteins. It could also be the result of a system in which p2H^'^ is capable, directly or 
indirectly, of regulating PI-3-K. The association of PI-3-K and p2H^"^ is direct (Rodriguez- 
Viciana et al., 1994) and a dominant negative p2H^*^ mutant inhibits the ability of NGF to 
elevate PI-3 phophorylated lipids levels in PC 12 cells in vivo. Furthermore, p2H '^ ‘^ 
coexpressed with p85 and p i 10 causes the elevation of cellular 3-phosphorylated 
phosphoinositides in CHO cells (Rodriguez-Viciana et al., 1994).
The physiological role of 3-phosphorylated phosphoinositides is not well known, but PI- 
3,4,5-P3 potently and selectively activated the Ca++-independent PKC isoforms (especially e 
and h) and the phorbol ester/DAG-insensitive PKC-Ç but was less effective or selective in 
activating conventional PKC (cPKC) (Nakanishi et ak, 1993). Many of the agents that 
stimulate PI-3 ,4 -P2 and PI-3,4,5-P3 production in vivo also stimulate production of DAG. 
Since PKC-6  and PKC-i) can be activated by either DAG or the phosphoinositides in vitro , 
some redundancy in the PI-3-K pathway and the PLC pathways is expected.
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In growth factor stimulated cells, PI-3,4-P2 and PI-3,4,5-P3 levels remain elevated much 
longer than Ca++ levels, indicating that this pathway may cause a much more prolonged 
activation of PKCs than the PLCy pathway. In addition, there is circumstantial evidence that 
PKC isoforms may mediate mitogenic effects of the PI-3-K pathway. PKC-Ç has also been 
reported to be critical for mitogenic signal transduction in fibroblasts (Berra et al., 1993) and a 
dominant negative PKC-z subspecies blocked NF-kB activation (Diaz-Meco et a l, 1994). It is 
therefore apparent that the novel and atypical PKC isoforms are signalling downstream of 
certain mitogenic pathways, such as the PI-3-K pathway. However, it is clear that this 
mitogenic signal ultimately depends on the cell types studied and the pattern of expression of 
PKC isoforms.
1.10 CALCIUM-PHOSPHOLIPID DEPENDENT PROTEIN KINASE C (PKC) SIGNALLINGPATHWAY
One of the earliest products of inositol phospholipid hydrolysis by PLCs and PLDs is DAG 
which remains membrane-associated, and initiates the activation of PKCs (Nishizuka, 1986, 
1988, 1995). PKCs constitute a family of enzymes transiently activated by Ca++, DAG and 
phosphatidylserine (PS). PKCs are involved in mediating responses as diverse as modulating 
ion conductance mediated by phosphorylating membrane proteins such as ion channels, pumps 
and ion exchange proteins, cell proliferation and differentiation (Nishizuka, 1986, 1988,
1995). It has been shown that PKC is the cellular receptor for tumour-promoting phorbol 
esters (Niedel et al., 1983) which induce expression of several proto-oncogenes such as c-fos 
(Sigmund et al., 1990). The PKC family of enzymes transduces the myriad of signals 
promoting lipid hydrolysis. The prevalence of this enzyme family in signalling is exemplified 
by the diverse transduction mechanisms that result in the generation of the PKC activator DAG. 
Signals that stimulate members of the large family of GPCRs, RTKs or non-RTKs can cause 
DAG production, either rapidly by activation of PLCs or more slowly and long lasting by 
activation of PLD to yield PA and then DAG. In addition, cis -unsaturated fatty acid (FFAs) 
generation by PLA2 activation modulates PKC activity (Nishizuka, 1995).
The members of the PKC family respond differently to various combinations of lipids 
including several phospholipids, particularly DAG, FFA, lyso-PC, PS and many other lipid 
metabolites in membranes, and hence the patterns of activation of the PKC isoforms may vaiy 
in extent, duration, and intraeellular localisation. In fact the PKC isoforms show distinct tissue 
distribution and specific intracellular localisation (Nishizuka, 1995). In most tissues, PKC is 
present mainly in the soluble fraction in its inactive form. After activation, PKC translocates to 
the plasma membrane. Recently, intracellular PKC receptors (RACK) have been identified 
which bind activated PKC in the presence of Ca++ and PS (Mochly-Rosen et ak, 1991).
52
Receptor-mediated activation of PKC is transient; DAG disappears from the cell membrane 
shortly after its formation either due to further degradation into AA, or to its conversion back to 
inositol phospholipids. Although the activity of PKC itself is transient, its consequence within 
the cell could potentially be long lasting, depending on the half life of specific phosphorylated 
substrates (Nishizuka, 1986, 1988, 1995).
1.10.1 PKC ENZYMATIC ACTIVITY
PKC uses ATP as substrate, with a Km for ATP in the low qM range (Newton, 1995). PKC 
typically phosphorylates serine or threonine residues in basic sequences but displays 
significantly less specificity than PKA. PKC have a wide range of targets, including members 
of the MAPK pathway (Newton, 1995).
The function of PKC is regulated by two equally important mechanisms. First, the enzyme is 
rendered catalytically competent by phosphorylation which regulates the active site and 
subcellular localisation of the enzyme. Second, binding of ligands or second messengers 
promotes the PKC membrane association and removes the pseudosubstrate from the substrate- 
binding site. Regulation of two independent mechanisms may provide exquisite fine-tuning for 
this family of enzymes, ensuring low basal activity in the midst of complex intracellular 
pathways (Newton, 1995).
PKC can be targeted for inhibition by taking advantage of either the catalytic or regulatory 
domains. The enzyme comprises a single polypeptide with the amino- terminal half containing 
the pseudosubstrate and cofactor binding sites, and the carboxy-terminal half containing the 
kinase core. The function of the protein can be inhibited by molecules such as calphostin C 
(CC) which binds the regulatory domain and competes with cofaetor binding, or by synthetic 
peptides based on its pseudosubstrate which block the substrate binding cavity (Newton,
1995).
1.10.2 PKC STRUCTURE
Members of the PKC family are a single polypeptide, comprised of : (i) an amino-terminal 
regulatory region (approximately 20-40 kDa) and (ii) a carboxy-terminal catalytic region 
(approximately 45 KDa). The amino-terminal half of the regulatory domain of cPKC contains 
two conserved regions. C l and C2, that play a role in the regulation of enzyme activity of PKC 
(Newton, 1995).
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The C l domain is about 150 amino acids and contains a pseudo substrate domain and two 
tandem repeats of a cys-rich region (zinc butterfly domains). The pseudosubstrate domain is a 
conserved sequence of amino acids that resembles a consensus phosphorylation site in PKC 
substrates. This site interacts with the substrate-binding pocket in the catalytic domain and 
represses PKC activity. The cofactor binding reduces the affinity of this interaction. The two 
tandem repeats of cysteine-rich, zinc finger-like motifs that forms the phospholipid-dependent 
and DAG/phorbol ester binding site are found in other signal transducers such as DAG 
kinases, Vav, a GNRF protein, which is known to be involved in the activation of p2D'^‘^ 
protein and n-chimaerin, a GAP protein, which inactivates another small G-protein, rac 
(Newton, 1995).
The C2 domain (CalB) contains 50 amino acids and is the recognition site for acidic 
phospholipids and the Ca++ -binding site. The CalB domains are also found in cPLA2, PLC-y 
and GAPs. The binding of intracellular Ca++ to the C2 region of the cPKC isoenzymes causes 
the translocation of these enzymes to the plasma membrane where they are activated following 
binding to DAG and PS. This binding is mediated by RACK proteins which act to facilitate 
intracellular docking that mediates the association and activation of signal transducer containing 
CalB domains to subcellular locations (Mochly-Rosen et ak, 1991).
The carboxy-terminal half of the PKC contains two additional highly conserved regions, C3 
and C4 domains. The C3 and C4 domains form the ATP- and substrate-binding lobes of the 
PKC. These domain halves are separated by a hinge region that becomes proteolytically labile 
when the enzyme is membrane-bound. The proteolytically generated kinase domain (protein 
kinase M), freed of inhibition of the pseudosubstrate, is constitutively active (Newton, 1995).
In the current model, inactive PKC is folded with the catalytic domain masked by the 
pseudosubstrate domain and the RACK binding site (CaLB) masked by interaction of a 
pseudoRACK sequence with the PKC carboxy-terminal region. Interaction with membrane 
lipids and RACKl causes conformational change and activation of PKC (Newton, 1995). 
Activation makes PKC more proteolytically sensitive, probably by unfolding the molecule. 
Thus, downregulation is caused by increased degradation in the absence of transcription or 
translation. Chronic activation by phorbol esters, such as PMA results in PKC isoform 
downregulation at different rates. Atypical PKCs, such as PKC-Ç are not downregulated or 
responsive to PMA (Newton, 1995).
Phorbol esters have been an important tool in studying the functions of PKC. They have a 
structure very similar to DAG and are able to activate PKC both in vivo and in vitro by 
increasing the affinity of the enzyme for Ca++. Phorbol esters are very stable molecules that 
induce a prolonged association of PKC with the membrane thereby inducing the degradation of
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PKC with the subsequent disappearance of PKC activity from the cell (Bazzi and Nelsestuen,
1988). This phorbol ester-induced depletion of PKC activity may interfere with the feedback 
control mechanisms of PKC and it has been suggested that this action may be involved in the 
uncontrolled cell proliferation reported for phorbol esters (Wilkinson and Hallam, 1994).
1.10.3 PKC SUBTYPES
PKC exist as a growing family of serine/threonine kinases with a wide range of physiological 
functions (Nishizuka, 1995). To date, 12 members have been described and subdivided into 
three groups: (i) classical or conventional PKCs (cPKC) comprising a , (31, [311 and y 
(activated by Ca++, phospholipid and DAG), (ii) new or novel PKCs (nPKC) comprising 5, e, 
T[ (L), 9 and oc (insensitive to Ca++) and (iii) atypical PKCs (aPKC) comprising i/X and Ç, a 
subgroup of PKC isoforms whose activity is not affected by phorbol ester or the natural 
activator DAG (Nishizuka, 1995). All the known members of the PKC family require PS for 
activity. Other lipids such as phosphatidylethanolamine (PE) exert cooperativity but 
phosphatidylcholine (PC) and sphingomyelin inhibit PKC activity.
DAG activates the cPKC isoforms in such a way that it increases greatly their appai'cnt affinity 
for Ca++ in the micromolar range (Nishizuka, 1995). However, these Ca++ concentrations are 
still above the physiological range, cis -unsaturated fatty acids, such as AA together with DAG, 
further increase the affinity of cPKC isoforms for Ca++, thereby causing full enzyme activation 
at the basal level of intracellular Ca++. For activation of cPKC isoforms, increase in the Ca++ 
concentration and phospholipid degradation are hence interrelated, and sometimes 
complementary to each other.
The nPKC isoforms, which lack the C2 region, do not require Ca++ for their activation, but the 
6, 8, and r\ (L) isoforms are activated by PI-3,4,5-P3, a product of the PI-3-K reaction. The 
PKC-Ô and PKC-8 isoforms are phosphorylated at tyrosine residues and this phosphorylation 
is enhanced by treatment of the cells with phorbol esters (Nishizuka, 1995).
The aPKC isoforms, also lack the C2 region and the C 1 domain contains only one cys-rich 
motif. The PKC-Ç isoform is dependent on PS for its catalytic activity and is activated by cis 
-unsaturated fatty acids, such as AA as well as PI-3,4-P2 and PI-3,4,5-P3. This isoform does 
not respond to DAG or phorbol esters. The signal pathway leading to the activation of the 
aPKC isoforms is relatively unknown, but the overexpression of this group of enzymes 
enhances the transcriptional activation of a set of cis -acting elements in response to serum and 
other growth faetors, but not phorbol esters.
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1.10.4 PKC AND THE MAPK PATHWAY
There is strong evidence that PKC activation is an early and important event in NGF-induced 
intracellular signalling. Direct measurement of PKC activity in PC12 cells indicate that NGF 
treatment of these cells produces a 4 to 5-fold increase in PKC activity after 30 to 60 minutes, 
returning to control levels within 7 hours, even in the continuous presence of NGF (Hama et 
ah, 1986; Heasley and Johson, 1989; Kondratyev et ah, 1990; Ohmichi et ah, 1993 a; Wooten 
et ah, 1994). Phorbol ester stimulation of PKC induces GTP loading of cellular p2H"^‘^’ 
(Downward et ah, 1990; Wood et ah, 1992) and phosphorylation of raf-1 (Morrison et ah,
1988), MAPKs (Chen et ah, 1991b; Wood et ah, 1992), p90^^^ (Chung et ah, 1991; Chen et 
ah, 1991 a, b; Wood et ah, 1992) in PC12 cells.
PC12 cells express multiple PKC isoforms: a , (3, y, 5, £ and Ç (Wooten et ah, 1992) and 
NGF treatment of PC 12 cells results in translocation as well as activation of PKC-Ô and PKC- 
Ç isoforms (Ohmichi et ah, 1993, Wooten et ah, 1994). More important, in cells deficient of 
phorbol ester/D AG-sensitive iso forms (a, |3, y, ô and e) NGF translocates the phorbol 
ester/D AG-insensitive isoform PKC-^ (Wooten et ah, 1994) and removal of PKC-Ç from cells 
deficient in the PMA-sensitive isoform inhibits NGF-induced neurite outgrowth (Coleman and 
Wooten, 1994).
In other systems, PKC-Ç operates in a cooperative fashion with p2H^'^ and integrates signals 
from both PC-PLC and PI-3-K pathways (Berra et ah, 1993; Nakanishi et ah, 1993). PKC-8 
and PKC-T) (Toker et ah, 1994) and PKC-Ç (Nakanishi et ah, 1993) are activated in vitro and 
in vivo by PI-3,4-P2 and PI-3,4,5-P3. Wortmannin can also block activation of rcif-1 and 
MAPKs in fibroblasts. Because phorbol esters can activate raf-1 in vivo , and PKCs can 
phosphorylate raf-1 in vitro (Morrison et ah, 1988), it could be argued that wortmannin is 
blocking PKC-dependent activation of raf-1 .
PKC is a common effector molecule activated by receptor ligand interaction that leads to 
MAPK pathway activation (Kazlauskas and Cooper, 1988; L'Allemain et ah, 1991). PKC-a 
has been shown to activate MAPK via p2F ’^ ‘^  in PC12 cells (Robbins et ah, 1992; Wood et al., 
1992; Crespo et ah, 1994) following exposure to phorbol esters. PKC-a may also directly 
phosphorylate raf-1 at Ser-499 (Kolch et ah, 1993). Recently it has been reported that a newly 
discovered protein tyrosine kinase, proline-rich tyrosine kinase 2 (PYK-2), acts as a switch 
that relays messages from PKCs and increased cytoplasmic Ca++ to the adapter molecule She 
thus activating p2K ‘^ ‘^ —mediated MAPK activation (Lev et ah, 1995). Constitutively active 
mutants of PKC-d activate the MEK/MAPK pathway in a manner independent of p2H ‘^ ‘^ and 
dependent of c-raf (Ueda et ah, 1996).
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1.10.5 PKC SIGNALLING TO NUCLEUS
PKCs as well as MAPKs, plays a pivotal role in cellular regulation. For example CHO cells 
overexpressing the PKC-a and PKC-6 isoforms exhibit prolonged activation of MAPKs upon 
treatment with phorhol esters and arrest of the cell division at the G2/M phase (Watanabe et al.,
1992). It has also been suggested that phorbol esters-induced myeloid differentiation is 
mediated by PKC-a and PKC-6 isoforms (Mischak et ah, 1993). Thus, these observations 
suggest that the PKC-a and PKC-6 isoforms distributed widely in all cell types and tissues 
have the potential to control nuclear functions, probably at specific points of the cell cycle. 
However, unusually sustained activation of the PKC signalling by phorbol esters may lead to 
unregulated cell proliferation. Well-coordinated regulation of PKC activation may be important 
for normal cell functions. In addition, mechanisms of down-regulation of MAPKs are probably 
involved in the effects of sustained activation of the PKC (Nebreda, 1994; Ueki et ak, 1994).
The PKC signalling pathway often converges with other signalling pathways at the point of 
nuclear protein transcription factors that are indispensable for gene transcription (Nishizuka,
1995). For example, API activity is related to phorbol esters and this gene activation may be 
integrated with the synergistic action of the Ca++ and PKC signalling pathways.
1.11 CALCIUM SIGNALLING PATHWAY
The divalent cation Ca++ is used by cells as a ubiquitous second messenger to control many 
cellular processes including muscle contraction, secretion, metabolism, neuronal excitability, 
cell proliferation and cell death (Clapham, 1995). The cytosolic level of Ca++ in resting cells is 
kept low (10-100 nM) but stimulation results in the level increasing to 50 to 1000 nM. The eell 
has access to two sources of Ca"'-+: (i) entry from the external medium by plasma membrane 
Ca++ channels (voltage-operated channels, receptor-operated channels and store-operated 
channels), and (ii) release from internal stores (IPs and ryanodine receptors) (Furuichi and 
Mikoshiba, 1995). These Ca++ ON mechanisms are balanced by Ca++ pumps which constitute 
the OFF mechanisms responsible for removing the Ca++ signal. The surface membrane has a 
Na+/Ca++-exchanger (found mainly in excitable cells) and the ubiquitous plasma membrane 
Ca++-ATPase. The latter is regulated by calmodulin, acidic phospholipids, PKA and PKC. 
The internal stores have a endoplasmic/sarcoplasmic reticulum (ER/SR) Ca++-ATPase 
(Simpson et ak, 1995).
Both the cytoplasm and the lumen of the ER/SR have proteins capable of buffering Ca++. As 
Ca++ is pumped into the lumen of the ER/SR, it is buffered by storage proteins such as 
calsequestrin and calreticulin which have a low affinity (Kd in the niM range) but a high
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capacity (approximately 50 Ca++ ions bound/molecule). When Ca++ enters the cytosol it is 
rapidly buffered by proteins such as calbindin, calretinin and parvalbumin. More than 90% of 
the Ca++ entering the cell is bound to these buffers with the remainder representing the 
stimulus-evoked elevation of Ca++ responsible for activating the Ca++ sensors and activation 
of the Ca++-mediated signalling pathways (Simpson et a l, 1995).
Most of the intracellular effects of Ca++ are mediated by two groups of proteins, the annexins 
and the EF-hand proteins. The annexins represent a heterogeneous family that share a common 
property of interaeting with membranes in a Ca++-dependent manner. Since they have a low 
affinity for Ca++ their action seems to be restricted to domains near membranes where Ca++ 
channels create localised high elevations of Ca++. Annexins have been implicated in the control 
of PLA2, cytoskeletal reorganisation, vesicle movement and some may function as Ca++ 
channels (Simpson et ak, 1995).
The EF hand proteins such as calmodulin (CaM) and troponin C (TnC), which have a 
characterised Ca++-binding domain between two helices (named after the E and F a-helices of 
parvalbumin), are the major Ca++ sensors. TnC functions in cardiac and skeletal muscle 
whereas CaM has a much more general role (Simpson et ak, 1995). CaM exerts its effects by 
stimulating a multifunctional CaM-dependent proteins, such as CaM-dependent kinases or 
CaM-dependent protein phosphatase known as calcineurin (PP2C).
CaM-dependent systems are activated in response to receptors that lead to an increase in 
cytoplasmic Ca++, either by stimulating influx from extracellular sources or from intracellular 
stores. GPCRs or RTKs potentially stimulate CaM-dependent processes by stimulation of the 
PI turnover through PLC activation, production of IPs and release of intracellular Ca++ or by 
increasing the activity of plasma membrane Ca++-channels (Simpson et ak, 1995). 
Alternatively, GPCRs or RTKs could change the level of expression of CaM or CaM-binding 
proteins (CaM-BPs).
CaM-K II is a large multimeric enzyme (630 kDa) composed of two related subunits with 9 of 
a  (50 kDa) and 3 of p (60 kDa) respectively, and like other kinases undergoes an 
autophosphorylation that seems to be an intramolecular process. CaM-K II have a relative 
broad substrate specificity with respect to endogenous proteins in the nervous system. CaM-K 
II is detected in PC 12 cells and the phosphorylation of the enzyme is increased by ionophore 
(A23187) treatment (Tokumitsu et ak, 1990). A specific inhibitor of CAM-K II, KN-62, 
blocked the phosphorylation of CAM-K II dose dependently in PC 12 cells (Tokumitsu et ak,
1990).
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1.12 NEUROPEPTIDE Y (NPY)
Over the last 20 to 30 years, there has been a radical change in the concept of 
neurotransmission. Until then, neurotransmission was thought to use small compounds 
including a number of modified amino acids such as adrenaline, noradrenaline, GAB A and 
serotonin, together with unrelated compounds such as acetylcholine. The discovery that a 
number of peptides were co-localised with these "classical" neurotransmitters within the same 
neurone and, furthermore, were co-released following nerve stimulation, challenged the 
prevailing concepts and formulated the concept of "peptidergic neurons" (Hokfelt, 1991).
At the same time, neuropeptides have also challenged the classification of chemical messengers 
either as endocrine hormones, acting at distance through release into the blood stream, or as 
neuro transmitters, acting locally in the synapse. Peptide neurotransmitters aie synthesised in 
the cell body and stored in synaptic vesicles, which are transported along the cytoskeleton of 
the axon to the synapse. At the synapse they await the electrical impulse, which causes Ca++ 
ions to enter the cell as a cue for the release of neurotransmitter. About 50 different 
neuro transmitters are known today. One of the most abundant peptide neurotransmitters in the 
human brain is neuropeptide Y (NPY) (Tatemoto, et ak, 1982).
1.12.1 NPY DISCOVERY
NPY belongs to a family of regulatory peptides which also includes pancreatic polypeptide 
(PP) and peptide YY (PYY). NPY was discovered using a chemical method to trace 
polypeptides with an amide structure at their carboxyl termini (Tatemoto and Mutt, 1978). This 
post-translational modification is char acteristic of many other biologically active peptide such as 
oxytocin, secretin, substance P, vasopressin and VIP although these were isolated on the basis 
of their biological activity rather than structure.
Sequence analysis revealed that NPY comprised 36 amino acids and had a tyrosine residue at 
its amino-terminus and tyrosine amide residue at its carboxy-terminus. Since the biological 
functions of these peptides were not established at the time of their isolation, their were named 
according to a convention to reflect the chemical structure of the amino- and carboxy-terminal 
amino acid using the international single letter code (Y represents tyrosine). As NPY and PYY 
have identical amino- and carboxy-terminal amino acids, the neural origin of NPY was used to 
differentiate between the two peptides, as PYY had been purified from porcine gut (Tatemoto 
and Mutt, 1980).
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NPY constitutes one of the most highly conserved neuroendocrine peptides known 
(Larhammar, 1996a). The predicted rat and human mature NPY amino acid sequences are 
identical and differ from the porcine isolate by a single amino acid substitution at position 17, 
where the leucine residue in porcine NPY is replaced by a methionine residue (Larhammar, 
1993, 1996a). It has been determined that NPY displays a high degree of homology within 
vertebrates showing a 92% sequence homology between the ray Torpedo marmorata and 
mammals, which separated more than 400 million yeais ago (Blomqvist et ah, 1992).
1.12.2 NPY STRUCTURE
NPY family of peptides consist of 36 amino acids and have an amidated carboxy-terminal 
tyrosine residue. The tertiary structure of this family of peptides has been referred to as the 
member of the "PP-fold structure" and was modelled by using the avian pancreatic polypeptide 
crystal structure determined by X-ray crystallography (Blundell and Wood, 1982; Glover et 
ak, 1983). The model shows that NPY has a tight, compact tertiary structure characterised as a 
hairpin-like structure where the amino and carboxy parts are stabilised by the hydrophobic 
moieties of a proline helix (residues 1-9) and an amphiphilic a-helix (residues 14-30) joined by 
a tight P-turn. This fold is followed by the carboxy terminal-tail of six amino acids which 
project away from the a-helix (Allen et ak, 1987a). This structure predicts that the amino- and 
carboxy-termini of NPY are spatially closely related. In fact, it has been shown that this 
proximity is essential for biological activity as the epitope that binds to the NPY-Y 1 receptor is 
composed of residues present in the combined amino- and carboxy-termini of the molecule 
(Washlestedt et ak, 1990).
1.12.3 NPY DISTRIBUTION
1.12.3.1 NPY IN CENTRAL NERVOUS SYSTEM
NPY is the most abundant neuropeptide in the rat brain (Allen et ak, 1983). Neurons 
containing NPY-IR are abundant in many areas of CNS and spinal cord with the exception of 
the cerebellum. Broadly, two basic types of neurons have been found to be immunoreactive for 
NPY. The first of these are the majority and constitute "interneurons". These cells give rise to 
short axons and to local connections. The second type is the long-projecting neuron, axons 
project a long distance from the cell body and innervate structures in other regions of the brain. 
Within the CNS, NPY is co-localised with a wide variety of other neurotransmitters. The 
pattern of co-localisation depends of the anatomical site of the NPY-containing neurons. In 
addition, NPY appears very early in the developing brain and can be transient in nature (Foster 
et ak, 1989).
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The distribution of NPY has mainly been studied in the rat brain, where it is especially 
concentrated in brain areas associated with the limbic system, including cortical aieas and the 
hippocampus, hypothalamus, amygdala and cortex (Allen et al., 1983). High concentrations of 
NPY are found in the hippocampus where it is localised in interneurons in the hippocampal 
formation. NPY co-exists with somatostatin and possibly with GAB A in the hippocamppus. 
The influence of NPY is largely inhibitory, acting at presynaptic nerve terminals to reduce the 
influx of Ca++ ions through voltage-dependent channels. Thus, NPY controls the excitatory 
throughput within the hippocampus.
High levels on NPY are also found in the arcuate nucleus and median eminence of the 
hypothalamus and from adrenergic and noradrenergic several brain stem nuclei nerve terminals 
found in the suprachiasmatic nuclei (Allen et al., 1983). Some of these nerve terminals can be 
found in association with the capillaries that form the hypothalamo-pituitary portal system 
providing support for the notion that NPY is secreted locally into this portal system to affect 
anterior pituitary functions. In CNS, NPY is particularly concentrated in the brain stem nuclei, 
particularly in the noradrenergic A1 and A4 nuclei and the adrenergic C l, C2 and C3 nuclei 
(Allen et al., 1983).
1.12.3.2 NPY IN PERIPHERAL NERVOUS SYSTEM
NPY is found exclusively in cells that have migrated from the neural crest. In the periphery, 
NPY is present in peripheral post-ganglionic sympathetic nerves supplying blood vessels in 
many tissues, such as nasal mucosa, submandibular gland, heart, kidney, lungs, pancreas, 
uterus and urinary bladder. It is also present in enteric and cardiac nerve endings. However, 
NPY is not exclusively localised in this branch of the autonomic nervous system, a small 
proportion of NPY has been traced to a subset of parasympathetic nerves (Grundemar and 
Hakanson, 1994).
The adrenal medulla of different species of mammals contains high concentrations of NPY 
where it is co-localised with catecholamines. In the adrenal medulla and in sympathetic nerve 
terminals, NPY is present only in the electron dense vesicles (Fried et al., 1985). NPY is 
frequently found in a number of a rodent and human cell lines derived from neural crest 
tumours such as ganglioneuroblastomas and phaeochromocytomas (Allen et al., 1987b).
The distribution of NPY and its related peptides in numerous nerve terminals and cell bodies 
suggests a wide-ranging role in somatic, sensory and cognitive brain functions as well as in 
endocrine regulation. In many neurons, NPY is co-localised and co-released with other 
neurotransmitters such as noradrenaline, somatostatin and GAB A which also suggests a 
modulatory role for NPY (Grundemar and Hakanson, 1994).
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1.12.4 EFFECTS OF THE NPY FAMILY OF PEPTIDES
1.12.4.1 NPY ACTIONS IN CENTRAL NERVOUS SYSTEM
Even at the time of its discovery, it was clear that NPY was present in high concentrations in 
the brain (Tatemoto et ah, 1982). Indeed, its concentration in certain regions of the brain 
exceeds those of cholecystokinin and somatostatin, which had previously been considered the 
most abundant neuropeptides in the human brain (Adrian et al., 1983).
In CNS, NPY has been associated with modulation of autonomic functions such as regulatory 
roles in most of the areas where it has been localised. It has been associated with central 
regulation of blood pressure (Fuxe et al., 1983), circadian rhythm (Albers and Ferris, 1985), 
feeding behaviour (Tempel et al., 1988), memory processing (Flood et al., 1989) and control 
of neuroendocrine functions (Kerkerian et al., 1986). Additional reported effects of NPY 
include regulation of anxiety, release of pituitary hormones, thermogenesis and energy balance 
as well as electrolyte homeostasis (Grundemar and Hakanson, 1994).
Many effects of NPY in CNS can be attributed to inhibition of neurotransmitter release. NPY 
inhibits excitatory synaptic transmission in CAl neurons of the rat hippocampus by 
suppression of glutamate release via inhibition of Ca++ currents. NPY also inhibits excitatory 
and inhibitory synaptic potential in 5-hydroxytryptamine containing cells of dorsal raphe 
nucleus and it reduces spontaneous firing rate in the locus coeruleus (Grundemar and 
Hakanson, 1994).
The study of the effects of NPY in the CNS has been approached by injecting the peptide or 
peptide analogues into discrete areas of the brain. Peripherally the physiological effects have 
been studied by administering NPY intravenously or to tissue preparations. Many of the effects 
of NPY have been observed primarily in experimental animals. However, caution has to be 
exercised when applying these effects to humans as demonstrated by differing distribution of 
receptor subtypes in rodents and humans (Lundell et ak, 1996; Dumont et ak, 1997).
1.12.4.2 NPY ACTIONS IN PERIPHERAL NERVOUS SYSTEM
In many different preparations, NPY has been shown to be a vasoconstrictor. Intravenous 
NPY causes a sustained rise in blood pressure in many different species including man. Use of 
a number of isolated vascular preparations either in vitro or in vivo has shown this 
vasoconstrictor action of NPY. This is a particularly prominent feature in the coronary and 
renal vasculature. The response to NPY on vascular smooth muscle is characteristically
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described as slow in onset and prolonged (Lundberg and Tatemoto, 1982). In addition to the 
vasoconstrictor action of NPY, the peptide also plays a role in potentiating the action of other 
vasoconstrictors (Ekblad et ak, 1984a). These observations have suggested that the 
physiologieal role of NPY may be more to modulate the action of catecholamines on vascular 
smooth muscle cells rather than a direct effect.
At the sympathetic neuroeffector junction, NPY acts both pre-synaptically and post- 
synaptically (Wahlestedt et ak, 1986). In this way, NPY mimics catecholamine actions and, in 
a similar fashion, the action of NPY on its two receptor subtypes (NPY-Yl and NPY-Y2) 
mimics that for catecholamine stimulation of the a l -  and a2-adrenoreceptor. A large number of 
binding studies have demonstrated the presence of NPY/PYY receptors in vascular smooth 
muscle. The predominant receptor mediating peripheral vasoconstriction is the NPY-Yl 
receptor, since this effect is evoked by NPY-Yl receptor agonists (Wahlestedts et ak, 1990). 
The recent emergence of specific antagonists BIBP 3226 (Rudolf et ak, 1994) and SR120819A 
(Serradeil-Le Gal et ak, 1994) made it possible to confirm that NPY-Yl receptors are 
implicated in the vasoconstrictor action of NPY (Malmstrbm and Lundberg, 1995; Serradeil-Le 
Gal, 1997). The presynaptic effects of NPY at the sympathetic neuroeffector junction are 
mediated through the NPY-Y2 receptor. This action of NPY on the NPY-Y2 receptor mimics 
activation of the a2-adrenoreceptor. NPY acts presynaptically to inhibit release of 
catecholamines and NPY itself into the synapse. Postsynaptic NPY-Y2 receptors may also 
mediate a direct effect on vasoconstriction (Grundemar and Hakanson, 1993).
In the adrenal gland, NPY is present in chiomaffin cells were it is co-stored with noradrenaline 
in large electron dense secretory vesicles (Lundberg et ak, 1982a; Ekblad et ak, 1984a). In the 
adrenal medulla, NPY co-exists with a complex mixture of adrenaline and noradrenaline and 
neuropeptides. Neuropeptides present in these vesicles include calcitonin gene related peptide 
and enkephalin. After stimulation of the splanchnic nerve innervating the adrenal medulla, these 
components are released and transported to their tai'get organs through the general circulation.
In the adrenal medulla, NPY-IR can be depleted by pretreatment with reserpine for 24 hours, 
which increases firing of sympathetic neurones (Lundberg et ak, 1985; Allen et ak, 1986 b). It 
has been shown that in the adrenal medulla, NPY mRNA expression can be regulated by 
preganglionic nerve activity. Insulin-induced hypoglycaemia produced an increase in 
splanchnic nerve activity causing a significant rise in NPY mRNA in the rat adrenal medulla 
(Fischer-Colbrie et ak, 1988). This effect on NPY mRNA is dependent on nerve activity as it 
could be prevented by bilateral transection of the splanchnic nerve and by pretreatment with 
chlorisondamine (Schalling et ak, 1991).
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1.13 NPY RECEPTORS
Physiological studies with different ligands as well as in situ hybridisation with radiolabelled 
ligands have revealed the existence of different NPY receptor subtypes located in different 
organs and brain regions (Dumont et al., 1997; Grundemar, 1997). Elucidation of the 
functions of the NPY family of peptides requires understanding of the various receptor 
subtypes the peptides act upon. NPY receptors are sensitive to pertussis toxin, which ADP- 
ribosylates, and thereby inactivates, some G-proteins including the three forms of Gj and Go 
(Larhammar et al., 1993a). The second messenger responses evoked by activation of NPY 
receptors are inhibition of forskolin-induced adenylyl cyclase activity and elevation of 
intracellular Ca++ levels. NPY receptors may be coupled to mobilisation of Ca''"*' from 
intracellular stores via inositol phosphate dependent and independent mechanisms (Michel,
1991).
1.13.1 CHARACTERISATION OF NPY RECEPTOR SUBTYPES
The existence of many subtypes of NPY receptors has been demonstrated by functional and 
binding studies after administration of a range of peptide analogues to cells, tissue and organ 
preparations. Early physiological studies (Wahlestedt et al., 1986; 1990) predicted two 
different subtypes of receptors, NPY-Yl and NPY-Y2. When using preparations of 
sympathetic neuro-effector junctions three different actions of NPY could be distinguished: (i) 
a direct postjunctional response of vasoconstriction, (ii) a postjunctional enhancement of 
noradrenaline-evoked vasoconstriction and finally (iii) a presynaptic suppression of 
noradrenaline release. By employing the full length peptide or carboxy-terminal parts of NPY 
or PYY molecules the two different subtypes of receptors were defined (Wahlestedt et al., 
1986; 1990).
The postjunctional response requires the full length NPY peptide and is defined as the NPY-Y 1 
receptor. The NPY-Yl receptor also binds NPY and PYY with similar affinity and can also be 
activated by [Leiri ^ -Pro^^]-NPY analogues where the amino acids 31 and 34 of NPY had been 
substituted for the corresponding amino acids from PP (Fuhlendorff et al., 1990). The 
prejunctional response could be evoked by amino terminally truncated peptides, NPY2-36 and 
NPY 13-36, and is defined as the NPY-Y2 receptor. The NPY-Y2 receptor binds both NPY and 
PYY with high affinity (Wahlestedt et al., 1986; 1990). To the date, six different receptors 
subtypes have been demonstrated to bind NPY. These NPY receptors are all G-protein 
coupled receptors (Wahlestedt and Reis, 1993; Gehlert, 1994; Larhammar, 1996a; Grundemar, 
1997; Larhaimnar, 1997).
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1.13.1.1 N PY -Y l RECEPTORS
NPY-Yl receptor sites are particulaily concentrated in the cortical areas of the brain, in the 
cerebral cortex and olfactory nucleus and mixed populations of NPY-Yl and NPY-Y2 
receptors are found in various central nuclei (Dumont et ah, 1997). In CNS, the NPY-Yl 
receptor has been linked with different physiological processes, including stimulation of 
feeding behaviour (Kalra et al., 1990), stimulation of luteinising hormone-releasing hormone 
release (McDonald, 1990; McDonald and Koening, 1993) and anxiolytic-sedative effect 
(Wahlested et al., 1993). In PNS, NPY-Y 1 receptor is found predominantly at the sympathetic 
postjunctional sites in blood vessels, where it mediates the contractile response to NPY of 
vascular smooth muscle cells, both directly and indirectly by potentiating the action of other 
pressor agents, such as noradrenaline and adrenaline (Wahlestedt et a l, 1986; 1990).
The NPY-Yl receptor has been identified in a number of cell lines, in particular it has been 
shown to be present on a number of human neuroblastoma cells (Sheikh et al., 1989). These 
cell lines include human erythro-leukaemia cells (HEL) and human neuroblastoma cell line 
(MC-IXC). The NPY-Y 1 receptor has been reported to be present on a rat pheochromocytoma 
cell line : PC12 cells (Schwartz et al., 1987; DiMaggio et al., 1994).
Studies of solubilised NPY-Yl receptors from neuroblastoma (MC-IXC) cells indicate that the 
receptor is a glycoprotein with a molecular weight of approximately 70 kDa (Wan and Lau, 
1993). It has been suggested that the NPY-Yl receptor binds to both the amino- and carboxy- 
termini of NPY peptide. The most notable feature of the NPY-Yl receptor is the loss of agonist 
potency when only one or two amino-terminal amino acid residues are eliminated or 
substituted. By contrast, substitutions in the carboxy-terminus have been introduced without 
loss of potency, although the carboxy-terminal amide tyrosine residue is essential for biological 
activity. On the basis of results of studies using NPY analogues, it has been suggested that the 
hairpin loop is not essential for binding but it promotes binding of the NPY-Yl receptor by 
bringing the amino- and carboxy-termini of NPY moleeule in close apposition (Allen et ak, 
1987a).
1.13.1.2 NPY-Y2 RECEPTORS
The majority of NPY receptors in CNS are NPY-Y2 in nature with high densities seen in the 
hippocampal formation. Activation of NPY-Y2 receptors inhibits the release of glutamate from 
terminals that synapse onto rat hippocampal CAl neurons. In PNS, the NPY-Y2 receptor is 
predominantly pre-junctional, principally in sympathetic, pai'asympathetic and sensory C-fibres 
(Grundemar and Hakanson, 1994). In these fibres the NPY effect is predominantly supression 
of transmitter release. Others effects associated with activation of NPY-Y2 receptors include:
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vasoconstriction (certain blood vessels), antisecretory effect (intestine), inhibition of lipolysis 
(lipocytes), enhanced memory retention (hippocampus), inhibition of consummatory behaviour 
(hypothalamus) and suppression of noradrenaline release (locus coeruleus) (Grundemar and 
Hakanson, 1994).
Like the NPY-Yl receptor, there are several human neuroblastoma cell lines that harbour NPY- 
Y2 receptors, including SMS-MSN, SMS-KAN, CHP-234 and SK-N-BE2 (Sheikh et al.,
1989). Some of these cell lines have been utilised as in vitro models for NPY-Y2 agonist 
assays. The NPY-Y2 receptor recognises a great variety of carboxy-terminal NPY/PYY 
fragments (Grundemar et al., 1993). NPY-Y2 receptor binding has also been found in PC12 
cells (DiMaggio et al., 1994).
1.13.1.3 NPY-Y3 RECEPTORS
A third receptor subtype NPY-Y3, was also demonstrated in early studies, which selectively 
bound NPY and NPY analogues but not PYY (Wahlestedt et al., 1992; Grundemar et al.,
1993). When NPY analogues are injected into the nucleus tractus solitarium of the brainstem of 
rats, bradycardia, hypotension and inhibition of glutamate effects are observed. In addition 
bilateral stimulation of NPY-Y3 receptors in the nucleus tractus solitarium results in elevated 
blood pressure and attenuated baroceptor reflex. These central cardiovascular effects are 
mediated by NPY-Y3 receptors in the nucleus tractus solitarium brainstem (Grundemar and 
Hakanson, 1994).
NPY-Y3 receptors have been observed on rat cardiac membrane (Balasubramaniam et al.,
1990) and on bovine adrenal chromaffin cells (Wahlestedt et al., 1992). In adrenal medulla, 
NPY-Y3 receptors suppress the nicotine-stimulated release of catecholamines, such as 
adrenaline. In adrenal cortex, NPY-Y3 receptors mediate the release of aldosterone 
(Grundemar and Hakanson, 1994).
1.13.1.4 PP-Y4 RECEPTORS
PP is released from pancreatic endocrine cells. PP receptors have been chaiacterised by binding 
or functional assays in liver, intestine, spinal cord, adrenal gland, brainstem nuclei and PC 12 
cells (Grundemar, 1997; Larhammar, 1997). PP exerts effects on pancreatic exocrine 
secretion, gall bladder contraction, gastrointestinal motility, gastric acid secretion and 
corticosterone secretion. PYY is also expressed in PP cells and in somatostatin cells as well as 
in endocrine cells of the large intestine. PYY has similar actions to PP and both are released 
into the circulation in response to meal.
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1.13.1.5 NPY-Y5 RECEPTORS
N PY  is a powerful stim ulant of food intake and is proposed to activate a specific hypothalamic 
""N PY Y 1-like feeding receptor" (Stanley et ah, 1986; 1992). This has been suggested by 
resu lts that show  that the specific N P Y -Y l recep tor analogue [Pro^^j-N PY  is a po ten t 
stim ulator o f feeding (Stanley et ah, 1992). How ever, this N P Y -Y l receptor analogue, is only 
able to give approxim ately half o f the feeding stim ulation of NPY (O 'Shea et al., 1997). The 
specific N PY -Y 2 recognising analogue, NPY2-36, is equally active as NPY w hen injected into 
the hypothalam us o f rats (Kalra et al., 1991). In addition, PYY is a potent stim ulator o f feeding 
in vivo w hereas ne ither ra t PP  nor NPY13-36 e lic it feed ing . T aken  together, this 
pharm acological profile to different N PY  analogues suggests a sepai'ate distinct N PY  receptor 
to mediate feeding.
The novel fragment [Pro^'^]-NPY3-36 is as effective at stimulating food intake as the classical 
NPY-Yl analogue [Pro^'^j-NPY. This new analogue bound to the NPY-Yl receptor with only 
l/20th of the affinity of NPY and failed to inhibit adenylyl cyclase through this receptor. In 
addition, the NPY-Yl receptor antagonist BIBP-3226, which does not bind NPY-Y2, PP-Y4 
and NPY-Y5 receptors, significantly reduced NPY induced feeding. These results suggested 
that the feeding effect of icv NPY involves a novel receptor and that is functionally distinct 
from the recognised receptor subtypes (O'Shea et al., 1997).
1.13.2 CLONING OF NPY RECEPTORS
1.13.2.1 N PY -Y l RECEPTORS
Molecular and physiological characterisation of receptors requires access to molecular clones 
that can be used for functional expression in cell lines and for design of specific DNA and 
RNA probes. Several of the above described receptors have now been cloned. Previous studies 
had described the molecular cloning of the NPY-Yl receptor cDNA from rat (Eva et a l, 1990; 
Krause et a l, 1992), mouse (Eva et a l, 1992; Nakamura et a l, 1995), human (Herzog et a l, 
1992; Larhammar et a l, 1992) and Xenopus (Blomqvist et a l, 1995).
1.13.2.2 NPY-Y2 RECEPTORS
Expression cloning allowed the isolation of the human NPY-Y2 receptor (Gerald et a l, 1995; 
Rose et a l, 1995; Gehlert et a l, 1996a; Rimland et a l, 1996). This receptor displays only 
31% and 33% amino acid identity to the NPY-Yl and PP1-Y4 receptors. The mouse 
orthologue was subsequently cloned by homology screening (Nakamura et a l, 1996).
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The human NPY-Y2 receptor is 381 amino acids in length and has a molecular mass of 
approximately 42 kDa. There is a single N-linked glycosylation site in the amino-terminal 
region and a cysteine in the carboxy-terminal region that may be involved in palmytoylation 
(Rose et ah, 1995). Northern blot analysis of poly(A)+ RNA from human brain regions 
revealed a 4.4 kb hybridising band. Brain regions expressing relatively high levels of mRNA 
encoding for NPY-Y2 receptor include the amygdala and hippocampus. Moderate levels were 
found in cerebral cortex. Lower levels were seen in the caudate, subthalamic nucleus and 
medulla. Very low levels were seen in the substantia nigra, thalamus and putamen. No 
hybridisation could be seen in the cerebellum and spinal cord (Gehlert et al., 1996a). Peripheral 
tissues displayed no detectable hybridisation. Tlris suggest that either another form of the NPY- 
Y2 receptor is found in the periphery or that mRNA transcript is present at levels undetectable 
by Northern Blot analysis (Gerald et al., 1995; Rose et a l, 1995; Gehlert et al., 1996a).
1.13.2.3 NPY-Y3 RECEPTORS
A bovine receptor clone, LCRl, was proposed to correspond to the NPY-Y3 receptor 
(Rimland et a l, 1991), however the human orthologue of LCRl exhibited no specific binding 
or functional response to NPY (Herzog et a l, 1993a; Jazin et a l, 1993a) and this receptor is 
no more similar to the NPY-Yl receptor than another GPCR. Recently, the LCRl receptor 
which is expressed in T helper cells, has been found to correspond to fusin, the CXCR-4 
receptor which serves as an entry cofactor for the HIV virus (Feng et a l, 1996).
1.14.2.4 PP-Y4 RECEPTORS
A high affinity human PP1-Y4 receptor with 53% amino acid identity in the transmembrane 
domains to the human NPY-Yl receptor was cloned by several groups (Bard et a l, 1995; 
Lundell et a l, 1995; Gehlert, et a l, 1996 b; Yan et a l, 1996). Mouse (Gregor et a l, 1996 b) 
and rat (Lundell et a l, 1996; Yan et a l, 1996) PP1-Y4 receptors have also been cloned.
The human PP1-Y4 receptor encodes a predicted protein of 375 amino acids with a molecular 
mass of 41 kDa. The human PP1-Y4 receptor has subnanomolar affinity for PP and nanomolar 
affinity for PYY and NPY, raising the possibility that it may be shared by all three pancreatic 
polypeptides. Tissue distribution studies in humans and mice suggest potential roles for PPl- 
Y4 in gastrointestinal tract, heart, prostate, as well as in neural and endocrine signalling 
(Gehlert et a l, 1996b).
The primary amino acid sequence of the rat PP1-Y4 receptor is only 75% similai’ to the human 
PP1-Y4 receptor. Both human and rat PP1-Y4 receptors bind PP with high affinity, but the rat 
PP1-Y4 receptor has substantially lower affinity for both PYY and NPY. Thus, PP is the
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endogenous ligand at the rat PP-Y4 receptor (Lundell et ah, 1996). The distribution of PP1-Y4 
receptor mRNAs is also found to differ between human and rat. The human PP1-Y4 receptor 
mRNA is abundantly expressed in colon, intestine and pancreas. It agrees well with the sites of 
PP and PYY synthesis and with the involvement of PP and PYY in regulating gastrointestinal 
functions (Lundell et al., 1995). In the rat, PP-Y4 receptor mRNA are detected in testis, lung, 
colon, while none was detected in small intestine and stomach (Lundell et al., 1996). In 
addition, PP have a prominent role in the CNS and control of gastrointestinal functions by 
acting on receptors in the rat brainstem. Thus, the sequence, the tissue distribution, and the 
binding profile of the PP1-Y4 receptor differ between rat and humans (Lundell et al., 1995; 
1996).
A novel member of this family was recently cloned and named PP2-Y4 (Gregor et al., 1996a). 
The coding region of the mouse PP2-Y4 gene reveals no introns and predicts a receptor of 371 
amino acids. Percent identities of the mouse PP2-Y4 receptor to mouse NPY-Yl, mouse PPL 
Y4 and human NPY-Y2 receptors are 53%, 42% and 31%, respectively (Gregor et al., 1996a). 
The human PP2-Y4 cDNA and gene sequences display a single base deletion in the coding 
region, resulting in a frameshift mutation that predicts a truncated receptor of 290 amino acids. 
This suggests that the human PP2-Y4 is either functionally inactive or its has acquired a PP- 
independent function (Gregor et ah, 1996a).
1.13.2.5 NPY-Y5 RECEPTORS
An additional receptor, NPY-Y5, referred to as the "feeding receptor" was also isolated using 
expression cloning from rat (Gerald et ah, 1996; Hu et al., 1996) and human (Gerald et ah,
1996). This receptor shows a binding profile that is consistent with that of the proposed 
"feeding reeeptor" in that it binds N PY , [Leu^^Pro^^J-N PY  and NPY2-36 with similar 
affinities and is expressed in regions of the hypothalamus which mediate food intake: arcuate 
nucleus, lateral hypothalamus and paraventricular nucleus. However, recent studies indie ate 
that the pharmacological profile for the expressed receptor is not identical that observed for the 
feeding response (O'Shea et al., 1997).
The rat cDNA encodes a 456 amino-acid protein with less than 33% overall amino acid identity 
to known NPY-type receptors. The human homologue has 88% amino acid identity to the rat 
receptor. The mRNA is found in the CNS, including the paraventricular nucleus of the 
hypothalamus but not in peripheral tissues. Southern blot analysis indicates both rat and human 
genomes contain a single NPY-Y5 receptor gene. The human NPY-Yl and NPY-Y5 receptor 
genes map, in opposite orientation, to the same locus on chromosome 4q (Herzog et ah,
1997).
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1.13.2.6 NPY-Y6 RECEPTORS
Concomitantly yet another receptor, independently also called NPY-Y5, later renamed NPY- 
Y6, with 56% amino acid identity to the rat NPY-Yl receptor, 47% overall identity to the rat 
PP1-Y4 receptor and only 33 % identity to the rat NPY-Y2 receptor was cloned in mouse with 
low stringency homology screenings using a NPY-Yl probe (Weinberg et al., 1996).
The murine NPY-Y6 gene encodes a predicted 371 amino acid polypeptide. Like the NPY-Y5 
receptor it exhibits a pharmacological profile that is similar to that described for the "feeding 
receptor" and has hypothalamic expression, including anterior hypothalamus, bed nucleus stria 
terminalis, the suprachiasmatic nucleus and the ventromedial nucleus with no localisation 
apparent elsewhere in the brain and with significant mRNA expression only within the kidney 
(Weinberg et al., 1996). The orthologue of the mouse NPY - Y 6 receptor has been cloned in 
human, rabbit and primates (Matsumoto et al., 1996). In the primates species the predicted 
receptor is truncated after TM6 by a frames hift mutation although its mRNA is abundantly 
expressed in heart and skeletal muscle, suggesting a novel function of the human gene. 
Southern blot analysis indicate that the human genome contains a single copy of this gene on 
the chromosome 5 (Matsumoto et al., 1996).
1.14 MOLECULAR BIOLOGY OF NPY-YlRECEPTOR
1.14.1 NPY-Yl RECEPTOR cDNA CLONES
The cDNA that encodes the NPY-Y 1 receptor has been defined although it was originally 
reported as an "orphan" seven transmembrane domain receptor belonging to the typical GPCR 
family (Eva et ah, 1990). By predicted sequence analysis, the receptor resembled the 
tachykinin family of receptors, possessing within the putative transmembrane domain 33% and 
31% amino acid homology with neuromedin K and substance K receptors, respectively. 
However, when transiently expressed, it failed to bind any known tachykinin (Eva et al.,
1990). It has subsequently been redefined as the NPY-Yl receptor as the expressed protein 
displays all the features of the NPY-Yl receptor binding (Herzog et al., 1992; Larhammar et 
al., 1992).
1.14.1.1 RAT N PY -Y l RECEPTOR
The rat clone, named FC5, which specified an open reading frame of 349 amino acids (34.4 
kDa) was obtained from a forebrain cDNA library (Eva et al., 1990). The predicted polypeptide 
contains three potential N-glycosylation sites in the amino-terminal extracellular domain. Other
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consensus sequences for post-translational modifieations include four target amino acids sites 
for protein kinases within the third intracellular loop and the intracellular located carboxyl 
terminus. There are two potential phosphorylation sites for PKC at residues Thr-257 and Ser- 
362, two sites for tyrosine kinase at Tyr-252 and Tyr-346 and one site for PKA at Ser-375. 
The presence of these sites suggest that the receptor may be regulated by phosphorylation (Eva 
et ah, 1990).
Northern blot analysis found a prominent mRNA species of approximately 4 Kb in rat cerebral 
cortex, hippocampus, hypothalamic nucleus and thalamic nuclei. No signal was observed in 
peripheral tissues (Eva et al., 1990). An expression vector carrying the NPY-Yl receptor 
cDNA was transiently expressed in human embryonic kidney 293 cells (ICi’ause et al., 1992). 
Inhibition of luteinising hormone-stimulated adenylyl cyclase and Ca++ mobilisation in 293 
cells was reported for NPY-stimulated cells and might reflect receptor coupling to a Gi protein.
1.14.1.2 HUMAN N PY -Y l RECEPTOR
The human NPY-Yl receptor was cloned from a fetal library (Herzog et al., 1992; Laihammar 
et a l, 1992). This receptor consists of 384 amino acids and show 94% identity to that deduced 
from the rat FC5 clone. It is notable that the sequence DRY (Asp-Arg-Tyr), which follows 
TM3 in most receptors belonging to the GPCR superfamily, reads ERH (Glu-Arg-His) in the 
NPY-Yl sequences of both human and rat. Several threonine and serine residues, candidates 
for phosphorylation are found in the carboxy-terminal sequence (Herzog et a l ,  1992; 
Larhammar et a l, 1992).
Northern blot analysis using a human neuroblastoma cell line, SK-N-MC, revealed a single 
3.5-Kb mRNA species. Southern hybridisation to human genomic DNA suggest that the 
genome contains a single NPY-Yl receptor gene. The cDNA of the human NPY-Yl receptor 
was transferred to an expression vector and used to transfect COS-1 cells. In COS-1 cells NPY 
and PYY aecelerated Ca++ influx and inhibited forskolin-stimulated cAMP accumulation 
(Larhammar et a l, 1992).
1.14.1.3 MOUSE N PY -Y l RECEPTOR
The mouse NPY-Y l a  receptor was cloned from a bone marrow cDNA library (Nakamura et 
a l, 1995). The polypeptide encoded by this cDNA is 93% homologous to the human NPY-Yl 
reeeptor. The cytoplasmic tail of this receptor contains 6 serine residues and 4 threonine 
residues, as possible phosphate acceptors. Furthermore, there are four N-linked glycosylation 
sites in the amino-terminal domain and the extracellular loops. Another isoform NPY-Ylp is 
identical to the NPY-Yl a  receptor from the 5'-untranslated region to the third extracellular
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region, but is completely different in the seventh transmembrane, the cytoplasmic tail and 3’- 
untranslated region (Nakamura et al., 1995).
Southern blot analysis of the mouse genomic DNA indicated that the two NPY receptor 
isoforms originate from a single gene (Nakamura et al., 1995). The mouse NPY-Ylp receptor 
is produced by RNA splicing of the third intron, located downstream from position 908 of the 
N PY -Y l a  receptor. Sequences around the putative junctions fit well with the proposed 
consensus sequences for RNA splicing. Despite the lack of seventh transmembrane domain 
and cytoplasmic tail, the NPY-Ylp reeeptor shows ligand binding characteristics identical to 
those of the NPY-Yl a  receptor. This suggest the extracellular loops rather than the seventh 
transmembrane domain plays a critical role for the ligand binding.
The two NPY receptor mouse isoforms were expressed in Chinese hamster ovary (CHO) cells. 
The binding of NPY to the NPY-Y 1 a receptor results in a significant increase of intracellular 
Ca++ and the inhibition of forskolin-stimulated cAMP accumulation (Nakamura et al., 1995). 
A transient generation of IP3 evoked by NPY and NPY-induced intracellular Ca++ increase 
was markledy suppressed by treatment with U-73122, a PLC inhibitor. When the CHO eells 
were treated with PTX, the intracellular Ca+"  ^ increases and inhibition of forskolin-induced 
cAMP production were completely abolished (Nakamura et al., 1995). This results suggest the 
NPY-Yl a receptor couples to PTX-sensitive G-pro teins, probably Gi/Go.
NPY activated MAPK in CHO cells and this activation was completely abolished by PTX 
treatment (Nakamura et al., 1995). Pre-treatment of the cells with wortmannin inhibited the 
MAPK activation in response to NPY. Treatment with wortmannin, did not affect intracellular 
Ca++ mobilisation (Nakamura et al., 1995). In addition, the MAPK activity was not inhibited 
by treatment with B APT A/AM, an intracellular Ca++ chelator, while it completely abolished the 
NPY-induced intraeellular Ca++ increase. These observations suggest that the NPY-Yl a  
receptor mediates MAPK activation via a Ca++-independent but a wortmannin-sensitive 
pathway. In contrast, NPY-evoked cell responses such as intracellular Ca++ increase, 
inhibition of forskolin-induced cAMP production or MAPK activation was not detected 
expressing the N PY -Y lP receptor in CHO cells. These later results suggest that the 
cytoplasmic tail of the NPY-Yl a  receptor may contribute to G-protein activation (Nakamura et 
al., 1995).
Gene expression analysis by Northern blots and RT-PCR indicate that the NPY-Yl a  receptor 
is highly expressed in the brain, heart, kidney, spleen, skeletal muscle and lung, whereas the 
other isoform, the NPY-Ylp receptor is expressed in mouse embryonic developmental stage (7 
and 11 days), bone marrow cells and several hematopoietic cell lines (Nakamura et al., 1995).
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These results suggest that the NPY-Ylp receptor is an embryonic and a bone marrow form of 
the NPY-Y 1 reeeptor, which decrease in expression during development and differentiation.
1.14.1.4 X e n o p u s  N P Y -Y l RECEPTOR
The Xenopus NPY-Yl receptor shares 81% amino acid sequence identity with the human 
NPY-Yl receptor in the transmembrane spanning regions I to VII (Blomqvist et al., 1995). 
The extracellular amino-terminal region, transmembrane IV and second extracellular loop 
contain several replacements suggesting that these portions have limited direct interactions with 
the peptide ligand. A conserved aromatic residue in the third intracellular loop is conserved in 
the mammalian and Xenopus NPY-Yl receptors in the sequence (YTBCIFLRLKRRN). This 
sequence is important in G-protein coupling to the PI pathway. Another conserved sequence of 
the NPY-Y 1 receptor family is the ERH motif in the beginning of the second extracellulai' loop 
(Blomqvist et al., 1995).
1.14.2 NPY RECEPTOR GENOMIC CLONES
1.14.2.1 MOUSE N PY -Y l RECEPTOR
The mouse gene for the NPY-Yl receptor was characterised by DNA sequencing and gene 
expression studies (Eva et al., 1992). The mouse NPY-Yl receptor shares 98% amino acid 
homology with the rat NPY-Yl receptor. It comprises three exons with a 6.4 Kb intron in the 
5'-untranslated region and a 80 bp internal intronic sequence immediately after transmembrane 
region V. The mouse NPY-Yl receptor also contain an alternate exon 4 located 15 kb 
downstream of exon 3 (Nakamura et al., 1995). The 6.4 Kb intron is flanked at the 5'-flanking 
region by 84 bp matching the rat cDNA sequence (Eva et al., 1992). Primer extension analysis 
indicates the presence of several transcription initiation sites all located closely to the end of the 
5'-untranslated region of the DNA.
The 5'-flanking region of this gene lacks canonical TATA or CCAAT consensus sequences in 
the proximity of the multiple transcription initiation sites, but contains consensus sequences for 
various transcriptions factors including an Spl binding site (GGGGCG), a CRE binding site 
(CGTCA), three sequences related to the AP-1 motif (TGAGTCA), three non-palindromic 
estrogen reeeptor elements (ERE), two in the form of TGACC and one in the form of GGTCA, 
five non-palindromic glucocorticoid receptor elements (GRE) (AGGACT) and one non- 
palindromic sequence (GGGATTTCAC) which bind to the transcription factor NF-kB (Eva et 
al., 1992).
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A 1,300 bp genomic fragment of the 5'-flanking region drives the expression of the lacZ 
reporter gene in NG108-15 cells, a mouse-rat hybrid neuroblastoma glioma cell line and 
primary cultures of cortical neurons from newborn rat brain which express the NPY-Yl 
receptor but not in glial and human embryonic kidney 293 cells which do not constitutively 
express this receptor, suggesting a restricted tissue specificity of the isolated promoter 
sequence (Eva et al., 1992). Analysis of this 1.3 kb genomic fragment with a reporter gene 
assay suggested the presence of a 181-bp cell type specific core and upstream of this region 
two positive and two negative regulatory regions (Musso et al. 1997). One of the positive 
regulatory sequence includes a ERE binding site (GGTCA) and a GRE binding site 
(AGGACT) and the another positive regulatory sequence includes an AP-1/GRE binding site 
(Musso et al., 1997).
Sequence analysis of the NPY-Yl receptor promoter identified two decamenc sequences 
corresponding to consensus binding sites for NF-KB/Rel proteins (Musso et al., 1997). NF- 
kB is an important regulator of genes activated during the immune response. Gel shift analysis 
indicated that a 29-bp oligonucleotide comprising the two putative kB sites, specifically binds 
KB-related complexes in nuclear extracts from rat brain areas, NG108-15 cells, and the murine 
T cell clone A.E7. In nuclear extracts from A.E7 and NG108-15 cells, this NF-KB sequence 
specifically binds an additional complex. Transient transfection studies demonstrated that this 
N F -kB  sequence acts as an enhancer element, inferring its potential role in regulation of the 
NPY-Yl receptor gene expression (Musso et al., 1997).
1.14.2.2 HUMAN N PY -Y l RECEPTOR
A 14 Kb region of genomic DNA encoding the human NPY-Yl receptor gene was cloned and 
the human gene localised to chi'omosome 4q (31.3-32) (Herzog et al., 1993b). The NPY-Yl 
receptor gene is divided into three exons. The first 80 nucleotides of the 5'-untranslated 
sequence of the human NPY-Yl receptor mRNA are separated by a 6 Kb intron from the 
second exon. The second intron (97 bp) contains an in-frame stop codon and is located after 
the fifth transmembrane domain (Herzog et al., 1993b). The nucleotide sequences of the two 
introns adjoining the splice junctions are consistent with the recognised splicing consensus 
sequence GT/AC.
In the 5'-flanking region a potential transcription start site was found 210 nucleotides upstream 
of the initiation methionine codon. A potential poly adénylation site (ATT A A A) was found 
which is consistent with the size (3.5 Kb) of the NPY-Yl receptor mRNA in Northern blot 
analysis of placenta and kidney (Herzog et al., 1993b). Several cDNA clones encoding the 
human NPY-Yl reeeptor have been isolated that contain different sequences at their 5'-ends 
(Ball et al., 1995). Analysis of NPY-Yl transcripts in the SK-N-MC neuroblastoma cell line
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shows that the at least three forms of the NPY-Yl receptor are generated by alternate exon 
splicing. The exons are found 6.4 (lA), 18.4 (IB) and 23.9 (1C) Kb upstream of exon 2 (Ball 
et al., 1995).
The exon lA  (hippocampus cDNA clone) was determined to be 80 bp, the exon IB (testis 
cDNA clone) was 106 bp and the exon 1C (SK-N-MC cDNA clone) was 109 bp (Ball et al., 
1995). The promoter A lacks a typical TATA and CCAAT box, however it contains a CRE 
binding site (CGACGTCA), an API binding site (TGAATCA) and an octamer-binding (Oct-1) 
site (ATTTGCAT). Promoter B also lacks canonical TATA and CCAAT motifs and has a high 
G+C content (approximately 70%) in the 200 bp preceding the transcription stait site. It contain 
two AP-2 binding sites (CCGCGGGC), a GRE binding site (TGTTCT), an AP-1 motif 
(TGAATAA) and a recognition site for NF-kB. The promoter C has a potential response 
element for a glucocorticoid receptor; this promoter also lacks a TATA and/or CCAAT box 
(Ball et al., 1995).
Alternative splicing of sequences within the 5'-untranslated region can regulate receptor 
expression at the translational level. For example, the presence of a open reading frame within 
the 5'-untranslated region can result in the inefficient initiation of translation and suppression of 
protein expression. The human NPY-Yl receptor gene contains a short open reading frame in 
the 5'-untranslated region situated on exon 1C; however, no start codons are present in either 
exon 1A or IB. The differential use of these exons may be a meehanism for translational 
regulation of the NPY-Yl receptor protein in a cell specific manner (Ball et a l, 1995).
Little is known about the transcriptional regulation of the NPY-Yl receptor gene. 
Administration of glucocorticoids to rats causes an up-regulation of NPY-Yl receptor 
expression in the arcuate nucleus, although it is not known if this is a direct effect of the 
glucocorticoids acting on the NPY-Yl receptor gene promoters. Moreover, in the human gene, 
there are potential binding sites for the glucocorticoid receptor in promoters A, B and C (Ball et 
a l, 1995), The molecular mechanisms responsible for regulation of human NPY-Yl receptor 
expression are unknown; however, they may result from alteration of the transcriptional 
regulatory pathway.
Undifferentiated PC 12 cells express the NPY-Yl receptor subtype and this receptor can be 
detected by binding studies in cells differentiated by either dexamethasone or NGF (DiMaggio 
et a l, 1994). The NPY-Y2 receptor, in contrast, could only be found by binding analysis in 
cells differentiated by NGF. Thus, no detectable binding of NPY-Y2 receptor-selective 
agonist, NPY 13-36 could be measured in undifferentiated or dexamethasone differentiated 
PC12 cells (DiMaggio et a l, 1994). This data suggests differential expression of NPY receptor 
subtypes. However, in this study, no measurements were made of the number of receptors
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following the different agents. Therefore, it is unclear whether differentiation agents affect 
NPY-Yl receptor numbers and gene expression.
1.14.2.3 HUMAN NPY-2 RECEPTOR
The human NPY-Y2 receptor gene spans 9 kb of genomic sequence and is encoded on two 
exons (Ammar et al., 1996). As in the NPY-Yl receptor gene, the 5'-untranslated region of the 
NPY-Y2 receptor is interrupted by an intervening sequence (aproximately 4.5 Kb), however 
the NPY-Y2 receptor gene does not contain an intron analogous to that present in the open 
reading frame of the NPY-Yl receptor (Herzog et al., 1993b). RT-PCR studies indicate that 
the transcription begins in the region upstream of position -1270, most likely within the 
adjacent 200 bp of sequence. Thus, the estimated length of the 5'-untranslated region is the 
1.3-1.4 Kb and the total length of the mRNA is approximately 4.5 kb, which is the estimated 
size of the single NPY-Y2 receptor mRNA detected in Northern blot analysis (Gerald et al., 
1995; Rose et al., 1995). The NPY-Y2 receptor gene maps to the human chromosome 4q31, 
the same region containing the NPY-Yl receptor (Herzog et al., 1993b) and NPY-Y5 (Herzog 
et al., 1997), suggesting that these subtypes may have arisen by gene duplication despite their 
structural difference. In addition, the NPY-Y5 reeeptor gene also is present in the same region, 
in the reverse orientation (Gerald et al., 1996; Herzog et al., 1997). Southern blot analysis of 
human genomic DNA indicates that the gene encoding the NPY-Y2 receptor is single copy and 
distinct from that encoding the NPY-Y 1 receptor.
1.14.2.4 HUMAN NPY-5 RECEPTOR
The human NPY-Yl and NPY-Y5 receptor genes are transcribed in opposite directions from a 
common promoter region on chromosome 4q31-32 (Herzog et al., 1997). One of the 
alternately spliced 5'-exons of the NPY-Yl receptor gene (exon 1C) is also an integral part of 
the large third intracellular loop of the NPY-Y5 receptor (Gerald et al., 1996).
The close proximity of the two NPY receptors genes suggests that they have envolved from a 
duplication event with the small intron interrupting the open reading frame of the NPY-Yl 
receptor gene converted into a functional sequence within the NPY-Y5 gene, while the reverse 
complementary sequence was utilised as an alternatively spliced 5'-exon for the NPY-Yl 
receptor gene (exon 1C). Thus, transcriptional activation of the NPY-Yl exon 1C would have 
an inhibitory effect on NPY-Y5 gene expression. However, such a mechanism may represent 
only one aspect of a regulatory interaction between these two receptors.
Analysis of different cDNA clones demonstrates that the NPY-Y5 clone also uses at least two 
alternatively spliced exons, encoding part of the 5'-untranslated region, which are controlled by
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different promoters. NPY-Y5 exon lA  and NPY - Y 5 exon IB are in close proximity to exon 
IB of the NPY-Yl receptor suggesting the possibility of a co-regulation of transcription of 
both genes through a common promoter region. As both NPY-Yl and NPY-Y5 receptors are 
thought to play an important role in the regulation of food intake, co-ordinate expression of 
their specific genes may be important in the modulation of NPY activity.
1.15 OBJECTIVES
The NPY-Yl receptor has been linked to important physiological process in the nervous 
system (Grundemar and Hakanson, 1994). Understanding the molecular mechanisms 
controlling NPY-Y 1 receptor gene expression will provide clues, not only about the numerous 
systems where this receptor plays a regulatory role, but also about the role of NPY receptors in 
general on the overall organization of the nervous system.
In this thesis the transcriptional control of the NPY-Yl receptor gene will be studied using the 
luciferase reporter system in a model of sympatho-adrenal system, P C I2 cells, which 
constitutively express this neuropeptide receptor (DiMaggio et al., 1994). This model will be 
useful in understanding the function of different activators and inhibitors of specific 
intracellular signalling pathways and the molecular mechanisms involved in the basal and 
induced transcriptional activation of this neuropeptide receptor gene by different factors, such 
as dexamethasone, NGF and PACAP. These factors are well known to affect the levels of 
expression of other late responsive genes in PC 12 cells (See Introduction) using the putative 
transcription factor sites, such as API, CRE and GRE present in the promoter region of the 
NPY-Yl receptor gene. Morover, specific deletions of these transcription factor sites wil be 
made to understand its specific role in the transcriptional control of this gene. Lastly, the post- 
transcriptional control of this gene will be measure using Northern blot, RPA or RT-PCR to 
determine the expression of the specific mRNA of the NPY-Yl receptor gene in PC 12 cells and 
compare with results obtaining the reporter assay systems.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 GENERAL LABORATORY SUPPLIES AND 
PROCEDURES
2.1.1 GENERAL STOCK CHEMICALS AND REAGENTS
General stock chemicals were of the best quality commercially available (analytical or molecular' 
biology grade) and with exception of those listed below were from BDH Chemicals Ltd, 
Poole, Dorset, U.K.
Ammonium acetate, bromophenol blue, n-butanol, caesium chloride, chloroform, denhardt's 
solution, dextran sulphate, diethylpyrocarbonate (DEPC), EDTA, ethidium bromide, 
formaldehyde, formamide, glycerol, guanidine thiocyanate, isoamyl alcohol, isopropanol, N- 
laurylsareosine, orange G, phenol, sodium acetate, sodium citrate, polyvinilpyrollidone 
(PVN), TEMED, Trizma acetate were obtained from Sigma (London) Chemical Co., Poole, 
Dorset, U.K.
Ammonium persulphate, acrylamide, boric acid, N,N’-methyiene bis - aery 1 amide, sodium 
dodecyl sulphate (SDS) were from Fisons Scientific Equipment, Loughborough, 
Leicestershire, U.K.
Low melting point (LMP), Nusieve and Seakem GTG agarose were supplied by EMC 
Bioproducts, Rockland, USA.
Filter paper was obtained from Whatman International, Maidstone, Kent, U.K.
2.1.2 MOLECULAR BIOLOGY ENZYMES AND KITS
Molecular biology enzymes with exception of those listed below were from Boehringer 
Mannheim Ltd., East Sussex, UK or Promega Corp., Madison, USA.
Avr II and Eco NI were from New England Biolabs, Hertfordshire, UK.
Dynazyme polymerase was from Finnzymes Oy, Flow Instruments, UK.
Taq DNA Polymerase, DOTAP and DOS PER liposomal transfection reagent were from 
Boehringer Mannheim Ltd., East Sussex, UK.
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Thermosequenase™ cycle sequencing kit and Redivue™ [a^^SJ-dATP, [a^^P]-UTP and [g- 
32p]-ATP were from Amershan LIFE SCIENCE Inc., Cleveland, USA.
GeneAmp® RNA-PCR kit was obtained from Perkin-Elmer (Roche Molecular Systems), New 
Jersey, USA.
Bio-Rad Protein Assay Dye reagent Concentrate and AG® 501-X8 Bio-Rex® MSZ 501 (D) 
were from Bio-Rad Laboratories Ltd, Hertfordshire, UK.
USBioclean™ MP Kit and slirimp alkaline phosphatase were from United States Biochemical, 
Cleveland, USA.
Polaroid Type 667 Black and White Instant Pack Film and DS-34 Camera System were from 
Polaroid Corp., Cambridge, USA.
Biomax MR^^^ film was from Eastman Kodak Company, USA.
Wizard™ Maxipreps DNA Purification system and Wizard DNA Clean-Up system, AMV 
Reverse Transcriptase Primer Extension System, Riboprobe® in vitro Transcription System, 
Cell Culture Lysis Reagent, Beetle Luciferin, Luciferase Assay System, Dual luciferase™ 
Reporter System and Luciferase Reporter Vectors were from Promega Corp., Madison, USA.
Ribonuclease Protection Assay (RPA IT^ '^ O kit was from Anibion, Austin, Texas.
PKC Assay kit, Lipofectin® and Lipofectamine® Reagent were from Life Technologies Inc., 
Paisley, Scotland.
Ligator Kit was from R&D System Europe Ltd., Abingdon, U.K.
2.1.3 BACTERIAL AND CELL CULTURE REAGENTS
All the tissue culture reagents were of the best quality commercially available and with 
exception of those listed below were from Life Technologies Inc., Paisley, Scotland.
Ampicillin, rat collagen type I, poly-D-Lysine, calcium chloride, HEPES buffer, insulin, 
transferrin, glutamine, putrescine, L-thyroxin, selenium, tri-iodo-thyroxin was from Sigma 
(London) Chemical Co., Poole, Dorset, U.K.
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Bacto-Agar, Bacto-Tryptone, Bac to-Yeast extract and LB medium were obtained from Difco 
Laboratories, Detroit, USA.
BSA patho-o-cyte 4 was from ICN-Flow Biomedicals, High-Wycombr, UK.
G-418 and H-89 were from Alexis Biochemical, Nottingham, UK.
PD98059 was from New England Biolabs , Hertfordshire, UK.
Calphostin C, dexamethasone, 17-b estradiol, progesterone, NGF, PACAP-38, DBG, 
forskolin, ionomycin, PMA, D H l, K252a, KN-62, wortmannin and LY 294002 were from 
Calbiochem-Novabiochem, Nottingham, U.K.
Compositions of all solutions and buffers used are listed in Appendix I when not specified in 
the text. Equipment is specified in the text. Water for general laboratory use was single-distilled 
or deionized. Solutions were sterilised by autoclaving to high temperature (12 PC ) with high 
pressure (15 Ib/in^) for 20 minutes in an autoclave or by filtration through 0.22 pm filter units 
(Millex-GV, Millipore).
In addition, general laboratory precautions and procedures were followed;
Toxic chemicals: many solvents such as chloroform, butanol, isoamyl alcohol and phenol are 
toxic. Other reagents such as ethidium bromide, DEPC and formamide are potential 
cai'cinogenic.
Radioactivity: ^^P and ^^S were used with appropriate shielding, stored and discarded in the 
appropriate radioactive area.
RNase contamination: RNase contamination was minimised in the laboratory. When working 
with solutions and equipment used for RNA analysis, gloves were worn at all times to prevent 
nueleases contamination. Sterile, disposable plasticware was used whenever possible and 
plastic disposable pipette tips and microcentrifuge tubes were autoclaved prior to use. All 
glassware and other bake able equipment, were baked at 270°C for at least eight hours. 
Separate chemical stocks were designated for RNA use only. Solutions for RNA use were 
treated overnight with 0.05-0.1% diethylpyrocarbonate (DEPC), a non-specific inhibitor of 
ribonuclease, and then autoclaved to destroy any remaining DEPC. Dilutions of stock 
chemicals and enzyme reaction buffers were made with DEPC-treated water.
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TABLE 2.1 BACTERIAL STRAINS AND PLASMIDS
Strain/Plasmid Genotype Source/Reference
Escherichia coli JM109
F’ [tra D36,pro A+B+, Lac Iq, 
lacZAM 15] rec A \,sup  E44, 
end h \ ,h s d  R17 (rkinik"^), gyr 
A96, thi -1, el4- (mcrA~) 
rel A l A (lac-pro A+B+)
Promega Corporation, 
Madison, USA.
Escherichia coli TGI
F' [tra D36,pro A+B+, Lac Iq, 
lacZAM15] sup E44, sup EA 
(hsd M-mcrB) 5 (r^- nik, McrB) 
thi -1 rel AlA {lac- pro A+B+)
Amershan, Cleveland, 
USA.
pBluescript SK+ 
(2961 bp)
General cloning plasmid Stratagene, La Jolla, USA.
pGL3-Basic 
(4818 bp)
Promoter-less firefly luciferase 
reporter vector
Promega Coiporation, 
Madison, USA.
pGL3-Control 
(5256 bp)
SV40-driven firefly 
luciferase reporter vector
Promega Corporation, 
Madison, USA.
pRL-CMV 
(4079 bp)
CMV-di’iven Renilla luciferase 
reporter vector
Promega Corporation, 
Madison, USA.
pRL-SV40 
(3705 bp)
SV40-driven Renilla luciferase 
reporter vector
Promega Corporation, 
Madison, USA.
pTAg 
(3816 bp) 
pT7-RNA 18S 
human
TA-cloning vector 
Antisense control template
R&D Systems, Abingdon, 
U.K.
Ambion, Austin, Texas.
For all Escherichia colt strains, the genes listed above signify that the bacterium carries a 
mutated allele. The genes listed above as being present on the F' episome, however, represent 
the wild-type alleles.
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2.3 MAMMALIAN CELL CULTURE
All cell lines were maintained at 37°C in a water-saturated atmosphere of 95% air and 6.5% 
C02 in tissue culture-designated incubators (Napco, model 5410). Cell culture was performed 
in laminar flow tissue culture hoods (Microflow, Biological Safety Cabinet). Solutions, 
materials and reagents used for eell culture were sterilised either by autoclaving to high 
temperature (121°C) with high pressure (15 Ib/in^) for 20 minutes or by filtration through 0.22 
pm filter units (Millipore, Millex-GV).
2.3.1 PREPARATION OF TISSUE CULTURE PLATES
2.3.1.1 PREPARATION OF COLLAGEN-COATED TISSUE CULTURE
PLATES
Tissue culture plates (Nunc) were coated with collagen to promote cell adhesion of PC 12 wild 
type cells. Plates were briefly incubated with 0.25 mg/ml type I rat tail collagen in 0.5 M acetic 
acid (See Appendix I) at room temperature in a laminar flood cabinet (Microflow, Biological 
Safety Cabinet). After the collagen solution was recovered for reuse, plates were washed once 
with 80% ethanol and then allowed to dry for two to three hours in a tissue culture hood. Plates 
were then replaced in their original storage plastic bags and sealed with adhesive tape. Plates 
prepared in this way were stored for up to a month at room temperature before use.
2.3.1.2 PREPARATION OF POLY-D-LYSINE TISSUE CULTURE PLATES
Tissue culture plates (Nunc) were coated with poly-D-lysine to promote eell adhesion of 
PC12asnl7-W7 cells. Add 5 mg poly-D-lysine to 30 ml sterile tissue culture water. Aliquot 
into 1 ml fractions and store at -20°C until required. Dilute 1ml aliquot into 10 ml tissue culture 
sterile water. Add to the plate and ensure that the bottom of the plate has an even covering in 
the laminar flood cabinet (Microflow, Biological Safety Cabinet). Leave for 30 minutes in the 
hood. Aspirate liquid and wash culture plate once with tissue culture sterile water. Following 
the plates were treated with rat tail collagen as a mentioned before.
2.3.1.3 DEXTRAN COATED CHARCOAL STRIPPED SERUM
Foetal ealf serum (PCS) was dialysed against Hank's Modified Buffer (Appendix I) over 48 
hours at 4°C and transferred to a glass container and heat inactivated for 45 minutes at 56°C. 
Serum was eooled to 4°C and added to a pellet of dextran coated charcoal (Appendix I). This
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solution was allowed to stir at 4°C for 30 minutes before centrifuguing at 12,000 g x 30 
minutes at 4°C. The supernant was filter sterilised through 0.22 qm filters (Millipore).
2.3.2 CULTURE CONDITIONS OF THE CELLS
2.3.2.1 PC12 PARENTAL CELL LINE
P C I2 cells were a gift of Dr X. Brakefield, Boston University, Boston. PC 12 cells were 
grown on collagen-coated polystyrene tissue culture plates (Nunc) in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 5% foetal calf serum (ECS), 10% heat- 
inactivated horse serum (HS), 2 mM glutamine, 100 units/ml penicillin, 100 mg/ml 
streptomycin. PC 12 cells were routinely maintained on 100 mm diameter collagen-coated plates 
and subcultured every third day at a plating density of approximately 1-5 x 10  ^cells/cm^. As 
the PC 12 adherent cells were only weakly attached, cells were dislodged and resuspended by 
vigorous pipetting.
2.3.2.2 PC12asnl7-W 7 CELL LINE
PC12asnl7-W7 cells (PC 12 cells stable transfected with a plasmid [pRSVN17] containing an 
inhibitory mutation of the human c-Ha-ms gene) (Buensuceso, 1995) were maintained using 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with SATO mix (Bottenstein, 
1985) containing (in mg/L): progesterone, 0.062; putrescine, 16.1; thyroxin, 0.4; selenium, 
0.039; apo-transferrin (human) 100; insulin (bovine pancreas), 10; tri-iodo-thyronine, 0.377. 
The medium was also supplemented with 1% BSA Path-o-cyte 4, 2% fetal calf serum (ECS), 2 
mM glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin, 800 pg/ml geneticin (G418; 
neomycin) and NGF (40 ng/ml). PC12asnl7-W7 cultures were maintained by routine passage 
in poly-D-lysine coated plates followed by air-dried rat tail collagen and recovered by 
incubation for 2-3 minutes with 0.05% trypsin, after resuspension in DMEM complete serum 
solution.
2.3.2.3 COS-7 CELL LINE
COS-7 cells were routinely grown on tissue culture plates (Nunc) in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10% ealf serum (CS), 2 mM glutamine, 100 
units/ml penicillin and 100 mg/ml streptomycin. Cells were routinely maintained on 100 mm 
diameter plates and recovered every third day by incubation for 2-3 minutes with 0.05% 
trypsin, after resuspension in DMEM complete serum solution. Cells were cultured in 60 mm 
plates for most transfection experiments.
83
2.3.2.4 RINmSf CELL LINE
RINm5f cells were a gift of Dr. Steve Ashcroft, Nuffield Department of Clinical Biochemistry, 
John Radcliffe Hospital, Oxford. RINmSf cells were routinely grown on tissue culture plates 
(Nunc) in RPMI 1640 medium supplemented with 10% foetal calf serum (PCS), 2 niM 
glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin. RINmSf cells were routinely 
maintained on 100  mm diameter tissue culture plates and recovered every third day by 
incubation for 2-3 minutes with 0.05% trypsin, after resuspension in RPMI complete serum 
solution.
2.3.2.S G T l-7  CELL LINE
GTl-7 cells were a gift Professor Pamela Mellon, University of California, San Diego. GTl-7 
cells were routinely grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented 
with 5% foetal calf serum (ECS), 5% horse serum (HS), 2mM glutamine, 100 units/ml 
penicillin and 100 mg/ml streptomycin. Cells were routinely maintained on 100 mm diameter 
plates and recovered every third day by incubation for 2-3 minutes with 0.05% trypsin, after 
resuspension in DMEM eomplete serum solution. Cells were eultured in 60 mm plates for most 
transfection experiments.
2.3.3 CELL QUANTIFICATION
Total cell counts were determined using a hemocytometer (Neubauer improved, model 
BS748). With the cover-slip in place, 15 pi of cells suspended in PBS (IX) solution were 
transferred to the hemocytometer. Cells were counted in the middle and four corner squares 
and included those on top and left touching middle line of the perimeter of each square. The 
average number of cells per millilitre was calculated to be the average count per square 
multiplied both by the dilution factor and 10 .^
2.3.4 MICROSCOPY OBSERVATIONS
Routine visualisation of the cells in culture was accomplished at 10-times magnification with a 
inverted microscopy (Nikon, model TMS). Cell quantification in the hemocytometer was 
accomplished at 40-times magnification with a contrast phase microscope (Nikon, model 
Labophot-2 phase).
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2.4 CELLS TRANSFECTIONS
2.4.1 CALCIUM-PHOSPHATE METHOD
Solutions (See Appendix I):
10 pg plasmid DNA
Tris-HCl (10 mM) pH 7.4/ EDTA (0.1 mM) pH 8.0 (TE buffer)
CaCl2 (0.5 M)
2X Hepes buffered saline (2X HBS) pH 7.05 (pH is critical)
Serum free DMEM. Complete DMEM
PC 12 cells (50-70% confluent plates) were transfected using the calcium phosphate co­
precipitation procedure. All the experimental conditions were performed in duplicate. Cells 
were plated the day before transfection in 60 mm plates. 10 pg of plasmid DNA to be 
transfected was brought to a final volume of 125 pi with a sterile solution containing TE buffer 
or double distilled sterile water. This DNA solution was mixed with an equal volume of 0.5 M 
CaCl2- While vortexing thoroughly, the DNA-CaCl2 solution was added drop by drop to 250 
pi Hepes Buffered Saline (2X HBS), pH 7.05 in a sterile 10 ml tube. The pH of the 2X HBS 
is critical (range 7.05-7.12).The mixture was let to stand for 30 to 60 minutes to allow the 
precipitate to form. Meanwhile, the medium was removed from the PC 12 cells and replaced by 
3 ml of serum-free DMEM medium pre-warmed to 37^C. After 30-60 minutes the DNA was 
dropped onto the cells and incubated overnight (14-20 hours). The following day, the cells 
were placed in pre-wai’med complete DMEM medium and treated with the different agents (See 
PC 12 cells treatment). In the case of the inhibitors the cells were incubated with these 
compounds for 60 minutes before any subséquents treatments. After this the cells were 
incubated for a further 48 hours before harvesting for measurement of luciferase activity (See 
Luciferase Reporter Assay).
2.4.2 DEAE-DEXTRAN METHOD
Solutions (See Appendix I):
DEAE-Dextran (10 mg/ml) in PBS (IX) filter sterile 
Chloroquine (100 mM) in PBS (IX)
Tris-HCl (10 mM) pH 7.5/ EDTA (O.lmM) pH 8.0 
DMEM, NU serum (10% v/v) plus usual additions 
COS medium 
10% DMSO
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COS-7 cells need to be split the day before to achieve about 50% confluency. In a sterile 1.5 ml 
eppendorf tube, 10 pg of plasmid DNA in 250 pi TE buffer was mixed with 50 pi of DEAE- 
Dextran (See Appendix I). The mix was incubated at room temperature for 30 minutes. In the 
meantime, DMEM medium supplemented with NU medium (See Appendix I) and chloroquine 
(100 pM) was warmed to 37°C. DMEM medium was removed from the COS-7 cells, and then 
the prewarm NU medium was added to the cells. The DNA mix was added drop by drop and 
incubated at 37°C for up to 4 hours. Thus, the COS-7 cells were incubated at room temperature 
for 2 minutes with 10% DMSO in PBS (IX) (DMSO shock). The cells were then washed once 
with sterile PBS (IX) and the placed in COS cell complete medium.
2.4.3 LIPOSOME-MEDIATED METHOD
PC 12 asnl7-W7 cells (ra5 -negative cell line), RINm 5f cells (rat insulinome cell line) and 
G Tl-7 cells (mouse hypothalamie eell line) were transfected using the liposome reagent 
(DOTAP/DOSPER) (Boehringer Mannheim) or (LIPOFECTIN®/LIPOFECTAMINE®) (Life 
Technologies) following the company instructions. However, the process have been optimised 
for liposome concentration, DNA concentration and incubation time.
DOTAP method use 2.5 pg of DNA (in 100 pi HEPES Buffer IX) and 30 pi of DOTAP (in 
100 pi HEPES Buffer IX). DOSPER method uses 1 pg of DNA (in 50 pi HEPES Buffer IX) 
and 5 pi of DOSPER (in 50 pi HEPES Buffer IX). Mix DNA and liposome solutions and 
ineubate 10-15 minutes and room temperature. LIPOFECTIN method use 2 pg DNA (in 100 
pi serum-free medium) and 20 pi LIPOFECTIN (in 100 pi serum-free medium). 
LIPOFECTAMINE method use 1 pg DNA (in 100 pi serum-free medium) and 10 pi of 
LIPOFECTAMINE (in 100 pi serum-free medium). Mix DNA and liposome solutions and 
ineubate 10-15 minutes at room temperature. Thus is then added dropwise the DNA/liposome 
complex to the cultures (in complete serum medium) and incubate overnight at 37°C in a cell 
culture incubator (See culture conditions of the cells).
2.5 CELL TREATMENTS
The different cells lines were treated for up to two days with various activators or inhibitors 
compounds to induce cell differentiation or proliferation. Compounds were added directly into 
the complete serum medium immediately after cells had been transfected (by overnight 
incubation). The inhibitors compounds were added to the cells one hour before treatment. 
Duplicate sets of cells were plated at a density of approximately 1-2 x 10^ in 60 mm plates. 
Control duplicate plates were prepared for the vehicle alone in a concentration up to 0.1% .
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TABLE 2.2 PHARMACOLOGICAL ACTIVATOR COMPOUNDS
CO M POUND STO CK  CONC. W O RK  CONC. E FFE C T
Dexamethasone, 1 mM * 1 pM Glucocorticoid
(synthetic) receptor
17-(3 Estradiol 1 mM * 1 pM Estrogen receptor
Progesterone 1 mM * 1 pM Progesterone receptor
Nerve Growth 2 0  mg/ml ** 100  ng/ml NGF receptor
Factor(mouse 2.5S)
PACAP-38 5 pM *** 5 nM PACAP receptor
(ovine)
Forskolin 10 mM **** 10 pM Adenylyl Cyclase
{Coleus forskohlii )
Dibutyiyl-cAMP 30 mM ***** 1 mM Protein Kinase A
(synthetic)
DHl 1 inM * * ^ 1 nM Protein Kinase C
(synthetic)
PMA 1 mM **** 1 nM Protein Kinase C
(synthetic)
Ionomycin 10 mM **** 10 pM Ca++ ionophore
(S. conglobatus )
Solubility of the different compounds (Store at -70°C):
Compound soluble in ethanol 
Compound soluble in serum free DMEM medium 
Compound soluble in 5 % acetie aeid/1 % BSA 
Compound soluble in anhydrous dimethyl sulfoxide (DMSO) 
***** Compound soluble in sterile water or PBS (IX)
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TABLA 2.3 PHARMACOLOGICAL INHIBITOR COMPOUNDS
CO M POUND STO CK  CONC. W O RK  CONC. E FFE C T
H-89 10 mM 10 pM Protein Kanase A
(synthetic) (Ki = 48 nM)
Calphostin C 1 mM **** 0.5 pM Protein Kinase C
{C.cladosporoides ) (IC50 = 50 nM)
Genistein 50 mM * 50 pM Tyrosine Kinase
(synthetic) (IC50 = 25 pM)
K-252a 200 pM **** 200 nM pMO^ '"'^  Tyrosine
(Nocardiopsis sp ) Kinase Receptor
KN-62 10 mM **** 10 pM CaM Kinase 11
(synthetic) (Ki = 900 nM)
LY 294002 10 mM 10 pM PI-3 Kinase
(synthetic) (IC50 = 1.4 pM)
Wortmannin 10 mM *''"' * 10 pM PI-3 kinase
(T. wortmannin ) (IC50 = 5 nM)
Sodium 100 mM ***** 50 pM Protein tyrosine
Orthovanadate phosphatase
PD 98059 20 mM **** 40 pM MEK-1 Kinase
(Synthetic) (IC50 = 2 pM)
Solubility of the different compounds (Store at -70^C) :
* Compound soluble in ethanol
** Compound soluble in DMEM medium
*** Compound soluble in 5% (v/v) acetic acid/1% (w/v) BSA
**** Compound soluble in anhydrous dimethyl sulfoxide (DMSO)
***** Compound soluble in sterile water or PBS (IX)
Calphostin C requires light for activation.
Na3V04 was activated by depolymerisation (See Appendix I)).
2.6 BACTERIAL CELL CULTURE
All bacterial work was performed at the laboratory bench using Escherichia coli.. Solutions, 
media, glassware and plastic ware were sterilised by autoclaving. The bench was swabbed 
with ethanol prior to use and a bunsen burner flame maintained aseptic conditions in the area 
and sterilised tools used, such as glass spreading devices were dipped in ethanol prior to 
flaming. Bacterial cultures were grown in liquid medium in a spinning wheel (Napco E series, 
model 301) or with shaking (flasks) at 37°C or on solid medium at 37°C in an incubator 
(Gallemkap). Bacteria in liquid or solid media were stored at 4^C for 4-6 weeks.
2.6.1 PREPARATION OF BACTERIAL MEDIUM
2.6.1.1 LIQUID MEDIUM (LB)
Premixed powdered Luria-Bertani medium (LB) consists of Bacto-tryptone (10 g/1); Bacto- 
yeast extract (5 g/1) and NaCl (10 g/1) formulated to have a final pH of 7.5. 20 g of LB premix 
powder (Difco) were dissolved per litre in distilled water and autoclaved at 121^0, 15 Ib/in^ for 
20 minutes. The medium was then allowed to cool to about 50°C before addition of antibiotics 
(See antibiotic supplements). The medium plus antibiotics was stored at 4°C.
2.6.1.2 SOLID MEDIUM (AGAR)
The LB agar premix powder (Difco) was prepared in a similar way to the liquid medium. 
Thirty-two grams of powder were added per litre of distilled water and the mixture was 
autoclaved at 121°C, 15 Ib/iiL for 20 minutes as instructed by the manufacturer. The medium 
was then allowed to cool to about 50°C before addition of antibiotics (See antibiotic 
supplements). After adding antibiotics, the medium was poured into 100 mm plastic bacteria 
plates using about 30 ml of medium per plate. The agar was allowed to solidify at room 
temperature and the plastic plates were dried at 37°C opened and inverted for 30 minutes. Once 
the plates were dry, they were either used directly to plate transformed bacteria or stored at 4°C 
in their original plastic storage sleeves for up to 4-6 weeks.
2.6.1.3 MINIMUM MEDIUM (M9)
Bacteria strains containing a F' episome, such as JM109 and TGI were grown on minimal 
plates (M9). To make a M9 minimum medium, 0.5 g NaCl; 1.0 g NH4CI; 3.0 g KH2PO4 ; 
6,0g Na^HPOq were dissolved in 900 ml of distilled water and the mixture was autoclaved at 
121°C, 15 \blivE for 20 minutes. After cooling to 50°C, filter sterized 0.1 ml CaCl2 (IM); 2.0
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ml MgSOq (IM) and 10.0 ml glucose (20%) were added to the medium and the volume was 
adjusted to 1 liter. This medium was stored at 4®C. A solution of thiamine-HCl (IM) was 
prepared in distilled water and filter-sterilized, and stored at -20°C. In order to prepare the 
minimal medium plates, 1.7 g agar was dissolved in 100 ml water and allowed to cool to about 
50°C. At this point 0.12 ml of thiamine solution and 1.2 ml of M9 medium were added to the 
agar solution and this mix was poured into 100 mm plastic bacteria plates using about 30 ml of 
medium per plate.
2.6.1.4 TYM MEDIUM
To make competentent cells, bacteria were grown in TYM broth medium. To make TYM 
medium Bacto-tryptone (20 g/1), bacto-yeast extract (5 g/1), NaCl (5.8 g/1) and MgCl2 (0.01 M) 
were added to distilled water and autoclaved at 121°C, 15 Ib/in^ for 20 minutes. TYM medium 
was stored at room temperature.
2.6.1.5 ANTIBIOTIC SUPPLEMENTS
Ampicillin was added to the medium to a final concentration of 100 pg/ml. A stock solution of 
100  mg/ml (ampicillin) was made in distilled water and sterilised by filtration (0 .2 2  \im filters, 
Millipore). Ampicillin stock solution was then aliquoted and store at -20°C.
2.6.2 COMPETENT BACTERIA PREPARATION
2.6.2.1 COMPETENT BACTERIA
The desired Escherichia coli strain (usually JM109 or TG I) was streaked on to an M9 
minimum medium agar bacterial plate and allowed to grow overnight at 37°C. The next day, a 
single colony was selected and transferred into 5 ml of TYM broth medium (see Appendix I) 
and allowed to growth in a spinning wheel at 37°C for 2 to 3 hours. This bacterial culture was 
then transferred to a 250 ml conical flask (eiienmeyer) containing 100 ml TYM broth medium 
and allowed to grow until the absorbance (optical density) of the suspension was about 0.5 at a 
wavelength of 550 nm (Beckman, model DU640B). Bacteria were cooled in an iced water bath 
for 10 minutes in order to achieve a quick drop in the temperature.
The bacterial suspension was then centrifuged in sterilised polypropylene tubes at 2,600 x g for 
10 minutes at 4°C (Beckman, model Avanti 125). The resultant bacterial pellet was drained and 
resuspended in 30 to 40 ml per 100 ml of Tfbl solution (see Appendix I), and incubated on ice 
for 5 minutes. The cells were centrifuged again for 10 minutes at 2,600 x g at 4°C (Beckman, 
model Avanti J25). The pellet was resuspended in 4 ml of Tfbll solution (See Appendix I) per
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100 ml of initial culture. The competent cells were aliquoted into 0.1 ml aliquots in 
polypropylene sterile microcentrifuge tubes, rapidly frozen in liquid nitrogen and stored at 
-70OC.
2.6.2.2 BACTERIA TRANSFORMATION
A 100 |il of competent cell was thawed on ice for each sample of plasmid DNA to be 
transformed. 10-100 ng of plasmid DNA was added to the suspension of competent bacteria 
and after mixing, incubated on ice for 15-30 minutes. The bacteria/DNA mixture were then 
"heat -shocked" by incubating for 1 minute at 42°C or 5 minutes at 37°C, chilled in ice and 
then made up to 400 |al with LB. Expression of antibiotic resistance was allowed for incubation 
for 1 hour at 37°C. Transformed bacteria were selected by plating 100-200 jll of this mixture 
on agar LB plates containing 100 ]ig/ml ampicillin.
Control transformation reactions using circular, non-recombinant plasmid vector were 
performed alongside experimental samples to assess transformation frequency. To test these 
cells 1 p.1 of 1 ng/ml or 1 pg/ml of plasmid DNA were transformed into 100 pi cells. The 
competence achieved was generally 10  ^ colonies/pg of plasmid. Reactions containing only 
water or linear plasmid were performed as a negative control of the transformation.
2.7 NUCLEIC ACID ISOLATION
2.7.1 TOTAL RNA ISOLATION
Solutions (See Appendix I):
Guanidium thiocyanate (4M)
Sodium citrate pH7.0 (25 mM)
Sarcosyl (0.5%) 
p-mercaptoethanol (100 mM)
Sodium acetate pH 4.0 (2 M)
Phenol (saturated with Tris pH 4.5)
Chloroform: isoamylalcohol (24:1)
Isopropanol (100%)
Cells were washed on the culture plate once with 2 ml phosphate-buffered saline solution 
(PBS) and harvested in 1 ml of PBS. Cells were subsequently kept on ice during total RNA 
extraction. Cells were pelleted by centrifugation at 8,000 x g at 4°C for few seconds and the 
resulting pellet was dissolved in 600 pi of the guanidinium isothiocyanate solution by pippeting
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up and down. Cell homogenates were then acidified with 0.1 volume of 2 M sodium acetate 
(pH 4) and extracted with one volume of acid-saturated phenol (pH 4.5) in the presence of 0.2 
volumes of chloroform: isoamyl alcohol (24:1 v/v). The mix was keep in ice for 15 minutes 
and then was centrifuged for 20 minutes at 8,000 x g at 4°C.
The aqueous phase, containing the RNA, was recovered and total RNA was precipitated by 
incubating for 60 minutes at -20°C adding one volume of 100% isopropanol. RNA was 
pelleted by centrifugation at 12,000 x g for 30 minutes at 4°C. After decanting the supernatant, 
the pellet was dissolved in 300 pi of guanidinium isothiocyanate solution and RNA was 
reprecipitated by adding one volume of 100% isopropanol. After centrifugation, the final pellet 
was dissolved in DEPC-treated water. RNA samples were stored as aqueous solutions at 
-70°C or as isopropanol precipitates at -20°C.
2.7.2 DNA (PLASMID) ISOLATION
2.7.2.1 PLASMID MINIPREP
Solutions (See Appendix I):
Tris-HCl (50 mM), pH 8.0, EDTA (10 mM ), 100 pg/ml RNase A (Solution I)
NaOH (0.2 M); SDS (1%) (Solution II) 
potassium acetate (1.32 M), pH 4.8 (Solution III), 
phenol : chloroform: isomy 1 alcohol (24 : 24 : 1)
NaOAc (3 M ), pH 7.0 
ethanol (1 0 0%) 
ethanol (70%)
Individuals colonies were picked from agar plates using sterile plastic disposable pipette tips 
and placed into 5 ml of LB medium with ampicillin contained in a 30 ml sterile glass test-tube. 
Bacteria were cultured at 37°C under constant agitation to saturation for 18 hours (New 
Brunswick Scientific, model G25). 1.5 ml of the bacteria suspension was poured into an 
microcentrifuge tube and the bacteria pelleted by centrifugation for one minute at 12 ,0 0 0  x g at 
room temperature. The supernatant was removed using an aspirator.
The bacterial pellet was resuspended in 100 pi of cell resuspension solution (solution I). 
Bacteria were lysed by addition of 200 pi of cell lysis solution (solution II). The samples were 
mixed by inversion and incubated in ice for 5 minutes. The lysates were neutralised by addition 
of 100 pi of a ice-cold neutralisation solution (solution III). Following mixing by inversion, 
the tubes were centrifuged for 5 minutes at 12,000 x g at room temperature and the supernatant 
poured into a microcentrifuge tube. An equal volume of phenol (pH 7.5) was added to the
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supernatant, vortexed and then centrifuged for 2  minutes at 12 ,0 0 0  x g at room temperature to 
separate the phases. The aqueous phase was removed to a new microcentrifuge tube.
The plasmid DNA was precipitated in ethanol. To do this, one tenth volume of 3 M NaOAc 
(pH 7.0) and 2 volumes of 100% ethanol were added and the DNA was precipitated by 
centrifugation for 5 minutes at 12,000 x g at 4°C. The pellet was rinsed twice with 70% 
ethanol, air dried and dissolved in 100 pi of TE buffer (See Appendix I).
2.7.2.2 PLASMID MAXIPREP
CsCl Method
solutions (See Appendix I):
Tris-HCl (50 mM), pH 8.0, EDTA (10 mM), 100 pg/ml RNase A (Solution I)
NaOH (0.2 M); SDS (1%) (Solution II) 
potassium acetate (1.32 M), pH 4.8 (Solution III), 
isopropanol (1 0 0  %)
Tris-HCl (50 mM), pH 8.0/EDTA (10 mM) (TE buffer)
4.0 g CsCl plus 250 pi EtBr 
n-butanol (equilibrated with 1 M NaCl)
NH40AC (7.5 M) 
ethanol (1 0 0%) 
ethanol (70%)
Typically, one litre of bacterial medium was prepared. Bacteria were plated the night before on 
LB agar plates with antibiotics and single colonies were picked as for miniprep. The selected 
bacterial clone was grown for 2 to 4 hours in 5 ml of LB medium and then added to a 2 litre 
flask containing 1 litre of LB medium containing 100 pg/ml ampicillin and allowed to grow 
overnight at 37°C in a shaker incubator (200-250 rotations per minute) (New Brunswick 
Scientific, model G25). The bacterial suspension was centrifuged in 250 ml centrifuge bottle 
for 5 minutes at 4°C and the supernatants discarded. The bacterial pellets were resuspended in 
a total of 20 ml of solution I (See Appendix I), 40 ml of solution II (See Appendix I) was then 
added and mixed gently without shaking. 20 ml of ice-cold solution III (See Appendix I) was 
then added and the suspension shaken 5 times vigorously.
Following centrifugation at 12,000 x g for 10 minutes at 4°C (Beckman, model Avanti J25), 
the supernatant was filtered through two layers of cheese cloth gauze into a clean 500 ml 
centrifuge bottle. An equal volume of isopropanol was then added to each bottle and the mix 
allowed to stand on ice for 15 minutes. The suspension was centrifugued at 12,000 x g for 10
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minutes at 4°C, after pouring off the supernatant, the pellet was washed twice with 70% 
ethanol. The pellet was then dissolved in a final volume of 3.5 ml TE buffer per initial litre. 
This solution was used to dissolve 4.0 g of ceasium chloride (CsCl). 250 pi of ethidium 
bromide (10 mg/ml) was then added to the DNA solution. The supernatant was transferred to a 
quick seal tube (Beckman) and centrifuged for 18 hours at 55,000 rpm at 18°C (Beckman, 
model Optima TL).
After centrifugation, two horizontal bands were usually observed, the upper band is bacterial 
chromosomal DNA, the lower band is the plasmid DNA. RNA migrate to the botton of the 
tube. The lower band was removed using a syringe and needle and placed into an butanol 
resistant 10 ml plastic tube. Ethidium bromide was extracted by addition of 5 to 6 ml of 
butanol saturated with IM NaCl. After shaking vigorously, the two phases were allowed to 
separate by standing the tube for several minutes. The upper butanol phase was removed and 
the DNA extracted a second and/or third time by addition of a further 5 to 6 ml of salt saturated 
butanol.
After removing all the butanol, the DNA was precipitated by adding 0.36 volume of 7.5 M 
NH4OAC (pH 7.0) and 2.5 volume of 100% ethanol. The DNA was pelleted by centrifuging 
for 15-30 minutes at 12,000 x g at 4°C (Beckman, model Avanti J25). The final pellet was 
washed with 70% ethanol, air dried and resuspended in TE buffer, usually 1 ml for each initial 
litre of bacterial culture depending on the DNA yield. These high quality plasmid DNA were 
routinely used for transfection experiments.
QUIAGEN OR WIZARD MAXIPREP METHOD
Large-scale plasmid preparations were performed using two kits: Quiagen plasmid midi kit 
(Qiagen) and Wizard Maxipreps DNA Purification System (Promega) exactly as instructed in 
the manufacturer protocols. This plasmid DNA was routinely used for subcloning, sequencing 
and other enzymatic reactions.
2.8 NUCLEIC ACID MANIPULATION
2.8.1 NUCLEIC ACID GENERAL METHODS
2.8.1.1 PHENOL/CHLOROFORM EXTRACTION
Protein and salts were removed from solutions of DNA or RNA by extraction with 
phenol/chloroform. One volume of phenol (equilibrated to pH 7.5 for DNA or equilibrated to
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pH 4.5 for RNA) was added to the nucleic acid solution, vortexed thoroughly and each sample 
was spun in a microcentrifuge at 12,000 x g for 5 minutes at room temperature (4°C for RNA 
samples). The upper aqueous layer was transferred to fresh microcentrifuge tubes and an equal 
volume of phenol : chloroform : isoamyl alcohol (24 : 24 : 1) was added to the mixture, mixed 
by vortex and then was centrifuged at 12,000 x g for 5 minutes at room temperature (4°C for 
RNA samples). The upper aqueous phase was removed and transferred to a clean tube taking 
care to avoid contamination with the protein-aqueous interphase.
2.8.1.2 ALCOHOL PRECIPITATION OF NUCLEIC ACID
DNA or RNA was precipitated by the addition of monovalent Na+ cations to 0.3M (sodium 
acetate 3M stock solution) or NH4+ to 0.5 M (ammonium acetate 7.5 M stock solution) and the 
subsequent addition of 2.0 volumes (for DNA), 2.5 volumes (for RNA) or 3 volumes (for 
oligonucleotides) of ethanol or 1 volume of isopropanol. Precipitation was allowed to proceed 
at -20°C for overnight incubation or -70°C for 10-15 minutes. When the amount or the size of 
nucleic acid to be precipitated was small, 10 pg of linear polyacrylamide or 10 pg of tRNA 
carrier was added to the tube to facilitate precipitation. Oligonucleotides were precipitated in the 
presence of 10 mM MgCU to optimise recovery. The DNA or RNA samples were centrifuged 
at 12,000 X g for 30 minutes at 4°C. After removal of the supernatants, the pellets were air- 
dried and resuspend in nuclease-free distilled water or TE buffer.
2.8.1.3 QUANTIFICATION OF NUCLEIC ACID
DNA or RNA was quantified by spectrophotometry measurements (Beckman, model DU- 
640B) at 260 nm. Contamination by carbohydrates was determinated at 230 nm and by 
proteins at 280 nm. For double stranded DNA quantification, 1 OD unit (260 nm) represented 
50 mg/ml, for RNA quantification 1 OD unit (260 nm) represented 40 mg/ml and for single 
stranded DNA 1 OD unit (260 nM) represent 33 mg/ml. Quantification of radioactive label 
incorporation was performed by liquid scintillation counting (Beckman, model LS 6500).
2.8.2 NUCLEIC ACID MODIFICATION
2.8.2.1 RESTRICTION ENDONUCLEASE REACTION
DNA was digested with restriction endonuclease enzymes using conditions and buffers as 
suggested and supplied for the manufacturers (Boehringer Manheim or Promega). Typically an 
enzyme would be provided with a lOX reaction buffer and DNA would be digested in a 10-20 
pi volume containing 1 unit enzyme/pg of DNA for 1 hour at 37®C. The reaction was
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terminated by incubation at 65°C for 15 minutes or phenol/chloroform extraction and ethanol 
precipitation.
2.S.2.2 PHOSPHORYLATION REACTION
T4 polynucleotide kinase was used to transfer the y-phosphate group of ATP to the 5'- 
hydroxyl terminus of oligonucleotides (primer extension assays) or DNA fragments. In a 
typical reaction, 10 pmol of oligonucleotide or DNA ends were phosphoiylated for one hour in 
a 20 pi reaction volume containing ATP (ImM), 2 pi kinase buffer (lOX) (see Appendix I) 
and 10 units of enzyme. The reaction was terminated by incubation at 65°C for 15 minutes.
2.8.2.3 DEPHOSPHORYLATION REACTION
Shrimp alkaline phosphatase (SAP) was used to remove the terminal 5'-phosphate group from 
plasmid DNA. Reactions were carried out for 30 minutes at 37°C in a reaction volume of 20 pi 
containing: 1-5 pg DNA, 2 pi phosphatase buffer (lOX) (See Appendix I) and 5 units of 
enzyme. The reaction was terminated by heating to 65°C for 15 minutes.
2.8.2.4 LIGATION R EACTIO N
T4 DNA ligase was used to catalyse the formation of a phosphodiester bond between adjacent 
3'-hydroxyl groups and 5'-phosphate termini in DNA. Ligations were carried out in a total 
volume of 20 pi with a 1:3 molar ratio of plasmid: insert DNA. Typically a ligation reaction 
was set up in a 20 pi volume containing: 100-500 ng of DNA, ATP (2 mM), ligase buffer (IX) 
(without ATP), 10 units of T4 DNA ligase and made up to 20 pi with distilled water. After 
chilling on ice, the reaction was allowed to proceed overnight to 15°C. The reaction was 
terminated by heating to 65°C for 15 minutes.
2.8.2.S DNA POLYMERIZATION (FILLING-IN) REACTION
Large fragment (Klenow) of the DNA polymerase I was used to convert the 5'-protruding end 
to a blunt end for subcloning purposes. The conversion were carried out in a 20 pi reaction 
containing: 1-5 pg DNA previosly cut with the specific restriction endonuclease enzyme, 2 pi 
polymerase buffer (lOX), 2 pi DTT (10 mM), 2 pi dNTPs mix (0.5 mM each) and 1-5 units 
DNA Klenow-polymerase I. The reaction was incubated for 15 minutes at 37°C and the DNA 
polymerase I was inactivated by heating to 65^C for 15 minutes or by phenol/chloroform 
extraction and ethanol precipitation.
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2.8.3 NUCLEIC ACID SIZE SEPARATION
2.8.3.1 AGAROSE ELECTROPHORESIS
2.8.3.1.1 RNA Formaldehyde Gel Electrophoresis
Solutions (See Appendix I):
MOPS buffer (lOX) 
formaiuide deionized (100%) 
formaldehyde (37%)
RNA loading buffer (lOX) 
iodoacetamide (1 M) 
etliidium bromide (10  mg/ml)
DEPC-treated water
RNA samples (in 15 pi DEPC water) were denatured at 65°C for 15 minutes in RNA sample 
buffer (See Appendix I) in a final volume of 45 pL Formaldehyde-denatured RNA was the 
mixed with 5 pi of RNA loading buffer (lOX) and resolved on 1% agarose gels (15 cm x 10 
cm X 1 cm) containing MOPS (IX ) running buffer, formaldehyde (1.5%), 0.1 M 
iodoacetamide and 0.5 pg/ml ethidium bromide.
Equal amounts of denatured RNA (20-50 pg) measured spectrophotometrically (Beckman, 
model DU-640) were loaded in each lane of the agai'ose gel. Electrophoresis was carried out at 
a voltage constant (10 V/cm) in MOPS buffer (IX) containing 0.5 pg/ml ethidium bromide for 
2-3 hours at room temperature. After electrophoresis, gels were visualized by ultraviolet light at 
254 nm to assess RNA integrity and loading precision. These gels were used for RNA blotting 
for hybridisation with specific DNA probes (Northern blot assay) (See Nucleic acid 
immobilization).
2.8.3.1.2 DNA Gel Electrophoresis
Solutions (Appendix I):
TAE buffer (50X) 
ethidium bromide (1 0  mg/ml)
DNA loading buffer (lOX)
DNA samples to be run in agarose gels were first mixed with an appropriate volume of lOX 
DNA loading buffer (See Appendix I). Samples were typically run in a 1 to 2 % agarose
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prepai’ed in IX TAE buffer containing ethidium bromide (0.5 pg/ml) and dissolved by heating 
in a microwave oven.
Gels were cast on 5 cm x 7 cm glass plates with teflon well combs. Electrophoresis was 
performed in a horizontal system for 30-60 minutes a 10 V/cm at room temperature in 1 X TAE 
buffer, 0.5 pg/ml ethidium bromide and molecular weight markers : (i) X Hind III/Eco RI- 
digested (Sigma) or (ii) 1 Kb Ladder (Life Technologies) were run alongside the samples. Gels 
were then photographed under ultraviolet illumination at 254 nm in a transilluminator 
(Fotodyne, model Foto/Prep I) using Polaroid 667 B/W film and a camera (Polaroid, model 
DS-34)
2.8.3.1.3 Oligonucleotide Gel Electrophoresis
Oligonucleotide quality was determined by electrophoresis in 5% Nusieve agarose (FMC 
products) containing 0.5 pg/ml of ethidium bromide at voltage constant (5 V/cm) for 1 hour. 
Typically 400 pmoles of oligonucleotides were first mixed with an appropriate volume of lOX 
DNA loading buffer (See Appendix I).
2.8.3.2 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
Solutions (Appendix I):
Aciylamide:Z?A -aciylamide solution (40%)
TBE buffer (lOX) 
ammonium persulfate (10  %)
TEMED
Urea
2.8.3.2.1 PAGE Gel for Ribonuclease Protection Assay (RPA)
Denaturing PAGE gels for ribonuclease protection assays (RPA) contained 4% acrylamide and 
7 M urea (See Appendix I). The gel was run in a vertical electrophoresis system (BRL) at 250 
V for 2-3 hours and the results were visualized by autoradiography (overnight incubation at 
-70°C with intensifying screen).
2.8.3.2.2 PAGE Gel for Primer Extension Assay (PEA)
Denaturing PAGE gels for primer extension assays contained 8 % acrylamide and 7 M urea 
(See Appendix I). The gel was run in a vertical system at 250 V for 2-3 hours and the results 
were visualized by autoradiography (overnight incubation at -70°C with intensifying screen).
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2.8.3.2.3 DNA Sequencing Gel Electrophoresis
The sequencing PAGE gels contained 8 % acrylamide and 7 M urea (See Appendix I). The 
sequencing gel was run using a sequencing apparatus at 60 W constant power. Gels were fixed 
in 10% acetic acid, 10% methanol for 30 minutes following electrophoresis and were vacuum 
dried onto a sheet of Whatman 3MM paper using a gel drier (Savant, model S6D4050). The 
dried gel was overnight autoradiographed at room temperature using a Biomax MS film 
(Eastman-Kodak).
2.8.4 NUCLEIC ACID PURIFICATION
2.8.4.1 AGAROSE DNA GEL PURIFICATION
2.8.4.1.1 Low M elting Point (LMP) Agarose
Low melting point agarose gels were used to purify DNA fragments. These gels (0.75-1%) 
were run in TAE buffer containing ethidium bromide (0.5 p.g/ml) at 5 V/cm at room 
temperature. Whilst viewing on a UV transiluminator (Fotodyne, Foto/Prep I) at 300-360 nm 
to minimise damage to the DNA, the required band was excised using a clean scalpel. The gel 
slice was melted in a equal volume of TAE buffer at 65°C for 5-10 minutes and an aliquot of 
this solution, such that the final concentration of agarose did not exceed 0 .2 % was used for 
enzymatic reactions, such as ligation, restriction or PCR reactions.
2.8,4.1.2 USBioclean Purification Kit
Following electrophoresis, DNA was extracted from IX TAE-agarose gels by binding to glass 
powder in high salt concentration using the USBioclean Kit (US Biochemicals). DNA was 
electrophoresed in IX TAE-buffered agarose gels containing ethidium bromide (0.5 pg/ml). 
DNA was visualised under UV illumination at 300-360 nm to minimise damage to the DNA. 
The band of interest was excised from the gel with a clean scalpel blade and the gel slice was 
transferred to a microcentiifuge tube.
DNA was extracted exactly as instructed in the manufacturer protocols (United States 
Biochemical). The DNA yiiid was determined spectrophotometrically and the integrity of the 
purified DNA was assesed by electrophoresis of an aliquot of the sample in ethidium- 
containing agarose gels. This plasmid DNA was routinely used for restriction, ligation and 
other enzymatic reactions.
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2.S.4.2 SOLUTION DNA PURIFICATION
Solutions (See Appendix I):
Isopropanol (80%)
Prewai’med (65-70 °C) distilled water or TE buffer
Concentration of DNA samples (between 50 and 500 pi), removal of small nucleotides from 
PCR reactions and purification of DNA from proteins or salts were made using the Wizard 
DNA Clean-Up System (Promega) according to the manufacturer instruction. This plasmid 
DNA was routinely used for restriction, ligation and other enzymatic reactions.
2.8.5 NUCLEIC ACID IMMOBILISATION
2.8.5.1 RNA TRANSFER TO MEMBRANE
Solutions (See Appendix I):
SSC buffer (lOX)
Water (DEPC-treated)
Transfer of size-separated, gel-electrophoresed RNA to nylon, charge modified membranes 
was made by capillary action for subsequent hybridisation analysis. After agarose gel 
electrophoresis and photography in the UV trasnsiluminator (See RNA formaldehide gel 
electrophoresis), the gel was then laid up upside down on several layers of filter paper 
(Whatmann, 3 MM) soaked in SSC buffer (lOX); these layers were overlaid on a filter paper 
wick extending from a tray filled with SSC buffer (lOX).
A piece of nylon membrane (Dupont, Genescreen), cut to the size of the gel and nicked in one 
corner for orientation purpose, was prewet in DEPC water and laid on top of the gel surface 
such that all the bubbles were excluded between the gel and membrane. Three layers of 
solution-saturated filter paper (Whatmann, 3MM) were placed on top of the membrane to 
produce the capillary force needed to transfer the RNA. These layers were placed avoiding 
trapping of bubbles and then a 4-6 cm pile of dry absorbent paper was placed on top. A glass 
plate added weight to ensure contact of dry paper with the wet filter paper. Transfer was cairied 
out overnight. The next day, the efficiency of the transfer was checked by examining the 
agarose gel in a UV transiluminator for the presence of rRNAs. The RNA was cross-linked to 
the nylon membrane by exposure of the blot for 30 seconds to each side on top of a UV 
transiluminator at 254 nm. The nylon membrane was stored at room temperature before 
hybridization.
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2.9 NUCLEIC ACID SYNTHESIS
2.9.1 OLIGONUCLEOTIDE DESIGN AND SYNTHESIS
The following oligonucleotides were designated, specific for (See Appendix II):
(i) the open reading frame of the rat NPY-Y1 receptor gene (2010-2011),
(ii) the 5'-flanking region of the rat NPY-Y 1 receptor gene (2023-2024),
(iii) the 3'-flanking region of the rat NPY-Y 1 receptor gene (2486-2487).
These oligonucleotides were synthesized commercially by Dr. V. Math, Division of 
Biochemistry and Molecular Biology, Institute of Biomedical and Life Science, University of 
Glasgow on an Applied Biosystems Model 280A DNA synthesiser using phosphoramidate 
technology. Oligonucleotides were supplied in 35% NH4OH and were purified by ethanol 
precipitation. They were dissolved in distilled water. The concentration of the purified 
oligonucleotide was determined by measuring the absorbance at 260 nm. Typically 20 pi of 
oligonucleotide solution was diluted in 3 ml of water and the absorbance measured in a 1 cm 
quartz cuvette, assuming that the OD of 1.0 corresponds to a concentration of 33 pg/ml of 
single stranded DNA.
The following oligonucleotides were designated specific for (See Appendix II):
(i) the open reading frame of the luciferase gene (T1886 and Y7464), 
ii) the 5'-flanking region of the NPY-Y 1 receptor gene (Y7465 to Y7468),
(iii) specific deletions of the 3'-flanking region of the rat NPY-Y 1 receptor gene (T5707- 
T5708),
(iv) specific deletions of the promoter region of the rat NPY-Y 1 receptor gene, including API 
site (V5339-V5340) and progressive deletions of the rat NPY-Y 1 promoter region (V7613 to 
V7617),
(v) the open reading frame of the rat cyclophilin gene (Y7462 to Y7463).
These oligonucleotides were synthesized commercially by Oswel DNA Service (University of 
Southampton) and were dissolved in sterile water. These oligonucleotides were previously 
quantified and were ready to use.
All the oligonucleotides were designated using the prime program (GCG software. University 
of Wisconsin) and checked for complementary hybridisation with the DNA data bank using the 
blast program (National Institute of Health, Bethesda, Maryland). The analysis of the 
sequence of the NPY-Y 1 receptor promoter for binding sites was made using the WEB Signal 
Scan 4.05 program (University of Minnesota).
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TABLE 2.4 OLIGONUCLEOTIDES
OLIGONUCLEOTIDE SOURCE U SE
2 0 1 0 -2 0 1 1 University of Glasgow PCR open reading frame of 
NPY-Y 1 receptor
2024-2025 University of Glasgow PCR promoter region of the 
NPY-Y 1 receptor gene
2486-2487 University of Glasgow RT-PCR 3'-coding region of 
NPY-Y 1 receptor mRNA
T7507-T7508 Oswel RT-PCR deletion 3’-coding of 
NPY-Y 1 receptor mRNA
T 1886 Oswel Reverse primer for RPA assay 
luciferase mRNA
Y7464-Y7467 Oswel RT-PCR for luciferase mRNA
V5339-V5340 Oswel PCR deletion of the AP-1 site
V7613-V7617 Oswel PCR progressive deletions of 
NPY-Y 1 promoter region
Y7642-Y7643 Oswel RT-PCR rat cyclophilin mRNA
Complete oligodeoxynucleotides sequences aie contained in Appendix II.
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2.9.2 cRNA SYNTHESIS BY IN  VITRO  TRANSCRIPTION
Lai'ge amounts of unlabelled cRNA were generated by iii vitro transcription for use as internal 
control for quantification of the NPY-Y 1 receptor mRNA by competitive RT-PCR using as a 
DNA template a deletion clone generated by RT-PCR (See DNA cloning).
The synthesis was made in a final volume of 100 |L il containing: 20 | i l  transcription buffer (5X) 
(See Appendix I), 10 jil of DTT (100 mM), 20 |L il rNTPs mix (25 mM each ribonucleotide), 
100 units of recombinant RNasin® ribonuclease inhibitor, 5-10 jig of linear DNA template 
(See DNA cloning), 2 jil T7 RNA polymerase (15-20 U/jil). The in vitro reaction was 
incubated at 37°C for 60-120 minutes and the DNA template was removed by incubation with 
RQl RNase-free DNase. The in vitro reaction was extracted with phenol/chloroform several 
times and precipitated at -70°C with ammonium acetate and ethanol (See removal of 
unincorporated nucleotides). After the removal of the DNA template and unincorporated 
nucleotides, the RNA concentration was determined by UV absorbance. The DNase-treated 
transcript was examined in agarose gels loaded with 1-2 jil of cRNA denaturated in 18-20 jil of 
a RNA sample buffer (See Appendix I) and 2-5 jil of RNA loading buffer (See Appendix I). 
The sample was heat for 5-10 minutes at 65-70°C prior to the loading and the gel was run 
under standard conditions of DNA samples (0.5X TBE or IX TAE buffer).
2.9.3 cDNA SYNTHESIS
2.9.3.1 PRIMER EXTENSION (AMV RT)
Analysis of the transcriptional initiation site of the 5 '-flanking (promoter) region of the rat 
NPY-Y 1 receptor gene present in the pYl-LUC in PC12 cells was made using the primer 
extension assay system kit (Promega). Typically a radiolabelled oligonucleotide (See 5’- 
labeling of oligonucleotides) was annealed to a cRNA control sample (actinomycin D) or a total 
RNA PC12 sample previosly transfected with the pYl-LUC vector. The reaction was 
incubated at 60°C for 30 minutes and then the reaction was placed at room temperature to cool 
for 10 minutes.
A "master" reverse transcriptase (RT) was prepared which included per tube, 5 jil of AMV 
primer extension (2X) buffer (See Appendix I), 1.4 jal sodium pyrophosphatase (40 mM), 5 
units of (AMV) reverse transcriptase and nuclease free water to a final volume of 9 jil. 
Immediatly aliquoted into each reaction tube which contained annealed primer/RNA. The RT- 
PCR reaction was incubated at 41-42°C for 30 minutes and 20 jil of RNA loading buffer (See 
Appendix I) was added to each tube. The tubes were heated at 90°C for 10 minutes and the
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samples were loaded directly onto a denaturing polyacrylamide gel (See PAGE gel for PEA). 
The remainder of the samples was stored at -20®C.
2.9.3.2 RT-PCR (MMLV RT)
Gene expression analysis of NPY-Y 1 receptor in PC I2 cells was performed by reverse 
transcription of the mRNA using the Moloney murine leukemia virus (MMLV) reverse 
transcriptase present in the Gene Amp® RNA-PCR kit (Perkin-Elmer).
Typically a 20 pi reaction was set up containing: 4 pi of MgCl2 (25 mM), 2 pi of PCR Buffer 
II (lOX) (See Appendix I), 8 pi of a dNTPs mix (10 mM each), 1 pi of RNase inhibitor (20 
U/pl), 1 pi of MuLV reverse transcriptase (50 U/pl), 1 pi of random hexamers (50 mM) or 
oligodT (50 mM) and 0.5-1 pg of total RNA from PC 12 cells transfected with the pY 1-LUC. 
Total RNA was previously incubated for 15 minutes at 37°C with RQl RNase-free DNAse 
(lu/pg plasmid) for remove the DNA template, extracted with phenol/chloroform and ethanol 
precipitated. RT-reactions were incubated at room temperature for 10 minutes and incubated at 
42°C for 15 minutes. RT-reactions were terminated by incubation at 99°C for 5 minutes and 
cooling at 4°C before proceeding with the PCR reaction .
2.9.4 DNA AMPLIFICATION (PCR)
2.9.4.1 cDNA AMPLIFICATION BY RT-PCR
Gene expression analysis of the rat NPY-Y 1 receptor were performed by reverse transcription 
(See cDNA synthesis) and amplification of the cDNA using the GeneAmp® RNA-PCR Kit 
(Perkin-Elmer) following the manufacturer instruction. Control positive reactions were 
included in the kit and control negative reaction included no reverse transcriptase enzyme and 
total RNA for cells (e.g. COS-7 cells) which do not constitutively express the rat NPY-Y 1 
receptor.
2.9.4.2 DNA AMPLIFICATION BY PCR
Polymerase chain reactions (PCR) were run in a termocycler (Stratagene, model RoboCycler® 
40 temperature cycler). DNA used as template for the PCR reaction was previously purificated 
by phenol/chlorophorm extraction and ethanol precipitation or using the Wizard DNA Clean- 
Up System (Promega). PCR reactions were carried using eppendorf tubes (500 pi) in a final 
volume of 100  pi of reaction.
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2.9.4.2.1 Dynazyme DNA Polymerase
DNA was amplified using the thermostable DNA polymerase Dynazyme (Finnzymes Oy, 
Fiowgen Instruments) according to the manufacturer instructions. Unlike many other 
thermostable DNA polymerases which result in amplified molecules with a single, 3' A- 
overhang, amplification with Dynazyme results in blunt ends products. This feature of 
amplification was exploited during subcloning of amplified cDNA fragments into plasmid 
(described below).
A typical reaction (100 pi) consisted: 10 pi of Dynazyme polymerase buffer (lOX) (See 
Appendix I); 0.2 pM of each primer; U5 ng of DNA template; 1 pi of all four dNTPs (25 mM);
2.5 units of Dynazyme polymerase and nuclease-free distilled water up to a final volume of 100 
pi. Further, 100 pi of mineral oil (DNAse free) was layered over the top of the reaction to 
reduce evaporation. The reaction profile was set up in a similar way to the Taq DNA 
polymerase.
2.9.4.2.2 Taq DNA Polymerase
Reactions were set up as follow: 10 pi of Taq polymerase buffer (See Appendix I); 8 pi of 
MgCl2 (25 mM); 0.2 pM of each primer; 1-5 ng of DNA template; 1 pi of all four dNTPs (25 
mM); 2.5 units of Taq polymerase (Boehringer Mannheim or Promega Corp.) and distilled 
water up to a final volume of 100 pi. Further 100 pi of mineral oil (DNAse free) was layered 
over the top of the reaction to reduce evaporation. Reaction mixtures containing only one 
primer or no target DNA were used as a control negative of the PCR reaction.
TABLE 2.5 PCR REACTION CONDITIONS
melting step annealing step polym erisation cycles
step
2 minutes (94®C) 1 cycle
1 minute (94°C) 1 minute (40-60°C) 1 minute (72°C) 30-40 cycles
7 minutes (72°C) 1 cycle
The exact annealing temperature used was dependent upon the calculated melting temperatures 
(Tm) of the primers and the desired stringency of the PCR reaction. The exact times of the 
valions cycle paiameters were also varied in order to optimise PCR conditions. On completion 
of the cycles, the samples were cooled immediatly to 4°C and 10 pi of the PCR reaction were 
mixed with the DNA loading buffer (See Appendix I) and visualised on a 1-2% agarose/TAE
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gel. The samples were then cleaned with phenol/chloroform extraction or using the Wizard 
DNA Clean-Up System kit (Promega) and stored at -20°C for late use.
2.10 DNA CLONING
2.10.1 SUBCLONING OF PCR PRODUCTS
2.10.1.1 DIRECT CLONING
2.10.1.1.1 B lunt-end Cloning
PCR products generated using the thermostable DNAzyme DNA polymerase, which generates 
blunt-end DNA products were cloned into the EcoRV site (blunt-end) of the poly linker region 
of the pBluescribe SK+ multifuctional vector (Stratagene). Using this method was cloned the 
open reading frame of the rat NPY-Y 1 receptor gene from a cDNA library of RINm5f cell line 
(See Chapter 7. Cloning of the ORE of the NPY-Y 1 receptor).
2.10.1.1.2 TA Cloning
The PCR products generated using the thermostable Taq DNA polymerase, which generates 
DNA products with 3'-A overhangs were cloned in the T-overhangs of the pTAg cloning 
vector using the LigATor kit (R&D System) following the manufacturer instructions. Using 
this method were cloned the deletions of the AP-1 site and the progressive deletions of the 5'- 
flanking (promoter) region of the rat NPY-Y 1 receptor gene (See Chapter 6 . Deletions of the 
NPY-Y 1 promoter region), as well as a fragment of the 3'-flanking region of the NPY-Y 1 
receptor gene and its deletions. This deletion clones were used in an attempt to made a 
competitive RT-PCR for study the NPY-Y 1 receptor gene expression in PC 12 cells (See 
Chapter 7. RT-PCR detection of the NPY-Y 1 receptor mRNA).
2.10.1.1 INDIRECT CLONING
PCR products generated using both thermostable DNA polymerases (DNAzyme or Taq) were 
indirectly cloned into the poly linker region of the pBluescribe SK+ multifunctional vector 
(Stratagene) after modification with specific restriction endonuclease digestion. The restriction 
enzymes were present at the 5'-region of the PCR primers or in the DNA amplified. Using this 
indirect method was cloned the 5'-flanking (promoter) region of the NPY-Y 1 receptor gene in 
pBluescribe SK+ (See Chapter 6 . Cloning of the NPY-Y 1 promoter region).
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2.10.2 SUBCLONING OF DNA PRODUCTS
PCR fragments cloned in pBluescribe SK+ (Stratagene) or pTAg (R&D Systems) vectors were 
further subcloned into the polylinker region of specific vectors, such as pGL3-Basic (luciferase 
reporter vector) (Promega) using specific restriction enzymes. This method was used to 
subclone in a bidirectional way the 5'-flanking region of the NPY-Y 1 receptor gene to create 
the pY l-LU C fusion gene (See Chapter 6 . Cloning of the NPY-Yl promoter region). 
Furthermore, specific deletion of the CRE binding element and the APl-GRE binding element 
present in the promoter region of the NPY-Yl receptor gene were deleted using specific 
restriction enzymes present in both sides of these sequences (See Chapter 6 . Deletions of the 
NPY-Yl promoter region).
2.11 DNA SEQUENCING
2.11.1 THERMOSEQUENASE™ CYCLE METHOD
ThermoSequenase™  cycle sequencing kit (Amershan) was used for double stranded 
sequencing of the deletion clones using the dideoxy chain termination method and PCR 
reaction. Template plasmid DNA was prepared using Quiagen (Qiagen Inc.) or Wizard 
Maxiprep System (Promega) kits following the manufacturer instructions.
2.11.1.1 LABELING STEP
This protocol was used to 3'-dNTP internal label cycle of oligonucleotides. For each set of 
four sequencing lanes a single labeling reaction is run, containing in a volume of 17.5 pi: 1 pi 
M13 universal cycle primer (0.5 pmol/pl), 2 pi sequencing reaction buffer (lOX) (See 
Appendix I), 5 pi DNA (100 ng), 1 pi 7-deaza-dGTP cycle mix, 1 pi dCTP cycle mix, 0.5 pi 
[a-35S] dATP (10 pCi/pl, 1000 Ci/mmol), 2 pi Thermo Sequenase™. Positive control 
reactions containing 5 pi of pUC18 The reaction was overlayed with 15 pi of mineral oil and 
run with the following parameters:
TABLE 2.6 LABELLING STEP
melting step annealing step polym erisation
step
cycles
2 minutes (95°C) 1 cycle
15 seconds (95°C) 30 seconds (60°C) 50-60 cycles
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2.11.1.2 TERMINATION STEP
For each labelling reaction, 4 tubes were set up such that each tubes labelled G, A, T, C 
contained either 4 pi of ddGTP, ddATP, ddTTP and ddCTP termination mix, respectivily. 
Once the labelling reaction was complete, 3.5 pi of labelling reaction was removed and transfer 
to the termination tubes, mixed by pipeting up and down several times and overlayed with 10 
pi of mineral oil. The termination reaction was run following the parameters;
TABLE 2.7 TERMINATION STEP
melting step annealing step polym erisation cycles
step
2 minutes (950C) 1 cycle
30 seconds (95°C) 30 seconds (60°C) 120 seconds (72°C) 50-60 cycles
Termination reaction was finish with 4 pi of stop solution (See Appendix I) and the samples 
were store at -20°C. The samples were boiled to 70*^0 for 2-10 minutes before loading 3 pi 
onto a 8 % polyacrylamide gel (See DNA sequencing gel).
2.12 NUCLEIC ACID LABELLING
2.12.1 DNA PROBES
2.12.1.1 5'-END LABELLING
Oligonucleotides probes were labelled using T4 polynucleotide kinase. The labelling reactions 
were set up in a 10 pi reaction containing: oligonucleotides in distillate water (8 -1 0  pmoles), 1 
pi T4 PNK buffer (10 X) (See Appendix I), 5 pi [y-^^P] ATP (at 3,000 Ci/mmol, 10 mCi/ml), 
1 pi T4 PNK (8-10 units), nuclease free water to a final volume of 10 pi. The reaction was 
incubated at 37°C for 30 minutes and terminated by heat inactivation at 90®C for 2  minutes then 
briefly spun in a microcentrifuge.
Unincorporated labeled dNTPs were removed by selective precipitation of the labeled DNA 
(See removal of unincorporated label). The percent of incorporation of the specific end-labelled 
nucleotide was determined by scintillation counter using filter-binding assay (See determination 
of the percent of incorporation) and the final concentration was adjusted by addition of 
nuclease-free water. The probe was stored in TE buffer or distilled water at -20°C for further 
use in the primer extension assays.
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2.12.1.2 RANDOM-PRIMER LABELLING
32p-labelled DNA fragments used for blot hybridisation were prepared by random-primed 
DNA synthesis using a High Prime kit (Boehringer Mannheim). In this method a mixture of 
random hexamers is used to prime DNA synthesis in vitro from any linear double stranded 
DNA template. A full length double stranded rat NPY-Y 1 receptor cDNA cloned in pBluescribe 
SK+ was used as a probe to analyse NPY-Y 1 receptor mRNA expression in PC 12 cells.
The NPY-Y 1 cDNA was released from the vector pBluescribe SK+ by digestion with Bam HI- 
Hind III restriction enzymes (See Cloning NPY-Yl receptor) followed by electrophoresis in a 
1% low melting point agarose gel. The DNA to be labelled was visualized by UV and the 
agarose containing the fragment (1.3 kb) corresponding to the open reading frame of the NPY- 
Y l receptor was excised from the gel. The agarose plug was placed into a eppendorf tube 
containing 20 |il of TE buffer and the agarose was melted at 95°C for 2 minutes to separate the 
two cDNA strands, after which the sample was kept at 37°C until was required.
In a typical reaction, approximately 100-500 ng of linearized DNA in 20 pi of TE buffer was 
strand-separated by boiling for ten minutes. 5 pi of this DNA was then snap-cooled on ice and 
4 pi High Prime buffer solution (5X) (See Appendix I), 5 units Klenow-fragment of the DNA 
polymerase I, 2 pi dNTP mix (0.125 mM dATP, dTTP, dGTP), 50 pCi [a^^PjdCTP (3000 
Ci/mmol, 10 mCi/ml, Amersham) and distilled water up to 20 pi of final volume was added. 
The reaetion was incubated for 15-30 minutes at 37°C. The reaction was terminated by heating 
at 95°C for 2 minutes and susequently chilling in an ice bath. EDTA was added to a final 
concentration of 20 mM.
Labelled DNA was dissolved in 50 pi of TE buffer and an aliquot of this mixture was used to 
determine the percent of incorporation by liquid scintillation spectrophotometry (See 
deteiTnination of the percent incoiporation). DNA was routinely labelled to a specific activity of 
approximately 1 X 10^ dpm/pg. The unincorporated nucleotides were removed by ethanol 
precipitation at -20°C following synthesis (See removal of unincorporated nucleotides). The 
labelled DNA was strand-separated by boiling for 10 minutes immediately prior to use in 
hybridisation of Northern blots.
12.2.2 RNA PROBES
2.12.2.1 I N  V I T R O  TRANSCRIPTION LABELLING
32p-labelled cRNA fragments used for ribonuclease protection assays (RPA) were prepared 
using a Riboprobe® in vitro transcription system (Promega). Antisense control cRNA was
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provided for the RPA II kit (Ambion) and consisted of a linearized pT7 RNA 18S (Ambion) 
containing a 80 bp human RNA 18S gene fragment in the antisense orientation under the 
transcriptional control of T7 promoter. The size of the transcript is 114 nucleotides when 
transcribed with T7 RNA polymerase.
In a typical reaction 100-500 ng of a linearised template DNA in distilled water or TE buffer 
was added to a tube containing: 4 pi transcription optimised buffer (5X) (See Appendix I), 2 pi 
of DTT (100 mM), 4 pi of ATP, CTP, GTP (2.5 mM each), 2.4 pi of UTP (100 pM), 50 pCi 
[a^^PJUTP (500 Ci/mmol, Amersham), 20 units of recombinant RNasin® ribonuclease 
inhibitor, 15-20 units of T7 RNA polymerase and nuclease-free water up to a volume of 20 pi. 
The reaction was incubate for 60 minutes at 37°C. DNA template was removed by digestion 
with RQl RNAse-free DNAse (lU /pg of DNA) at 37°C for 15 minutes. The reaction was 
extracted with phenol/chloroform several times, and selectivity precipitated with ammonium 
acetate and ethanol for incubation at -20°C for 30 minutes.
2.12.3 REMOVAL OF UNINCORPORATED NUCLEOTIDES
Unincorporated labelled dNTPs were removed by selective precipitation of the DNA or RNA. 
The DNA or RNA labelled sample was precipitated with 0.5 volume of ammonium acetate (7.5 
M) and 2 volumes (DNA) or 2.5 volumes (RNA) of ethanol. The mixture was centrifugued at
12.000 X g for 15 minutes and the pellet was resuspend in 100 pi of ammonium acetate (2M) 
and 200 pi of ethanol and incubated at -20<^ C for 30 minutes. This solution was centrifuged at
12.000 X g for 5 minutes at 4°C, the supernatant was removed and the DNA or RNA pellet 
was resuspend in 10-20 pi of TE buffer (DNA) or DEPC-treated water (RNA) for be used as a 
probe in Northern blot or ribonuclease protection assay.
2.12.4 DETERMINATION OF PERCENT OF INCORPORATION
2.12.4.1 DNA PERCENT INCORPORATION (FILTER-BINDING ASSAY)
The level of the incorporation of the radiolabel into the DNA sample was determined by 
spotting I pi of the diluted sample 1:100 in 0.2 M EDTA (pH 8.0) before and after the 
removal of the unincorporated nucleotides onto two filters (Whatman, DE-81) and the filters 
were air-dried. Each filter was placed in a scintillation vial and then were counted in a 
scintillation counter (Beckman, model LS6500).
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2.12.4.2 RNA PERCENT INCORPORATION (TCA PRECIPITATION)
The labelling reaction mixture was diluted 1:10 in water and 1 pi of the diluted sample was 
spotted onto a glass-fiber filter (Whatman, GF). The filter was air-dried and keept aside to 
determine total cpm. Other 1 pi of the dilution sample was added to 100 pi of carrier nucleic 
acid (tRNA at 1 pg/ml), mixed and then was added 0.5 ml of ice-cold 5% TCA. The mixture 
was incubated on ice for 5 minutes. The precipitated RNA was collected by vacuum filtration 
onto a glass-fiber pre-wet with 5% TCA and washed twice with 5 ml of ice-cold 5% TCA. The 
glass-fiber filters were rinsed with 2 ml of acetone and air-dried. Each filter was placed in a 
scintillation vial and there were counted in a scintillation counter (Beckman, model LS6500).
2.13 NUCLEIC ACID HYBRIDISATION
2.13.1 NORTHERN BLOT HYBRIDISATION
Northern blots were analysed by hybridisation with radioactively-labelled cDNA (random 
primer) or cRNA {in vitro transcription) fragments. Sheared, strand-separated salmon sperm 
DNA or poly A DNA was used to block non-specific sites on blots during both 
prehybridisation and hybridisation.
2.13.1.1 cDNA PROBES
Solutions (See Appendix I):
0.77 M  N a2P04 (pH 7.2)
SDS 20 %
PolyA (2 pg/pl)
Samon sperm DNA (100 pg/ml)
For hybridisation with cDNA probes, filters were prehybridised for at least 30-60 minutes at 
55°C in 20-30 ml of 0.77 M phosphate buffer (pH 7.2) containing 6.6% SDS and 100 pg poly 
A DNA in plastic bags in a hybridisation oven (Techne Ltd., model HB-2D). The probe was 
boiled for 10 minutes and added directly to the hybridization bag. After addition of the labelled 
probe, hybridisation was allowed to proceed overnight at 55®C. The next day filters were 
washed once in 2 x SSC/1% SDS at room temperature for 30 seconds and then for a further ten 
minutes at 55°C. Washed filters were laid on wash-solution-saturated filter paper and sealed 
into plastic bags.
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2.13.1.2 cRNA PROBES
Solutions (See Appendix I): 
deionized formamide (100 %)
SSC (20X)
Denhardt's solution (50X)
Salmon sperm DNA (100 pg/ml)
For hybridisation with cRNA probes, filters were prehybridised for 1-2 hours in 5 to 10 
ml/100 cm^ of hybridisation solution containing formamide (50%), SSC (5X), Denhard's 
solution (5X), SDS (1%), 50 mM sodium phosphate buffer (pH 7.0), 10 mM EDTA and 100 
pg/ml of salmon sperm DNA at 55°C in plastic bags or in a hybridisation oven (Techne corp., 
model HB-2D). Labelled cRNA probe was then added to the blots and hybridisation allowed to 
proceed overnight at the same temperature. Blots were washed twice for 15 minutes in 0.2 X 
SSC/0.1% SDS at room temperature and then twice for 15 minutes in 1 X SSC/0.1 % SDS at 
55^C and the blot was prepared for exposure as described above.
2.13.2 SIGNAL DETECTION
Blots were appeased to film X-OMAT-AR (Estman-Kodak) with or without intensifying screen 
and allowed to expose at -70°C. Film was developed using conventional photographic 
technology. Alternatively, blots were exposed to phosphorimager (PI) screens with cassettes 
and the resulting images captured from the screens to a database using the bio-imaging analyser 
(Fuji Photo Film Co. Ltd, Fujix BAS 1000 MacBAS). Hardcopy images of the data were 
obtained using Adobe Photoshop software (Adobe Systems Incorporated).
2.13.3 REHYBRIDISATION
Blots were stripped of radioactive probe for rehybridisation by incubating blots three times in 
boiled 0.1 X SSC/0.1 % SDS until the solution reached room temperature. Stripped blots, laid 
upon stripping solution-saturated filter paper in sealed hybridisation bags, could be stored at 
-20°C before rehybridisation .
2.14 RIBONUCLEASE PROTECTION ASSAY
Ribonuclease Protection Assay (RPA) is an sensitive procedure for detection and quantification 
of mRNA in a complex sample mixture of total cellular RNA. The ribonuclease protection 
assay was performed using the RPA 11'^ '^  kit (Ambion).
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2.14.1 HYBRIDISATION OF PROBE AND SAMPLE RNA
Solutions (Appendix I):
Ammonium acetate (5 M)
Ethanol (100%)
Hybridization buffer (solution A)
RNase digestion buffer (solution B)
RNase Inactivation/Precipitation mixture (solution D)
RNA Loading buffer (solution E)
Probe elution buffer (solution F)
RNase mixture (solution R)
For each experimental tube the labelled probe (2-8 x 10  ^cpm) was mixed with the sample RNA 
(10-50 pg) in a 1.5 ml microfuge tube. 1 negative control tube was set up for every probe to 
be used containing 10 pg of yeast RNA.The probe was co-precipitated with the sample RNAs 
by adjusting the concentration of ammonium acetate to 0.5 M and adding 2.5 volumes of 
ethanol. The mixture was incubated at -20°C for 15 minutes and then centrifugued at 12,000 x 
g for 15 minutes at 4°C. The supernatant was removed and the samples air-dried for 5 minutes 
at room temperature. The pellet was resuspended in 20 pi solution A (hybridisation buffer) by 
thoroughly vortexing and then were centrifugued briefly. All the tubes were heated at 95°C for 
3-4 minutes, re-vortexed and re-centrifuged briefly. The tubes were incubated at 45°C 
overnight to permit hybridisation of the probe and complementary mRNA in the sample RNA. 
The required hybridisation time was extended because the low abundance of target RNA 
(NPY-Yl receptor) in the PC 12 sample.
2.14.2 RNase DIGESTION OF HYBRIDISED PROBE AND 
SAMPLE RNAs
Working dilutions of solution R (concentrated RNase A/RNase T1 mixture) were prepared in 
solution B (RNase digestion buffer). The standard dilution was 1:100 (2 pi of solution R in 
200 pi of solution B). 200 pi of diluted RNase solution (RNase digestion buffer and RNases) 
was added to all the experimental tubes, and to the control negative tube (yeast RNA). The 
tubes were vortex and centrifugued briefly. The mixture was incubated for 30 minutes at 37°C 
and then 300 pi of solution D (RNAse inactivation/precipitation mixture) was added to each 
tube. The RNA was precipited for incubation at -20^C for at least 15 minutes. The tubes were 
centrifugued at 12,000 x g for 15 minutes at 4°C and each pellet was dissolved in 8 pi of
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solution E (gel loading buffer for denaturing gels) and all the samples were heated for 3-4 
minutes at 95°C and run in a denaturing polyacrylamide gel (PAGE gel).
2.14.3 SEPARATION AND DETECTION OF PROTECTED
FRAGMENTS
A denaturing PAGE gel suitable for separation of protected fragments of expected size 
(typically 4% polyacrylamide plus 7 M urea) was prepared (See denaturing PAGE for 
ribonuclease protection assay) and run at approximately 250 volts for about 1-2 hours in TBE 
(IX) buffer. The gel was covered with plastic wrap, and exposed to X-ray film X-OMAT 
(Estman-Kodak) at -70^C with an intensifying screen.
2.15 LUCIFERASE REPORTER ASSAY
Transfected PC12 cells were washed and harvested in PBS (IX). Luciferase activity was 
measured using the protocol and Luciferase Assay system kit (Promega). The amount of total 
protein in each sample was determined spectrophotometrically using the Bradford Bio-Rad 
procedure. The amount of the luciferase activity was determined using a luminometer (Turner, 
model TD-20e).
2.15.1 GENERAL CONDITIONS
Light intensity is a measure of the rate of catalysis by luciferase, and is therefore dependent 
upon temperature. The temperature optimum for luciferase activity is approximately room 
temperature (20-25°C). The sample to be assayed and the Luciferase Assay Reagent were fully 
equilibrated to room temperature before the measurements. Luciferase activity is stable for 
several hours at room temperature (See Chapter 3. Transfection of PC 12 cells).
2.15.2 INSTRUMENT CONSIDERATIONS
Luminometers provide the most convenient, versatile and sensitive means of quantifying light 
emission from the luciferase reaction. The most sensitive luminometers utilise photomultiplier 
tubes to detect photons (Turner, model 20e). The photomultiplier luminometers have two 
important properties which affect performance: the background signal developed by the 
photomultiplier tube is temperature-dependent, therefore is important to ensure that they are at 
ambient temperature (19-23°C) and the sensitivity of photomultipliers is wave-length 
dependent. The photomultiplier tubes requires 1-3 seconds to stabilize after the sample is 
introduced. Therefore an initial delay of at least 3 seconds was allowed and then the 
luminiscence was measured for 15 seconds.
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The linear range of the light detection method was determinated (See Chapter 3. Transfection of 
PC 12 cells) because luminometers usually experience signal saturation at high light intensities. 
A standard curve of light units vs. relative enzyme concentration was raaked using a serial 
dilutions of luciferase (cell culture extract) in cell culture lysis (IX) with 1 mg/ml BSA (See 
Chapter 3. Transfection PC 12 cells). The addition of BSA is necessary to ensure that luciferase 
is not lost from solution by adsorption on to container surfaces.
2.15.3 STANDARD LUCIFERASE ASSAY
2.15.3.1 pGL3 LUCIFERASE REPORTER VECTORS
pGL3 Luciferase Reporter Vectors (Promega) were used for a quantitative analysis of factors 
that regulate mammalian gene expression. The Luciferase reporter vectors carry a modified 
coding region for firefly (Photinus pyralis ) luciferase that has been optimised to monitor 
transcriptional activity in transfected eukaryotic cells. The assay of this genetic reporter is 
rapid, sensitive and quantitative.
pGL3 Luciferase Reporter Vectors contain a high copy number prokaryotic ColEl origin of 
replication for maintenance in E. coli,, an ampicillin-resistance gene for selection, and a 
filamentous phage origin of replication (f 1 origin) for single-stranded DNA production.pGL3 
vectors carries a modified luciferase gene (/mc+ ) which contains multiple new features which 
were made to increase luciferase expression, improve in vivo vector stability, and provide 
greater flexibility in genetic manipulations (Promega).
2.15.3.1.1 pGL3-Basic Vector
pGL3-Basic vector (Promega) lacks eukaryotic promoter and enhancer sequences allowing 
maximum flexibility in cloning putative regulatory sequences. Expression of the luciferase 
activity in cells transfected with this plasmid depends on insertion and proper orientation of a 
functional promoter upstream of the luciferase gene. This plasmid was used to clone the 
promoter region of the NPY-Y 1 receptor gene.
2.15.3.1.2 pGL3-Control Vector
pGL3-Control vector (Promega) contains a simian virus 40 (SV40) early promoter/enhancer 
sequences resulting in a strong expression of luciferase in many types of mammalian cells. 
This plasmid was used to monitor transfection efficiency in PC I2 cells.
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2.15.3.2 LUCIFERASE ASSAY METHOD
Solutions (See Appendix I):
Luciferase Assay Substrate 
Lueiferase Assay Buffer 
Cell Culture Lysis Reagent (5X)
PBS (IX)
Constructs were transfected into mammalian cells and after 48 hours, luciferase activity was 
measured. The Luciferase Assay Reagent was prepared adding 10 ml of luciferase assay buffer 
(Promega) to a vial containing 7 mg of lyophilised luciferase assay substrate (Promega). To 
avoid exposure to multiple freeze/thaw cycles, the reconstituted luciferase reagent were placed 
into working aliquots (1ml) and stored at -70*^C.
The standard luciferase assay (Promega) was made following the manufacturer instructions : 4 
volumenes of PBS (IX) were added to 1 volume of Cell Culture Lysis (5X) Reagent (CCLR) 
to produce a IX stock. This diluted Lysis Reagent (IX) and a aliquot of Luciferase Reagent 
was equilibrated to room temperature. The growth medium was removed from the cells. The 
cells were washed once in PBS buffer (IX) and then resuspended in 1.5 ml of PBS Buffer 
(IX). The cells were centrifuged at 12,000 x g for 5 seconds in a microcentrifuge and the pellet 
was resuspended in 100-200 pi of CCLR (IX) (per 60 mm culture dish) and incubated a room 
temperature for 10-15 minutes. The mixture was spun briefly (5 seconds) in a microcentrifuge 
to pellet large debris and the supernatant was placed in a new tube. The cell extract was stored 
indefinitely at -70°C.
At this point, a 5-10 pi aliquot was used for protein quatification using the Bradford method 
(See Total Protein Quantification). Up to 20 pi of cell extract equilibrated were mixed with 80 
pi of Luciferase Assay Reagent equilibrated at room temperature in disposable polypropylene 
cuvettes (8 x 50 mm) (Promega). The mixture was vortex briefly (few seconds) and the light 
produced was measured for a period of 15 seconds in a lumimometer (Turner, model 20e).
2.15.4 DUAL LUCIFERASE ASSAY
2.15.4.1 pRL LUCIFERASE REPORTER VECTORS
The pRL family of Renilla luciferase {Rluc ) control reporter vectors contain the cDNA of the 
luciferase from a anthozoan coelenterateRen/Z/f^ reniformis (sea pansy). Expression of {Rluc ) 
was drived by one of two promoter elements (CMV or SV40), as described below. These 
vectors were used as internal control of the transfection efficiences in PC 12 cells.
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2.15.4.1.1 pRL-CM V
pRL-CMV vector contains the cytomegalovirus (CMV) immediate-early enhancer/promoter 
region which provides constitutive expression of Renilla luciferase in many types of 
mammalian! cells, including PC 12 cells.
2 .15 .4 .1 .2  pRL-SV40
pRL-SV40 vector contains the simian virus 40 (SV40) early enhancer/promoter region and 
contains the SV40 origin of replication, which allows transient, episomal replication in cells 
expressing the SV40 large T antigen, such as COS-1 and COS-7 cells. This vector also 
provides constitutive expression of Renilla luciferase in many types of mammalian! cells, 
including PC 12 cells.
2.15.4.2 DUAL-LUCIFERASE™ REPORTER METHOD
Dual-iuciferase™ reporter assay system (Promega) and the pRL vectors (Promega) were used 
to provides an internal control value {Renilla luciferase) to which the expression of the 
experimental firefly luciferase reporter gene may be normalized.
Solutions (Appendix I):
Luciferase Assay Buffer II 
Luciferase Assay Substrate 
Stop & Glo™ Buffer 
Stop & Glo™ Substrate 
Stop & Glo'T^ Substrate Solvent 
Passive Lysis Buffer (5X)
Quantification of the luminiscent signal from each of the two luciferase reporter enzymes was 
performed immediately following lysate preparation. The firefly luciferase reporter assay was 
initiated by adding an aliquot of lysate to the Luciferase Assay Reagent II (Promega). 
Quenching of firefly luminiscence and concominant activation of Renilla luciferase was 
accomplished by adding Stop & Glo' '^^ reagent (Promega) to the sample tube immediatly after 
quantification of the firefly luciferase reaction. The passive lysis buffer (PLB) (Promega) is 
designated to provide optimum performance and stability of the firefly and Renilla luciferase 
reporter enzymes. PLB was supplied as a 5X concentrate and was diluted in a IX working 
concentration with PBS (IX).
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The Luciferase Reagent II (Promega) was prepared by resuspending the lyophilized Luciferase 
Assay Substrate (Promega) in 10 ml of the Luciferase Assay Buffer II (Promega). This reagent 
was placed in aliquots (1 ml) and stored at -70°C. The Stop & Glo™ substrate (50X) was 
prepared by transfering 200 pi of the Stop & Glo™ substrate solvent (Promega) into the vial 
containing the dried Stop & Glo'^^ substrate (Promega). This reagent was stored at -70°C. The 
Stop & Glo™ reagent was prepared fresh by adding 20 pi of Stop & Glo™ substrate 
(Promega) to 1ml of Stop & Glo™ buffer (Promega). This reagent was stored at -70°C.
The assays for firefly luciferase activity and Renilla luciferase activity were performed 
sequentially using one reaction tube. The growth medium was removed from the cells and the 
cells were washed once in PBS buffer (IX) and resuspend in 1.5 ml of PBS Buffer (IX). The 
cells were centrifuged at 12,000 x g for 5 seconds in a microcentrifuge and the pellet was 
resuspended in 100-200 pi of passive lysis (IX) Reagent (per 60 mm culture dish) and 
incubated a room temperature for 10-15 minutes. The mixture was spun briefly (5 seconds) in 
a microcentrifuge to pellet large debris and the supernatant was placed in a new tube. The cell 
extract was stored at -70°C. At this point, a 5-10 pi aliquot was used for protein quantification 
using the Bradford method (See Total Protein Quantification). Up to 20 pi of cell extract 
equilibrated was mixed with 80 pi of Luciferase Assay Reagent II equilibrated at room 
temperature in polypropylene cuvettes (8 x 50 mm, Promega). The mixture was vortexed for 
few seconds and the reaction was placed in a luminometer (Turner, model 20e). The light 
produced was measured for a period of 15 seconds with a 3 seconds delay. Thus, 80 pi of 
Stop & Glo'^^ were addedd to mesure the Renilla luciferase activity for a period of 15 seconds 
with a 3 seconds delay in a lumimometer.
2.16 Ca++- PHOSPHOLIPID DEPENDENT PROTEINKINASE (PKC) ASSAY
The PKC Assay System kit (Life Technologies) is base on the phosphorylation of a synthetic 
peptide from myelin basic protein (Ac-MBP 4-14) which is acetylated in the amino-terminal 
glutamine in order to maintain its stability. PKC specificity is confirmed by using the PKC 
pseudosubstrate inhibitor peptide PKC (19-36) which acts a potent inhibitor for this substrate, 
as well other physiological relevant substrates such as myosin light chain kinase (MLCK) and 
peptides derived from glycogen synthase.
2.16.1 CELL EXTRACT PREPARATION
Solutions (See Appendix I):
Buffer A (extraction buffer)
PBS (IX)
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Total cellular PKC activity was measured using the PKC assay kit (Life Technologies, Inc). 
PC 12 cells were plated in 60 mm tissue culture plates and incubated overnight. 
Pharmacological activator compounds (NGF and PMA) were added directly to the cells from 
suitable stocks (See Cell treatments). After incubation, cells were washed once with 2 mi PBS 
(IX) and then resuspended in 1.5 ml of PBS buffer (IX). The cells were centrifuged at 12,000 
X g for 5 seconds in a microcentrifuge and the pellet was resuspended into 500 pi of ice cold 
buffer A (See Appendix I). PC 12 cells were homogenised by 10-15 strokes on ice pre-cooled 
dounce homogenizer, always maintaining the tubes on ice. At this point, a 10 pi aliquot was 
saved for protein determination using the Bradford micromethod (See Total Protein 
Quantification). The samples were incubated on ice for 30 minutes. The cell debris was 
removed by centrifugation for 2 minutes at 12,000 x g at 4°C and supernatants were saved in 
clean eppendorf tubes.
2.16.2 PARTIAL PURIFICATION OF PKC ACTIVITY
Solution (See Appendix I):
Buffer B (DEAE wash buffer)
Buffer C (DEAE elution buffer)
PKC was then partially purified from these cell extracts by DEAE cellulose ion-exchange 
chromatography. 0.25 g of DEAE cellulose (Whatman, DE-52) was resuspended in 1 ml 
buffer B (Appendix I). The DEAE-cellulose was poured into 5 ml plastic columns (1 column 
per cell extract) and washed with 2 ml of buffer B (DEAE wash buffer). Once the buffer level 
had reached the surface of the resin, cell extracts were loaded onto the columns and once the 
extract had entered the resin, these were washed with 5 ml of buffer B. Samples were eluted 
with 5 ml of buffer C (Appendix I). Eluents were recovered in fresh tubes and kept on ice.
2.16.3 PKC ACTIVITY ASSAY
Solutions (See Appendix I):
Buffer C (DEAE elution buffer)
Lipid mixture (lOX)
Inhibitor solution (5X)
['Y„32p]ATP/substrate solution (5X)
PKC activity for each plate of cells were assayed in duplicate. Incorporation of ^^P-ATP into a 
specific PKC substrate was measured using [y-32-p]ATP (6000 Ci/mmol) (Amersham) as a 
donor. The substrate consisted of an acetylated synthetic peptide from myelin basic protein
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(MBP). 5 to 25 |Lil of cell extract was adjusted to a final volume of 25 pi with elution buffer C 
and mixed with 5 pi of lOX lipid mixture (Appendix I) and 10 pi water. Control samples 
containing the PKC inhibitor, PKC (19-36), which is based on the pseudosubstrate region 
common to the a-, [3- and y- isozymes of PKC were prepared in the same way but substituting 
the lipid mixture for 10 pi of 5X inhibitor solution (See Appendix I) and 5 pi water. Samples 
were incubate a room temperature for 20 minutes to allow inhibitor to bind and then mixed with 
10 pi 5X [y-32p]/^YP/substrate solution (Appendix I). These were incubated for 5 minutes at 
30°C, and the reaction stopped by spotting 25 pi from each sample on to phosphocellulose 
paper discs. All the samples were spotted in phosphocellulose discs (Whatman, DE-51) and 
this discs were washed twice in 500 ml of phosphoric acid (1%) in a rocker for 3-5 minutes. 
The sheet was then washed twice with 500 ml of distilled water for 2-3 minutes each time. 
Each phophocellulose disc was punched out into scintillation vials. 5 ml of scintillation fluid 
was added to each vial and samples were counted in a (3-counter for 3 minutes (Beckman, 
LS6500).
2.16.4 TOTAL PROTEIN QUANTIFICATION
The BioRad Protein Assay Dye Reagent Concentrate (BioRad) containing an acidic solution of 
Coomasie Brilliant Blue G-250 was used to determine total protein concentrations. Typically, 
5-10 pi of cells extract (Bradford method) was added to a mix of 200 pi of the dye reagent 
(5X) (See Appendix I) and 800 pi of distilled water for each sample in a eppendorf tube and 
vortexed immediately avoiding excess foaming. After 5 minutes but before of 45-60 minutes, 
sample absorbance was assessed in a spectrophotometer at 595 nm (Beckman, model DU- 
640B). "Blank" control reaction contained lysis buffer and dye concentrated reagent. All the 
measurement were made in triplicate.
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CHAPTER 3
GENERAL ASPECTS OF THE TRANSCRIPTIONAL ACTIVATION OF THE NPY-Yl RECEPTOR GENE
IN PC12 CELLS
3.1 INTRODUCTION
3.1.1 REPORTER ASSAY SYSTEMS
Genetic reporter systems have contributed to the study of eukaryotic gene expression and 
regulation. Although reporter genes have played a significant role in numerous applications, 
they are most frequently used as indicators of transcriptional activity in cells. Typically, a 
reporter gene is joined to a promoter sequence in an expression vector that is transferred into 
the cells. Following the transfer, the cells are assayed for the presence of the reporter, this can 
be achieved by directly measuring the amount of reporter mRNA, the reporter protein itself or 
the enzymatic activity of the reporter protein. An ideal reporter gene is not endogenously 
expressed in the cell type of interest, and is amenable to assays that are sensitive, quantitative, 
rapid, easy and reproducible (Groski'eutz and Sehenborn, 1996).
One popular reporter system uses bioluminescence. The luciferase enzyme used most 
frequently for this reporter gene technology is derived from the cloned sequence of the 
luciferase gene obtained from the North American firefly Photinus pyralis (Groskieutz and 
Sehenborn, 1996). The gene encoding firefly luciferase is highly effective for this purpose 
because the luciferase assay is extremely sensitive (sensitivity to 10"20 moles of luciferase), 
high degree of linearity (at least 8 orders of magnitude), rapid and easy to perform (cell lysis 
and assays in 5 minutes), flexible (can be used with a luminometer or scintillation counter), 
safe (no radioactivity) and relatively inexpensive (Wood, 1991).
Renilla luciferase, a 36kDa monomeric protein, is composed of 3% carbohydrate when 
purified from its natural source, the sea pansy Renilla reniformis (Wood, 1991). However, 
like firefly luciferase, post-translational modification is not required for activity and the enzyme 
may function as a genetic reporter immediately following translation. Since the firefly and 
Renilla luciferases are of distinct evolutionary origins, they have dissimilar enzyme structures 
and substrate requirements. These differences make it possible to discriminate between their 
respective bioluminescent reactions. Thus, using the Dual-LuciferaseT^ Reporter Assay 
System, the luminescence from firefly luciferase ("experimental" reporter) may be quenched 
while simultaneously activating the luminescent of Renilla luciferase ("control" reporter).
The use of dual reporter refers to the simultaneous expression and measurement of two 
individual reporter enzymes within a single system. Typically, the "experimental" reporter 
reflects the effect of the specific experimental conditions on the level of gene expression, while 
the activity of the co-transfected "control" reporter provides an internal control by which each 
value within the experimental set can be normalised. The control reporter gene is usually driven
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by a strong, constitutive promoter and is co-transfected with "experimental" vectors. The 
experimental regulatory sequences are linked to a different reporter gene so that the relative 
activities of the two reporters gene products can be assayed individually. Thus, a "control" 
gene vector can be used to normalise for transfection efficiency or cell lysate recovery between 
treatments or transfections experiments. Normalising the activity of the experimental reporter to 
the activity of the internal control effectively eliminates inherent vaiiabilities that can undermine 
experimental accuracy.
Reporter vectors allow functional identification and characterisation of cis-acting transcriptional 
elements (promoter and enhancers) because expression of the reporter is correlated with the 
transcriptional activity of the reporter gene. For these types of the studies, promoter regions are 
cloned upstream of the reporter gene and enhancer elements are cloned upstream or 
downstream from the gene. The fusion gene is introduced into cultured cells by transfection 
methods or into a germ cell to produce transgenic organisms. Using reporter gene technology, 
promoter and enhancer have been characterized that regulate cell-, tissue- and developmentally- 
defined gene expression (Groskieutz and Sehenborn, 1996).
3.1.2 TRANSFECTION METHODS
The ability to introduce recombinant DNA into heterologous cellular systems has increased the 
knowledge of mechanisms governing regulation of gene expression. Initially, these studies 
relied on the creation of clonal cell lines that contained the promoter of interest (Wigler et ai., 
1978). This approach was time-consuming and the activity of the promoter could be greatly 
affected by its chromosomal location. This was later replaced by systems in which the DNA is 
located in plasmid vectors and transiently introduced into the cells (Gorman et al., 1982). This 
approach has been used to study transcriptional activity of many genes providing a suitable 
system to manipulate gene stincture and expression.
Chemical (calcium phosphate, DEAE-dextran, liposomes), electrical (electroporation) and 
physical (microinjection) methods are used to introduced nucleic acids in a process referred to 
as transfection. An ideal method to transfer genes or macromolecules of interest into eukaiyotic 
cells exhibit the following features: (i) high efficiency of transfection, (ii) low toxicity, (iii) 
reproducibility and (iv) suitability for in vivo and in vitro applications.
3.1.3 EUKARYOTIC TRANSCRIPTION REGULATION
In eukaryotes, three RNA polymerase complexes play important roles in transcription. RNA 
polymerase I transcribes ribosomal RNAs (rRNAs), RNA polymerase II transcribes protein- 
encoding genes (mRNAs), and RNA polymerase III transcribes transfer RNA genes (tRNAs).
122
The RNA polymerase II basal transcription complex consist of RNA polymerase II, which 
itself is a multi-subunit complex, together with several other protein factors (or general 
transeription factors) such as TBP (TATA-Binding Protein) and TFIIB. This mega-complex 
associates with DNA sequences in the promoter region in close proximity to the transcription 
initiation site preceding the gene coding region (McKnight and Yamamoto, 1992).
Other regulatory sequences, in addition to the promoter sequences which associate with the 
RNA polymerase II mega-complex, can influence the transcriptional activity of the genes. The 
region of DNA upstream from the transcription initiation site should be expected to be rich in 
cis -acting elements that comprise promoters, enhancers and silencers that regulate transcription 
directed by RNA polymerase II. The cis -acting sequences are recognised by sequence specific 
DNA binding proteins that act in trans to either activate or repress the rate of transcription of a 
particular gene. These specific transcription factors may act individually or in combination to 
modify basal transcription activity (McKnight and Yamamoto, 1992).
Over the last few years DNA consensus sequences that are recognised by trans -activating 
factors have been defined. Although the presence of such consensus sequences on the gene 
does not constitute, itself, evidence that particular trans -activating factors are functionally 
involved in the regulation of the gene, their presenee provides clues about the mechanisms of 
control of the expression of a particular gene. Several DNA-binding proteins possess 
characteristics structural motifs which define classes or families of related transcription factors. 
Other features in addition to DNA sequenees play a role in the binding of transcription factors 
to DNA. An additional level of transcriptional regulation is provided by protein:protein 
interaction, which contributes to the binding specificity of some groups of transcription factors. 
Lastly, the activities of some factors can be controlled by other enzymes such as kinases, 
phosphatases, pro teases or other modifying enzymes which regulates the protein structural 
state and affects its DNA-binding ability.
3.1.4 PROMOTER REGION OF THE RAT NPY-Yl GENE
The region of the rat NPY-Y1 receptor gene that lies upstream to the open reading frame has 
been attached to the reporter function, lueiferase, so that the expression of this enzyme has 
been placed under the control of this 5'-flanking region of the rat NPY-Yl receptor gene. In 
Figure 3.1, the partial sequence of the promoter region of the rat NPY-Yl receptor gene 
spanning the sequences -600 bp to the 4-160 to the putative transcription start site is shown 
indicating consensus sequences for vaiious transcription factors.
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1 GCTACTTTGG CTTTTTAAAG GACTTCTTTTT GTTCTCTTA GACTGGGGGA
GRE GRE
51 AGTAACTTCT CGGTAGTGGC GTGCGGAATAG TTGAGCGTC ACAAGAGCAG
CRE
101 GGGGAAACGC ATTAGCGGAG GCTTTGCGGTG AAGTGCATC CATCCCCCTT
151 CœGTAAATA AGCTCTCCCC TTCATTCTTGA CTAGGGCTT AAAGCTCGGA
201 GTGTGGGAGG AAAAGGACTT CGGCACAAGATGGCACTGAG GTGCAGACAA
GRE ERE
251 AGGAAATAGG GGTGGGATTG AGTTTTAAAAC AGGGTTGTA AATGGGGCTT
301 GGGTGAGTGA AGGACTAGTG GGGTGAGAGGTCTGTGTGTTGGGGTGTGAA 
API GRE
351 AGTGTGGGTT AGGTTTATGT GGTTTTGTTTG GAGAATTGG TAGGGAAGGG
401 AGATGGGAGGTGTGGATGGGAGGTGTTGGGAGGAGGTTGTGGGGGAAAGG
451 TTGGGTGATGGTGGTGGGGTGGGGTGAGATGATGGTGGATGAGGTGGAGT
CRE
501 TGGGGTTTAA GGGGGGGTGT GTTGTATGTTG GTGAATGTTTAGGGTTTGA 
Spl CAAT
551 GGAGGAGAAA TAGGAAGAGA TGTTTGTTGGG JCCAGTGACACTCGTCCCG 
TATA +1
601 CTTCAACACA GGCGAACAGA CGGATTCTTTA AAAGA GTATTCAGTTCAAG
EXON I EXON II
651 GGAACGAAGA AUGAGAATrATTfTTGGTGA ATGGATTCA AATAAATGGA
701 ATAAGAGACA GCTGAAGATC TGATCCAUTC GAAGAACCC TAACAGTCCG
751 TTTGTCTAATCCATAACAACAAAACGTAAAA A ATGAATTC
MET
FIGURE 3.1 SEQUENCE OF RAT NPY-Yl GENE
Sequence of 790 bp of the 5'-flanking region of rat NPY-Yl receptor gene (Gene Bank 
accesion number: X95507; Lundell and Larhammar, 1996). CRE (cAMP responsive element), 
GRE (glucocorticoid responsive element), ERE (estrogen reponsive element), API (API 
responsive site), S p l (Spl responsive site), CAAT (CAAT-like box), TATA (TATA-like 
box), +1 (putative transcription start site), MET (methionine).
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The promoter region of the NPY-Y 1 receptor gene upstream to the open reading frame was 
aligned to the presence of consensus sequences (WEB Signal Scan 4.05 program, University 
of Minnesota). This gene contains in this region several consensus sequences for transcription 
factors (Figure 3.2); an AT-rich "TATA-like" box (AAATA) is located at -20 bp (using as a 
reference the putative transcription start site) and there is a proposed "CAAT" box (CAATCT) 
at -45 bp, a GC rich Spl site (GGGGCG) at -73 bp, one AP-1 site (TGAGTCA) at -273 bp, 
two partial cAMP response elements (CRE) (CGTCA) at -113 bp and -493 bp, one non- 
palindromic esteroid responsive element (ERE) (TGACC) at -350 bp and four non-palindromic 
glucocorticoid response elements (GRE): three in the form of AGGACT at -230 bp, -373 bp 
and -553 bp and one in the form of TGTTCT at -540 bp.
This chapter deals primarily with the establishment of a reporter function assay to study the 
transcriptional regulation of the rat NPY-Yl receptor gene using the enzyme luciferase. The 
fusion gene (pYl-LUC) has been expressed in PC 12 cells, a clonal cell line derived from a rat 
pheochromocytoma (Greene and Tischler, 1976), which expresses constitutive levels of the 
NPY-Yl receptor (DiMaggio et a l, 1994).
3.2 RESULTS
3.2.1 TRANSFECTION OF PC12 CELLS
In order to establish the optimal conditions for PC 12 cells transfection, one method was 
initially tested: calcium phosphate co-precipitation. Previous results in this laboratory using a 
different reporter vector reveal that calcium phosphate was the optimal method of introducing 
DNA into PC 12 cells (Balbi, 1994). This procedure was therefore adopted and used to study 
the efficiency in the transfection of the luciferase reporter vector. In order to obtain information 
about the transfection efficiency, PC 12 cells were initially transformed with one construet: 
pGL3-Control (Promega), in which the luciferase transcription is driven by an SV40 early 
enhancer/promoter. This is a strong viral promoter/enhancer active in many types of cells, 
including PC 12 cells. This construct was used to optimise and standardise the conditions 
necessaiy to PC 12 cells transfection and obtain measurable levels of luciferase enzyme activity.
Optimal conditions were found empirically and these were used routinely for all subsequent 
experiments. When transforming cells with DNA constructs containing the luciferase gene, 
several parameters can affect the levels of luciferase activity obtained in cell extracts, such as 
amount and quality of DNA added to the cells, the time the cells were incubated with the DNA 
or the use of compounds (DMSG, glycerol) which improve the transfection efficiency. All the 
experiments were performed in duplicate and the results are shown as the mean ± standard 
deviation of at least three experiments.
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DBC-FORSKOLIN NGF-PMA DBC-FORSKOLIN
CREE FOS-JUN
Luciferase
GRE GRE CRE GRE ERE AP1 GRE CRE SP1 CAAT BOX TATA BOX
GLUCOCORTICOIDS ESTROGEN BASAL LEVEL
Pst I AvRII Eco NI Pvu
STEROID Eco RI
m R N A  lu c ife ras e
A A A ALuciferase
FIGURE 3.2 RESTRICTION ENZYME AND PUTATIVE 
BINDING SITES OF RAT NPY-Yl PROMOTER
Restriction enzymes sites (Avr II, Eco RI, Eco NI, Pst I, Pvu II) and putative 
binding sites in the promoter region of rat NPY-Y 1 receptor gene cloned in the luciferase 
reporter vector (pYl-LUC). CRE (cAMP responsive element), GRE (glucocorticoid 
responsive element), ERE (estrogen reponsive element), API (API responsive site), S p l  
(Spl responsive site), CAAT (CAAT-like box), TATA (TATA-like box), +1 (trascription 
initiation site). LUC (Luciferase open reading frame).
126
3.2.1.1 DNA QUALITY
The success of a particular gene transfer experiment depends largely on the quality of the DNA 
preparation. Indeed, the requirement for highly purified form I (covalently closed circular 
supercoiled) plasmid molecules to ensure both consistency and optimal levels of gene 
expression in "transient" assays is well documented. Therefore, in order to ensure 
homogeneity on DNA preparations, DNA used in these experiments was prepared using the 
large scale maxiprep alkaline-lysis method and purified by ultracentrifugation through caesium 
chloride (CsCl) gradient (See Chapter 2. DNA plasmid isolation).
3.2.1.2 DNA CONCENTRATION
The amount of DNA is a parameter known to affect the efficiency of the transfection. Initially, 
different concentrations of pGL3-Control reporter vector were tested for the transfection 
experiments (Figure 3-3). Maximum luciferase activity was obtained using 10 |0.g of control 
plasmid, increasing amounts of plasmid did not increase significantly the levels of luciferase 
activity. In the following experiments, 10 p.g of plasmid DNA was therefore chosen for 
transfection in PC 12 cells.
3.2.1.3 TIME POINT OF HARVESTING
Using 10 fig of pGL3-Control, the maximum levels of luciferase activity were detected in 
PC 12 cell extracts after 2 days of transfection (Figure 3-4). Cell extracts of non-transformed 
PC 12 cells showed no detectable luciferase activity as compared with cells transformed with 
pGL3-Control during each day (data not shown). This is an absolute requirement of the 
reporter assay method as it important that the only source of luciferase activity be derived from 
the plasmid DNA transformed into the PC 12 cells.
3.2.1.4 LINEARITY OF THE ASSAY
A PC 12 cell extract was diluted over a 100 fold range and the luciferase activity was measured 
(Figure 3-5). These results demonstrated that the luciferase activity was linear over this range 
of dilution, which means it is possible detect small variations in the levels of luciferase activity 
over this range of concentration of firefly luciferase enzyme in PC 12 cells.
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FIGURE 3.3 PLASMID CONCENTRATION EFFECT
Concentration effect on luciferase expression of pGL3-SV40 (Promega). PC 12 cells were 
transfected with different concentrations of the pGL3-SV40 and 48 hours after transfection the 
cells were collected for luciferase assay (Promega). Each experiment represents the absolute 
luciferase activity of transfected cells compared to corresponding untransfected cells. Values 
are mean ± SEM from 3 or more transfections experiments, each performed in duplicate with 
plasmids from at least two different preparations.
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FIGURE 3.4 TIME COURSE EFFECT
Time course effect on luciferase expression of pGL3-SV40 (Promega). PC12 cells were 
transfected with pGL3-SV40 (10 ftg) and then collected at the indicate times for luciferase 
assay (Promega). Each experiment represents the absolute luciferase activity of transfected cells 
compared to corresponding untransfected cells. Values are mean ± SEM from 3 or more 
transfections experiments, each performed in duplicate with plasmids from at least two 
different preparations.
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FIGURE 3.5 LINEAR RESPONSE LUCIFERASE ASSAY
Linear response of luciferase assay from cell extracts of COS-7 cells transfected with pGL3- 
SV40 (1 |ig) and collected 48 hours after transfection for luciferase assay (Promega). Each 
experiment represents the absolute luciferase activity of transfected cells compared to 
corresponding untransfected cells. Values are mean from 3 or more transfections experiments, 
each performed in duplicate with plasmids from at least two different prepai'ations.
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3.2.1.5 REPRODUCIBILITY OF THE ASSAY
Different aliquots of the same PC I2 cell extracts were assayed for luciferase activity under 
identical conditions. Similar levels of luciferase were obtained with the different aliquots (data 
not shown).These results demonstrated that the luciferase reporter assay is highly reproducible.
3.2.1.6 THERMAL STABILITY OF THE LUCIFERASE ENZYME
A cell extract was frozen and thawed several times and the luciferase activity was measured. 
Similar levels of luciferase were obtained with the different assays (data not shown). These 
results demonstrated that luciferase is a stable enzyme.
3.2.2 DESIGN AND CONSTRUCTION OF THE pYl-LUC
FUSION GENE
The transcriptional activity of the rat NPY-Y 1 receptor gene was measured using a fusion gene 
reporter system, the luciferase assay (Promega) in which a fragment of approximately 760 bp 
of the 5'-flanking region of this gene was synthesized by polymerase chain reaction (PCR) 
from a rat hypothalamic clone (pRHT35) obtained from Professor Dan Larhammar, Uppsala 
University, Department of Medical Genetics (Figure 3-6). This clone was selected in a 
screening of a commercial rat hypothalamic library and has on the 5'-side of the open reading 
frame of the NPY-Y 1 gene approximately 600 bp of the promoter region of the gene.
3.2.2.1 OLIGONUCLEOTIDES FOR AMPLIFICATION OF THE PROMOTER
The oligonucleotides 2023-2024 (Appendix II) were used to amplify by PCR the rat NPY-Yl 
promoter from a rat hypothalamic clone (Figure 3-7A). The 5'-region of the reverse primer 
(2023) was modified to include a Bam HI site to be used for subcloning this promoter in the 
pGL3-Basic reporter vector (Promega). This primer anneals to the 5'-UT region (at the exon 
II) of the rat NPY-Yl gene (-36 to -57 from the first ATG). Thus, this PCR fragment excludes 
the first ATG codon (methionine) but includes the putative cap site and the potential start 
transcription sites of the rat NPY-Yl receptor gene. The forward primer (2024) was also 
modifed at the 5'-region to include a Bam HI site. This primer bind at the 5'-flanking promoter 
region of the NPY-Yl gene (-795 to -774 from the first ATG). Thus, these primers (2023- 
2024) were used to amplify by PCR 600 bp of the rat NPY-Yl promoter region (Figure 3.7B). 
PCR fragment (760 bp) (Figure 3-7B) of the promoter of the NPY-Yl gene generated using 
the primers (2023-2024) was cloned in the Bam HI site of the pBluescribe SK+ vector 
(Stratagene) and then subcloned in the Bgl II site of the pGL3-Basic vector (Promega) in order 
to study the factors involved in the transcriptional control of the NPY-Y 1 gene.
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RAT HYPOTHALAMIC CLONE: RH35
PCR REACTION
NPY-Y1 RAT PROMOTER REGION (760 bp)
CLONING (BamHI site)
MULTIFUNCTIONAL VECTOR : pBLUESCRIBE
SUBCLONING (Bgl II site)
BASIC
VECTOR
r ~
DEX
REPORTER VECTOR: LUCIFERASE
TRANSFECTION PCI 2 CELLS
Y1-LUC
VECTOR
CONTROL
VECTOR
TREATMENT PC12 CELLS
NGF PACAP
FIGURE 3.6 STRATEGY FOR CLONING THE PROMOTER 
REGION OF THE NPY-Yl RECEPTOR GENE
Methodological strategy used for cloning the 5'-flanking region of the rat NPY Y 1 receptor 
gene into the reporter vector pGL3-Basic (Promega)
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3.2.2.2 SUBCLONING OF THE PROMOTER OF THE NPY-Yl GENE
The promoter of the NPY-Y 1 gene was amplified by PCR using rat hypothalamic DNA clone 
(Figure 3-7A). A PCR fragment of the predicted molecular weight, approximately 760 bp 
(Figure 3-7B) was generated using both primers (2023-2024). PCR product containing 
approximately 600 bp of the NPY-Yl promoter was extracted with phenol/chloroform and the 
DNA precipitated by addition of 2 volumes of ethanol and overnight incubation at -20^ >C. This 
PCR fragment was digested with Bam HI (only present at the 5'-region of the primers) and 
extracted again with phenol/chloroform and ethanol precipitated. In parallel, the pBluescribe 
SK+ (Stratagene) was also digested with Bam HI and the enzyme was then inactivated by 
heating the reaction for 15 minutes at 65°C. The free ends of the vector were dephosphorylated 
with shrimp alkaline phosphatase (SAP) and the enzyme was inactivated by heating for 15 
minutes at 65®C.
PCR product (760 bp) was ligated in a bidirectional manner into the Bam HI site of the 
poly linker region of the pBluescribe SK+ (Stratagene) (Figure 3.7 C). 10 pi of each ligation 
reaction were transformed into competent JM109 or TGI bacteria. Positive clones were used to 
miniprep extractions and the plasmids were cut with Hind Ill-Pjr I to determine the orientation 
of the cloning (Figure 3.7 D). One positive clone (pBS-Yl gene) containing the expected 
fragment was used to large scale plasmid purification using the Wizard Maxiprep kit 
(Promega). This fusion gene (pBS-YIgene) was used to subcloning the promoter region of the 
NPY - Y 1 receptor gene into the Bgl II restriction site of the polylinker region of the reporter 
vector pGL3-Basic (Promega). This clone (pBS-YIgene) was also used to delete one of the 
CRE sites of this promoter by restriction enzyme digestion (See Chapter 6. Mutagenesis 
studies of the promoter region of the rat NPY-Y 1 receptor gene).
Following, the pBS-Yl gene was digested with Bam HI, the DNA separated by size in a 
agarose gel and the insert was purified from the gel using the USBioclean kit (US 
Biochemicals). In parallel, the pGL3-Basic vector (Promega) was digested with Bgl II and the 
enzyme was inactivated by heating for 15 minutes at 65®C. The free ends of the vector were 
dephosphorylated by treatment with SAP and the enzyme was also inactivated by heating for 
15 minutes at 65®C. The insert (760 bp) containing the promoter of the NPY-Yl gene was 
ligated into the Bgl II site of pGL3-Basic (Promega). Positive clones were cut with different 
restriction enzymes to determined the orientation of the insert (Figure 3-7 F). One clone (pYl- 
LUC) with the insert in the correct orientation was used to transfect and develop the luciferase 
reporter assay in PC 12 cells (Figure 3.7 F).
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FIGURE 3.7 SUBCLONING OF THE PROMOTER OF NPY-Yl 
RECEPTOR GENE
A. The 5'-flanking region of the NPY-Yl receptor gene was amplified by PCR from a rat 
hypothalamic clone (pRH35).
B. Agarose gel showing a expected 760 bp fragment of the NPY-Yl receptor gene.
Lane 1: MWM (À, x Hind \H~Eco RI). Lane 2: NPY-Yl promoter (760 bp).
C. PCR product was cloned into Bam HI site of the pBluescribe-SK+ (pBS-Ylgene).
D. Agarose gel showing the orientation of NPY-Yl promoter cloning.
Lane 1: MWM {X \H in d  III-Fco RI) Lane 2: pBS-SK"*" xH ind  III-P.s^ I.
Lane 3: pBS-Ylgene x Hind III-Pv I. Lane 4: pBS-YIgene x Hind III-P^'/ I.
E. PCR product was subcloned into the Bgl II site of the pGL3-Basic (pYl-LUC).
F. Agarose gel showing the restriction map of NPY-Yl promoter.
Lane 1: MWM {X x Hind \Jl-Eco RI). Lane 2: pYl-LUC uncut
Lane 3: pYl-LUC x TR-Kpn I. Lane 4: pYl-LUC x lll-Mlu II.
Lane 5: pYl-LUC x Hind III- Pst I Lane 6: pYl-LUC x Hind III- Pst I
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3.2.3 BASAL LEVELS OF LUCIFERASE ACTIVITY OF THE
pYl-LUC IN PC12 CELLS
To determine whether the NPY-Yl receptor genomic fragment upstream to the open reading 
frame contains promoter sequences, transfection experiments were completed in PC 12 cells. 
Expression levels of luciferase were compared for this construct (pYl-LUC) in unstimulated 
PC I2 cells to the levels achieved after transfection of either the promoterless plasmid, pGL3- 
Basic, or to the maximal levels of luciferase obtained after transfection of the plasmid pGL3- 
Control, in which the luciferase transcription is driven by the SV40 promoter/enhancer.
Very low levels of luciferase activity were observed in PC 12 cells transfected with the pGL3- 
Basic indicating that the vector itself contained no sequences that could activate gene expression 
(Figure 3-8). Maximal activity was achieved with a control plasmid, pGL3-Control (Figure 3- 
8). Transfection of the fusion gene Yl-LUC, in which the luciferase was placed under the 
control of the promoter region of the rat NPY-Yl gene, resulted in slightly higher levels of 
luciferase activity compared to the promoterless plasmid but were considerably less than the 
maximal activity obtained with the control vector (Figure 3-8). These results indicate a 
constitutive level of NPY-Yl transcription in PC 12 cells in keeping with the observation that 
these cells express NPY-Yl receptors on their cell surface (Di Maggio et ah, 1994). Use of 
pGL3-Conti’ol indicates that PC 12 cells are capable of produce high levels of luciferase and that 
maximal levels are well above of the levels measured for the NPY-Yl promoter. The luciferase 
assay is therefore able to report factors that increase or decrease transcriptional activity in PC 12 
cells.
Moreover, this promoter region is active in other cells lines such as G Tl-7, an mouse 
hypothalamic cell line (Mellon et ah, 1990) and RINm5f, an rat pancreatic cell line (Polak et 
ah, 1990) which also express this neuropeptide receptor. In these cell lines the pYl-LUC also 
results in slightly higher levels of luciferase activity compared to the promoterless vector 
(pGL3-Basic) but considerable less that the activity obtained with the control vector (pGL3- 
Control), indicating that the luciferase is a good reporter system to study mechanisms of 
transcriptional control of this gene in this cells. This results open the possibility of more 
detailed studies in two different systems: a hypothalamic neurosecretoiy neuron (GTl-7) which 
control reproductive function by producing GiiRH and a p-pancreatic secretory cell (RINm5f) 
which control energy homeostasis by producing insulin.
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FIGURE 3.8 BASAL LEVELS OF LUCIFERASE ACTIVITY IN 
PC12 CELLS
A. Diagramatic structure of promoterless reporter vector (pGL3-Basic), NPY-Yl promoter- 
luciferase fusion gene (pYl-LUC) and SV40 reporter vector (pGL3-Control).
B. Basal luciferase activity levels of transfected PC 12 cells with BASAL (pGL3-Basic, 10 
pg), Y l-L U C  (pYl-LUC, 10 pg) and CO NTROL (pGL3-Control, 10 pg). The cells were 
collected 48 hours after transfection for luciferase assay (Promega). Each experiment 
represents the absolute luciferase activity of transfected cells compared to corresponding 
untransfected cells. Values are mean ± SEM from 3 or more transfections experiments, each 
performed in duplicate with plasmids from at least two different preparations.
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Experiments in an african green monkey kidney cell line, COS-7 cells, that does not 
constitutively express NPY-Yl receptors showed that the expression of the luciferase gene 
driven for the rat NPY-Yl promoter was similar that the obtained using the pGL3-Basic (data 
not shown). However, these cells were able to make active luciferase enzyme as the pGL3- 
Control was functional (data not shown). Taken together, this data suggests a restricted tissue- 
specific expression of this neuropeptide receptor consistent with the known distribution.
3.2.4 TRANSCRIPTIONAL ACTIVATION OF THE RAT NPY-Yl
GENE IN PC12 CELLS
Once the calcium phosphate transfection was adjusted to provide reproducible and detectable 
luciferase activity in PC 12 cells, subsequent experiments were designed to study factors 
affecting the NPY-Yl promoter activity. In all these experiments non-transformed PC 12 cells 
showed no detectable luciferase activity and the pGL3-Basic promoterless vector was 
unresponsive to the different treatments (data not shown). All the experiments were made in 
duplicate and the results are the mean ± standard deviation of at least three independent 
experiments. Untreated PC12 cells were grown in the presence of vehicle (up to 0.1%) in 
DMEM complete medium.
The transcription of the NPY-Y 1 gene was increased by various pharmacological agents in 
PC 12 cells (Figure 3-9):
(i) Dexamethasone (1 jiM), a synthetic glucocorticoid, increased luciferase activity 2.79 ± 
0.21 fold over basal levels.
(ii) Nerve Growth Factor (NGE) (100 ng/ml), a neurotrophic factor, increased luciferase 
activity 2.76 ± 0.18 fold over basal levels.
(iii) Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) (5 iiM), a polypeptide, 
increased luciferase activity 3.01+0.18 fold over basal levels.
(iv) Forskolin (30 pM), an activator of adenylyl cyclase, increased luciferase activity 3.48 + 
0.14 fold over basal levels.
(v) Dibutyryl cyclic AMP (DBG) (1 mM), an analogue of cAMP, increased luciferase activity 
2.83 ± 0.25 fold over basal levels.
(vi) Phorbol-12-miristate-13 acetate (PMA) (1 nM), an phorbol ester, increased luciferase 
activity 1.81 ± 0.16 fold over basal levels.
(vii) DHl (1 iiM), an synthetic activator of PKC, increased luciferase activity 3.20 ± 0.2fold 
over basal levels.
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FIGURE 3.9 TRANSCRIPTIONAL ACTIVATION OF THE 
NPY-YI RECEPTOR GENE
Effect of different agents in the transcriptional activity of the NPY-Yl receptor gene. PC 12 
cells were transfected with pYl-LUC (10 pg). 20 hours after transfection the cells were treated 
with D E X  (dexamethasone, 1 pM), N G F (nerve growth factor, 100 ng/ml), F A C A F  
(pituitary activating adenylyl cyclase polypeptide, 5 nM), FORSK (forskolin, 10 pM), DBG 
(dibutyryl cyclic AMP, 1 mM), D H l (1 nM) or FMA (phorbol-12-myristate-13-acetate, 1 
nM) for 48 hours and then the cells were collected for luciferase assay (Promega). Each 
experiment represents the percent of luciferase activity in treated cells compared with that the 
percent (100%) in the corresponding control cells (0.1% vehicle only). Values are mean ± 
SEM from 3 or more independent transfections experiments, each performed in duplicate with 
plasmids from at least two different preparations.
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Other pharmacological agents, such as the steroids 17-P estradiol (1 pM) and progesterone 
(IpM ), and a calcium ionophore, ionomycin (10 pM) did not increase the luciferase activity 
over basal levels in PC12 cells (data not shown). However, In preliminary results in GTl-7 
cells, the transcription of this neuropeptide receptor is induced under steroid, 17-P estradiol 
(IpM) and progesterone (1 pM) treatment (data not shown).
NPY-Yl receptor gene was unresponsive to NGF (100 ng/ml) and PACAP (5 nM) activation 
in COS-7 cells, a monkey kidney SV40-transformed cell line (data not shown). Taken 
together, these results showed that the mechanisms which control the transcription of this 
neuropeptide receptor gene are cell- or tissue-dependent consistent with the loiown distribution 
of the this neuropeptide receptor gene in rat (Eva et ah, 1990).
Additionally, when reporter functions are used to study gene regulation, it is important to 
confirm that differences in the levels of reporter activity reflect differences in transcriptional 
activity of the gene and are not a result of influences on post-transcriptional effects, such as 
niRNA stability. Previous experiments demonstrated that pGL3-Control, had high levels of 
luciferase activity in PC 12 cells (Figure 3-8) and this viral promoter should be unresponsive to 
exogenous agents in these cells.
pGL3-Control was used indirectly to analyse for effects on mRNA stability because assay 
changes in luciferase activity can only result from post-transcriptional effects. Results showed 
that pGL3-Control driven luciferase activity was unresponsive to the different pharmacological 
agents used to increase pYl-LUC-driven luciferase aetivity in PC12 cells (data not shown). 
This indicates that the differences observed in the luciferase activity using this different 
pharmacological agents were primarily due to differences in the transcriptional activity of the 
NPY-Yl receptor gene.
3.2.5 DUAL LUCIFERASE™ REPORTER ASSAY SYSTEM
Dual-Luciferase™ Reporter (DLR) Assay System (Promega) combines the speed and 
sensitivity of two luciferase reporter enzymes into an integrated, single-tube, dual-reporter 
assay format. DLR assay system provides sequential quantification of both firefly {Photinus 
pyralis ) and sea pansy {Renilla renifoiinis ) luciferase in cell lysates. Quantitating the 
luminescent signal from each of the two luciferase reporter enzymes may be performed 
immediately following lysate preparation, without the need for dividing samples or performing 
additional treatments.
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pRL-CMV vector contains the cytomegalovirus (CMV) immediate early enhaneer/promoter 
region, which provides constitutive expression of Renilla luciferase in PC I2 cells (Figure 3- 
10). pRL“SV40 vector contains the SV40 promoter/ enhancer, and also provides with a strong 
expression of Renilla luciferase in PC12 cells (Figure 3-10). To help ensure independent 
genetic expression between experimental and control reporter genes, it is necessary to perform 
preliminary eo-transfection experiments to optimise both the amount of vector DNA and the 
ratio of co-reporter vectors added to the transfection mix.
The extreme sensitivity of both firefly and Renilla luciferase assays, and the large linear range 
of luminiscence, allows accurate measurement of even vastly different experimental and control 
luminescence values. Therefore, it is possible to add relatively small quantities of a pRL vector 
to provide low-level, constitutive expression of Renilla luciferase activity. Ratios of 10 : 1 for 
experimental vector (pYl-LUC) (10 jig): control vector (pRL-CMV or pRL-SV40) (1 p,g) 
result in measurable and no saturable levels of both luciferase (firefly and sea pansy) in PC 12 
cells (Figure 3-10). These results shown that the Renilla luciferase is co-expressed from both 
vectors, pRL-CMV and pRL-SV40 with the firefly luciferase from pYl-LUC and both pRL 
reporter vectors can be used as internal control for determining transfection efficiencies in 
PC12 cells.
PC I2 cells transfected with pRL-CMV (1 jig) were treated with different activator compounds 
for 48 hours in a DMEM complete medium. Dexamethasone (1 pM) and NGF (100 ng/ml) 
increased the Renilla luciferase activity over basal levels, 2.4 and 2.9 fold respectively (Figure 
3-11) indicating that this reporter vector is not suitable to be used as an internal control in PC 12 
cells treated with these agents. Additionally, PC 12 cells treated with PACAP (5 nM) and 
Forskolin (10 pM) also increase the Renilla luciferase activity in comparison to basal levels, 
1.6 and 2.3, respectivily (Figure 3-11), and therefore the pRL-CMV cannot be used as internal 
eontrol in PC 12 cells treated with these compounds.
PC 12 cells transfected with pRL-SV40 (1 pg) were treated with different agents for 48 hours 
in a DMEM complete medium. Dexamethasone (IpM ) and NGF (100 ng/ml) increased the 
Renilla luciferase activity, 3.7 and 2.1 fold over basal levels, respectivily (Figure 3-12). 
However, PC 12 cells treated with PACAP (5 nM) and Forskolin (10 pM) did not increase the 
Renilla luciferase activity in comparison to the basal levels in PC 12 cells (Figure 3-12) and for 
this reason, the pRL-SV40 can be used as internal control in PC 12 cells treated with PACAP 
and other PKA activators, such as forskolin (See Chapter 5).
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FIGURE 3.10 CO-EXPRESSION OF FIREFLY AND R E N I L L A  
LUCIFERASE IN PC12 CELLS
Co-expression effect of firefly luciferase directed by the NPY-Yl promoter (pYl-LUC) and 
Renilla luciferase directed by the cytomegalovims (CMV) promoter (pRL-CMV, Promega) or 
the simian virus 40 (SV40) promoter (pRL-SV40, Promega). PC 12 cells were co-transfected 
with NPY-Yl (pYl-LUC, 10 pg) and CMV (pRL-CMV, 1 pg) or SV40 (pRL-SV40, 1 pg) 
and 48 hours transfection the cells were collected for Dual-luciferase assay (Promega). Each 
experiment represents the luciferase activity of transfected cells compared to corresponding 
untransfected cells. Values are mean ± SEM from 3 or more transfections experiments, eaeh 
performed in duplicate with plasmids from at least two different prepar ations.
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FIGURE 3.11 TRANSCRIPTIONAL ACTIVATION OF THE 
CMV-DIRECTED R E N IL L A  LUCIFERASE IN PC12 CELLS
Effect of different agents in the transcriptional activation of the Renilla luciferase gene directed 
by the CMV immediate early enhancer/promoter. PC 12 cells were transfected with pRL-CMV 
(1 pg). 20 hours after transfection the cells were treated with DFX (dexamethasone, 1 pg), 
N G F (nerve growth factor, 100 ng/ml), PA C A P (pituitary activating adenylyl cyclase 
polypeptide, 5 nM), FORSK (Forskolin, 10 pM) or PMA (phorbol-12-myristate-13-acetate, 
1 nM) for 48 hours when the cells were collected for Dual-luciferase assay (Promega). Each 
experiment represents the percent of luciferase activity in treated cells normalized to 100% for 
the control cells (0.1% vehicle only). Values are mean ± SEM from 3 or more transfections 
experiments, each performed in duplicate with plasmids from at least two different 
preparations.
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FIGURE 3.12 TRANSCRIPTIONAL ACTIVATION OF THE 
SV40-DIRECTED R E N I L L A  LUCIEERASE IN PC12 CELLS
Effect of different agents on the transcriptional activation of the Renilla luciferase gene directed 
by the SV40 early enhancer/promoter. PC 12 cells were transfected with pRL-CMV (1 pg). 20 
hours after transfection the cells were treated with DEX (dexamethasone, 1 pg), NGF (nerve 
growth factor, 100 ng/ml), PACAP (pituitary activating adenylyl cyclase polipeptide, 5 nM), 
FO RSK  (Forskolin, 10 pM) or PMA (phorbol-12-myristate-13-acetate, 1 nM) for 48 hours 
when the cells were collected for Dual-luciferase assay (Promega). Each experiment represents 
the percent of luciferase activity in treated cells normalized to 100% for the control cells (0.1% 
vehicle only). Values are mean ± SEM from 3 or more transfections experiments, each 
performed in duplicate with plasmids from at least two different prepai'ations.
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3,2.6 TRANSCRIPTION INITIATION SITE OF THE NPY-Yl
GENE
3.2.6.1 PRIMER EXTENSION ANALYSIS
In order to obtain information about the location of the transcription initiation site in the 
promoter region of the NPY-Yl receptor gene present in the pYl-LUC fusion gene, primer 
extension analysis were carried out using an 25-mer antisense oligonucleotide (T1886) (See 
Appendix II) corresponding to the nucleotides 107 to 83 to the ORF of the luciferase gene 
(Figure 3-13).
In this reaction, 10 pmol of antisense oligonucleotide (T1886) (Appendix II) was end-labelled 
using the AMV reverse transcriptase primer extension system kit (Promega) following the 
manufacturer instructions (See Chapter 2. Primer extension assay). The primer extension 
product of the luciferase mRNA was expected to be approximately 300 bases in length (taking 
as a start transcription site the putative cap site of the rat NPY-Y1 promoter) (Figure 3-12). As 
a positive control 10 pmol of control primer was used which anneals to 25 fmol of an in vitro 
transcribed product (1.2 kb kanamycin positive control cRNA) supplied with the primer 
extension system kit (Promega). Primer extension product of the control RNA is 87 bases in 
length. As a negative control RNase-free water replaced the control RNA was used. As DNA 
markers a end-labelled (j)X174 Hinf I DNA supplied with the primer extension system kit was 
used.
Initially, the primer extension reaction was carried out using 10 p.g of total RNA from PC 12 
cells transfected with 10 jig of pYl-LUC fusion gene. The aliquots were taken after 4 hours, 
12 hours and 24 hours of transfection. The transfection efficiency was monitored following the 
luciferase activity of an aliquot of the transfected PC 12 cells (data not shown). In addition, the 
integrity of the total RNA was determined using a RNA-formaldehyde denaturing gel (data not 
shown). As seen in the figure 3-14A, the PAGE-gel of the primer extension products reveal a 
band of 87 bases in length corresponding to a positive control product, however the expected 
band of the luciferase mRNA did not appear. Further experiments, increasing the amounts of 
total RNA (up to 50 jig) and/or reducing the stringency of the hybridization conditions (from 
58°C to 35°C) did not reveal the primer extension product for the luciferase mRNA (data not 
shown). For this reason was used a more sensitive approach to study the transcription initiation 
site of the NPY-Yl gene : RT-PCR amplification.
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FIGURE 3.13 TRANSCRIPTION INITIATION SITE OF THE 
NPY-Yl RECEPTOR GENE IN PC12 CELLS
A. Diagramatic structure of the region closer to the putative transcription start site of the 
promoter of the NPY-Yl receptor gene (pYl-LUC). Putative binding sites for transcription 
factors and annealing sites of the primers aie presented.
B. Schematic size of expected PCR products are showed. TATA (TATA-like box), CAAT 
(CAAT-like box) and S p l (Spl responsive element). +1 (putative start transcription site).
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3.2.6.2 RT-PCR ANALYSIS
To determine the approximate location of the transcription start site in the NPY-Yl receptor 
gene present in the pYl-LUC fusion gene, RT-PCR was used to amplify the 5'-end of the 
luciferase transcript. First strand cDNAs were synthesized using 1 jig of total RNA from PC 12 
cells transfected for 1 day with pYl-LUC (10 jig) (See Chapter 2. Cell transfection). Total 
RNA was incubated for 15 minutes at 37 °C with RQl RNase-free DNAse (lu/j.ig plasmid) to 
remove the DNA template before the RT reaction, extracted twice with acid phenol/chloroform 
and ethanol precipitated. The transfection efficiency was monitored by measuring the luciferase 
activity in an aliquot of the transfected PC 12 cells (data not shown). In addition, the integrity of 
the total RNA extracted from PC12 cells was determined using a RNA-formaldehyde 
denaturing gel (data not shown).
For the RT reaction a 15-mer antisense oligonucleotide (Y7464) was used (Appendix II). This 
primer anneals to residues 97 to 83 of the open reading frame of the luciferase gene present in 
the pYl-LUC (Figure 3-13B). Amplifications were performed using primers corresponding to 
upstream sequences (see below), and the products were analyzed by agarose gel 
electrophoresis (Figure 3-14B). As a negative control RT-PCR reactions were performed using 
total RNA extracted from PC 12 cells and RT-PCR reactions in which the reverse transcriptase 
enzyme (MMLV) was omited (to discard genomic or plasmid contamination). These RT-PCR 
reactions showed no detectable products (data not shown), indicating that the RT-PCR 
products obtained were derived from the luciferase mRNA specifically transcribed for the pY 1 - 
LUC fusion gene.
PCR products of the expected sizes were amplified using the following primers (Appendix II):
(i) Y7465 corresponding to residues -35 to -20 (342 bp PCR product)
(ii) Y7466 corresponding to residues -19 to -5 (327 bp PCR product)
(iii) Y7467 corresponding to residues +2 to +17 (300 bp PCR product)
These results suggests that the transcription of the NPY-Y 1 receptor gene begins upstream to 
the putative transcription start site (cap site). However more precise location of the transcription 
stait site requires the design of upstream forward primers and further RT-PCR experiments.
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FIGURE 3.14A PRIMER EXTENSION ASSAY OF THE NPY-YI 
PROMOTER
Primer extension assay assay of luciferase mRNA under the control of NPY-Yl promoter 
(pYl-LUC). Total RNA (10 jig) of PC 12 cells was extracted after 4 hours, 12 hours and 24 
hours of transfection. As a negative control RNAse free water was used and kanamycin cRNA 
(primer extension assay kit, Promega) was used as a positive control. PAGE gel. Run 250 
Volts X 2 hours. Autoradiograph exposure time: overnight without intensifying screen (70®C). 
Lane 1: MWM (4)X174 x Hinf I)
Lane 2: RNAse free water (negative control )
Lane 3: cRNA kanamycin (positive control)
Lane 4: mRNA luciferase (PC 12, 4 hours)
Lane 5: mRNA luciferase (PC 12, 12 hours)
Lane 6: mRNA luciferase (PC 12, 24 hours)
FIGURE 3.14B RT-PCR AMPLIFICATION OF THE NPY-YI 
PROMOTER
Agarose gel electrophoresis of RT-PCR products of luciferase mRNA under the control of the 
NPY-Yl promoter (pYl-LUC). PC12 cells were transfected with pYl-LUC (10 |ig) and 24 
hours after transfection the cells were collected for total RNA extraction. Total RNA (1 |ig) 
was amplified by RT-PCR and products of the expected size were obtained:
Lane 1: MWM (1 Kb ladder)
Lane 2: RT-PCR product (342 bp) (primers Y7464-Y7465)
Lane 3: RT-PCR product (327 bp) (primers Y7464-Y7466)
Lane 4: RT-PCR product (300 bp) (primers Y7464-Y7467)
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3.3 DISCUSSION
3.3.1 LUCIFERASE REPORTER ASSAY IN PC12 CELLS
The nervous system contains diverse populations of cells which interconnect in precise 
manners. The identity of these cells is determined by their ability to transcribe a paiticular set of 
genes. The factors participating in NPY-Yl receptor gene expression have to satisfy unique 
criteria since NPY-Yl receptor is distributed in a variety of cell populations throughout the 
central and peripheral nervous system (See Chapter 1. NPY receptors). These experiments 
represent the first characterisation of a rat NPY-Y 1 gene transcriptional activity using reporter 
functions (luciferase enzyme) in a pheochromocytoma cell line; PC 12 cells.
The use of reporter functions offers several advantages for the study of regulation of gene 
transcription. Once the 5'-flanking region of the gene has been cloned, it is possible to delete, 
substitute or alter specific sequences and study how these modifications affect the normal 
response of the gene. Several reporter genes have been defined; one of these is the gene for the 
firefly enzyme, luciferase. This gene is not present in mammalian cells, therefore, any 
measurable activity is derived from the transfected DNA (Wood, 1991). It is readily translated 
into protein in eukaryotic cells and, therefore, levels of luciferase activity relate directly with 
levels of gene transcription (Wood, 1991).
Several methods can be used to transfect PC 12 cells. Previous results in this laboratory 
revealed that the CaP04 co-precipitation was the optimal method to introducing DNA into this 
cell line (Balbi, 1994). However, optimal transfection conditions were found empirically using 
the pGL3-Control vector (Promega), in which the luciferase transcription is driven by a SV40 
early promoter/enhancer. Using this reporter vector it was found that 10 p.g of CsCl-derived 
plasmid DNA (type I form), overnight (12-16 hours) incubation with the transfection mix 
(calcium phosphate plus DNA) and harvesting the cells two days (48 hours) after transfection 
resulted in maximum levels of luciferase activity. These conditions were used routinely for all 
subsequent transfections.
In addition it was found that the luciferase activity was: (i) lineai' over the range of dilution (1:5 
to 1: 20) used in the assay, (ii) highly reproducible and (iii) resistant to repeat cycles of freeze- 
thawing. Finally it was found that cell extracts of non-transformed PC 12 cells showed no 
detectable luciferase activity indicating that the only source of luciferase was derived from the 
plasmid transfected into the PC 12 cells.
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Firefly luminiscence has been the most extensively studied bioluminiscence system (Wood, 
1991). The light-producing reaction requires the enzyme (E) luciferase, the substrate (LHz) 
luciferin, Mg++, ATP and molecular oxygen (02). The initial reaction is the rapid conversion, 
in the presence of Mg++ and ATP, of luciferin to luciferyl adenylate, which, in the presence of 
luciferase, combines with molecular oxygen to give an oxylucifeiyl adenylate-enzyme complex 
in the excited state :
Mg++
LH2 (luciferin) + E (enzyme) + ATP   E : LH2 ; AMP + PP
After light emission, the ground-state complex dissociates to form enzyme, AMP, oxyluciferin, 
and carbon dioxide (C02), the last being derived from the carboxyl group of luciferin :
E : LPÏ2 : AMP + Ü2 ...........  E + L = O (oxyluciferin) + CO2 + AMP + light
(hn max., 562 nm)
The reaction catalysed by firefly luciferase [Photynus pyralis luciferin: oxygen 4- 
oxydoreductase (decarboxilating, ATP-hydrolysing) EC 1.13.12.7] is the mono-oxidative 
decarboxylation of beetle D-luciferin, utilising ATP and O2 as co-substrates with concomitant 
production of a photon of green light. The oxidation occurs from an enzyme intermediate, 
luciferyl AMP. However, coenzyme A (CoA) is also substrate of luciferase, and in the 
presence of CoA, oxidation occurs from luciferyi-CoA with more favourable total kinetics, as it 
produces constant light intensities which gradually decreases after 60 seconds with greater 
sensitivity. The basis of the extended "glow" reaction of the enhanced firefly luciferase assay 
is that energy, provided by splitting of ATP, is released from the reaction in the form of light, 
which can be measured using a luminometer or standard liquid scintillation counters. Because 
light output is lineally proportional to the amount of luciferase, luminiscence correlates directly 
to the expression of the luciferase reporter gene in transfected cells or cell lysates.
Luciferase is a monomeric protein of 60.7 kDa that does not require post-translational 
processing for enzymatic activity (Wood, 1991). Thus, it can function as a genetic reporter 
immediately upon translation. Light production by luciferase enzyme has the highest quantum 
efficiency known of any bioluminiscent reaction and allows for greater enzymatic turnover of 
luciferase, resulting in greater light intensity that is nearly constant for measurements of up to 
several minutes (Wood, 1991).
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Luciferase allow 100-1000 times greater sensitivity that is expected from the CAT assay. 
However, compared to CAT, the firefly luciferase protein has a shorter half-life in transfected 
mammalian cells, making the luciferase reporter suited for transient assays and short-lived 
effects. An added advantage is that the luciferase assay results can be obtained in minutes 
compared to hours, or even days, for the radioactive CAT assay. In addition, the linear range 
of the firefly luciferase assay extends over 8 orders of magnitude of firefly concentration 
(Wood, 1991).
The lueiferase assay is a good reporter system for PC 12 cells. Very low levels of luciferase 
activity was achieved with the promoterless plasmid (pGL3-Basic) indicating that this vector- 
contained no sequences that could activate gene expression in PC 12 cells. Maximum levels was 
achieved with the control vector (pGL3-Control) indicating that PC 12 cells were capable of 
producing high levels of active luciferase enzyme. Finally, slightly higher levels of luciferase 
activity was achieved with the fusion gene pYl-LUC (in which the luciferase was placed under 
the control of the promoter region of the rat NPY-Yl gene) compared to the promoterless 
vector but considerably less that the activity obtained with the control vector. This is in keeping 
with previous results that indicate that these cells have low constitutive levels of NPY-Y 1 gene 
expression (DiMaggio et al., 1994).
3.3.2 RAT NPY-Yl RECEPTOR PROMOTER REGION
Previous to the initiation of this project, a construct (plasmid RHT 35) containing the promoter 
region of the NPY-Yl gene was cloned from a rat hypothalamic library (see above). This 
construct contains 1.3 Kb of the rat NPY-Yl gene, including approximately 600 bp of the 
promoter and 700 bp of the transcriptional region of the gene, including 230 bp of the 5'-UT 
region (approximately 80 bp of the exon I and 150 bp of the exon II), and including 470 bp of 
the ORF. This clone has also correctly spliced away intron 1 (Prof. Larhammar, personal 
communication) (Figure 3-15).
The promoter region of the rat NPY-Yl receptor gene contains several consensus sequences 
that constitute putative binding sites for different transcription factors (Figure 3.1), including :
(i) an AT-rich "TATA-like" box (AAATA) located at -20 bp
(ii) a putative "CAAT" box (CAATCT) located at -45 bp,
(iii) a GC rich Spl site (GGGGCG) located at -73 bp.
iv) one AP-1 site (TGAGTCA) located at -237 bp.
v) two cAMP response elements (CRE) (CGTCA) located at -113 bp and -493 bp.
vi) one non-palindromic steroid responsive element (ERE) (TGACC) at -350 bp.
vii) four non-palindromic glucocorticoid response elements (GRE): three in the form of 
AGGACT located at -230 bp, -373 bp and -553 bp and one in the form of TGTTCT at -540 bp
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CFE SP1 C A A T - TATA N PY-Yl
NPY-Y1 RECEPTOR HUMAN GENE
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CAATGRE SRIGREGRE TATAAP1-GRE N PY-Yl
NPY-Y1 RECEPTOR MOUSE GENE
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CAAT -  TATACREGRE GRE SP1 NPY-Y1API-GRE
NPY-Y1 RECEPTOR RAT GENE
FIGURE 3.15 PUTATIVE BINDING SITES OF HUMAN, MOUSE 
AND RAT NPY-Yl RECEPTOR GENES
Comparison of the putative binding sites present in the 5'-flanking promoter region of the 
human, mouse and rat NPY-Yl receptor genes. CRE (cAMP responsive element), GRE 
(glucocorticoid responsive element), ERE (estrogen reponsive element), A P I (API 
responsive site), Sp l (Spl responsive site), CAAT (CAAT-like box), TATA (TATA-like 
box), NPY-Yl (NPY-Yl open reading frame).
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3.3.2.1 BASAL RESPONSIVE ELEMENTS
These consensus sequences for transcription factors are located using as a reference the 
putative transcription cap site of the human NPY-Yl promoter (Herzog et ah, 1993). A 
sequence comparisons between the mouse, rat and human promoters of the NPY-Yl gene 
shows a high degree of homology in the region close to the putative start site, including a 
highly conserved (AAATA) "TATA-like" box and the (CAATCT) "CAAT-like" box (Figure 3- 
15). These elements are likely to be involved in the control of the basal levels of transcriptional 
activity of this gene in PC12 cells. The "TATA-like" box is conserved in mouse, rat and human 
NPY-Yl genes (Figure 3.15). The TATA-box is the binding site for TFIID (TATA-Binding 
protein), a transcription factor involved in the formation of an active complex in vitro capable 
of initiating RNA synthesis by RNA polymerases (McKnight and Yamamoto, 1992). 
However, preliminary results using RT-PCR (Figures 3-14B) suggest that the transcription 
start site in this gene is upstream of the putative cap site. Further RT-PCR studies will be 
necessai'y to obtain more precise location of the transcription start site of this gene.
The (GGGGCG) GC-box rich constitutes the putative Spl binding site. This DNA element is 
only conserved in mouse and rat NPY-Yl gene (Figure 3.15) and constitutes another element 
that may contribute to the basal activity of the NPY-Yl gene. The Spl binding site has been 
reported to be non-inducible but is an enhancer of constitutive expression of several genes, 
specially housekeeping genes (Kadonaga et al., 1987; Minth and Dixon, 1990).
3.3.3.2 AP I RESPONSIVE ELEMENT
The promoter region of the NPY-Y 1 gene has a complete AP I site (TGAGTCA) at -273 bp of 
the putative transcriptional start site. This element is only conserved in mouse and rat NPY-Y 1 
gene (Figure 4-14). However the promoter region of the human NPY-Yl gene has an AP I 
site at position -763 (Ball et al., 1995) which is shared with the mouse NPY-Yl gene (Musso 
et ah, 1997).
The AP-1 site present in this region constitutes the most likely element to mediate the NGF- 
PMA transcriptional activation of the NPY-Yl receptor gene (Figure 3-9). This element 
constitutes a consensus binding site for the transcriptional factor AP-1, comprising dimers of 
the c-fos and c-jun family of proteins (Curran and Franz a, 1988). Expression of these 
proteins is known to be activated by NGF and phorbol esters, in PC 12 cells (Bartel et ah, 
1989). Although the mechanisms mediating eontrol of gene expression differs from gene to 
gene, AP-1 mediated transcriptional control has been reported in PC 12 cells (Machida et ah, 
1991).
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3.3.3.3 CRE R ESPO NSIVE ELEM ENT
The promoter region of the rat NPY-Yl gene has two CRE sites (CGTCA). These sequences at 
position -113 (conserved in rat and human NPY-Yl gene) and -493 (conserved in mouse, rat 
and human NPY-Yl gene) were also found in the other neuropeptides gene, where it is 
essential for biological activity of the cAMP-regulating enhancement (Roesler et al., 1988). 
Diverse agents which increase the levels of cAMP in PC 12 cells, including the peptide 
PACAP, an activator of adenylyl cyclase via GPCRs, forskolin, a direct activator of adenylyl 
cyclase and dibutyryl cAMP (DEC), an analog of cAMP increase the levels of luciferase 
activity in pYl-LUC transfected PC 12 cells (Figure 3-9). Therefore, it is possible that the CRE 
were mediating the response of the NPY-Yl promoter to PACAP and other activators of the 
PKA second messenger pathway in PC 12 cells (See Chapter 5).
3.3.3.4 GRE R ESPO N SIVE ELEM ENT
Several reverse complement GRE non-palindromic consensus sequences (AGGACT) were 
found at -230 bp, -373 bp and -553 bp (conserved in mouse, rat and human) and one 
(TGTTCT) at -540 bp (conserved only in rat) of the putative transcriptional start site (Figure 3- 
14). Interestingly each of the four elements in the 5’-flanking region of the NPY-Yl gene do 
not comprise palindromic structures. However the close location of the GRE at -540 and -553 
in the NPY-Yl gene, may allow these two sites to act cooperativily with monomeric 
glucocorticoid receptors. It has been also reported that GRE without palindromic structure can 
form a functional complex with monomeric glucocorticoid receptor in murine mammary tumour 
virus (MMTV) and activate gene transcription (Chapelakis et al., 1990). The four GRE binding 
elements of the NPY-Yl gene may explain the dexamethasone-inducibility of the NPY-Yl gene 
transcription (Figure 3-9). Moreover, the GR has been found to repress AP-1 stimulated 
transcription (Lopes da Silva and Burbach, 1995). The NPY-Yl promoter has an overlapping 
API-GRE consensus site and the interactions between these two factors may affect the NPY- 
Yl gene transcription.
These DNA binding elements are the primary candidates involved in the transcriptional control 
of the NPY-Yl receptor gene in PC I2 cells, although it is not possible to rule out the presence 
of other less conspicuous but important regulatory elements. The transcriptional activity of this 
gene may be controlled by differential interactions of these proteins with the promoter. Further 
diversity could be generated by controlling the regulatory activity of these DNA binding 
proteins. In this way a combination of several transcription elements could result in a specific 
expression pattern observed for the NPY-Yl receptor gene in the nervous system (See Chapter
1. NPY-Yl receptors).
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3.3.3 PO ST-TR ANSCR IPTIO NA L CONTROL OF THE LUCIFERASE GENE
IN PC12 CELLS
It is important to confirm that the differences observed in the levels of luciferase activity using 
the activators compounds reflect differences in the transcriptional activity of NPY-Yl receptor 
gene and ai*e not result of post-transcriptional effects, such as mRNA stability. For this reason 
the pGLS-Control in which the luciferase activity is under the control of the SV40 early 
enhacer/promoter was used. Results showed that the levels of luciferase aetivity driven for the 
pGL3-Control (Promega) were not altered by the different activator compounds which are 
known to increase the luciferase activity driven for the pYl-LUC fusion gene in PC 12 cells 
(data not shown). This result suggests that the differences in transcriptional activation by the 
different phaiinacological compounds were due to a differences in the transcriptional activity of 
the NPY-Yl receptor gene in PC 12 cells.
3.3.4 DUAL-LUCIFERASE™  REPORTER ASSAY SYSTEM
A control reporter vector (pRL) and the Dual-Luciferase™ reporter assay system (Promega) 
was used in order to normalize for tranfection efficiency or cell lysate recovery between 
transfection experiments. Sources of variation in transfection efficiency include: quality of the 
DNA preparations, small changes in the pH of the transfection solutions or differences in the 
cell density or healthy, among others. Typically, pRL-CMV or pRL-SV40 were used as a 
control reporter gene in co-transfected experiments with the pYl-LUC vector. These control 
vectors were used because they are linked to a different reporter gene {Renilla luciferase) and 
were under the control of a strong constitutive viral promoters. Optimal conditions for the co­
transfection of both plasmids were found empirically. This co-transfection experments indicate 
that ihcRenilla luciferase driven for these reporters vectors are active in PC 12 cells and can be 
co-expressed with the firefly lueiferase (Figure 3-10).
However, CMV immediate early enhancer/promoter present in the pRL-CMV vector was 
responsive to all the pharmacological activator compounds tested: dexamethasone (IjiM), NGF 
(100 ng/ml), PACAP (5nM) and forskolin (10 |lM) (Figure 3-11) which precluded its use as 
internal control. SV40 early enhancer/promoter present in the pRL-SV40 reporter vector was 
responsive to dexamethasone (1 pM) and NGF (100 ng/ml), but was unresponsive to PACAP 
(5 nM) and forskolin (10 pM) (Figure 3-12). These results suggest that this vector can be used 
as as internal control in PC 12 cells treated with PACAP and other activators of the PKA 
signalling pathway, such as forskolin (See Chapter 5).
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Dexamethasone and NGF-dependent activation of the Renilla luciferase activity driven by the 
pRL-SV40 vector could be a consecuence of post-transcriptional effects, such as increase of 
the mRNA stability of the Renilla luciferase enzyme in PC I2 eells or due to intrinsic 
differences between the reporter vectors, such as non-specific response by sequences present 
in the pRL-SV40. Further experiments, including studies of the mRNA stability of the Renilla 
luciferase enzyme using specific inhibitors of the RNA synthesis, such a actynomicin D will be 
necessary to undertand this differences in the dexamethasone and NGF-dependent response of 
the SV40 early enhancer/promoter present in this two reporter vectors in PC 12 cells. In 
addition, cloning the promoter region of the NPY-Y 1 receptor gene in the promoterless pRL- 
null vector (Promega) and mesurements of the Renilla luciferase activity under dexamethasone 
(IpM ) or NGF (100 ng/ml) treatment of PC12 cells may indicate the possible effect of the 
vector in the transcriptional activation of this gene.
3.3.5 TRANSCRIPTIONAL CONTROL OF N P Y -Y l IN OTHER CELL LINES
NPY-Yl mRNA is highly expressed in several regions of the rat forebrain, including the 
hippocampus and hypotalamus (See Chapter 1. NPY receptors). 600 bp of the 5'-flanking 
region of the NPY-Yl gene contains a functional promoter that is active in a neural crest- 
derived cell line: PC 12 cells. In addition, this promoter is active in G Tl-7, a mouse 
hypothalamic cell line (Mellon et ah, 1990) and RINm5f, an rat pancreatic cell line (Polak et 
ah, 1993) which also express this neuropeptide receptor (See Chapter 8) but not in a kidney- 
derived SV40-transformed cell line: COS-7 cells. These results suggest that the NPY-Yl gene 
contains a cell-type specific core promoter consistent with the known distribution of the NPY- 
Y 1 receptor gene.
Results obtained using GTl-7 and RINmSf cells open the possibility of more detailed studies 
of the transcriptional activation of the NPY-Yl reeeptor gene in two different systems. GTl-7 
cells are a model of hypothalamic GnRH neurons which control the hormonal cascade 
regulating mammalian reproduction (Mellon et ah, 1990). Previous results have been shown 
that NPY is a peptide involved in the control of the reproductive function in mammals (See 
Chapter 1. Effects of NPY family of peptides). It will be important to know the effect of 
steroids, such as estrogen and progesterone in the control of the expression of this 
neuropeptide receptor. RINni5f cells are a model of a p-pancreatic secretory eell (RINm5f) 
which control energy homeostasis by producing insulin (Polak et ah, 1993). NPY is involved 
in the insulin secretion in this cell line by binding to a NPY-Yl receptor. It will be also 
important to known the effect of different agents which control the secretion of insulin in the 
expression of this neuropeptide receptor gene.
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In preliminary results in GTl-7 cells the transcription of NPY-Yl is induced by steroid 
(progesterone and estrogen) treatment. It is possible that the estrogen response element (ERE) 
(TGACC) located 350 nucleotides upstream to the putative transcription start site is the cis 
-element involved in this estrogen-induced response. In experiments in COS-7 cells the 
promoter of the NPY-Yl gene was unresponsive to NGF and PACAP activation (data not 
shown). These results suggest that the mechanisms controlling the transcriptional activation of 
the NPY-Yl gene are cell-type specie, and the differences are a consecuence of the expression 
and activation of a different subset of transcription factors.
3.4 SUMMARY
The major results from this chapter were:
1.- The promoter region of the rat NPY-Yl receptor gene was cloned upstream  
to the luciferase reporter enzyme.
Approximately 600 bp of the 5'-flanking promoter region of the rat NPY-Yl gene that lies 
upstream to the open reading frame has been attached to the reporter function, luciferase, such 
that the expression of this enzyme has been placed under the control of this promoter region .
2.- The promoter region of the rat NPY -Y l receptor gene contain consensus 
sequences for transcription factors.
This gene contains in this region several consensus sequences for transcription factors : a AT- 
rich "TATA-like" box (AAATA) at -20 bp (using as a reference the putative transcription start 
site), a proposed "CAAT" box (CCATCT) at -45 bp, a GC rich Spl site (GGGGCG) at -73 
bp, one AP-1 site (TGAGTCA) at -237 bp, two partial cyclic AMP response elements (CRE) 
(CGTCA) at -113 bp and -493 bp, one non-palindromic estrogen responsive element (ERE) 
(TGACC) at -350 bp and four non-palindromic glucocorticoid response elements (GRE): thiee 
(AGGACT) at -230 bp, -373 bp and -553 bp and one (TGTTCT) at -540 bp.
3.- O ptim al conditions for transfection o f the Y l-L U C  were obtained  
em pirically .
Optimal conditions for parameters which improve the transfection efficiency and can affect the 
levels of luciferase activity obtained in PC 12 cells, such as amount and quality of DNA added 
to the cells , the time the cells were incubated with the DNA and conditions of the luciferase 
assay were found empirically and used in all the transfection experiments.
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4.- The luciferase assay was a good reporter system in PC12 cells.
4.1- Very low levels of luciferase activity were obtained in PC 12 cells transfected with the 
promoterless vector (pGL3-Basic) indicating that this plasmid contained no sequences that 
could activate gene expression in PC 12 cells.
4.2- Maximal activity was achieved by transfecting PC 12 cells with a control vector (pGL3- 
Control) in which the luciferase has been placed under the control of a SV40 early 
promoter/enhancer. Use of the control SV40-driven early promoter/enhancer indicates that 
PC 12 cells are capable of producing high levels of active luciferase enzyme and that maximal 
levels of enzyme activity are well above the levels measured for the rat NPY-Yl promoter, 
indicating that the luciferase assay is therefore able to report factors that increase or decrease 
transcriptional activity in PC 12 cells.
4.3- Transfection of the fusion gene Yl-LUC (in which the luciferase was placed under the 
control of the 5'-flanking region of the rat NPY-Yl receptor gene) resulted in slightly higher 
levels of luciferase activity compared to the promoterless plasmid but were considerably less 
than the maximal activity obtained with the control vector . These results indicate a constitutive 
level of transcription of the rat NPY-Yl gene in PC 12 cells in keeping with the observation that 
these cells express a few receptors on their cell surface (DiMaggio et a l, 1994).
5.-Differents pharm acological agents increased the transcriptional activity of 
the rat NPY-Yl promoter in PC12 cells.
PC 12 cells were transformed with the fusion gene pYl-LUC were treated with different agents 
for 48 hours in a DMEM complete medium :
5.1- dexamethasone (1 pM), increased luciferase activity 2.79+ 0.22 -fold over basal levels.
5.2- NGF (100 ng/ml), increased luciferase activity 2.76 + 0.18-fold over basal levels,
5.3- Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) (5nM), increased luciferase 
activity 3.01 ± 0.18-fold over basal levels,
5.4- forskolin (10 pM), increased luciferase activity 3.48 ± 0.14-fold over basal levels,
5.5- Dibutyryl Cyclic AMP (DBC) (1 mM), increased luciferase activity 2.83 ± 0.25-fold over 
basal levels,
5.6- phorbol-12-miristate-13 acetate (PMA) (1 nM) increased luciferase activity 1.82 ± 0.16 
-fold over basal levels, and
5.7- DHl (1 nM), increased luciferase activity 3.20 ± 0.20-fold over basal levels
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6.- The same pharm acological agents which increased the luciferase activity  
driven for the rat N PY -Y l promoter in PC12 cells, did not increase the 
luciferase activity driven for pGL3-Basic or pGL3-Control vectors.
The levels of luciferase activity driven of the promoterless vector (pGL3-Basic) were 
unresponsive to the same concentrations of different pharmacological agents which increase the 
luciferase activity driven for the pYl-LUC fusion gene, indicating that the vector itself no 
contains sequences that will drive a specific response for these different activator compounds. 
Additionally, the SV40-driven levels of luciferase activity of the control vector (pGL3-Control) 
were also unresponsive to the same agents, indicating that the increases observed in the 
luciferase activity for the pYl-LUC in PC 12 cells treated with this agents is a consecuence of 
the transcriptional activation of the NPY-Yl gene and not a result of influences on post- 
transcriptional effects, such as mRNA stability.
7.- Rat N PY -Y l receptor promoter drive the expression of the luciferase in 
G T l-7  cells and was responsive to steroids (estrogen and progesterone) 
(prelim inary results).
In preliminary results in GTl-7 cells, a mouse hypothalamic neurosecretory cell line, the 
transcription of the NPY-Yl receptor gene is induced by steroid (estrogen and progesterone) 
treatment.
8.- Rat N P Y -Y l receptor prom oter did not drive the expression of the 
luciferase in COS-7 cells and was unresponsive to NGF and PACAP  
activation .
In COS-7 cells the expression of the luciferase driven for the rat NPY-Y 1 promoter was similar 
to the basal levels of luciferase activity obtained using the promoterless vector (pGL3-Basic). 
However, these cells were able to make active luciferase enzyme as the control vector (pGL3- 
Control) results in high levels of luciferase enzyme. This data suggests a restricted cell- or 
tissue-specificity of the rat NPY-Yl receptor gene consistent with the known NPY-Yl receptor 
gene expression. In addition, in COS-7 cells the rat NPY-Yl receptor gene was unresponsive 
to the NGF and PACAP transcriptional activation observed in PC 12 cells. This results 
indicated that the NGF and PACAP response is a specific response of neural crest-derived 
cells, such as PC 12 cells.
9.- pRL-CMV vector was not a good internal control in PC 12 cells treated with 
the different pharm acological agents which increase the luciferase activity  
driven by the pYl-LUC fusion gene in PC12 cells.
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pRL-CMV vector contains the cytomegalovirus (CMV) immediate early enhancer/promoter 
region, which provides constitutive expression of Renilla luciferase in PC 12 cells and can be 
co-expressed with the firefly luciferase enzyme. This promoter was responsive to 
dexamethasone (1 pM) and NGF (100 ng/ml), increasing the levels of Renilla luciferase 
activity, indicating that this reporter vector is not suitable to be used as internal control in PC 12 
cells treated with these agents. In addition, PC 12 cells treated with PACAP (5 nM) and 
Forskolin (10 pM) also increase the Renilla luciferase activity over basal levels, and therefore 
pRL-CMV cannot be used as internal control in PC 12 cells treated with these agents which 
increase intracellulai- cAMP.
10.- pRL-SV40 vector was not a good internal control in PC12 cells treated 
with dexamethasone and NGF but was a good internal control in PC12 cells 
treated with PACAP and forskolin.
The pRL“SV40 vector contains the SV40 eai’ly promoter/enhancer, which provides constitutive 
expression of theRenilla luciferase in PC 12 cells and can be co-expressed with the firefly 
luciferase enzyme. This promoter was responsive to dexamethasone (IpM ) and NGF (100 
ng/ml), indicating that this reporter vector is not suitable to be used as internal control in PC 12 
cells treated with these agents. However, PC 12 cells treated with PACAP (5 nM) and 
Forskolin (10 pM) did not increase the Renilla luciferase activity in comparison to the basal 
levels in PC 12 cells.Thus, pRL-SY40 can be used as internal control in PC 12 cells treated with 
PACAP and other PKA activators, such as forskolin.
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CHAPTER 4
NGF-INDUCED EFFECTS IN THE TRANSCRIPTIONAL ACTIVATION OF THE NPY-Yl RECEPTOR GENEIN PC12 CELLS
4.1 INTRODUCTION
4.1.1 PROTEIN PHOSPHORYLATION
Phosphorylation is the major language used within the cells to communicate information from 
the environment. Covalent modification by phosphorylation serves to alter the structure and 
function of proteins involved in cellular structure, metabolism, cell growth, among many other 
functions. Thus, it is not surprising that 30% of eukaryotic proteins are estimated to be 
phosphoproteins. It is estimated that there are over a thousand kinases, so that over 1% of the 
genes would encode kinases. These kinases differ in their regulation, their substrate- 
specificity, and their cellular’ localization (Walaas and Greengard, 1991).
In the nervous system in particular, reversible phosphorylation is involved in processes as 
diverse as biosynthesis of neurotransmitter, activity of ion channels and cell differentiation. 
Protein phosphorylation is also central to the process involved in regulation of gene 
transcription. Many transcription factors are activated by phosphorylation thus increasing or 
decreasing transcription of specific genes (Hunter and Karim, 1992).
With the myriad of kinase families and isozymes within kinases families, it has been difficult to 
dissect the contribution of specific kinases in specific signalling pathways. To this end, recent 
advances using antisense DNA, expression of dominant negative mutant kinases or the use of 
cell-permeable activators or inhibitors has allowed much headway in understanding how 
different signals pathways are transduced.
4.1.2 NGF SIGNALLING PATHWAY
When NGF binds to its receptor on the cell membrane of target cells, it triggers several signal 
transduction mechanisms. Two different receptors have been proposed for NGF. A high 
affinity receptor comprising the trk A protooncogene (p i40^ '"^ ) is a member of the tyrosine 
kinase family of tr ans membrane receptors (Martin-Zanca et al., 1991). This high-affinity 
receptor mediates most of the known biological effects of NGF. The second receptor is a cell 
surface glycoprotein of 75-80 kDa with a single transmembrane domain (p75^+i^). This low- 
affinity receptor lacks structural features in its cytoplasmic domain known to mediate signal 
transduction in other receptors (Berg et a l, 1991).
Activation of trk A receptor is followed by receptor dimerization and trans-autophosphorylation 
of five tyrosine residues on trk A (Loeb et a l, 1994). These phosphotyrosine residues act as 
docking sites for downstream effector substrates by specifically binding and activation of
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intracellular proteins : PLC (PLCyl), She, PI-3-K and MAPK-1 (Kaplan and Stephens, 
1994). The binding to trkA molecules initiates a cascade of signalling events that leads to 
neuronal differentiation (Figure 4-1). These initial tyrosine phosphorylation events triggered by 
NGF are followed by activation of several protein serine/ threonine kinases that include 
members of the PKC, r a / ,  MEK, MAPK and ribosomal S6 kinase families (Cantley et ah, 
1991) (See Chapter 1. NGF signalling pathway).
NGF was the first neurotrophic agent to be identified and now serves as the prototype for this 
class of polypeptide growth factors (Thoenen and Barde, 1980). NGF is required for the 
maintenance of specific neuronal crest-derived cell types which include sympathetic 
postganglionic neurons. Responses of explanted sympathetic neurons to this target-derived 
agent includes general anabolic alterations, induction of neuronal morphology and increased 
survival of the cells. Morphologically, the cells initiate neurite outgrowth and increased cell 
body size (Greene and Tiscler, 1992). Thus, classic markers of sympathetic neuronal 
differentiation which include specific morphological alterations as well as various anabolic 
responses are initiated by NGF.
4.1.3 PC12 CELL LINE
The clonal cell line, PC 12 was established from an rat adrenal medullary tumour 
(phaeochromocytoma), which was passaged subcutaneously in New England Deaconess 
Hospital Sprage-Dowley rats (Warren and Chute, 1972; DeLellis et al., 1973). This cell line 
can be induced to undergo differentiation to a neuronal phenotype upon treatment with NGF 
(Tischler and Greene, 1975). PC12 cells have become a important model system to study the 
mechanisms involved in mediating NGF effects on target cells in areas such as neuronal 
development and nerve injury. It is thought that the effects of NGF on PC 12 cells are 
representative of the events that occur during sympathetic neuronal differentiation, particularly 
for cells derived from the neural crest (Tischler and Greene, 1978).
In resting state, PC 12 cells undergo mitosis and display ultrastructural and biochemical 
characteristics of immature adrenal medullary chromaffin cells which constitute their non- 
neoplasic counterpait, including cathecholamine synthesis, storage and release from both large, 
dense core granules and small synaptic-like vesicles (Greene and Rein, 1977a). In the presence 
of nanomolar concentrations of NGF, PC 12 cells differentiate rapidly but reversibly into a 
phenotype which resembles mature postganglionic sympathetic neurons (Greene and Tischler, 
1976). PC 12 cells flatten down, decrease their proliferative rate (cease mitosis), undergo cell 
hypertrophy, increased cell-substratum adhesiveness and extend long, branching neurites with 
prominent growth cones (Guroff, 1985) (See Chapter 1. PC 12 cells).
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FIGURE 4.1 NGF SIGNALLING PATHWAY
Schematic NGF signal transduction pathways in PC I2 cells (Taken from Signal Transduction 
of Neurotrophin Receptors. Neural Notes. Volume 1. Issue 1. Promeg a). Abbreviations: 
tyrosine residues (Y); stimulation signal (+); inhibitoiy signal (-); putative signalling (dashed 
line).
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4.1.4 NEUROPEPTIDE Y -Y l RECEPTOR
Neuropeptide Y (NPY) is a 36 amino acid polypeptide that is found widely distributed 
thi’oughout the peripheral and central nervous system. NPY is found in high concentrations in a 
number of peripheral neurons, including those of the sympathetic nervous system 
(postganglionic neurons), particularly supplying cardiac structures and vascular tissue beds 
(Allen et al., 1986a). NPY is also found in a subpopulation of adrenal medullary chromaffin 
cells (Varndell et al., 1984).
The actions of NPY at a number of peripheral neuroeffector junctions have been particularly 
well studied (Whalestedt et al., 1986, 1990). NPY produces both pre- and postsynaptic 
effects. In virtually all the instances, the presynaptic effects of NPY are manifest as inhibition 
of neurotransmitter release. For example, NPY is a powerful inhibitor of noradrenaline (NA) 
release from sympathetic neurons. Postsynaptically, NPY is a well characterized 
vasoconstrictor and is able to enhance the effects of other vasopressor agents, such as NA. It is 
generally accepted that the postsynaptic actions of NPY are mediated through NPY-Yl 
receptors, whereas the presynaptic actions are mediated through NPY-Y2 receptors 
(Wahiestedt et al., 1986, 1990).
High concentrations of NPY are found in PC 12 cells (Allen et al., 1984). Undifferentiated 
PC I2 cells contain NPY niRNA which is further translated to the prohormone and processed to 
the mature peptide. This NPY mRNA content in PC 12 cells is increased markedly by NGF 
(Allen et al., 1987b, Balbi and Allen, 1994). Undifferentiated PC 12 cells, also express NPY 
receptors of the Y1 subtype (Schwartz et al., 1987).
PC 12 cells differentiated to a sympathetic-like neuronal phenotype by NGF are also responsive 
to the NPY-Yl receptor-selective agonist [Pro^ ’^-j-NPY with inhibition of evoked cAMP and 
enhanced evoked catecholamine overflow (DiMaggio et al., 1994). However, PC 12 cells 
treated with NGF are also responsive to NPY-Y2 receptor-selective agonist NPY13-36 with 
inhibited accumulation on evoked cAMP and inhibition cathecolaraine overflow (DiMaggio et 
al., 1994). Moreover, PC 12 cells differentiated to a mature adrenal chromaffin-like cells with 
dexamethasone are responsive to [Pro^'^j-NPY with inhibition of evoked cAMP and enhanced 
agonist evoked catecholamine overflow, but dexamethasone-differentiated PC 12 cells were 
unresponsive to NPY13-36 (DiMaggio et al., 1994) Thus, in this model, sympathetic-like 
neurones express both NPY-Yl and NPY-Y2 receptors. However, mature adrenal chromaffin- 
like cells express only functional NPY-Yl receptors but not NPY-Y2 receptors.
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Model systems are required in order to simplify the study of the factors and molecular 
mechanisms that affect the expression of NPY receptor genes. In the case of adrenal 
chromaffin cells and post-ganglionic sympathetic neurones, PC 12 cells may be an adequate 
model to study the regulation of the NPY-Yl receptor gene expression by NGF and other 
growth factors.
This chapter deals primarily with the characterisation of the molecular mechanisms involved in 
the transcriptional activation of the NPY-Yl receptor gene in PC 12 cells following NGF 
treatment. The luciferase reporter system was used to study the role of the cAMP dependent 
protein kinase (PKA), Ca++/ phospholipid-dependent protein kinase (PKC), MAP kinase 
(MAPK) and PI-3 kinase (PI-3-K) signalling pathways in the NGF-mediated response in 
PC 12 cells.
4.2 RESULTS
Due to variability between different PC 12 cell sublines, and in order to obtain consistent and 
reproducible results, all the experiments were performed using PC 12 cells from the same 
source. It is also well known that these cells can mutate and lose some or all their 
characteristics. In order to minimise these events, initial stocks of PC 12 cells were replicated 
by a maximum of 10 passages, working cells were discarded and new vials of frozen cells 
thawed.
4.2.1 NGF CONCENTRATION EFFECTS IN THE 
TRANSCRIPTIONAL ACTIVATION OF THE NPY-Yl GENE
In the previous chapter, PC 12 cells were shown to respond to NGF by differentiating into a 
phenotype that resembles postganglionic sympathetic neurones. Cells transfected with the pY 1 - 
LUC fusion gene and treated with NGF (100 ng/ml) demonstrated a consistent 2.76 ± 0.18- 
fold increase in the measurable luciferase activity compared to the basal levels (Figure 3-9). 
This activation of the NPY-Yl receptor gene in PC12 cells was also observed at low 
concentrations of NGF (Figure 4-2). Thus, the threshold concentration of the NGF induction 
of NPY-Yl receptor gene was 10 ng/ml (Figure 4-2). Increasing concentrations above this 
threshold resulted in significant increases in the levels of the luciferase activity (Figure 4-2). 
These results show that the effect of NGF on the transcription of the NPY-Yl gene in PC 12 
cells is concentration dependent. A value of 100 ng/ml of NGF was chosen for all subsequent 
experiments as it lies in the linear region of the concentration response, thus any variation of 
this response could easily detected.
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FIGURE 4.2 NGF CONCENTRATION EFFECT
Effect of a range of NGF concentration on the transcriptional activity of the NPY-Yl receptor 
gene. PC12 cells were transfected with pYl-LUC (10 |ig). 20 hours after transfection PC12 
cells were treated with different N G F concentrations for 48 hours when the cells were 
collected for luciferase assay (Promega). Each experiment represents the percent of luciferase 
activity in NGF treated cells normalised to 100% for thecontrol cells (0.1% vehicle only). 
Values are mean ± SEM from 3 or more transfections experiments, each performed in duplicate 
with plasmids from at least two different preparations.
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4.2.2 MECHANISMS INVOLVED IN THE NGF-INDUCED 
TRANSCRIPTIONAL ACTIVATION OF THE NPY-Yl GENE
In order to study the role of different second messenger pathways in mediating the NGF 
activation of the NPY-Yl receptor gene in PC I2 cells, the effect of various inhibitors of 
specific signalling pathways were examined (Figure 4-1). For all these experiments, P C I2 
cells were transiently transformed with the pYl-LUC (10 |lg) and the next day cells were 
preincubated for one hour with specific protein kinases inhibitors before addition of NGF (100 
ng/ml). The cells were maintained with the inhibitors and neurotrophic stimuli for 48 hours and 
the relative levels of luciferase activity was measured in a luminometer.
All the experiments were performed in duplicate and the results are shown as the mean ± SEM 
of at least three independent experiments. Untreated PC 12 cells were grown in the presence of 
vehicle (up to 0.1% ) in DMEM complete medium.
4.2.2.1 EFFECT OF THE TYROSINE KINASE PATHWAY
4.2.2.1.1 trk  A  tyrosine kinase receptor inhibitor (K-252a)
Pretreatment of PC 12 cells with K-252a (200 iiM) completely blocked the 2.76 ± 0.18-fold 
NGF transcriptional activation of the NPY-Yl gene (Figure 4-3). K-252a at this nM 
concentration is a specific inhibitor of trk A tyrosine kinase receptor and is known to block the 
biological effects of NGF in PC12 cells (Berg et al., 1992). The inhibitory effect of K-252a on 
the NGF induction of NPY-Yl receptor gene transcription in PC 12 cells was shown to be 
concentration dependent (Figure 4-3). However, K-252a (200 nM) had no effect on the 
maintenance of the basal levels of activity of the NPY-Yl receptor gene in PC 12 cells (Figure 
4.3).
4.2.2.1.2 General tyrosine kinase and phosphatase inhibitors (Genistein and
Vanadate)
Genistein is a synthetic general inhibitor of many different protein tyrosine kinases and is 
known to inhibit EGFR tyrosine kinase (ICso = 2.6 fxM) and pp60^" '^'  ^ (ICso = 25 pM) by 
acting as a competitive inhibitor of ATP (Akiyama et al., 1987). Genistein (50 pM) resulted in 
a paradoxical effect on NPY-Yl receptor gene expression as it increased, both the basal- and 
NGF-induced transcriptional activity of the NPY-Yl receptor gene in PC 12 cells (Figure 4-4).
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FIGURE 4.3 K-252a CONCENTRATION EFFECT ON THE NGF 
RESPONSE
Effect of a range of K-252a concentration on the NGF-dependent transcriptional activation of 
the NPY-Y 1 receptor gene. PC 12 cells were transfected with pY 1-LUC (10 pg). 20 hours after 
transfection the PC 12 cells were pretreated for 1 hour with different K-252a concentrations 
and then treated with NGF (100 ng/ml) for 48 hours when the cells were collected for 
luciferase assay (Promega). As a control experiment PC 12 cells were treated with K-252a 
(200 nM) (basal effect) or NGF (100 ng/ml) alone for 48 hours. Each experiment represents 
the percent of luciferase activity in K-252a treated cells normalised (100%) for the control cells 
(0.1% vehicle only). Values are mean ± SEM from 3 or more transfections experiments, each 
performed in duplicate with plasmids from at least two different preparations.
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FIGURE 4.4 GENISTEIN AND VANADATE EFFECT ON THE 
NGF RESPONSE
GEN (genistein, 50 pM) and VAN (sodium orthovanadate, 30 pM) effect in the basal- and 
NGF-dependent transcriptional activity of the NPY-Yl receptor gene. PC 12 cells were 
transfected with pY 1-LUC (10 pg). 20 hours after transfection the cells were pretreated for 1 
hour with GEN (genistein, 50 pM) or VAN (sodium orthovanadate, 30 pM) and then the 
cells were treated with N G F (100 ng/ml) for 48 hours when the cells were collected for 
luciferase assay (Promega). As a control experiment PC 12 cells were treated with G EN  
(genistein, 50 pM), VAN (sodium orthovanadate, 30 pM) (basal effects) or NGF (100 ng/ml) 
alone for 48 hours. Each experiment represents the percent of luciferase activity in treated cells 
normalised (100%) for the control cells (0.1% vehicle only). Values are mean ± SEM from 3 
or more transfections experiments, each performed in duplicate with plasmids from at least two 
different preparations.
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Sodium orthovanadate (Na3V04) is a broad range inhibitor of protein tyrosine phosphatases 
(PTPases) (Gordon, 1991). Sodium orthovanadate (30 pM) reduced both the basal- and NGF- 
induced transcriptional activity of the NPY-Yl receptor gene in PC 12 cells (Figure 4-4). These 
effects of sodium orthovanadate (Na3VÜ4) and genistein on the basal- and NGF-induced 
transcriptional activity of the NPY-Yl receptor gene indicate that is possible an intrinsic 
tyrosine kinase activity different to the associated with the trk A receptor inhibits the 
transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. This specific tyrosine 
kinase activity remains to be elucidated.
4.2.2.2 EFFECT OF THE RAS-MAP KINASE PATHWAY
4.2.2.2.1 NGF effects in a ras-negative PC12 cell line
A stable mutant PC 12 cell subline (PC 12 asnl7-W7) (Buensuceso, 1995) over-expressing a 
dominant negative human gene (encoding p21N17, a human c-Ha-rn^’ gene with a
point mutation in codon 17 resulting in a serine to asparagine substitution in the translated 
protein) (Feig and Cooper, 1988) was used to examine the role of the ras -MAP kinase 
pathway in mediating the effect of NGF on the transcriptional activation of the NPY-Yl 
receptor gene. This cell line was a gift from Dr. Mark V. Rogers from Cellular Bioassay 
Design Group, Lead Discovery Unit, Glaxo-Wellcome, UK.
NGF (100 ng/ml) did not induce the known morphological changes in PC12asnl7-W 7 
compared to PC 12-wild type cells (data not shown). However, NGF (100 ng/ml) resulted in 
similar transcriptional activation of the NPY-Yl receptor gene in this VCl2-ras dominant 
negative cell line in comparison with the effect in the PC 12-wild type cells (Figure 4-5). This 
result indicated that the p2H''^‘^ protein is not involved in mediating the NGF-induced 
transcriptional activation of NPY-Yl receptor gene in PC 12 cells.
4.2 .2 .2 .2  MEK-1 kinase inhibitor (PD 98059)
PD 98059 is a cell permeable and potent inhibitor of MEK-1 known to block the 4-fold 
increase in MAPK activity induced by NGF in PC 12 cells (ICso = 2pM) (Alessi et al., 1995). 
PD 98059 (20 |iM) was shown to induce a increase in both the basal- and NGF-dependent 
transcriptional activation of the NPY-Yl receptor gene in PC 12 cells (Figure 4-6). This potent 
increase of the luciferase activity of the pY 1-LUC mediated by PD 98059 (20 p.M) suggests 
that MEK-1 kinase activity has an inhibitory action on both, the basal- and NGF-mediated 
transcriptional activation of the NPY-Yl receptor gene in PC 12 cells.
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FIGURE 4.5 RAS EFFECT ON THE NGF RESPONSE
Effect of different agents on the transcription of the luciferase gene directed by the NPY-Yl 
promoter gene in a PC12-ra.s' negative cell line (Buensuceso, 1995). PC12 asnl7-W7 were 
transfected with pY 1-LUC (2.5 |ig) using the liposome-mediated method. 20 hours after 
transfection the cells were treated with NGF (nerve growth factor, 100 ng/ml) or PM A  
(phorbol- 12-myristate-13-acetate, 1 nM) for 48 hours when the cells were collected for 
luciferase assay (Promega). Each experiment represents the percent of luciferase activity in 
treated cells normalised (100%) for the control cells (0.1% vehicle only). Values are mean ± 
SEM from 3 or more transfections experiments, each performed in duplicate with plasmids 
from at least two different prepaiations.
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FIGURE 4.6 PD98059 EFFECT ON THE NGF RESPONSE
PD98059 effect on the basal- and NGF-dependent transcriptional activity of the NPY-Yl 
receptor gene. PC I2 cells were transfected with pYl-LUC (10 pg). 20 hours after transfection 
the cells were pretreated with PD (PD98059, 20 pM) for 1 hour and then the cells were treated 
with NGF (nerve growth factor, 100 ng/ml) for 48 hours when the cells were collected for 
luciferase assay (Promega). As a control experiment PC 12 cells were treated with PD  
(PD98059, 20 uM) (basal effect) or N GF (nerve growth factor, 100 ng/ml) alone for 48 
hours. Each experiment represents the percent of luciferase activity in PD98059 treated cells 
normalised (100%) for the control cells (0.1% vehicle only). Values are mean ± SEM from 3 
or more transfections experiments, each performed in duplicate with plasmids from at least two 
different preparations.
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4.2.2.3 EFFECT OF THE PKC PATHWAY
4.2.2.3.1 Protein kinase C inhibitor (Calphostin C)
Calphostin C was shown to block the effect of NGF on NPY-Yl receptor gene transcription in 
PC 12 cells in a concentration dependent fashion (Figure 4-7). Preincubation of PC 12 cells with 
calphostin C (1 pM), a highly specific inhibitor of PKC (Ki = 50 nM) (Kobayashi et al., 1989) 
completely blocked the NGF-induced increase in transcriptional activity of the NPY-Yl gene 
(Figure 4-7).
4.2.2.3.2 PMA effects on N PY -Y l transcriptional activity
Phorbol diesters such as phorbol-12-myristate-13-acetate (PMA) activates PKC in vitro and in 
vivo even at nanomolar concentrations (Nishizuka, 1988). In the previous chapter, PMA (1 
nM) was shown to produce a reproducible 1.82 ± 0.16-fold increase in the transcriptional 
activity of the NPY-Yl receptor gene in PC12 cells (Figure 3-9). This 1.82 ± 0.16-fold 
transcriptional activation was shown not to be affected by increasing concentrations ( 1 nM to 
10 pM) of the calcium ionophore ionomycin (data not shown) indicating that increases in 
intracellulai* calcium had no effect in mediating this PMA effect in PC 12 cells. Furthermore, the 
effect of PMA on the transcriptional activation of the NPY-Yl receptor gene was shown to be 
concentration dependent in PC 12 cells (Figure 4-8). Increasing (in the high nM range) or 
decreasing (in the high pM range) the concentration of PMA resulted in a decrease of luciferase 
activity, indicating that the maximal transcriptional activation of the NPY-Yl receptor gene in 
PC 12 cells was obtained in the low nanomolar range of PMA, specifically between 1-10 nM 
(Figure 4-8).
Similar results were obtained using D Hl, a synthetic PKC activator which binds PKC at the 
same site as phorbol esters. DHl (1 nM) was shown to produced a 2.8 ± 0.10-fold increase in 
luciferase activity over basal levels (Figure 4-9). This increase is higher that the increase 
produced by PMA (1 nM), and is similar to the 2.76 ± 0.17-fold increase obtained by NGF- 
dependent activation of the NPY-Yl gene. However, DHl was shown to produce a similar 
concentration response effect on the transcriptional activity of the NPY-Yl gene in PC 12 cells 
in comparison that the concentration response obtained by PMA (Figure 4-8). Maximal 
luciferase activity was observed in the low nanomolar range between 1-10 nM and increasing 
concentrations of DHl (high nM range) reduced the luciferase levels obtained using the pY l- 
LUC in PC12 cells (Figure 4-9).
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EIGURE 4.7 CALPHOSTIN C CONCENTRATION EFFECT ON 
THE NGF RESPONSE
Effect of a range of calphostin C concentration on the NGF-dependent transcriptional activity 
of the NPY-Yl receptor gene. PC I2 cells were transfected with pY 1-LUC (10 pg). 20 hours 
after transfection the cells were pretreated with different concentrations of CC (Calphostin C) 
for 1 hour and then the cells were treated with NGF (nerve growth factor, 100 ng/ml) for 48 
hours when the cells were collected for luciferase assay (Promega). As a control experiment 
PC 12 cells were treated with CC (Calphostin C, 1 pM) (basal effect) or NGF (nerve growth 
factor, 100 ng/ml) alone for 48 hours. Each experiment represents the percent of luciferase 
activity in Calphostin C treated cells normalised (100%) for the control cells (0.1% vehicle 
only). Values are mean ± SEM from 3 or more transfections experiments, each performed in 
duplicate with plasmids from at least two different preparations with similai’ results.
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FIGURE 4.8 PMA CONCENTRATION EFFECT
Effect of a range of PMA concentration on the transcriptional activity of the NPY-Yl receptor 
gene. PC 12 cells were transfected with pY 1-LUC (10 pg). 20 hours after transfection the cells 
were treated with different concentrations of PMA (phorbol-12-myristate-13-acetate) for 48 
hours when the cells were collected for luciferase assay (Promega). Each experiment represent 
the percent of luciferase activity in PMA treated cells normalised (100%) for the control cells 
(0.1% vehicle only). Values are mean ± SEM from 3 or more transfections experiments, each 
performed in duplicate with plasmids from at least two different prepai-ations.
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FIGURE 4.9 D H l CONCENTRATION EFFECT
Effect of a range of DHl concentration on the transcriptional activity of the NPY-Y 1 receptor 
gene. PC12 cells were transfected with pY 1-LUC (10 pg). 20 hours after transfection the cells 
were treated with different D H l concentrations for 48 hours when the cells were collected for 
luciferase assay (Promega). Each experiment represents the percent of luciferase activity in 
DHl treated cells normalised (100%) for the control cells (0.1% vehicle only). Values are mean 
± SEM from 3 or more transfections experiments, each performed in duplicate with plasmids 
from at least two different preparations.
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Calphostin C (1 pM) resulted in a complete inhibition of both, the PMA- and DHl-mediated 
(Figure 4-10) transcriptional activation of the NPY-Yl gene in PC 12 cells. However, 
preincubation with H-89 (30 pM), K-252a (200 nM) and KN-62 (IpM ) (See Chapter 2. 
Inhibitor compounds) did not affect the subsequent PMA- or DHl-dependent response of the 
NPY-Yl receptor gene in PC 12 cells (data not shown).
In addition, the response of the NPY-Yl receptor gene to PMA (InM) was identical in the 
PC12-ras negative cells compared to the PC 12-wild type (Figure 4-5). These results indicated 
that DHl - and PMA-dependent increase of the transcriptional activity of the NPY-Yl receptor 
gene in PC 12 cells is primarily dependent in PKC activation and is independent on the 
activation of another intracellular signalling pathways, including PKA, CaM-K II and thotrkA- 
receptor pathway.
4.2.2.3.3 NGF and PMA effects on PKC activity in PC12 cells
The previous results of this chapter, suggest a direct involvement of PKC in mediating the 
NGF and PMA transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. In order 
to test whether NGF and PMA indeed increased PKC activity in these cells, PC 12 cells were 
treated with NGF (100 ng/ml) and two concentrations of PMA (InM and IjiM).
Direct measurement of PKC activity in PC 12 cell extracts demonstrated a 2.0-fold increase 
following the addition of NGF (100 ng/ml) (Figure 4-11). This rise in PKC activity was 
observed within 1 hour following the addition of NGF (100 ng/ml). A similar increase (1.8- 
fold) in the PKC activity was observed using PMA (InM) but this increase was completely 
suppressed using higher concentrations of PMA (1 pM) (Figure 4-11). This suppression of 
PKC activity is well documented as PMA is routinely used to downregulate PKC by long term 
incubations (Nishizuka, 1988).
4.2.2.4 EFFECT OF THE PHOSPHOLIPASE D PATHWAY
Pretreatment of PC 12 cells with 1-butanol (0.3%) 1 hour before the cells were treated with 
NGF (100 nM) did not affect the NGF-induced increase in the transcriptional activation of the 
NPY-Yl gene (data not shown).This preliminary result suggest that the putative supression of 
the PLD activity did not affect the luciferase activity of the pY 1-LUC in PC 12 cells.
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FIGURE 4.10 CALPHOSTIN C EFFECT ON THE D H l OR PMA 
RESPONSE
Calphostin C effect on the DHl- and PMA-induced transcriptional activation of the NPY-Yl 
receptor gene. PC12 cells were transfected with pYl-LUC (10 pg). 20 hours after transfection 
the cells were pretreated with CC (calphostin C, 1 pM) for 1 hour and then the cells were 
treated with D H l (1 nM) or PMA (phorbol-12-myristate-13-acetate, 1 nM) for 48 hours when 
the cells were collected for luciferase assay (Promega). As a control experiment the cells were 
treated with CC (Calphostin C, 1 pM), D H l (1 nM) or PMA (phorbol-12-myristate-13- 
acetate, 1 nM) alone. Each experiment represents the percent of luciferase activity in treated 
cells normalised (100%) for the control cells (0.1% vehicle only).Values are mean ± SEM from 
3 or more transfections experiments, each performed in duplicate with plasmids from at least 
two different preparations.
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FIGURE 4.11 NGF AND PMA EFFECT ON THE PKC ACTIVITY 
IN PC12 CELLS
Effect of NGF and PMA stimulation on PKC activity in PC 12 cells. PC 12 cells were treated 
with NGF (nerve growth factor, 100 ng/ml) and two different PMA concentrations (phorbol- 
12-myristate-13-acetate, 1 nM or 1 pM) for 1 hour and then the cells were collected for 
measurement of the PKC activity (Life Technologies). Data shown are mean ± SEM of 
triplicate assays of one representative experiment performed two times with similai' results.
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4.2.2.S EFFECT OF THE Ca++/CALMODULIN KINASE II PATHWAY
KN-62 (1 pM), a specific inhibitor of a rat brain CaM-K II (Ki = 900 nM) (Tokumitsn et ak,
1990) had no effect in the NGF-induced transcriptional activation of the NPY-Yl receptor gene 
in PC 12 cells. In addition, KN-62 (1 pM) did not alter the basal levels of luciferase activity of 
the pY 1-LUC in PC 12 cells. These results indicated that the CaM-K II activity has no effect on 
the maintenance of the basal- or NGF-induced transcriptional activation of the NPY-Yl 
receptor gene in PC 12 cells.
4.2.2.6 EFFECT OF THE PI-3-KINASE PATHWAY
Two selective and potent inhibitors of PI-3-K were examined. Wortmannin is a fungal 
metabolite known to be an irreversible, cell permeable and potent inhibitor of PI-3-K in 
purified preparations and cytosolic fractions ( IC 5 0 =  5 nM) (Nakanishi et al., 1992, 1994). LY 
294002 is a synthetic, cell permeable and specific PI-3-K inhibitor that acts on the ATP binding 
site of the enzyme ( IC 5 0 =  1.4 pM, Ki = 1.6 pM).
Neither, Wortmannin (10 pM) or LY 294002 (10 pM) inhibited the basal- or NGF-induced 
transcriptional activation of NPY-Yl receptor gene in PC 12 cells (data not shown). These 
results indicating that the PI-3-K signalling pathway, which is know can be activated by NGF 
in PC 12 cells (See Chapter 1. PI-3-kinase signalling pathway) had no effect on the 
maintenance of the basal levels or in the NGF-induced increase of the NPY-Yl transcriptional 
activity of PC 12 cells.
4.2.2.7 EFFECT OF THE PKA PATHWAY
Pretreatment of PC 12 cells with H-89, dihydrochloride (30 pM), a synthetic cell-permeable 
and specific inhibitor of the cAMP-dependent protein kinase A (PKA) (Ki= 48 nM) (Chijiwa et 
al., 1990), had no effect on the NGF-stimulated transcriptional activation of the NPY-Yl 
receptor gene in PC 12 cells (data not shown).
However, H-89 (30 pM) reduced the basal levels of luciferase activity of the pYl-LUC fusion 
gene in PC 12 cells (See Chapter 5). These results indicated that PKA signalling pathway is 
involved in the maintenance of the basal transcriptional activity of the NPY-Y 1 receptor gene in 
PC 12 cells but not in the NGF-induced response.
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4.3 DISCUSSION
In this chapter, an attempt was made to study the intracellular mechanisms behind the 
transcriptional control by NGF of the NPY-Yl receptor gene in PC 12 cells using a luciferase 
reporter assay system (Promega). In particular the role of different intracellular pathways 
activated by NGF in PC 12 cells, including the ras -MAPK, the PKC and the PI-3-K signalling 
pathways have been examined. Another pathways, such as the PKA and the CaM-K II 
pathway were also examined.
Effects of NGF on the transcriptional activation of several genes has been suggested to be 
mediated by activation of both PKA and PKC second messenger pathways as specific 
activators of both systems mimic and potentiate the effects of NGF in PC 12 cells (Greene et 
al., 1984). Results presented in this chapter support the hypothesis that NGF-induced PKC 
activity mediates the transcriptional activation of NPY-Yl receptor gene in a ras - and M EKl- 
independent manner in PC 12 cells.
4.3.1 NGF CONCENTRATION EFFECTS ON THE 
TRANSCRIPTIONAL ACTIVATION OF THE NPY-Yl GENE
NGF is the best characterized member of a family of "neurotrophins" that includes BDNF, NT- 
3 and NT-4/5 (Barde, 1989). These molecules promote the differentiation, growth and survival 
of distinct neuronal cell populations through specific RTKs. Neurotrophin receptors are 
encoded by a gene family, designated trk , which so far includes three related loci: trl<A , trkB 
and trkC (Chao et al., 1992).
Previous studies have shown that NGF differentiated PC 12 cells were responsive to a NPY-Y 1 
receptor selective agonist [Pro^'^j-NPY (DiMaggio et al., 1994). The data presented in this 
chapter shows that NGF increased in a concentration dependent manner the transcriptional 
activity of the NPY-Y 1 receptor gene in PC 12 cells (Figure 4-1).
4.3.2 MECHANISMS INVOLVED IN THE NGE-INDUCED 
TRANSCRIPTIONAL ACTIVATION OF THE NPY-Yl GENE
4.3.2.1 EFFECT OF TYROSINE KINASE PATHWAY
Protein tyrosine phosphorylation plays a role in regulating fundamental cellular processes 
including differentiation, proliferation and tumorigenesis (Brewster et al., 1993) 
Phosphorylation at tyrosine residues occurs as a cellular response to a variety of stimuli
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including growth factors, hormones and cytokines. The initial events include activation, 
dimerization and autophosphorylation of RTKs. This in turn initiates intracellular signalling 
cascades involving the phosphoiylation of several other key regulatory proteins. The balance of 
tyrosine phosphorylation is controlled by the opposing activities of protein tyrosine kinases and 
protein tyrosine phosphatases (Walton and Dixon, 1993)
4.3.2.1.1 trk  A  tyrosine kinase receptor inhibitor (K-252a)
Pretreatment of PC 12 cells with K-252a, was shown to block in a concentration dependent 
manner the NGF-induced transcriptional activation of the NPY-Yl receptor gene (Figure 4-3). 
However, K-252a (200 nM) had no effect in the maintenance of the basal levels of activity of 
the NPY-Yl receptor gene in PC 12 cells (Figure 4-3). This results suggest that the effect of 
NGF on the NPY-Yl transcriptional activation is dependent on trkA receptor activation, but 
trkA receptor tyrosine kinase activity is not involved in the maintenance of the basal levels of 
activity of the NPY-Yl gene in PC 12 cells.
K“252a is a fungal alkaloid-like compound isolated from Nocardiopsis sp. and originally 
characterized as an inhibitor of PKC and cyclic nucleotide-dependent kinases. However, K- 
252a had no effect on the response of PC 12 cells to DEC or PMA. Interestingly, K-252a in 
nanomolar quantities has been shown to be a specific inhibitor of NGF-induced biochemical 
responses and neurite outgrowth in PC 12 cells (Berg et al., 1992). Virtually all of the known 
biochemical events induced by NGF in PC 12 cells are inliibited by K-252a, including tyrosine 
phosphorylation of cellular proteins, increase in c-fos transcription (Lazarovichi et al., 1989), 
MAPK-2 activation (Tsao et al., 1990), p2P^'^‘^ activation (Rovelly et al., 1993) and MEK-1 
activation (Jaiswal et al., 1993).
K-252a exerts its action upon NGF-specific signal transduction in PC 12 cells by inhibiting in 
vivo and in vitro tyrosine phosphorylation and kinase activity of the trkA receptor, while 
having no effect on the EGF- and FGF-stimulated responses (Berg et al., 1992). However, K- 
252a has a paiadoxical neurotrophic effect in some other cells lines without apparently altering 
trk activity or stimulating known trk substrates (Rasouly et al., 1992). K-252a treatment of 
PC 12 cells in the absence of any growth factor stimulation, results in neuronal differentiation 
(data not shown). This neurotrophic effect in PC 12 cells appears to occur through signal 
transduction pathways that are independent from those used by trk (Rasouly et al., 1992) and 
may involve tyrosine kinase family members and a 145 kDa tyrosine phosphorylated
protein, suggesting that trJcA may be not be the only cellular target of K-252a (Rasouly et al., 
1992).
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4.3.2.1.2 General tyrosine kinase and phosphatase inhibitors (Genistein and
Vanadate)
Genistein, a broad range tyrosine kinase inhibitor acts as a competitive inhibitor of ATP. 
Genistein (50 jtiM) has been shown to increase both the basal- and NGF-induced (Figure 4-4) 
transcriptional activity of the NPY-Yl gene in PC12 cells. The effect of genistein (50 pM) on 
basal transcriptional activity of the NPY-Yl receptor gene suggests that an intrinsic tyrosine 
kinase, different from the trkA receptor associated tyrosine kinase, is involved in regulating 
basal transcriptional activity of the NPY-Yl receptor gene in PC 12 cells.
ppôO^ "-^ ''^  has been implicated in the propagation of differentiation signals which involve the ras 
-dependent activation of MAPKs (Wood et al., 1992). ppdO'^ '-^ '''^  is thought to act downstream 
of trkA in the NGF-induced signalling pathway in PC 12 cells and there are two lines of 
evidence to support this view. Firstly, PC 12 cells transfected with pp60^"' '^'^ temperature- 
sensitive gene undergo phenotypic change and express neurites at the permissive temperature 
resembling NGF-induced phenotypic change (Rausch et a l, 1989). Secondly, NGF-induced 
neurite outgrowth could be blocked by microinjection of monoclonal antibodies to either the 
SFI2 domain of pp60^-' '^'^ or the unique amino-terminal region of ppôO'^ '-^ '''^  (Ki'emer et a l ,
1991). Moderate basal pp60‘^ "‘^ ''‘^ activity is observed in control PC12 cells as shown by 
autophosphorylation. This probably relates to the fact that basal ppôOc-' '^ c activity is necessary 
for an intrinsic function as growth or inhibition of apoptosis (Rukenstein et a l , 1991; 
Batistatou and Greene, 1991).
Moreover, sodium orthovanadate (30 |iM), a broad range tyrosine phosphatase inhibitor 
(Gordon, 1991) decreased both the basal- and NGF-induced (Figure 4-4) transcriptional 
activity of the NPY-Yl receptor gene in PC 12 cells. Vanadate, which mimics the transition 
state of phosphate (Gordon, 1991) affects the activity of enzymes which form phosphoenzyme 
intermediates with enzyme-phosphate bonds and is a well-established inhibitor of protein 
tyrosine phosphatases. Vanadate treatment of intact cells results in accumulation of 
phosphotyrosine in many proteins and as consequence has been shown to effect mitogenic and 
differentiation signals in many different cell types (Gordon, 1991). Vanadate (30 |iM) induced 
neurite outgrowth in PC I2 cells (data not shown) by stimulation of tyrosine kinase activity 
following inhibition of specific tyrosine phosphatases. The vanadate-induced neurite outgrowth 
is not inhibited by the specific inhibitor of trkA tyrosine kinase receptor activity, K-252a, 
indicating there are fundamental differences in the tyrosine kinases involved in vanadate- and 
NGF-induced neuronal differentiation of PC 12 cells (Buensuceso, 1995).
182
Effect of vanadate on is complex. ppdO^ '-^ '"'^  tyrosine kinase activity is increased by
vanadate indicating that the regulatory carboxy-terminal phosphoiylation site (Tyr-527) which 
is known to supress ppbO^-' '^^ activity (Cooper et al., 1986) is not phosphorylated by the C- 
terminal kinase {csk ) which phosphorylate this site on this kinase (Okada et al., 1991). The 
prolonged nature of p p 6 0 ^ a c tiv a t io n  lasting more than 30 minutes in response to vanadate 
would be similar to the sequential src-ras actions in NGF signalling which has already been 
described (Kremer et al., 1991) and can explain the vanadate inhibitory effect in the basal- and 
NGF-induced transcriptional activity of the NPY-Yl gene in PC 12 cells.
Genistein is also known to inhibited the increase of ras -GTP induced by NGF and PMA 
(Nakafaku et al., 1992). In addition, MAPK activity can be induced by Na3V04 independently 
from NGF (Tsao et al., 1990). Taken together, these results suggested that activation of a 
intrinsic tyrosine kinase activity may have a negative effect on NPY-Yl transcriptional activity 
and in the effects of genistein and vanadate could be involved the ras -MAPK pathway.
4.3.2.2 EFFECTS OF THE RAS-MAP KINASE PATHWAY
4.3.2.2.1 NGF effects in a ras -negative PC12 cell line
A common pathway leading from cell surface growth factor receptors to MAPKs involves 
p2ira5, a member of a small GTP-binding proteins from the ras family (See Chapter 1. NGF 
signalling pathway). Treatment of the PC 12 cells with NGF induces a rapid increase in 
tyrosine phosphorylation of multiple cellular proteins. Induction of tyrosine phosphorylation 
triggered by NGF in PC 12 cells can be separated into: (i) ras -dependent and (ii) ras 
-independent events, ras -dependent events include the phosphorylation of MAPK, p90'"'^  ^ and 
raf-1. ras -independent events include NGF-induced activation of trkA , tyrosine 
phosphorylation of PLC-gl (Thomas et al., 1992) and activation of the expression of neuronal 
specific genes, such as voltage-gated Na++ channel (Fanger et al., 1993).
Substitution of asparagine for serine at position 17 decreased the affinity of c-Ha-ra^' for GTP 
20- to 40-fold without significantly affecting its affinity for GDP (Feig and Cooper, 1988). A 
stable mutant PC12 cell subline (PC 12 asnl7-W7) (Buensuceso, 1995) over-expressing this 
dominant inhibitory human p2 P'®s gene was used to examine the role of the ra^-MAP kinase 
pathway in mediating the effect of NGF on the NPY-Yl transcriptional activation. NGF (100 
ng/ml) results in a similar transcriptional activation of the NPY-Y 1 receptor gene in the PC12- 
ras negative cell line in compaiison with the PC 12-wild type cells (Figure 4-5). These results 
demonstrated that the NGF-induced transcriptional activation of the NPY-Y 1 receptor gene is 
ras -independent in PC 12 cells.
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4.3.2.2.2 MEK-1 kinase inhibitor (PD 98059)
Many RTKs activate a class of intracellulai' protein serine/thi’eonine kinases, MAPKs. In PC 12 
cells, two related MAPKs, MAPK-1 (p44"^^Pk) and MAPK-2 (p42iT^^P )^ are phosphorylated 
and activated on tyrosine and threonine residues following NGF treatment (Tsao et al., 1990). 
MAPKs activation is associated with both cell proliferation and differentiation and it is the 
duration of MAPKs activation that determines whether a stimulus elicits proliferation or 
differentiation (Traverse et al., 1992).
PD 98059 is a small molecular weight non-competitive (with respect to ATP) in vivo and in 
vitro inhibitor of the upstream kinase activator of MAPKs, MEK-1 kinase (Alessi et al., 
1995). PD 98059 binds to the inactive forms of MEK-1 and prevents both the activation and 
phosphorylation of MEK-1 in vitro by upstream activators such as c-raf or MEKK-1 (ICso = 
5-10 pM) and also inhibits the activation of MEK-2 hyc-raf (IC50= 50 pM) (Alessi et al., 
1995).
PD 98059 selectively blocks growth factor-induced phosphorylation and activation of MAPKs 
in vitro and in vivo (Pang et al., 1995) and also blocks the 4-fold NGF-induced stimulation 
of MAPKs in PC 12 cells with a half-maximal inhibition at approximately 2 pM and complete 
inhibition at 10-100 pM (Pang et al., 1995). PD 98059 completely blocks the tyrosine 
phosphorylation of MAPKs but does not affect the autophosphorylation of thetrkA receptor, 
the phosphorylation of its substrate She and NGF-dependent activation of PI-3-K (Pang et al., 
1995). PD 98059 completely blocks NGF-induced neurite formation in PC12 cells without 
altering cell viability indicating that the phosphorylation and activation of the MAPK pathway is 
required for NGF-induced neuronal differentiation in PC 12 cells.
PD 98059 (20 pM) was shown to increase both, the basal- and NGF-dependent transcriptional 
activation of the NPY-Yl receptor gene in PC12 cells (Figure 4-6). This paradoxical increase 
of the NPY-Y 1 promoter activity after PD 98059 (20 pM) treatment suggests that basal- and 
NGF-dependent MEK-1 kinase activity have a negative effect in the transcriptional activation of 
the NPY-Yl gene in PC12 cells.
4.3.2.3 EFFECT OF THE PKC PATHWAY
PI turnover has been implicated in the action of NGF in PC 12 cells (Traynor, 1984; Contreras 
and Guroff, 1987). PI-PLC, the enzyme responsible for hydrolysis of inositol phospholipids 
is activated by trkA receptor thi'ough tyrosine phosphorylation (Vetter et al., 1991). However, 
IP3 and the intracellular mobilisation of Ca++ is not generated in response to NGF in PC 12 
cells (Chang et al., 1989). Moreover, the NGF stimulation of IP turnover occurs only in the
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presence of other agonists and may merely reflect non-specific increases in phospholipid 
synthesis (See Chapter 1. NGF signalling pathway).
PKC activation is believed to be an early event after NGF stimulation in PC 12 cells (Hama et 
al., 1986; Heasley and Johnson, 1989; Kondratyev et al., 1990; Ohmichi et al., 1993; Wooten 
et al., 1994). Staurosporine, a PKC inhibitor causes a concentration-dependent inhibition of c- 
fos induction by NGF, consistent with the finding that the c~fos gene regulation may be 
influenced by PKC (Sheng and Greenberg, 1990).
4.3.2.3.1 Protein kinase C inhibitor (Calphostin C)
PKC is a major mediator of signal transduction, and is activated in vivo by DAG and Ca++. 
DAG activates PKC by decreasing its Km for calcium. PKC can also be activated by tumour 
promoting phorbol esters, such as PMA and this activation is a central point involved in a wide 
range of cellular responses (See Chapter 1. PKC signalling pathway).
Calphostin C is a microbial compound isolated from Clodosporium cladosporioides which is a 
cell permeable, potent and highly specific inhibitor of PKC (Ki = 50 nM) (Kobayashi et al.,
1989). Calphostin C interacts with the regulatory domain of PKC by competing at the binding 
site of diacylglycerol and phorbol esters and does not compete with Ca++ or phospholipids 
(Kobayashi et al., 1989).
PKC inhibitory activity of calphostin C is reported to be light-dependent (Bruns et al., 1991). 
Calphostin C and others PKC inhibitors which contain a so-called "3-10 perylenequinone" 
must be illuminated in the presence of PKC in order for it to show inhibition of pH]-phorbol 
12,13-dibutyrate binding or inhibitory activity against the enzyme (Bruns et al., 1991). This 
light requirement for the inhibitory effect of calphostin C was found only by chance. These "3- 
10 perylenequinone" compounds are not closely analogous, but they all contain numerous 
fused aromatic rings and absorb visible light. Thus, as a class they indicate that PKC has one 
or more binding domains which accept certain planar or nearly planar polycyclic aromatic 
compounds (Bruns et al., 1991)
Preincubation of PC 12 cells with calphostin C completely blocked in a concentration dependent 
manner the increase in transcriptional activity of the NPY-Yl gene induced by NGF (Figure 4- 
7). Calphostin C (1 |iM) also reduced the basal levels of luciferase activity of the pY 1-LUC 
fusion gene (Figure 4-7). These results showed that the PKC signalling pathway is involved in 
the basal- and NGF-dependent transcriptional activity of this neuropeptide receptor gene in 
PC12 cells.
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4 .3.2.3.2 PMA effects on NPY -Y l transcriptional activity
Phorbol esters, the tumour-promoting activators of PKC, share certain biological activities of 
NGF in PC12 cells (Greenberg et al., 1985). Several key second messenger pathways known 
to co-ordinate the responses to NGF in PC 12 cells have been shown to be activated by PKC. 
These includes activation of raf-1 (Morrison et al., 1988), B-raf (Oshima et al., 1991), MEK 
(Jaiswal et al., 1993), MAPK (Chung et al., 1991) and p90'"'^^ (Chen et al., 1991). PMA is 
able to produce only a modest increase in MEK activity (Jaiswal et al., 1993) and this 
correlates with the modest stimulation of MAPKs by phorbol esters in PC 12 cells (Chung et 
al., 1991). However, PMA prevents the subsequent decline in MAPK phosphorylation and 
activity and this decline is accentuated by downregulation of PKC, suggesting that PKC may 
negatively regulate phosphatases that dephosphorylate and deactivate MAPK (Tsao et al., 
1990). Although these results taken together do not directly prove that NGF action involves the 
stimulation of PKC, they suggest that active PKC occurs high up in the NGF signalling 
pathway and is necessary for the some of the NGF-dependent cascade of events in PC 12 cells.
PMA (InM) produced a 1.82 ± 0.16-fold increase in the transcription of the NPY-Yl receptor 
gene in PC 12 cells (Figure 3-9). Furthermore, the effect of PMA on the transcriptional 
activation of the NPY-Yl receptor gene was shown to be concentration dependent in PC 12 
cells (Figure 4-8). Increasing (in the high nM range) or decreasing (in the high pM range) the 
concentration of PMA resulted in a significant decrease of luciferase activity, indicating that the 
maximal transcriptional activation of the NPY-Yl promoter in PC 12 cells was obtained in the 
low nanomolar range of PMA, specifically between 1-10 nM (Figure 4-8).
This 1.82 ± 0.16-fold PMA-mediated increase is relative low in comparison to the 2.76 ±
0.18-fold NGF-mediated increase and is not affected by co-incubation with increasing 
concentrations (1 nM to 10 |iM) of the calcium ionophore ionomycin (data not shown), 
lonophores, such as ionomycin are hydrophobic molecules that increase the membrane 
permeability of specific inorganic ions. They shield the charge of the ion to be transported, 
enabling it to penetrate the hydrophobic interior of the lipid bilayer. Ionomycin is natural 
compound isolated from Streptomyces conglobatus and is a highly specific divalent cation 
mobile ion carrier which binds Ca+‘*‘ in a one-to-one steochiometry. Results presented here 
indicate that increases in cytosolic free intracellular Ca++ resulting from the addition of 
ionomycin did not affect the PMA-induced transcriptional activation of the NPY-Yl receptor 
gene in PC 12 cells. However, elevations of intracellular Ca++ and phorbol esters activation of 
PKC are known to act synergistically in some biological systems (Wilkimson and Hallam, 
1994).
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Similar results were obtained using D Hl, a synthetic protein kinase activator which binds PKC 
at the same site as phorbol esters (Mastro and Grove, 1991). DHl embody a modified 3,5- 
diaminobenzyl alcohol derivatives, which a potency sligtly weaker than those typical of 
diacylglycerols. DHl (1 nM) was shown to produced a 2.8 ± 0.10-fold increase in luciferase 
activity over basal levels (Figure 4-9). DHl also produce a similar concentration dependent 
response on the transcriptional levels of the NPY-Yl receptor gene in PC 12 cells compared to 
that obtained by PMA (Figure 4-9). Maximal luciferase activity was observed in the low 
nanomolar range between 1-10 nM and increasing concentrations of DHl (high nM range) 
reduced the luciferase levels obtained using the pY 1-LUC in PC12 cells (Figure 4-9).
Calphostin C (1 p,M) results in a complete inhibition in both, the PMA (InM)- and DHl 
(InM)-mediated (Figure 4-10) transcriptional activation of the NPY-Yl gene in PC12 cells. 
However, preincubation with different pharmacological inhibitors (See Chapter 2. Inhibitor 
compounds): H-89 (30 p,M), K-252a (200 nM) and KN-62 (1 |iM) did not affect the 
subsequent response of the NPY-Yl promoter to PMA (1 nM) or DHl (1 nM) in PC 12 cells 
(data not shown). These results indicate that the D H l- and PMA-mediated increase of the 
transcriptional activity of the NPY-Yl gene in PC 12 cells is dependent in PKC activation and is 
independent on the activation of other signalling pathways, including PKA, CaM-K II and trkA 
-receptor pathways.
4.3.2.3.3 NGF and PMA effects on PKC activity in PC12 cells
Direct measurement of PKC activity in PC 12 cells treated for 1 hour with NGF (100 ng/ml) 
showed a 2.0-fold increase in comparison to basal levels (Figure 4-11). This increase in PKC 
activity is similar to the NGF-mediated transcriptional activation of the NPY-Yl receptor gene 
in PC12 cells (Figure 4-2). Moreover, when PC 12 cells were treated with PMA (1 nM), the 
response of PKC activity was comparable (1.8-fold increase) to that obtained with NGF 
(Figure 4-11). However, PC 12 cells treated for 1 hour with PMA (1 jiM) had a PKC activity 
similar to that obtained in PC12-untreated cells (basal levels). Previous results in this 
laboratory have shown that PKC activity was significantly lower than basal levels after 3 hours 
of treatment with PMA (0.4 p.M) while levels returned only to basal values following NGF (50 
ng/ml) treatment for 3 hours (Balbi and Allen, 1994). This result suggests that the PMA 
inhibitory effect on the transcriptional activation of NPY-Yl gene in PC 12 cells will be a 
consequence of a downregulation of the PKC.
The results obtained in this work and previous results in this laboratory make it necessary to be 
cautious in the interpretation of the effect of PMA on PKC activity in PC 12 cells. It has been 
reported that short term treatment with PMA produces a transient activation of PKC 
(Nishiznka, 1988). However, phorbol esters have a secondary effect on PKC prolonging the
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association of the protein with the cellular membrane. This prolonged association is thought to 
promote the degradation of the enzyme and its disappearance from the cells (Nishizuka, 1988). 
Moreover, persistent activators of PKC, such as phorbol esters, may act supraphysiologically 
and activate processes via PKC that are not normally driven by physiologically relevant 
activators. DAG and related analogues have only a transient existence in a cell, being rapidly 
metabolised by both DAG lipase and DAG kinase. By contrast phorbol esters are only poorly 
metabolised; the presence of PMA, has been detected in cells several hours after administration.
Stimulation with supramaximal concentrations of phorbol esters can also cause the 
phosphorylation of "non-specific" substrates. Furthermore, it would appear* that the specificity 
of PKC for substrates in intact cells is less precise as the concentration of exogenously applied 
activator is increased. Phorbol esters also bind other receptors in the cell. For example, 
neuronal chimaerin binds phorbol esters with high affinity, sterospecificity and requirement for 
phospholipids enabling it to regulate p2P'^^-GTPase activity (Wilkinson and Hallam, 1994). 
Together, this information raises the possibility that the effect of PMA on the transcriptional 
activation of the NPY-Yl receptor gene may be a complex biphasic response to both short and 
long term effect of PMA on PKC activity on PC 12 cells.
4.3.2.3.4 EFFE C T  OF TH E PH O SPH O L IPA SE D PATHW AY
DAG is a messenger generated either as a result of hydrolysis of PI by PLC (which also 
generates IP3, in turn releasing intracellular Ca++) or via hydrolysis of PC by PLD. Diverse 
agents activates PLD in PC 12 cells, which in turn hydrolyses PC to generate PA and choline 
(See Chapter 1. Phospholipase D). NGF also causes a rapid increase of DAG in PC 12 cells, 
which peaks by about 2-3 minutes and declines to basal levels by 5 minutes. After its 
formation, DAG is rapidly phosphorylated to produce PA (Chang et al., 1989). However, 
there is a second wave of slow DAG production after 5 minutes of NGF treatment which 
suggest the activation of PLD (Chan et al., 1989).
PC12 cells were pretreated 1 hour with 1-butanol (0.3%) before the cells were treated with 
increasing concentrations of NGF (10-100 nM). 1-butanol (0.3%) inhibited the production of 
PA and in turn DAG in other cell systems, diverting the reaction to the production of 
phosphatidylbutanol (See Chapter 1. Phospholipase D). However, this treatment did not affect 
the NGF-induced increase in the transcriptional activation of the NPY-Y1 receptor gene in 
PC 12 cells. These preliminary results sugests that PLD-activity is not involved in the NGF- 
induced increase of NPY-Yl gene transcription in PC 12 cells. However, direct measurements 
of PLD activity in PC 12 cells treated with NGF are necesary for confirm this results.
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4.3.3.S EFFECT OF THE Ca++/CALMODULIN KINASE II PATHWAY
KN-62 is a cell permeable and potent inhibitor of rat brain CaM-K II (Ki=900 nM) (Tokomitsu 
et al., 1990). KN-62 inhibits the CaM-dependent autophosphorylation of both, a (50 kDa) and 
b (60 kDa) subunits of CaM-K II. However, KN-62 did not inhibit the activity of already 
autophosphorylated (activated) CaM-K II (Tokomitsu et ak, 1990). Kinetic analysis indicate 
that this inhibitory effect of KN-62 was competitive with respect to calmodulin but not ATP, 
however, KN-62 is not a calmodulin antagonists but a specific CaM-K II enzyme inhibitor. 
Thus, KN-62 affects the interaction between calmodulin and CaM-K II following inhibition of 
this kinase activity by directly binding to the calmodulin site of the enzyme (Tokomitsu et al.,
1990).
KN-62 (1 jiM) had no effect on the NGF-induced transcriptional activation of the NPY-Yl 
receptor gene in PC 12 cells. KN-62 (1 |iM) also did not block the basal levels of luciferase 
activity of the pYl-LUC in PC 12 cells. These results indicated that CaM-K II activity had no 
effect on the maintenance of the basal levels or in the NGF-induced transcriptional activity of 
the NPY-Yl receptor gene in PC 12 cells. This result directly supports others in showing that 
Ca++ signalling pathways itself are not involved in mediating NGF effects (See Chapter 1. 
Ca++ signalling pathway).
4.3.2.6 EFFECT OF THE PI-3-KINASE PATHWAY
NGF has been shown to stimulate the levels of PI-3,4-P2 and PI-3,4,5-P3 in PC12 cells, 
whieh reaeh a maximum after 3 minutes and decline after 10 minutes (Kimura et al., 1994). 
Pretreatment of PC 12 cells with wortmannin (100 nM) for 30 minutes abolished the elevation 
of PI-3,4,5-P3 level after NGF stimulation and completely inhibit PI-3-kinase activity (Kimura 
et al., 1994). Wortmannin did not affect the tyrosine phosphorylation of PLC-y, She and 
MAPK. Transient inhibition of PI-3-K activity at the time of NGF stimulation had no effect on 
activation of tr1<A receptor tyrosine kinase, p2H ‘^ ‘^ or neurite formation.However, continuous 
inhibition of PI-3-K blocked differentiation at the step just before neurite formation (Kimura et 
al., 1994) .
Wortmannin is a low-molecular weight cell-permeant hydrophobic compound with a sterol- 
type structure (Nakanishi et ak, 1990,1992). This fungal metabolite isolated from Talaromyces 
wortmannin K Y I2420 is a potent inhibitor of PI-3-kinase. The inhibition is non-competitive 
with respect to phosphatidyl inositol or ATP and is irreversible (Nakanishi et ak, 1990,1992). 
Wortmannin covalently binds the p i 10 catalytic subunit of PI-3-K in a region that is either 
within the active site or that functionally interacts with it. Wortmannin also inhibits other
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kinases such as myosin light chain kinase (IC50 = 200 nM) and PI-4 kinase (ICso = 300 nM) 
and also has been shown to block receptor-mediated PI-PLC, PLD and PLA2 in Swiss 3T3 
cells (Nakanishi et ak, 1990,1992) indicating that is not a specific inhibitor of PI-3-K. 
Inhibition of PI breakdown by wortmannin would certainly interfere with DAG formation and 
PKC activation and could, therefore, secondarily affect the PKC-dependent activation of PLD. 
Wortmannin also blocks p70'"^  ^activation and in contrast to rapamycin does not inhibit PMA 
activation of p70'*'^  ^ (Nakanishi et ak, 1990,1992).
LY 294002 is a cell-permeable, potent and specific synthetic PI-3-K inhibitor that acts on the 
ATP-binding site of the enzyme (IC50 =1.4  p.M, Ki = 1.6 p.M). Does not affect the activity of 
MAPK, PKC, p9 0 i'sk or ^6QCsrc (Vlahos et ak, 1994). Neither, LY 294002 (10 p.M) or 
wortmannin (10 jxM) inhibit the basal- or the NGF-induced increase in the transcriptional 
activation of NPY-Yl receptor gene in PC 12 cells. These results indicated that the PI-3-K 
signalling pathway had no effect on the maintenance of the transcriptional basal levels or the 
NGF-induced increase of the NPY-Yl transcriptional activity in this cells.
4.3.2.7 EFFECT OF THE PKA PATHWAY
Evidence of the potential role of PKA in mediating NGF effects on target cell are contradictory. 
Early reports proposed that cAMP mediates the neurotrophic actions of NGF (Race and 
Wagner, 1985). NGF has been described to increased cAMP levels in PC 12 cell after NGF 
exposure. PKA activity seems to be necessary for the NGF induced phosphorylation of TH, at 
least in some of the potential phosphorylation sites (Cremins et ak, 1986). In addition, distinct 
cellular RNA and protein levels and morphology patterns have been identified to be induced by 
cAMP and NGF (Gunning et ak, 1981). However, many other reports have refuted claims that 
NGF induces cAMP synthesis (Halegoua et ak, 1991). PC12 cells containing a mutated 
regulatory subunit of PKA showed a comparable responses to parental cells in several aspects 
of the NGF induced differentiation such as neurite outgrowth and protein phosphorylation 
(Ginty et ak, 1991). NGF induced activation of GAP-43, erg-1 and neurite development are all 
unaffected in these PKA-deficient cells suggesting that NGF is able to produce all these 
responses via PKA-independent mechanisms. However, PKA activity is necessary for the 
post-translational modification of Na++ channels in NGF treated PC I2 cells (Ginty et ak,
1992).
Moreover, H-89, dihydrochloride a synthetic isoquinolinesulfonamide, is a potent and selective 
inhibitor of PKA activity (Ki = 50 nM) (Chijiwa et ak, 1990). Pretreatment of PC12 cells with 
H-89 (30 |iM) led to a concentration-dependent inhibition of the forskolin-induced protein 
phosphorylation but the NGF-induced protein phosphorylation was not inhibited (Chijiwa et 
ak, 1990).
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Furthermore, early experiments showed that the NGF-induced priming of P C I2 cells was 
different to the priming induced by DBC, an analogue of cAMP and activator of PKA. When 
PC 12 cells were treated for several days with NGF and then replated in the presence of NGF, 
they regenerate their neurites within 24 hours. Instead, when PC 12 cells were pre-treated with 
DBC and then replated in the presence of NGF they do not regenerate their neurites as rapidly 
(Greene, 1978). It is not clear whether NGF treatment of PC 12 cells induces an increase in 
PKA activity in these cells. It has been suggested that NGF is able to affect cAMP metabolism, 
but by mechanisms independent of activation of adenylyl cyclase activity in PC 12 cells as 
measured by conversion of [2- ^H] adenine to pH] cAMP (Race and Wagner et al., 1985).
In concordance with these results, pretreatment of PC 12 cells with H-89 (30 p.M) had no effect 
on the NGF-stimulated transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. 
However, H-89 (30 |llM) reduced the basal levels of luciferase activity of the pYl-LUC fusion 
gene in PC 12 cells (See Chapter 5), indicating that PKA is involved in the maintenance of the 
basal levels of transcriptional activity of the NPY-Yl receptor gene in PC 12 cells.
4.4 SUMMARY
1.“ Effect of NGF on the promoter region of the N PY -Y l receptor gene in 
PC12 cells is concentration dependent.
The threshold concentration of the NGF induction of NPY-Yl receptor gene was 10 ng/ml. 
Increasing concentrations above this threshold resulted in significant increases in the levels of 
the luciferase activity.
2.- Effect of NGF on the N PY -Y l transcriptional activation is dependent on 
trkA  activation.
Pretreatment of the PC 12 cells with K-252a, a specific inhibitor of trkA tyrosine kinase 
receptor completely blocked in a concentration dependent manner the NGF transcriptional 
activation of the NPY-Yl receptor gene. However, K-252a had no effect on the maintenance of 
the basal levels of transcription of the NPY-Yl receptor gene in PC 12 cells.
3.- Effect of both, basal- and NGF-induced transcriptional activation of the 
NPY -Y l gene is inhibited by a tyrosine kinase activity.
Genistein (50pM), a broad range inhibitor of tyrosine kinases increased both, the basal- and 
NGF-indueed transcriptional activity of the NPY-Yl receptor gene in PC12 cells. Sodium 
orthovanadate (Na3V04) (30jiM), a broad range inhibitor of protein tyrosine phosphatases
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(PTPases) reduced both, the basal and NGF-induced transcriptional activity of the NPY-Yl 
receptor gene in PC I2 cells.
4 .- Effect of NGF on the NPY-Yl transcriptional activation is independent of 
p2ir«5 and is inhibited by MEK-1 activity.
4.1- NGF resulted in similar transcriptional activation of the NPY-Yl receptor gene in a PC12- 
ras negative cell line, indicating that the p2P''^‘^ protein had no effect on the NGF-induced 
transcriptional activation of NPY-Yl gene in PC 12 cells.
4.2- PD 98059 (20 p.M) resulted in a increase in both, basal- and NGF-dependent 
transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. This PD 98059 (20 p.M) 
increase of the NPY-Yl transcriptional activity suggesting that NGF-dependent MEK-1 kinase 
activity, may inhibit the transcriptional activation of the NPY-Yl receptor gene in PC 12 cells.
5.- Effect of both, basal- and NGF transcriptional activation of the N PY -Y l 
gene is dependent on PKC activation
5.1- Preincubation of PC 12 cells with calphostin C decreased in a concentration dependent 
manner the basal-dependent and NGF-induced transcriptional activity of the NPY-Yl gene.
5.2- DHl and PMA, which are specific activators of PKC increased in a concentration- 
dependent manner the transcriptional activity of NPY-Yl gene, and these activation was 
completely block by calphostin C (1 pM).
5.3- Direct measurement of PKC activity in PC 12 cell extracts showed a increase following the 
addition of NGF. Similar increase in the PKC activity was observed using PMA (InM) but not 
PMA (1 pM).
6.- Effect of NGF on the NPY -Y l transcriptional activation is independent on 
PKA, CaM-K II , PI-3-K and PLD activation
6.1- Pretreatment of PC12 cells with H-89 (30 pM), a specific inhibitor of PKA had no effect 
in the NGF-stimulated transcriptional activation of the NPY-Yl gene in PC12 cells. However, 
H-89 (30 pM) reduced the basal levels of transcriptional activity of this gene.
6.2- Pretreatment of PC12 cells with KN-62 (1 pM) a CaM-K II inhibitor, LY 294002 (10 
pM) or wortmannin (10 pM), PI-3-K inhibitors had no effect in the basal- or NGF-induced 
transcriptional activation of the NPY-Yl gene in PC 12 cells.
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6.3- Preliminary results indicated that pretreatment of PC 12 cells with 1-butanol (0.3 %), 
which is known to inhibit PLD activity in other cells systems, had no effect in the basal- or 
NGF-induced transcriptional activation of the NPY-Yl receptor gene in PC 12 cells.
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CHAPTER 5
PACAP-38 INDUCED EFFECTS IN THE TRANSCRIPTIONAL ACTIVATION OF THE NPY-Yl RECEPTOR GENE IN PC12 CELLS
5.1 INTRODUCTION
5.1.1 PEPTIDERGIC REGULATION OF GENE EXPRESSION
Neuronal plasticity depends on the capacity of cells to make long-term adjustments to 
environmental stimuli. Neurons, in addition to the classical neurotransmitter, contain one or 
more peptides which have the potential role to acting as neurotransmitters .Neurons can produce 
a variety of peptides that are secreted from axons and dendrites and are collectively known as 
neuropeptides. These polypeptides are believed to serve as neurotransmitters and 
neuromodulators by their interaction with specific receptors after secretion and have been 
implicated in the control of behaviour as well as autonomic and motor functions. The co­
existence and co-release of two or more messengers constitutes a fundamental principle in the 
nervous and endocrine system (Kupfermann, 1991). Co-transmission is a important signalling 
process which generates a more diverse set of responses by pre- or post-synaptic mechanisms.
In the autonomic nervous system, continuous low frequency stimulation of sympathetic fibers 
favour the preferential release of small classical neurotransmitter-containing vesicles while 
high-firing frequency stimulation in bursts causes the release of large vesicles containing 
peptides in addition to classical neurotransmitters (Bartfai et al., 1988). The response of post­
ganglionic-sympathetic neurons in the sympathetic ganglia is regulated by interaction with 
multiple transmitters. Afferent fibres to the ganglia, such as pre-ganglionic sympathetic 
neurones (Ki'ukoff, 1987), small intensily fluorescent cells (SIF) (Lars-Gosta et al., 1993) and 
primary sensory fibres (Quigg et al., 1990) store and release combinations of ACh, 
catecholamines and neuropeptides. PACAP and VIP are in pre-synaptic fibres of the 
sympathetic nervous system, including fibres innervating adrenal chromaffin cells. In P C I2 
cells, they exert a regulatory effect on the synthesis of tyrosine hydroxylase (TH) (Wessels- 
Reikeretal, 1991) and NPY (Colbert et ak, 1994). Thus, trans-synaptic activation of TH and 
NPY synthesis in postganglionic sympathetic nerves via non cholinergic neuromoduladors, 
such as VIP and PACAP present in pre-ganglionic nerve terminals is implicated in the 
restoration of synaptic stores of cathecolamines and NPY.
Thus, the activity-dependent release of peptide neurotransmitters begins a cascade of events 
which culminates in post-synaptic changes in gene expression. Trans-synaptic activation 
requires, as its initial step, the binding of the peptide to its receptor. It is well established that 
interaction of catecholamines/peptides with their specific receptors leads to activation of two 
major intracellular signalling pathways: the PKA and the PKC pathways. Several receptor 
systems mediate postsynaptic changes in gene transcription through these second messenger
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pathways, which are activated upon ligand binding. They link the neurotransmitter receptors to 
the molecular regulators of gene transcription (Armstrong and Montniinty, 1993).
5.1.2 G-PROTEIN COUPLED RECEPTORS (GPCRs)
All biological systems have the ability to process and respond to enormous amount of 
information. Much of this information is provided to individual cells in the form of changes in 
concentration of hormones, growth factors and neuromodulators. Several families of cell 
surface receptors have been characterised that are coupled to different mechanisms of signal 
transduction; one of these are coupled to G-proteins (Simon et ak, 1991). Signal transduction 
by G-proteins occur in two forms, the "small G proteins" that are found as single polypeptides 
and the heterotrimeric G-proteins that are made up of a , P, and y subunits. Signal transduction 
by heterotrimeric G-proteins is initiated by ligand binding which stabilises an alternative 
conformational form of the receptor and thus transmits information across the cell membrane. 
The ligand-bound receptor initiates two processes: one leads to desensitisation and the other 
generates a signal that begins with the activation of the G-protein (Simon et ak, 1991).
GPCRs can be further classified into three subfamilies, termed the rhodopsin/b-adrenergic, 
secretin/glucagon/VIP and metabotropic glutamate receptor families (Strader et ak, 1995). The 
secretin/glucagon/VIP family includes receptors for the peptides secretin, glucagon, glucagon­
like peptide I, parathyroid hormone, VIP, PACAP, calcitonin and growth hormone releasing 
hormone. These receptors share 25-50% amino acid identity among themselves and all contain 
an amino-terminal hydrophobic domain, which is presumed to served as signal sequence 
followed by a hydrophilic domain, preceding the seven transmembrane (TM) domains (Strader 
et ak, 1995). All members of the secretin/glucagon/VIP subfamily of receptors are coupled to 
Gs and upon activation of intracellular cAMP (Strader et ak, 1995). In addition to coupling to 
Gs, many of these receptors, such as glucagon, calcitonin, PACAP, VIP, among others, have 
been reported to activate other G-proteins, such as Gq, leading to increases in intracellular 
Ca++ levels and inositol phosphate hydrolysis. Thus, it appears that the potential to signal 
through multiple second messenger pathways may be a hallmark of this GPCR subfamily.
5.1.3 PACAP POLYPEPTIDE
PACAP was discovered as a consequence of a search for candidate novel hypothalamic- 
releasing hormones (Arimura, 1992a; Arimura and Shioda, 1995). The search strategy centred 
around the observations that known pituitary releasing hormones increase cAMP as a common 
response parameter in hypothalamic tissues. The search for a candidate hormone that increases 
cAMP in pituitary cell cultures resulted in the isolation of two substances from ovine
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hypothalamus which are now known as PACAP-27 and PACAP-38 (Miyata et ak, 1989). 
PACAP has a amino acid homology with VIP and has been localised by immunohistochemistiy 
to CNS (e.g. hypothalamic area), gastrointestinal and respiratory tract, adrenal gland and testis 
(Arimura, 1992a). Receptors localised in CNS, pituitary, adrenal medulla and germ cells of the 
testis are highly specific for PACAP and not are shar*ed with VIP (Arimura, 1992a).
They are two types of PACAP receptors on the basis of phamiacology and signalling activation 
and distribution (Harmar and Lutz, 1994; Journot et ak, 1994; Arimura and Shioda, 1995). 
The type I receptor has a high affinity for PACAP but much reduced affinity for other members 
of the secretin/glucagon/VIP family while the type II receptor can bind PACAP and VIP with 
similar affinities (Arimura, 1992b). The PACAP type-I receptor (found in hypothalamus, brain 
stem, pituitary, adrenal gland and testes) specific for PACAP is coupled to adenylyl cyclase 
and PLC. The existence of a PACAP type II distinct from type I was characterised on the basis 
of pharmacology by nature of its similar affinities for VIP or PACAP (Harmar and Lutz,
1994). Thus, there is a consensus that the PACAP type II receptor is identical to the VIP type I 
receptor since their distribution, pharmacology and putative signalling coupling mechanisms 
appear to be the same (Harmar and Lutz, 1994).
PACAP is a hypophysiotrophic hormone, neurotransmitter, neuromodulator or vasoregulator 
that may play a multifunctional role in the CNS and PNS, with excitatory receptors linked to 
adenylyl cyclase (Tatsuno et ak, 1991). The state of differentiation and secretory profile of 
mammalian cells of the SA neuronal lineage are altered by VIP but typically at lO'^ M or higher 
concentrations (Colbert et ak, 1994; Okumura et ak, 1994). However, the 27- and 38-amino 
acids forms of PACAP elevate cAMP levels and stimulate adenylyl cyclase in PC 12 cells with 
an EC50 near 10'^ M (Deutsch and Sun, 1992). PACAP-38 is also a potent activator of the IP 
turnover in PC 12 cells, elevating the content of IP by 8-fold (ECso = 7 xlQ-9 M) and is a 
effective inducer of neuronal morphology (Deutsch and Sun, 1992). In PC12 cells, PACAP 
has been shown to increase intracellular cytosolic Ca++ using two different mechanisms: 
release of intracellulai* stores and entry of external Ca++ (Hernandez et ak, 1995) (Figure 5.1).
The change in neuronal pattern of morphology observed in PC 12 cells following the addition 
of VIP or PACAP suggests that these peptides may play an important trophic role in CNS and 
PNS, in addition to the accepted neurotransmitter function in post-ganglionic sympathetic 
nerves. Thus, it is possible that, within pre-ganglionic sympathetic nerves, the trophic role of 
these peptides may be their primary action in the developing nervous system, whereas their 
regulation of sympathetic nerve function may occur latter once the specialised environment are 
achieved by steroid input to the adrenal medulla and the establishment of NGF dependence in 
the sympathetic nervous system.
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FIGURE 5.1 NGF-PACAP SIGNALLING PATHWAY
Schematic of the NGF-PACAP intracellular signaling pathways in PC I2 cells.
NGF (nerve growth factor), Trk (pl40^^^ receptor). PI-3-K (phosphoinositol-3-kinase). 
SHC {src -homology collagen), Grb2 (growth factor receptor bound protein-2). SOS (Son 
of sevenless protein). MEKK (Mitogen or extracellular-regulated kinase kinase). Raf (c-Raf 
kinase). B-raf (B-raf kinase). MEK (Mitogen or extracellular-regulated kinase). ERK 1/2 
(Extracellular signal-regulated kinase). PACAP (pituitary adenylyl cyclase activating 
polypeptide). Gs (Ga subunit protein). AC (adenylyl cyclase). PKA (protein kinase A). PLC 
(phospholipase C). IPs (inositol triphosphate). DAG (diacylglycerol). Ca++ (intracellular 
calcium). PKC (protein kinase C).
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Ill this chapter, an attempt was made to further study the molecular mechanisms involved in the 
role of PKA, PKC and the ras -MAPK second messenger pathways in the PACAP-38 
transcriptional activation of NPY-Yl gene in PC 12 cells by using the Dual-luciferase'^'^ reporter 
system (Figure 5.1). The role of PACAP-38 was studied as there is evidence that this peptide 
increases NPY gene expression in PC12 cells (Colbert et ah, 1994).
All the experiments were performed in duplicate and the results are shown as the mean ± SEM 
of at least three independent experiments. Untreated PC 12 cells were grown in the presence of 
vehicle (up to 0.1%) in DMEM complete medium. Reporter vector, pRL-SV40 (Promega) was 
used as a internal control of the transfection efficiency in PC 12 cells.
5.2 RESULTS
5.2.1 PACAP-38 INDUCE A CONCENTRATION DEPENDENT 
INCREASE IN THE NPY-Y I TRANSCRIPTIONAL ACTIVITY
PC 12 cells were shown to respond to PACAP-38 (5 nM) by differentiating into a neuronal-like 
phenotype (data not shown). PC 12 cells co-transfected with the "experimental reporter vector" 
pYl-LUC (10 |Lig) fusion gene and the "control reporter vector" pRL-SV40 (1 pg), and treated 
with PACAP-38 (5 nM) for 48 hours resulted in a 2.79 ± 0.18-fold increase in the 
transcriptional activation of the NPY-Yl gene compared to the basal levels (Figure 5-2). 
However, the levels of Renilla luciferase activity of PC 12 cells treated with PACAP-38 (5 nM) 
were similar to the basal levels (data not shown). These results indicated that this reporter 
vector is a good internal control to discriminate between plate-to-plate transfection efficiencies 
in PC 12 cells treated with PACAP-38 (5 nM).
PACAP-38-mediated increase of the transcriptional activation of the NPY-Yl receptor gene in 
PC 12 cells was concentration dependent (Figure 5-2). The threshold concentration of the 
PACAP-38 induction of NPY-Yl receptor gene expression was 0.5 nM (Figure 5-2). 
Increasing concentrations above this threshold resulted in a increases in the levels of the 
luciferase activity. A value of 5 nM of PACAP was chosen as it lies in the linear region of the 
concentration response (Figure 5-2). Thus, any variation due to inhibition or stimulation of this 
PACAP-38 response could be easily detected.
These range of concentration (0.5-50 nM) of the PACAP-38 effect on the transcription of the 
NPY-Yl gene is consistent with the binding affinity of the PACAP type I receptor and the 
biological potency of PACAP-38 in PC 12 cells (Deutsch and Sun, 1992) suggesting receptor 
specificity and physiological relevance of the NPY-Yl transcriptional stimulation by PACAP- 
38 in PC 12 cells.
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FIGURE 5.2 PACAP CONCENTRATION EFFECT
Effect of a range of PACAP-38 concentration on the transcriptional activation of the NPY-Yl 
receptor gene. PC 12 cells were co-transfected with pYl-LUC (10 jig) and pRL-SV40 (1 jig). 
20 hours after transfection PC 12 cells were treated with different PACAP (PACAP-38) 
concentrations for 48 hours when the cells were collected for Dual-luciferase assay (Promega). 
Each experiment represents the normalized luciferase activity (using the pRL-SV40 Renilla 
luciferase as internal control) in PACAP treated cells compared to that percent (100%) in the 
corresponding untreated cells (0.1% vehicle only). Values are mean ± SEM from 3 or more 
independent transfections experiments, each performed in duplicate with plasmids from at least 
two different preparations.
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5.2.2 EFFECT OF THE PKA PATHWAY IN THE 
NPY-Yl TRANSCRIPTIONAL ACTIVITY
5.2.2.1 EFFECT OF THE INCREASE OF INTRACELLULAR cAMP
Different pharmacological agents known to increase intracellular cAMP can activate the NPY- 
Y l transcriptional activity in PC I2 cells. Forskolin increases intracellular cAMP levels by 
direct binding and activation of adenylyl cyclase (EC50= 10 jiM) (Laurenza, 1989). This in 
turn increases the activity of PKA signalling pathway. Forskolin resulted in a concentration- 
dependent activation of the NPY-Yl transcriptional activity in PC12 cells (Figure 5-3). The 
thi'eshold of forskolin activation was 1 p,M and a increasing concentrations above this threshold 
resulted in increases in the levels of luciferase activity (Figure 5-3). In the following 
experiments was used 10 pM of forskolin, as this concentration was in the linear range of 
transcriptional activation of the NPY-Yl gene in PC 12 cells and did not affect the levels of 
Renilla luciferase activity of the pRL-SV40 control vector (data not shown).
DBC permeates the cell membrane and is metabolised in the cell to generate the active cAMP 
analogue (Posternak and Weiman, 1974). DBC also results in a concentration-dependent 
increase in the NPY-Yl transcriptional activation in PC 12 cells (Figure 5-4). The threshold of 
DBC activation was 0.1 mM and increasing concentrations resulted in increases in the 
transcriptional activation of the NPY-Yl gene (Figure 5-4). In the following experiments 1 mM 
DBC was used, as this concentration was in the linear range of pYl-LUC derived luciferase 
activity in PC 12 cells and also did not increase or decrease the levels of Renilla luciferase 
activity of the pRL-SV40 control reporter vector (data not shown).
The levels of transcriptional activity of the NPY-Yl receptor gene reached with forskolin 
(Figure 5-3) and DBC (Figure 5-4) were higher than the levels obtained with PACAP-38 
(Figure 5-2). These results suggested that forskolin and DBC at these range of concentrations 
results in a more robust and/or long lasting activation of the cAMP-PKA pathway in PC 12 cells 
than obtained with PACAP-38. Alternative, PACAP-38 can activate the Ca++ signalling 
pathway (Hernandez et ak, 1995) and in consequence a CaM phosphodiesterase. Moreover, 
preliminary results indicated that forskolin (10 |iM) and DBC (1 mM) act synergistically with 
PACAP-38 (5 nM) to increase the NPY-Yl transcriptional activity in PC 12 cells (data not 
shown). Taken together, these observations indicated that the activation of the cAMP-PKA 
pathway was involved in the PACAP-38 stimulation of the NPY-Yl transcriptional activity in 
PC 12 cells, as pharmacological agents which are well known to increase the intracellular levels 
of cAMP and in turn increase PKA activity in PC 12 cells, mimic this PACAP-38 response.
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FIGURE 5.3 FORSKOLIN CONCENTRATION EFFECT
Effect of a range of forskolin concentration on the transcriptional activation of the NPY-Yl 
receptor gene. PC 12 cells were co-transfected with pY 1-LUC (10 |ig) and pRL-SV40 (1 pg). 
20 hours after transfection PC 12 cells were treated with different FOR (forskolin) 
concentrations for 48 hours when the cells were collected for Dual-luciferase assay (Promega). 
Each experiment represents the normalized luciferase activity (using the pRL-SV40 Renilla 
luciferase as internal control) in forskolin treated cells compared to that percent (100%) in the 
corresponding untreated cells (0.1% vehicle only). Values are mean ± SEM from 3 or more 
independent transfections experiments, each performed in duplicate with plasmids from at least 
two different prepaiations.
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FIGURE 5.4 DBC CONCENTRATION EFFECT
Effect of a range of DBC concentration on the transcriptional activation of the NPY-Y 1 receptor 
gene. PC12 cells were co-transfected with pYl-LUC (10 pg) and pRL-SV40 (1 pg). 20 hours 
after transfection PC 12 cells were treated with different DBC (dibittyril cAMP) concentrations 
for 48 hours when the cells were collected for Dual-luciferase assay (Promega). Each 
experiment represents the noimalized luciferase activity (using the pRL-S V40 Renilla luciferase 
as internal control) in DBC treated cells compared to that percent (100%) in the corresponding 
untreated cells (0.1% vehicle only). Values are mean ± SEM from 3 or more transfections 
experiments, each performed in duplicate with plasmids from at least two different 
preparations.
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S.2.2.2 EFFECT OF PKA INHIBITOR (H-89)
In order to study the role of the PKA second messenger pathway in mediating the PACAP-38 
activation of the NPY-Yl receptor gene in PC 12 cells, the effect of a specific inhibitor of this 
signalling pathway was examined. For all these experiments, PC 12 cells were transiently co­
transfected with pYl-LUC (10 pg) and pRL-SV40 (1 pg). The next day the cells were 
preincubated for one hour with H-89, a specific PKA inhibitor before addition of PACAP-38 
(5 nM). PC12 cells were then preincubated with H-89 for 1 hour and then treated with 
PACAP-38 for 48 hours and the relative levels of firefly and sea pansy activity were measured 
in a luminometer using the Dual-Luciferase'^^ Reporter Assay kit (Promega). Both, H-89 (30 
pM) and PACAP-38 (5 nM) did not increase the Renilla luciferase activity over basal levels 
(data not shown), indicating that the reporter vector pRL-SV40 was a good internal control for 
these experiments.
Pretreatment of PC 12 cells with H-89, a potent and selective inhibitor of PKA (Ki = 50 nM) 
(Chijiwa et ak, 1990) led to a concentration-dependent inhibition of the PACAP 38 (5 nM) 
induced increase in the NPY-Yl transcriptional activity (Figure 5-5). Thus, the threshold 
concentration for H-89 inhibitory effect was 10 pM and 30 pM completely blocked this 
PACAP-38 response in PC 12 cells. H-89 (30 pM) also reduced the basal levels of 
transcriptional activity of the NPY-Yl receptor gene in PC12 cells (Figure 5-5), indicating that 
the PKA signalling pathway is also involved in the maintenance of the basal levels of 
transcription of the NPY-Yl gene in PC 12 cells. Moreover, DBC (1 mM) and forskolin (10 
pM)-mediated transcriptional activation of the NPY-Yl gene were completely blocked by H-89 
(30 pM) in PC 12 cells (data not shown).
These results using H-89 suggested that PC 12 cells have an intrinsic PKA activity which is 
involved in the constitutive expression of the NPY-Y 1 receptor gene in PC 12 cells consistent 
with previous results which shown a constitutive binding of NPY-Yl receptor agonist 
(DiMaggio et ak, 1994). Moreover, the PKA second messenger pathway is also involved in 
the PACAP-38 (5 nM) mediated transcriptional activation of this gene. Finally, the H-89 (30 
pM) block of the DBC and forskolin-mediated NPY-Yl gene transcriptional activity confirms 
this previous result. Taken together, these results indicated that the cAMP-PKA second 
messenger pathway is involved in the transcriptional activity of this neuropeptide receptor gene 
in PC 12 cells.
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FIGURE 5.5 H-89 CONCENTRATION EFFECT ON THE PACAP 
RESPONSE
Effect of a range of H-89 concentration on the PACAP-38 induced transcriptional activation of 
the NPY-Yl receptor gene. PC12 cells were co-transfected with pYl-LUC (10 pg) and pRL- 
SV40 (1 pg). 20 hours after transfection PC 12 cells were pretreated for 1 hour with different 
H-89 concentrations and then the cells were treated with PACAP (PACAP-38, 5 nM) (P+H) 
for 48 hours when the cells were collected for Dual-luciferase assay (Promega). As a control 
experiment the cells were treated with H-89 (30 pM) and PACAP (PACAP-38, 5 nM) alone 
for 48 hours. Each experiment represents the normalized luciferase activity (using the pRL- 
SV40 Renilla luciferase as internal control) in treated cells compaied to that percent (100%) in 
the corresponding untreated cells (0.1% vehicle only). Values are mean ± SEM from 3 or more 
transfections experiments, each performed in duplicate with plasmids from at least two 
different preparations.
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5.2.3 EFFECT OF THE PKC PATHWAY IN THE 
NPY-Yl TRANSCRIPTIONAL ACTIVITY
5.2.3.1 EFFECT OF PKC INHIBITOR (CALPHOSTIN C)
Preincubation of PC I2 cells with calphostin C (1 pM), a highly specific inhibitor of PKC (Ki 
= 50 nM) (Kobayashi et ah, 1989) reduced by 55% the PACAP-38 (313.3% + 18.6%) 
mediated transcriptional activation of the NPY-Yl receptor gene to 175% ±7.07%  (Figure 5- 
7). This concentration of calphostin C did not affect the levels of Renilla luciferase activity in 
comparison with the basal levels (data not shown). In the previous chapter calphostin C (1 pM) 
has also been shown to inhibit the basal levels of luciferase activity of the pYl-LUC in PC 12 
cells (Figure 4-7). These results suggested that the PKC second messenger pathway is 
involved in both, the basal- and the PACAP 38-induced transcriptional activity of the NPY-Y 1 
gene in PC 12 cells.
5.2.4 EFFECT OF THE CaM KINASE II PATHWAY
KN-62 (1 pM), a specific inhibitor of a rat brain CaM-K II (Ki = 900 nM) (Tokumitsu et ak, 
1990) had no effect in the PACAP 38 (5 nM)-induced transcriptional activation of the NPY-Y 1 
gene in PC 12 cells (data not shown). This result indicates that CaM-K II activity appear not be 
involved in the PACAP 38-induced transcriptional activation of the NPY-Yl receptor gene in 
PC12 cells.
5.2.5 EFFECT OF THE RAS-MAP KINASE PATHWAY
PACAP-38, forskolin and DBC stimulate the MAPK activity in PC 12 cells (Frodin et ak, 
1994; Young et ak, 1994; Barrie et al., 1997). PACAP-38 (5 nM) is a efficient activator of 
MAPK, showing a rapid (5 minutes) and long lasting activity peak (Barrie et ak, 1997). For 
this reason, the effect of thera.5' -MAPK pathway in the PACAP-38 mediated transcriptional 
activation of the NPY-Yl gene was studied.
5.2.5.1 PACAP-38 EFFECTS IN A RAS-NEGATIVE PC12 CELL LINE
A stable mutant PC 12 cell subline (PC 12 asnl7-W7) over-expressing a dominant inhibitory 
human p2H ^‘^ gene (Feig and Cooper, 1988) was used to examine the role of the ras -MAP 
kinase pathway in mediating the effect of PACAP-38 on the transcriptional activation of the 
NPY-Yl receptor gene. This cell line was transfected with the pY 1-LUC fusion gene using the 
liposome-mediated method.
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FIGURE 5.6 CALPHOSTIN C CONCENTRATION EFFECT ON 
THE PACAP RESPONSE
Calphostin C concentration effect in the PACAP-38 induced transcriptional activation of the 
NPY-Yl receptor gene. PC 12 cells were co-transfected with pY 1-LUC (10 pg) and pRL-SV40 
(1 pg). 20 hours after transfection PC 12 cells were pretreated for 1 hour with different CC 
(Calphostin C) concentrations and then the cells were treated with PACAP (PACAP-38,5 nM) 
(P + CC) for 48 hours when the cells were collected for Dual-luciferase assay (Promega). As 
a control experiment the cells were treated with CC (Calphostin C, 1 pM) and PA C A P 
(PACAP-38, 5 nM) alone for 48 hours .Each experiment represents the normalized luciferase 
activity (using the pRL-SV40 Renilla luciferase as internal control) in treated cells compai'ed to 
that percent (100%) in the corresponding untreated cells (0.1% vehicle only). Values are mean 
± SEM from 3 or more transfections experiments, each performed in duplicate with plasmids 
from at least two different prepaiations.
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PACAP-38 (5 nM) induced similar morphological changes in PC12asnl7-W7 compared to 
wild type cells (data not shown) and a similar increase of the MAPK activity (Barrie et ah, 
1997). PACAP-38 (5 nM) also resulted in a similar transcriptional activation of the NPY-Yl 
receptor gene in the FCl2-ras negative cell line in comparison to the PC 12-wild type cells 
(Figure 5-7). This result indicated that the protein appeal' not be involved in the PACAP
38-induced transcriptional activation of NPY-Yl receptor gene in PC 12 cells.
5 .2.S.2 EFFECT OF MlEK-1 KINASE INHIBITOR (PD 98059)
PD 98059 is a inhibitor of MEK-1 known to block the increase in MAPK activity by NGF in 
PC12 cells (Alessi et ah, 1995). In the previous chapter, PD 98059 (20 pM) resulted in a 
increase in both, the basal- and NGF-dependent (Figure 4-6) transcriptional activity of the 
NPY-Yl gene in PC12 cells. Moreover, PD 98059 (20 pM) increased the PACAP-38 (5 nM) 
mediated transcriptional activation of the NPY-Yl gene in PC 12 cells (Figure 5-8). Taken 
together these results suggests that the increase of MEK-1 kinase activity mediated by PACAP- 
38 in PC 12 cells has an inhibitory effect in the transcriptional activation of the NPY-Yl gene.
5.3 DISCUSSION
In the present chapter has been demonstrated that the transcription of the NPY-Yl gene 
increases in response to peptidergic stimulation (PACAP-38) and in response to several 
pharmacological agents known to increase cAMP and in turn PKA activity in PC 12 cells. 
Furthermore, the role of both, the PKC and the ras -MAPK pathway in the PACAP-38 
transcriptional activation of NPY-Yl gene were studied using specific activators and inhibitors 
of each pathway, and a mutant PC12 ras -negative cell line (PC12asnl7-W7).
5.3.1 PACAP-38 INDUCES A CONCENTRATION DEPENDENT 
INCREASE IN THE NPY-Yl TRANSCRIPTIONAL ACTIVITY
PACAP induces adenylyl cyclase activity and elevates cytosolic Ca++ levels in adrenal tissue 
(Watanabe et ak, 1995) and stimulation of the splanchnic nerve increases PACAP levels in 
adrenal perfusates (Wakade et ak, 1992). PACAP has also been demonstrated to modulate 
catecholamine and NPY expression in rat SCG (May and Braas, 1995) and stimulate the 
phosphorylation of TH (Strong et ak, 1992). Thus, like VIP, PACAP would appear to 
function as a physiological noncholinergic neurotransmitter in the rat SA system (Watanabe et 
ak, 1995). Moreover, in other cells of this lineage, such as neonatal chromaffin cells (Wolf and 
K'ieglstein, 1995) and PC12 cells (Deutsch and Sun, 1992; Colbert et ak, 1994; Hernandez et 
ak, 1995) which are well known to be responsive to VIP in micromolar amounts, PACAP 
stimulates neurite formation generally at more physiological (nanomolar) concenti’ations.
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FIGURE 5.7 RAS EFFECT ON THE PACAP RESPONSE
Effect of PACAP and forskolin on the transcription of the luciferase gene directed by the 
promoter region of the NPY-Yl receptor gene in a PC12-ras negative cell line (Buensuceso,
1995). PC12asnl7-W7 cells were transfected with pY 1-LUC (1-2.5 pg) using the liposome- 
mediated method. 20 hours after transfection the cells were treated with PACAP (PACAP-38, 
5 nM) or FORSK (forskolin, 10 pM) for 48 hours and then the cells were collected for 
luciferase assay (Promega). Each experiment represents the luciferase activity of treated cells 
compared to that percent (100%) in the corresponding control cells (0.1% vehicle only). Values 
are mean + SEM from 3 or more transfections experiments, each performed in duplicate with 
plasmids from at least two different preparations.
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FIGURE 5.8 PD98059 EFFECT ON THE PACAP RESPONSE
PD98059 effect on the basal- and PACAP-dependent transcriptional activity of the NPY-Yl 
receptor gene. PC 12 cells were co-transfected with pY 1-LUC (10 pg) and pRL-SV40 (1 pg). 
20 hours after transfection PC 12 cells were pretreated for 1 hour with PD98059 (20 pM) and 
then the cells were treated with PACAP (PACAP-38, 5 nM) for 48 hours when the cells were 
collected for Dual-luciferase assay (Promega). As a control experiment the cells were treated 
with PD98059 (20 pM) and PA C A P (PACAP-38, 5 nM) alone for 48 hours. Each 
experiment represents the normalized luciferase activity (using the pRL-SV40 Renilla 
luciferase as internal control) in treated cells compared to that percent (100%) in the 
corresponding untreated cells (0.1% vehicle). Values are mean ± SEM from 3 or more 
transfections experiments, each performed in duplicate with plasmids from at least two 
different prepaiations.
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PC 12 cells were co-transfected with pYl-LUC and pRL-SV40, and treated for 48 hours with 
increasing concentrations of PACAP-38 (0.05 to 50 nM) (Figure 5-2). This experiment 
showed that PACAP-38 increased the transcriptional activity of the NPY-Yl receptor gene in 
PC12 cells in a concentration-dependent fashion (Figure 5-2). The range of concentration of 
the PACAP 38-mediated increase (0.5 to 50 nM) was consistent with the binding affinity of the 
PACAP type I receptor and the biological potency of PACAP-38 in PC 12 cells (Deutsch and 
Sun, 1992). These results suggested a receptor specificity and physiological relevance of the 
stimulation of the NPY-Yl transcriptional activity by PACAP-38 in PC 12 cells.
The 2.79 ± 0.18-fold increase in the transcriptional activity of the NPY-Yl receptor gene 
mediated by PACAP-38 (5 nM) appear to be independent of variations on the transfection 
efficiencies as the levels of Renilla luciferase activity of PC 12 cells co-transfected with the 
pRL-SV40 control vector and treated with PACAP 38 (5 nM) were similar to the levels of 
Renilla luciferase activity of untreated PC 12 cells (data not shown). Previous results has been 
shown that the control reporter vector pRL-SV40 alone did not increase Renilla luciferase 
activity in response to PACAP-38 (5 nM) in PC 12 cells (Figure 3-12). Thus, normalising the 
firefly luciferase activity of pY 1-LUC to the sea pansy luciferase activity of pRL-SV40 
eliminates inherent variabilities that can undermine experimental accuracy.
5 3 .2  EFFECTS OF THE PKA PATHWAY IN THE NPY-Yl 
TRANSCRIPTIONAL ACTIVITY
cAMP functions to coordinate diverse metabolic process by mechanisms which are pleiotropic 
in nature, altering numerous steps in the metabolic pathway simultaneously. Since the 
discovery of PKA, the mechanisms of action of a number of additional extracellular signals 
have been found to involve regulation of the formation of cAMP and thereby control of its 
target enzyme, PKA (See Chapter 1. cAMP in signalling pathway).
The biologically relevant effects of cAMP are mediated by activation of the PKA. PKA is a 
tetramer consisting of two regulatory subunits and two catalytic subunits. Upon binding of 
cAMP to the regulatory subunit, the holoenzyme dissociates to yield a regulatory subunit dimer 
and two free catalytic subunits which are available to phosphorylate cellular substrates. The 
active catalytic subunit (c-PKA) phosphorylate several cytoplasmatic substrates. In addition, a 
fraction of the c-PKA translocates to the nucleus where it phosphorylates nuclear transcription 
factors that are responsible for the activation of cAMP-induced genes (Roesler et ah, 1988). 
PKA is found in two classes which differ in their regulatory subunits: PKA type I is soluble 
and widely expressed, whereas the PKA II isoforms, PKAIIoc and PKAIIp, are membrane 
anchored and particularly abundant in neuroendocrine cells, such as PC 12 cells (Cassano et ah,
1996).
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PC 12 cells, extend neurites in response not only to NGF but also to cAMP-enhancing agents, 
however these neurites appear to be different both in their length and in the mechanism by 
which they are formed. Elevation in intracellular levels of cAMP in PC I2 cells also increases 
TH enzyme activity by both, PKA phosphorylation and by activating transcription and also 
increase phosphorylation of ribosomal S6 and histone H2b (Ginty et ah, 1991). In addition, 
DEC and forskolin increase the expression of neuronal-specific genes, such as egr-1 (lEGs), 
VGF and GAP-43 (LRGs) in PC12 cells (Ginty et ah, 1991; Okumura et ah, 1994) (See 
Chapter 1. cAMP in signalling pathway).
5.3.2.1 EFFECT OF THE INCREASE OF INTRACELLULAR cAMP
Previous results have shown that PACAP-38 results in a increase in neurite density in PC 12 
cells (Deutsch and Sun, 1992; Colbert et ah, 1994; Hernandez et ah, 1995). This 
morphological change is mimicked using different pharmacological agents known to increase 
intracellular levels of cAMP in PC 12 cells, such as forskolin (10 p,M) or DEC (1 mM) 
(Flernandez et ah, 1995). Morever, forskolin also stimulates NPY expression in PC 12 cells 
(Higuchi et ah, 1988) and rat brain cells (Magni and Earnea, 1992). VIP and PACAP-38 also 
increase the transcriptional activity of the NPY gene in PC 12 cells (Colbert et ah, 1994).
Results shown in the previous section of this chapter demonstrated that PACAP-38 increased 
in a concentration-dependent manner the NPY-Yl transcriptional activity in PC 12 cells (Figure 
5-2). Forskolin is a diterpene isolated from the Indian plant Coleus forskohlii which activates 
adenylyl cyclase in membranes and intact cells ( E C 5 0 =  5-10 |iM) (Laurenza, 1989). This 
activation of adenylyl cyclase by forskolin is rapid, reversible and does not require guanine 
nucleotides. The increase in cAMP in turn increases the activity of PKA (Laurenza, 1989). 
Forskolin also increased in a concentration-dependent fashion the NPY-Yl transcriptional 
activity in PC 12 cells (Figure 5-3). The range of concentration (10-30 |LlM) of the forskolin 
effect in the transcriptional activity of the NPY-Yl gene was consistent with the known 
biological potency (eg. PKA activation) of this phar macological agent in PC 12 cells (Ealbi and 
Allen, 1994).
Dibutyryl-cAMP (DEC) is a cell-permeable cAMP analogue that specifically activates PKA 
(Posternak and Weiman, 1974). DEC also resulted in a concentration-dependent transcriptional 
activation of the NPY-Yl receptor gene in PC 12 cells (Figure 5-4). Preliminary results indicate 
that the DEC (1 mM) and forskolin (10 fiM) transcriptional activation of the NPY-Y 1 gene was 
synergistic with PACAP-38 (5 iiM) supporting a role of the cAMP-PKA pathway in this 
PACAP-38 mediated response in PC 12 cells (data not shown).
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However, the increase of NPY-Yl transcriptional activity reached with forskolin and DBC was 
higher than the maximal levels obtained with PACAP-38, suggesting that both forskolin and 
DBC induced increases of the intracellular levels of cAMP and in turn activation of the PKA 
pathway in PC 12 cells were in a more robust or/and long lasting way than the obtained by 
PACAP-38. Direct measurements of the PKA activity in PC 12 cells following PACAP-38, 
forskolin and DBC treatment will be necessaiy to answer this hypothesis.
PACAP-38 has been shown to increase the intracellular levels of Ca++ in PC 12 cells 
(Hernandez et ah, 1995), which in turn could activate CaM-dependent enzymes such as the 
type I phosphodiesterase or calcineurin, a serine/ threonine phosphatase. cAMP is hydrolysed 
by phosphodiesterases in the cell, leading to cessation of the cAMP dependent biological 
effects. At least five major class of phosphodiesterases have been reported that differ in their 
kinetic properties (See cAMP in signalling pathway). The type I phosphodiesterases are CaM- 
dependent and selectively inhibited by 8-methoxymethy 1-3-isobutyl-1 -methylxanthine (IBMX). 
Further experiments with specific inhibitors of the CaM-dependent phosphatases or 
phosphodiesterases, will be necessai'y to determine the involvement of these enzymes in the 
PACAP-38 induced transcriptional activation of the NPY-Yl gene in PC 12 cells.
S.3.2.2 E FFE C T  OF PKA IN H IB IT O R  (H-89)
H-89 is a potent and selective inhibitor of the PKA activity (Ki = 50 nM) in competitive fashion 
against ATP in PC12 cells (Chijiwa et al., 1990). Pretreatment of PC12 cells with H-89 (30 
jlM) results in a inhibition of the forskolin-induced protein phosphorylation, with no decrease 
in intracellular cAMP levels (Chijiwa et ah, 1990) and also significantly inhibited the forskolin- 
and DBC-induced neurite outgrowth (Chijiwa et al., 1990).
H-89 had been shown to result in a concentration-dependent inhibition of the PACAP-38 (5 
nM) mediated increase in the NPY-Yl transcriptional activity in PC 12 cells (Figure 5-5). H-89 
(30 |iM) results in a complete inhibition of this PACAP-38 (5 nM) response in PC 12 cells. 
Moreover, this is the same concentration use for block the biological effects (eg. neurite 
formation) of forskolin and DBC in PC12 cells (Chijiwa et al., 1990). Furthermore, the DBC 
(1 mM) and forskolin (10 jiM) mediated transcriptional activation of the NPY-Yl gene were 
blocked by H-89 (30 |iM) in PC 12 cells (data not shown). Taken together, these results 
indicated a cAMP-PKA involvement in the PACAP-38 (5 nM) transcriptional activation of the 
NPY-Yl receptor gene in PC 12 cells.
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5.3.3 EFFECTS OF THE PKC PATHWAY IN THE 
N PY-Yl TRANSCRIPTIONAL ACTIVITY
VIP, when added at 10'^ M, is quite effective in promoting differentiation and survival of 
PC12 cells (Colbert et ah, 1994; Okumura et ah, 1994). VIP added to SA cells at 10"  ^M not 
only activates adenylyl cyclase, but also has been found to activate the PI pathway (Malhotra et 
al., 1989). PACAP-38 but not PACAP-27 is also a potent activator of the inositol phospholipid 
signalling cascade in PC 12 cells, elevating the content of inositol phosphates by 8-fold at 10"  ^
M (EC50 = 7 X 10“9 M) (Deutsch and Sun, 1992). PACAP-38 at 10“^  M is also an effective 
inducer of neuronal morphology in PC 12 cells, whereas PACAP-27 is much less potent in 
promoting neurite outgrowth (Deutsch and Sun, 1992).
Speculatively, other signalling molecules stimulated as part of the PI cascade may also play a 
role in the PACAP-38 response in PC 12 cells, such as PKC and CaM-K II. Pharmacological 
activators of PKC, like phorbol esters (PMA) and DHl increased the NPY-Yl transcriptional 
activity in a concentration-dependent manner (Figures 4-8 and 4-9). For this reason, the effect 
of the PKC signalling pathway in the PACAP38 mediated NPY-Yl transcriptional activation in 
PC 12 cells was studied.
5.3.3.1 EFFECT OF PKC INHIBITOR (CALPHOSTIN C)
Preincubation of the PC 12 cells with calphostin C, a specific inhibitor of PKC (Ki = 50 nM) 
(Kobayashi et al., 1989) reduced the PACAP-38-mediated NPY-Yl transcriptional activation 
in a concentration-dependent fashion (Figure 5-6). PACAP-38 (5 nM) response was markedly 
reduced (55%) following preincubation with calphostin C (1 |iM) but the forskolin and DBC 
stimulation were not affected by calphostin C (1 jiiM) (data not shown), indicating that at this 
concentration, calphostin C selectively blocks the PKC-dependent transcriptional activation of 
the NPY-Yl receptor gene in PC 12 cells. These results suggested that PKC activity was also 
involved in the PACAP 38-mediated transcriptional activation of this neuropeptide receptor 
gene in PC 12 cells. Taken together, these results suggests that both PKA and PKC pathways 
are involved in the PACAP-38 activation of the NPY-Yl transcription in PC12 cells.
5.3.4 EFFECT OF THE CaM KINASE II PATHWAY
Previous studies suggested that the CaM-dependent and the cAMP-PKA signalling pathways 
could converge in their effects on some gene regulatory events in PC 12 cells (Sheng et ah, 
1990). In addition, exposure of PC 12 cells to PACAP-38 resulted in elevation of intracellular 
levels of Ca++ in PC12 cells (Hernandez et ah, 1995). KN-62 is a cell-permeable and specific
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inhibitor of CaM-K II in PC 12 cells (Ki = 900 nM) (Tokumitsu et ah, 1990). However, KN- 
62 (1 |iM) had no effect in the PACAP 38-induced transcriptional activation of the NPY-Yl 
receptor gene in PC 12 cells (data not shown). This result indicated that CaM-K II activity has 
no effect on the PACAP 38-induced transcriptional activity of the NPY-Yl receptor gene in this 
cell line.
5.3.5 EFFECT OF THE RAS-MAP KINASE PATHWAY
MAPKs are activated not only by stimulation of RTKs, but also by GPCRs (See Chapter 1. G- 
protein as mitogens). Different pharmacological agents known to increases cAMP, such as 
IBMX, cholera toxin, forskolin and DBC has been shown to stimulate MAPKs activity in 
PC12 cells (Frddin et ah, 1994; Young et ah, 1994). PACAP-38 has been shown to be an 
activator of MAPKs (Barrie et ah, 1997). PACAP-38 stimulation of MAPKs is inhibited by 
PKC down-regulation and preincubation with calphostin C, a specific PKC inhibitor (Barrie et 
ah, 1997). PM A also has been shown to promote a sustained activation of MAPK (Fro din et 
ah, 1994; Young et ah, 1994). These results suggests that MAPKs cascade may integrate and 
amplify signals originating from receptors employing both PKA- and PKC-dependent 
pathways, such as the PACAP type I receptor.
5.3.5.1 PACAP-38 EFFECTS IN A RAS-NEGATIVE PC12 CELL LINE
PACAP-38 (5 nM) results in a transcriptional activation of the NPY-Yl receptor gene in the 
VCl2-ms negative cell line in a similar manner to the PC12-wild type cells (Figure 5-7). This 
result indicated that the p2H"‘^ ‘^ protein is not involved in mediating the PACAP 38-induced 
activation of NPY-Yl receptor gene in PC 12 cells.
5.3.S.2 EFFECT OF THE MEK-1 KINASE INHIBITOR (PD 98059)
PACAP-38 results in a activation of MEK-1 which was overall similar to that the observed 
with cAMP in combination with PMA (Frodin et ah, 1994). PD 98059 has also been shown to 
inhibited the PACAP 38-mediated activation of the MAPKs in PC 12 cells (Bairie et ah, 1997). 
Results in the previous chapter has been shown that PD 98059 (20 fiM) results in a increase in 
both the basal- and NGF-dependent (Figure 4-6) transcriptional activation of the NPY-Y 1 gene 
in PC 12 cells. PD 98059 (20 |lM) also increase the PACAP 38-mediated tianscriptional activity 
of the NPY-Yl gene in PC12 cells (Figure 5-9). This results suggests that PACAP-38 
mediated increase of MEK-1 kinase activity has an inhibitory effect in the transcriptional 
activation of the NPY-Yl receptor gene in PC 12 cells.
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5.4 SUMMARY
1.- PACAP-38 induce a concentration dependent transcriptional activation of 
the N PY -Y l gene in PC12 ceils.
The threshold concentration of the PACAP 38 induction of NPY-Yl receptor gene was 0.5 
nM. Increasing concentrations above this thi'eshold resulted in significant increases in the levels 
of the luciferase activity .
2.- PACAP-38 (5 nM) induce a transcriptional activation of NPY-Yl gene in a 
PKA-dependent manner in PC 12 cells.
2.1- Pharmacological agents known to increase cAMP, such as forskolin and 
DBC mimicked the PACAP-38 effect on the NPY-Yl transcription.
2.1.1- Forskolin increased in concentration-dependent manner the NPY-Yl transcriptional 
activity in PC12 cells. The threshold of forskolin activation was 1 pM and increasing 
concentrations increase the transcriptional activation of the NPY-Y 1 receptor gene.
2.1.2- DBC increased in concentration-dependent manner the NPY-Yl transcriptional activity 
in PC12 cells . The threshold of DBC activation was 0.1 niM and increasing concentrations 
increase the levels of luciferase activity.
2.2- A specific PKA inhibitor (H-89) significantly block the PACAP-38 (5 
nM) activation of the NPY-Yl transcription
Pretreatment of PC 12 cells with H-89 led to a concentration-dependent inhibition of the 
PACAP 38-dependent increase in the NPY-Yl transcriptional activity. H-89 (30 pM) 
completely reduced this PACAP-38 response in PC 12 cells, indicating that in this 
transcriptional activation is involved PKA activity.
2.3- A specific PKA inhibitor (H-89) block the forskolin (10 pM) and DBC 
(ImM ) activation of NPY -Y l transcription.
DBC (1 mM) and forskolin (10 pM)-mediated transcriptional activation of the NPY-Yl gene 
were blocked by H-89 (30 pM) in PC 12 cells, indicating that in this forskolin and DBC- 
mediated response was involved PKA activity.
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3.- PACAP-38 induce a transcriptional activation of the N PY -Y l gene in a 
PKC-dependent manner in PC 12 cells.
3.1- A specific PKC inhibitor (calphostin C) significantly inhibited the 
PACAP-38 (5 nM) activation of the NPY-Yl transcription.
Preincubation of PC 12 cells with calphostin C resulted in a concentration-dependent reduction 
on PACAP-38 (5 nM) mediated increase in the NPY-Yl transcriptional activity. Calphostin C 
(1 pM) significantly reduced (55%) this PACAP-38 response indicating that in this 
transcriptional activation was involved PKC activity.
3.2- A specific PKC inhihitor (calphostin C) did not reduced the forskolin (10 
pM) and DBC (1 mM) activation of the NPY-Yl transcription.
Pretreatment of PC 12 cells with calphostin C (500 nM) did not affect the forskolin (10 pM) 
and DBC (1 mM) mediated transcriptional activation of the NPY-Yl gene, indicating that this 
forskolin and DBC response was independent of PKC activation (data not shown).
4.- PACAP-38 (5 nM) induced a activation of the NPY-Yl transcription in a 
Ca++/CaM kinase II independent manner in PC12 cells.
Pretreatment of the PC12 cells with KN-62 (1 pM) did not no affect the PACAP-38 (5 nM) 
induced transcriptional activation of the NPY-Yl receptor gene in PC 12 cells, indicating that 
this PACAP-38 response was independent of CaM-K II activity.
5.- PACAP-38 (5 nM) induced a activation of the NPY-Yl transcription in a 
ras -independent manner in PC 12 cells.
PACAP-38 (5 nM) results in similar transcriptional activation of the NPY-Yl receptor gene in 
the PC12-rai’ negative cell line in comparison to the PC 12-wild type PC 12 cells, indicating 
that in this PACAP-38 response is not involved the protein.
6.- PACAP-38 (5 nM) induced activation of the NPY -Y l transcription was 
inhibited by MEK-1 kinase activity.
Pretreatment of the PC 12 cells with PD 98059 (20 pM) increase the PACAP-38 (5nM) 
mediated activation of the NPY-Yl transcription (Figure 5-9), indicating that the PACAP-38 
induced MEK-1 kinase activity has an inhibitory effect in the transcriptional activation of this 
neuropeptide receptor gene.
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CHAPTER 6
MUTAGENESIS STUDIES OF THE PROMOTER REGION OF THE RAT NPY-Yl RECEPTOR GENE
6.1 INTRODUCTION
6.1.1 MUTAGENESIS TECHNIQUES
Alteration of a DNA sequence by specific chemical, physical or enzymatic methods 
(mutagenesis) is a valuable technique in molecular biology. These techniques allow very 
precise structural genetic manipulations and are used in many applications, such as DNA 
sequencing, cloning, DNA structural analysis, protein expression studies and the study of 
structure-function relationship of cloned gene products. These techniques also offer the 
possibility to study in great detail the interaction between a particular gene and the machinery 
involved in regulating its expression. The effect of such manipulations can then be studied in 
suitable cell lines or even animal models. Mutagenesis techniques can be classified on the type 
of mutation introduced (deletion, insertion or substitution), as well as by the method (random 
or sequence-specific).
The location of functional elements within a DNA fragment are often determined by making a 
set of unidirectional deletions. This random method takes advantage of the unique properties of 
Exonuclease III (Exo III) which will specifically digest DNA from 5'-protruding or blunt-end 
restriction site, but not 3'-overhangs (Henikoff, 1987). Oligonucleotide or site-directed 
mutagenesis is another technique that enables the researcher to create very specific 
modifications of a cloned DNA (Kunkel, 1985). By using this technique the role of specific 
sequences in the regulatory regions of genes can be studied in detail by deleting, exchanging or 
adding sequences to the putative regulatory regions of a gene. In this chapter, another 
technique, the polymerase chain reaction (PCR) was used to make specific deletions of the 
promoter region of the NPY-Y 1 gene.
PCR is a relative simple technique by which a DNA template is amplified many thousand- or 
million-fold quickly and reliably (Mullis and Faloona, 1987). PCR process is exquisitely 
sensitive. By amplifiying just a small portion of a nucleic acid target, this technique effectively 
isolates that portion from the rest of the nucleic acids. Using this technique, were created 
specific deletions in the promoter region of the NPY-Yl gene that can be difficult to create 
using other techniques. One approach was made specific deletions of the putative DNA binding 
sites for transcription factors, such as the AP-1 and the GRE site (Figure 6-1). Another 
approach was made specific progressive deletions in this promoter region (Figure 6-2).
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5'-primer BAM— .
-553 bp
5'-primer
SAC
-ŒE_
-493 bp -373 bp
SAC3'-primer
-273 bp -113 bp
...GFG. .ARIrQRE 0 £ _ SE1 -GAAT -
-73 bp
..TATA
-45 bp -20 bp
 BAM
3'-primer
p B S -Y 1 g e n e
LUCIFERASE
BAM  0=E
-553 bp
CFE -  QqE -SAC SAC
-493 bp -373 bp -113 bp -73 bp -45 bp
BAM PCR PRO DUCTS
5'-primer 
BAM-----
p Y l-L U C -A P I
BAM- SAM'
-553 bp -493 bp -373 bp -113 bp -45 bp -20 bp  BAM
CAAT -  TATACPE CPE -----  SP1 LUCIFERASE
3-primer
FIGURE 6.1 DELETION OF THE API SITE OF THE PROMOTER 
OF THE NPY-Yl GENE
Methodological approach used to delete a putative API binding site of the promoter region of 
the rat NPY-Yl receptor gene by PCR. TATA (TATA-like box), CAAT (CAAT-like box), 
S p l (Spl responsive site), CRE (cAMP responsive element), GRE (glucocorticoid 
responsive element), ERE (estrogen reponsive element), APl-GRE (API-GRE responsive 
element). LUCIFERASE (luciferase open reading frame). 5 '-primer (forward primer). 3’- 
primer (reverse primer).
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5'-primer
CFE . _0=E APl-GRE CRE SP1 -GAAI. TATA
-553 bp -493 bp -373 bp -273 bp
5'-primer
-113 bp -73 bp -45 bp -20 bp
LUCIFERASE
3'-prlmer
. Ç F L 0=E APl-GRE CRE SP1 -CAAI TATA
-493 bp -373 bp -273 bp
5'-primer
-113 bp -73 bp -45 bp -20 bp
LUCIFERASE
3-primer
APl-GRE CFE SP1
-373 bp -273 bp -113 bp -73 bp
..CAAI. TATA LUCIFERASE
5'primer 3'-primer
-273 bp -113 bp -73 bp -45 bp -20 bp
.CAAI.SP1 TATACPEAPl-GRE LUCIFERASE
5'-prlmer 3'-primer
-113 bp -73 bp -45 bp -20 bp
5'-prlmer 3’-primer
C A A I.
C A A I2E1 TATA
LUCIFERASE
LUCIFERASE
-73 bp -45 bp -20 bp
3'-prirner
FIGURE 6 .2  PROGRESSIVE DELETIONS OF THE PROMOTER 
OF THE NPY-Yl
Methodological approach to the progressive deletions of putative binding sites for transcription 
factors of the promoter region of the rat NPY-Y 1 receptor gene by PCR. TATA (TATA-like 
box), CAAT (CAAT-like box), S p l (Spl responsive site), CRE (c-AMP responsive 
element), GRE (glucocorticoid responsive element), ERE (estrogen reponsive element), 
A P l-G R E  (APl-GRE responsive element). LUCIFERASE (luciferase open reading 
frame). 5 -primer (forward primer). 3 -primer (reverse primer).
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6.1.2 TRANSCRIPTION FACTORS
The transcription process is the essential first step in the conversion of the genetic information 
from the DNA into protein and this process is also the major point at which gene expression is 
regulated. In most cases, gene regulation is achieved by activating (or repressing) the 
transcription of particular genes. Once this has occured, all the other stages of gene expression 
(RNA processing, translation, post-translation) follow and the appropiate protein is 
synthesized in a cell-type specific or inducible manner. Both the basal process of transcription 
itself and its regulation are controlled by specific short DNA sequences in the gene, promoters 
or enhancers (McKnight and Yamamoto, 1992). These sequences act by binding specific 
proteins known as transcription factors, which then influence the rate of transcription of the 
gene.
Candidate regulatory regions are defined consensus sequences known to mediate the activity of 
transcription factors in other genes and systems. However, the fact that a gene possesses a 
consensus sequence does not necessarily constitute evidence that it is relevant to the mechanism 
being studied. For a consensus sequence to be defined as functional in the transcriptional 
regulation of a gene, several criteria must be met. Firstly, the relevant transcription factor must 
be shown to be present in the cell and that it is appropriately activated. A direct interaction 
between the DNA sequence and the transcription factor must also be demonstrated. Finally, it 
must have an effect on the transcriptional activity of the gene.
There are several possible approaches to demonstrate that a particular transcription factor is 
involved in the regulation of a particular gene. It is possible to block its biological activity by 
microinjecting specific antibodies into cells. In the case of transcription factors that are not 
constitutively present in the cell, but which require stimulation of gene transcription and 
translation, it is also possible to use antisense oligonucleotides to specifically block 
transcription and/or translation of the gene that encodes for it. Another approach is mutate the 
consensus sequences for transcription factors present within the gene and study how these 
modifications affect the transcriptional control of the gene. The use of reporter function 
systems has simplified the problem of defining elements within a gene responsible for 
transcriptional regulation. In combination with mutagenesis, it is possible to define a role for a 
particular sequence.
6.1.3 DELETIONS OF THE PROMOTER OF THE NPY-Yl GENE
The promoter region of the rat NPY-Yl receptor gene is under the control of the PKA 
signalling pathway as suggested in the previous chapter (See Chapter 5). This promoter region
220
contains two partial CRE sites which have been reported to mediate transcriptional control by 
cAMP in other systems (Roesler et ah, 1988). These two partial CRE sites (CGTCA) are 
located at approximately -113 bp and -493 bp (using as a reference the putative transcription 
start site) in the NPY-Yl receptor gene and constitute the primary candidates to be tested as 
possible mediators of transcriptional activation of the NPY-Yl gene by factors which increases 
cAMP, such as PACAP-38, forskolin and DBC in PC 12 cells (See Chapter 5). In order to 
delete the CRE binding site (CGTCA) located at -113 bp two restriction enzymes located on 
either side of this consensus sequence were used (Figure 6-3).
The promoter region of the NPY-Yl gene contains a AP-1 consensus site (TGAGTCA) located 
at approximately -273 bp (using as a reference the putative transcription start site). Evidence, 
indicates that PKC mediates the NGF (See Chapter 4) and PACAP-38 (See Chapter 5) 
transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. In particular, the 
activation of the AP-1 transcription factor by NGF and, specifically by PKC, has been well 
documented (See Chapter 1. NGF signalling pathway), and suggests that this site may be 
involved in the PKC-mediated transcriptional activation of the NPY-Yl gene. In order to delete 
the AP-1 consensus site present in this promoter region, the PCR was used (Figure 6-1).
The promoter region of the NPY-Y 1 receptor gene also contains GRE (AGGACT) consensus 
sequence overlapping with the API-site, located at approximately -230 bp (using as as 
reference the putative transcription stait site). The putative interaction between two transcription 
factors can affect the gene transcription of the NPY-Yl gene. This promoter region also 
contains one additional GRE site (AGGACT) located at approximately -373 bp and one 
imperfect palindromic GRE site located at approximately -540 bp (using as a reference the 
putative transcriptional start site). These GRE sites are the primary candidates to mediate the 
dexamethasone-mediated transcriptional activation of the NPY-Yl gene in PC 12 cells (See 
Chapter 3). In order to delete these GRE sites as well as other consensus sites, progressive 
deletions of the promoter of the NPY-Yl gene were obtained by PCR (Figure 6-2).
This chapter describes the mutagenesis of the promoter region of the NPY-Y 1 gene in order to 
deleted specific DNA consensus sequences for transcription factors, such as AP-1, CRE and 
GRE. These deletion constructs will be used to examine the role of these sequences in mediate 
the transcriptional control of this neuropeptide receptor gene by pharmacological agents, such 
as dexamethasone, NGF and PACAP, capable of activating several signalling pathways in 
PC12 cells (See Chapter 1), including nuclear hormone receptors, PKC and PKA pathways, 
among others (See Chapters 3, 4 and 5) or in other cell lines which expressing this receptor, 
such as RINm5f and GTl-7. The luciferase reporter assay developed in this thesis (See 
Chapter 3) provides a suitable system to test the effect of these mutations in the transcriptional 
control of the NPY-Yl gene.
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A pBS-Y1gene 
Bam H1
Barn H1
Bam H1
D pBS-CRE
Avr II
Avr II
BLUNT
CRE
CRE
T
E g o  N1 Bam H1
RESTRICTION ENZYME DIGESTION
E g o  NI Bam H1
100 bp
KLENOW FRAGMENT (DNA POL)
BLUNT Bam H1
T4 DNA LIGASE
Bam H1 BLUNT Bam HI
E pYl-CRE
Bam H1 BLUNT
RESTRICTION ENZYME DIGESTION 
T4 DNA LIGASE
Bam H1
LUCIFERASE
FIGURE 6 3  DELETION OF THE CRE SITE OF THE PROMOTER
OF THE NPY-Y l GENE
Methodological approach used to delete a putative CRE binding site of the promoter region of 
the rat NPY-Yl receptor gene by restriction enzyme digestion.
A. The promoter region of the NPY-Yl gene was digested with Avr II and Eco NI.
B. The two fragments were separated by agarose gel electrophoresis,
C. The plasmid ends were made blunt by the Klenow fragment DNA polymerase.
D. Both ends were ligated by T4 DNA ligase, transformed in bacteria and plasmid recovered 
for DNA sequencing.
E. The CRE-deleted NPY-Yl promoter was subcloned into the pGL3-Basic (pYl-CRE).
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6.2 RESULTS
6.2.1 OLIGONUCLEOTIDES FOR DELETION OF THE 
PROMOTER OF THE NPY-Yl GENE BY PCR
6.2.1.1 DELETION OF THE AP-1 SITE
The oligonucleotides (V5339-V5340) (Appendix II) were used to deleted the putative AP-1 
binding site of the promoter region of the NPY-Yl gene (Figure 6-1). The internal forward 
primer (V5339) was modified at the 5'-region to add a Sac II restriction site. This restriction 
site is not present in the pTAg cloning vector (R&D Systems) and in the promoter region of the 
NPY-Yl gene and was used for subcloning purposes (Figure 6-1). This primer (V5339) 
anneals to the nucleotides -265 to -246 from the putative start transcription site of the NPY-Yl 
gene. The internal reverse primer (V5340) was also modified at the 5'-region to add a Sac II 
restriction site. This primer (V5340) anneals to the nucleotides -283 to -301 from the putative 
start transcription site of the NPY-Y 1 receptor gene.
The forward primer (2024) and the internal reverse primer (V5340) were used to generate a 
PCR fragment of approximately 310 bp of the promoter region of the NPY-Yl gene (Figure 
6.4). The internal forward (V5339) and the reverse primer (2023) were used to generate 
another PCR fragment of approximately 430 bp of the promoter region of the NPY-Yl gene 
(Figure 6-4). These two PCR fragments were cut with Sac II, the enzyme was inactivated by 
incubation at 65°C for 15 minutes and ligated to the pTAg-cloning vector (see Cloning PCR 
products).
6.2.1.2 Progressive Deletions of the Promoter of the NPY -Y l Gene
Oligonucleotides (V7613 to V7617) (Appendix II) were used as forward primers to 
progressive delete the promoter region of the NPY-Yl receptor gene by PCR using the original 
reverse primer (2023) and the pYl-LUC as template (Appendix II) (Figure 6-2). All of these 
oligonucleotides were modified at the 5'-region to add a Bam HI restriction site for subcloning 
purposes in the pGL3-Basic reporter vector (Promega).
These oligonucleotides anneals to the promoter region of the rat NPY-Y 1 receptor gene at the 
following sequences (from the putative start transcription site) :
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(i) the forward (V7613) primer was used to delete two GRE binding sites and anneals to the 
nucleotides -540 to -519 generating a PCR product of 700 bp,
(ii) the forward (V7614) primer was used to delete a CRE binding site and anneals to the 
nucleotides -420 to -399 generating a PCR product of 580 bp,
(iii) the forward (V7615) primer was used to delete a second GRE binding site and anneals to 
the nucleotides -310 to -289 generating a PCR fragment of 470 bp,
(iv) the forward (V7616) primer was used to delete a APl-GRE binding site and anneals to the 
nucleotides -270 to -249 generating a PCR product of 430 bp,
(v) the forward (V7617) primer was used to delete a second CRE binding site and anneals to 
the nucleotides-110 to -89 generating a PCR product of 270 bp.
6.2.2 CLONING OF THE PCR PRODUCTS
6.2.2.1 CONSTRUCTION OF A FUSION GENE LACKING THE CRE SITE 
OF THE PROMOTER OF THE NPY-Yl GENE
In order to delete one of the CRE consensus sites (CGTCA) located at approximately -113 bp 
from the putative cap site within the promoter region of the NPY-Yl receptor gene two 
restriction enzymes located on either side of this consensus sequence were used (Figure 6-3). 
The promoter of the NPY-Y 1 gene has a unique Avr II restriction site located 5' to this CRE 
site. A second unique Eco NI restriction site is located 3’ to the CRE consensus site. These 
restriction enzymes sites are not present in the pBluescribe SK+ (Stratagene) and are separated 
by approximately 100 bp (Figure 6-3).
The pBS-Yl fusion gene (pBS-Ylgene) was cut with Eco NI, and the restriction enzyme was 
heat inactivated. Following the pBS-Yl gene was cut with Avr II. The restriction reaction was 
extracted with phenol-chloroform and precipitated with ethanol (Figure 6-3A). 5'-overhangs 
were filling-in with the Klenow (large) fragment of the E. coli DNA polymerase I and excess 
of dNTPs (0.4 mM) (Figure 6-3B). Blunt-end fragments were ligated by overnight incubation 
with T4 DNA ligase and the ligation products were used to transformed JM109 or TGI bacteria 
(Figure 6-3C). Several positive colonies were recovered, the plasmids were extracted and cut 
with Bam HI. One positive clone (pBS-CRE) was obtained by size in a 2% agarose gel and 
used for large scale plasmid purification using the Wizard maxiprep system (Figure 6-3D). 
This clone (pBS-CRE) was further used to subclone in a bidirectional manner the CRE-deleted 
NPY-Yl promoter region into the Bgl II site of polylinker of the pGL3-Basic vector 
(Promega).
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pBS-CRE was cut with the restriction enzyme Bam HI, DNA separated by size in a agarose 
gel and the insert was excised from the gel using a scalpel. DNA was purified using the 
USBioclean kit (United States Biochemical). In parallel, the pGL3-Basic vector was cut with 
the restriction enzyme Bgl II, extracted with phenol-chloroform and precipitated with ethanol. 
The free ends of the vector were dephosphorylated by treatment with shrimp alkaline 
phosphatase (SAP). This enzyme was heat inactivated before the overnight ligation. Ligation 
products were used to transformed JM109 or TGI bacteria, and several positive clones were 
selected in LB plates with ampicillin, the plasmid extracted by miniprep extraction and cut with 
the Hind Ill-P.s'r I restriction enzymes for determine the orientation of the insert.
One positive clone (pY 1 -CRE) with the CRE-deleted promoter of the NPY-Y 1 gene in the 
correct orientation was used to large scale plasmid purification (CsCl method). This clone 
(pYl-CRE) will be used for luciferase reporter analysis involving the factors in the cAMP- 
mediated transcriptional activation of the NPY-Yl gene in PC 12 cells.
6.2.2.2 CONSTRUCTION OF A FUSION GENE LACKING THE AP-1 
CONSENSUS SITE OF THE PROMOTER OF THE NPY-Yl GENE
In order to delete the AP-1 consensus site (TGAGTCA) present within the promoter of the 
NPY-Yl gene, the PCR was used (Figure 6-1). NPY-Yl promoter present in the pYl-LUC 
was amplified using the "original" forward primer (2024) (Appendix II) and a "internal" 
reverse primer (V5340) (Appendix II) located immediately upstream of the AP-1 site (Figure 6- 
4A). This pair of primers (2024-V5340) generated a PCR product (product I) of approximately 
310 bp which is similar in molecular weight of a band seen in a 2 % agarose gel (Figure 6-4B). 
The "internal" forward primer (V5339) (Appendix II) located immediately downstream of the 
API-site and the "original" reverse primer (2023) (Appendix II) were also used to amplified a 
PCR product (product II) from the pYl-LUC as template. This pair of primers (V5339-2023) 
generated a second PCR product (product II) of approximately 430 bp, which is similar to a 
band seen in the 2 % agai’ose gel (Figure 6-4B).
The "original" forward primer (2024) and reverse primer (2023) were modified at the 5’-end to 
add a Bam HI restriction site not present in the promoter region of the NPY-Y 1 receptor gene 
and used to subclone the ligated PCR products in a compatible Bgl II restriction site of the 
polylinker of the pGL3-Basic reporter vector (Promega). The "internal" reverse primer 
(V5340) and forward primer (V5339) were also modified at the 5'-end to add ?iSac II 
restriction site not present in both, the promoter region of the NPY-Y 1 receptor gene and the 
pTAg cloning vector (R&D Systems). This Sac II restriction site was used to ligate the two 
PCR products in a correct orientation for subsequent cloning in the pTAg vector (Figure 6-1).
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Following PCR amplification, the two PCR products (products I and II) were digested with the 
Sac II restriction enzyme by overnight incubation, extracted with phenol-chloroform and 
ethanol precipitated. These PCR products were ligated by overnight incubation with T4 DNA 
ligase in the presence of the pTAg-cloning vector (R&D Systems). In theory, only the correct 
ligated products transformed in competent JM109 or TGI bacteria results in positive colonies 
when where plated on agar plates containing ampicillin, because the linear DNA is only poor 
transformed in bacteria. The vector alone was used to transform the bacteria and check the 
integrity of the T-overhangs as a negative control. Plasmid DNA was isolated from positive 
colonies and cut with the Sac 11 restriction enzyme. This Sac 11 restriction site is no present in 
the pTAg vector (R&D Systems) and only plasmids with the correct ligated product can be 
linearised.
One positive clone (pTA-APl) was amplified by large scale plasmid purification using the 
Wizard Maxipreps System (Promega) and the insert was verified by sequencing using the 
Thermosequenase"^^ cycle-sequencing kit (Amershan). This clone containing the API-deleted 
NPY-Yl promoter region was subcloned into the Bgl II site of the pGL3-Basic vector 
(Promega).
pTA-API was cut with the Bam HI restriction enzyme, and the DNA was separated by size in 
a agarose gel. A DNA band with the expected molecular weight (780 bp) containing the API- 
deleted promoter region of the NPY-Yl gene was excised from the agarose gel with a scalpel 
and purified using the USBioclean kit (USB). In parallel, the pGL3-Basic was cut with the 
restriction enzyme Bgl 11, extracted with phenol-chloroform and precipitated with ethanol. 
The free ends of the vector were dephosphorylated by treatment with SAP (USB). This 
enzyme was heat inactivated before overnight ligation. Positive colonies were isolated and the 
DNA plasmid was isolated and cut with Hind lll-Pst I restriction enzymes to verify the 
orientation of the insert (data not shown).
One positive clone (pY 1-APl) with the API-deleted promoter region of the NPY-Yl gene in 
the correct orientation was used to large scale plasmid purification using the CsCl method (See 
Chapter 2). This clone (pYl-APl) will be used to analyse using the luciferase reporter function 
the effect of this putative binding site in the transcriptional activation of the NPY-Yl receptor 
gene mediated by pharmacological agents which are known to increase the expression of this 
transcription factor in PC 12 cells, such as NGF and PMA (see Chapter 4).
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FIGURE 6.4 SUBCLONING THE API-DELETED AND THE 
PROGRESSIVE DELETED NPY-Yl PROMOTER
Strategy used for subcloning the API-deleted promoter regions of the NPY-Yl receptor gene 
into the pGL3-Basic reporter vector (Promega).
A. Two fragments of the promoter region of the NPY-Yl receptor gene present in the pY l- 
LUC were amplified by PCR.
B. Agarose gel showing the two PCR products.
Lane 1; MWM (A. xHind XLl-Eco RI). Lane 2: PCR product (NPY-Yl promoter)
Lane 3: PCR product I (313 bp) Lane 4: PCR product II (429 bp)
C. PCR products were cut with Sac II and ligated into the pTAg-cloning vector (pTA-API). 
Insert was obtained by Bam HI digestion and subcloned into the pGL3-Basic reporter vector 
(pYl-APl).
Strategy used for subcloning the progressive-deleted promoter regions of the NPY-Y 1 receptor 
gene into the pGL3-Basic reporter vector (Promega).
D. Five deletion fragments of the promoter region of the NPY-Yl receptor gene present in the 
pYl-LUC were amplified by PCR. Agai’ose gel showing the five PCR products.
Lane 1: MWM {X x Hind lll-Eco RI) . Lane 2: PCR deletion I (Clone A).
Lane 3: PCR deletion II (Clone B). Lane 4; PCR deletion III (Clone C).
Lane 5: PCR deletion IV (Clone D). Lane 6: PCR deletion V (Clone E).
E. PCR products were ligated to the pTAg-cloning vector (R&D Systems). The expected 
inserts were obtained by Bam HI digestion and subcloned into the pGL3-Basic vector 
(Promega). Agarose gel of the restriction enzyme digestions.
Lane 1: MWM (A, x Hind lH-Eco RI) . Lane 2; PCR deletion I (Clone A).
Lane 3: PCR deletion II (Clone B). Lane 4: PCR deletion III (Clone C).
Lane 5: PCR deletion IV (Clone D). Lane 6: PCR deletion V (Clone E).
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6.2.2.3 CONSTRUCTION OF PROGRESSIVE DELETIONS OF THE 
PROMOTER OF THE NPY-Yl GENE
Progressive deletions of the 5'-fianking promoter region of the rat NPY-Yl receptor gene 
present in the pYl-LUC were obtained using PCR (Figure 6-2). These deletion clones were 
amplified from the pYl-LUC as template using a set of different forward primers (V7613 to 
V7617) but only one reverse primer (2023) (Figure 6-2). The different forward primers were 
designed to result in progressive deletions of putative consensus sequences for a transcription 
factors present in the NPY-Yl promoter (Figure 6-2).
Five diferent clones (A to E) containing progressive deletions of different putative binding sites 
(AP-1, CRE, GRE) for transcription factors present in the 5'-flanking promoter region of the 
NPY-Y 1 receptor gene were obtained by PCR (Figure 6-4D):
(i) the first deletion clone (clone A) lacks approximately 60 bp which includes two non- 
tpalindromic GRE. These GRE sites may be involved in the dexamethasone-mediated 
transcriptional activation of the NPY-Yl gene,
(ii) the second deletion clone (clone B) lacks approximately 120 bp which also includes a CRE 
binding site. This CRE site may be involved in the PACAP-38, forskolin and DBC-mediated 
transcriptional activation of the NPY-Yl gene,
(iii) the third deletion clone (clone C) lacks approximately 180 bp which also includes a non- 
palindromic GRE . This second GRE site may be also involved in the dexamethasone-mediated 
transcriptional activation of the NPY-Yl gene,
(iv) the fourth deletion clone (clone D) lacks approximately 290 bp which also includes a AP-1 
consensus site and a non-palindromic GRE. This API site may be involved in the NGF and 
PMA-mediated ti'anscriptional activation of the NPY-Yl gene,
(v) the fifth deletion clone (clone E) lacks approximately 390 bp which also includes a second 
CRE binding site. This second CRE site may be also involved in the PACAP-38, forskolin and 
DBC-mediated transcriptional activation of the NPY-Yl gene. This clone E contains only the 
"basal" promoter sequence of the NPY-Yl gene, including the Spl, CAAT-like box and 
TATA-like box sites.
All the forward primers (V7613 to V7617) and the "original" reverse primer (2023) were 
modified at the 5'-end by adding a Bam HI restriction site not present in the 5'-flanking 
promoter region of the NPY-Yl receptor gene (See oligonucleotide for deletion of the promoter 
of the NPY-Yl gene). This Bam HI restriction site was further used for subcloning in a 
bidirectional manner the PCR products into the Bgl II restriction site of the polylinker of the 
pGL3-Basic vector (Promega).
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PCR products for all the deletions (products A to E) were separated by size in a 2 % agarose 
gel (Figure 6-4D). The DNA products were excised from the gel with a scalpel and the DNA 
purified using the USBioclean kit (United States Biochemical). Following, these PCR products 
containing the different deletions of the promoter of the NPY-Yl receptor gene were cloned 
directly into a pTAg-cloning vector (D&R Systems) by overnight incubation with T4 DNA 
ligase. Ligations products were used to transform competent JMlOl or TGI bacteria. Positive 
colonies were obtained and plasmid DNA was isolated from these colonies (miniprep 
extraction) and cut with Bam HI. Positive clones (A to E) containing DNA bands with the 
expected molecular weights were subsequently used for large scale plasmid purification using 
the Wizard Maxipreps System (Promega). The inserts containing the progressive deletions of 
the promoter of the NPY-Yl gene were sequenced using a Thermosequenase™ cycle 
sequencing kit (Amershan).
These deletion clones (A to E) were cut with Bam HI and the inserts were separated by size in 
a 2 % agarose gel (Figure 4E). DNA products were excised from the gel with a scalpel and the 
DNA was purified using the USBioclean kit (USB). In parallalel, the pGL3-Basic vector was 
cut with Bgl I I , extracted with phenol-chloroform and precipitated with ethanol. The free ends 
of the pGL3-vector were dephosphorylated by treatment with shrimp alkaline phosphatase 
(SAP). Inserts containing the progressive deletions of the promoter of the NPY-Y 1 gene were 
subcloned into the Bgl II site of the pGL3-Basic vector (Promega). Several positive clones 
were obtained and cut with different restriction enzymes to verify the orientation of the insert. 
Positive clones were isolated and plasmid DNA was purified using the CsCl method (See 
Chapter 2).
These deletion clones (A to E) will be used for analysis of the luciferase reporter function in 
PC 12 cells. In particulai', the role of the putative binding sites for transcription factors in the 
levels of the basal and induced transcriptional activity of the NPY-Yl receptor gene will be 
determine. These deletions clones will be useful to understand the molecular mechanisms 
involved in the transcriptional control of this neuropeptide receptor gene in PC 12 cells.
6.3 DISCUSSION
In this chapter, putative consensus sequences mediating dexamethasone, NGF and PACAP 
regulation of NPY-Yl receptor gene transcriptional activity were deleted from the 5'-flanking 
promoter region of this gene using standard deletion techniques, such as restriction enzymes 
digestion or PCR. Using these molecular biology techniques, several different constructs were 
made, each one with a defined deletion corresponding to consensus sites for transcription 
factors. The effect of these deletions on the transcriptional control of the NPY-Yl receptor gene 
will be analysed using the luciferase reporter assay system described in the chapter 3.
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6.3.1 PUTATIVE ROLE OF THE CRE SITES
All the c AMP-regulated genes aie expressed in tissues which are responsive to hormones or 
regulatory factors, and their rate of transcription is rapidly altered by cAMP. The promoter- 
regulatory regions of several of these genes has been isolated and cAMP responsive elements 
(CRE) characterized by functional analysis (Roessler et ah, 1988). There are two classes of 
genes which are transcriptionally induced by cAMP. Group 1 genes are those which are rapidly 
regulated by cAMP, usually within minutes in cycloheximide-insensitive manner, while the 
transcription of genes of group 2 are increased after several hours of cAMP treatment and are 
cycloheximide-sensitive.
There are two classes of cis -acting elements identified in the cAMP-regulated genes (Roesler et 
ah, 1988). A 8-bp palindromic sequence T(G/T)ACGTCA, originally termed a CRE lies 
generally within the first 150 bp of the 5’-flanking region. Available evidence supports a dual 
role for this CRE as both a basal and an inducible transcriptional enhancer element. There are 
two partial CRE sites (CGTCA) located at -113 bp and -493 bp (using as a reference the 
putative transcription start site) in the NPY-Yl promoter region (Figure 3-1). The other is the 
regulatory consensus sequence CCCCAGGC, termed Activator Protein 2 (AP-2) which can be 
induced by treatment with either forskolin or phorbol esters. However, this sequence is not 
found in the promoter of the rat NPY-Y 1 gene.
A protein has been purified with a relative molecular mass of 43-kDa which binds specifically 
to the CRE site. This cAMP responsive element binding protein (CREB) is phosphorylated in 
vitro by the catalytic subunit of PKA and in vivo by treatment of the cells with forskolin 
(Roesler et al., 1988). However, CREB is ubiquitious distributed in a variety of tissues and its 
PKA phosphorylation does not seem to increase the amount of CRE binding activity but is 
essential for transcriptional activation. Thus, rapid changes in the intracellular levels of cAMP 
lead to a PKA-mediated modification of the transcriptional activation domains of CREB, 
already bound to their respective elements in the promoter-regulatory region of the gene 
(Riabowol et ah, 1988; Mellon et al., 1989). This modification in the binding protein can alter 
transcription levels of a cAMP-regulated genes.In addition, phosphorylated CREB can turn on 
transcription of the gene for at least one other transcriptional activator, c-fos (Edwards, 1994), 
a member of the AP-1 protein, which in turn can contribute to activation of the NPY-Yl 
receptor gene. Thus, it is conceivable that these two mechanisms work cooperativily for the 
CREB-mediated regulation of the NPY-Yl gene transcription in response to same stimuli in 
PC 12 cells.
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NPY-Yl receptor gene is under the control of cAMP as sugested in the previous chapter. The 
NPY-Yl promoter contains two CRE sites (CGTCA) which have been reported to mediate 
transcriptional control by cAMP in several systems, including a group of neuropeptides genes 
such as somatostatin, proenkephalin and VIP (Roessler et ah, 1988). Thus, these CRE sites 
constitutes the primary candidate to be tested as mediators of the cAMP-dependent 
transcriptional control of this gene. In order to define the region of the gene conferring 
responsiveness to known pharmacological agents which increase cAMP in PC 12 cells , such as 
PACAP-38, forskolin and DBC, the construct pYl-CRE was made in which one of the CRE 
binding sites was deleted from the promoter region of the NPY-Yl gene.
6.3.2 PUTATIVE ROLE OF THE AP-1 SITE
A class of cellular genes, termed immediate early genes (lEG), have been identified whose 
transcription is rapidly and transiently activated. Several members of the lEG family encode 
putative transcription factors, critical to the response of the cell to growth factors, c-fos and c~ 
jun proto-oncogenes are the most extensively studied of these genes (Sheng and Greenberg 
\99Qi).c-jun , is a DNA-binding protein that binds to a phorbol-ester responsive element (5'- 
TGAGTCA-3’) either as homodimers or as heterodimers. The c-fos family bind to DNA as 
heterodimers with the c-jun family and with selected members of the ATF/CRE-BP family 
(Sheng and Greenberg, 1990).
In most cell types, members of the c-fos and c-jun gene families are expressed at relatively 
low levels, but they are induced transiently by a wide range of extracellular stimuli (Sheng and 
Greenberg 1990). c-fos has become a model gene for the study of inducible expression 
because c-fos activation occurs in a wide range of cell types in response to a diverse set of 
agents ineluding specific growth factors, phorbol esters, neurotransiuitters and agents that 
elevate intracellulai’ calcium or cAMP (Bai’tel et ah, 1989).
It is well known that NGF and PMA transiently activate members of the AP-1 family such as c- 
fos and c-jun , and that this activation is at least partially dependent on PKC activity (Sigmund 
et al., 1990). AP-1 consensus sites are present in several genes regulated by NGF and PMA 
such as the gene for c-fos (Koening et al., 1989), transin (Machida et al., 1991) and NGFIA 
(DeFranco et al., 1993). Moreover, previous results, has been shown that the NGF-PMA 
mediated transcriptional activation of the NPY gene is dependent on PKC activity (Balbi and 
Allen, 1994). A specific deletion of the AP-1 site present in the promoter of this neuropeptide 
gene significantly reduced the NGF response whereas the response to PMA was completely 
abolished (Balbi, 1994).
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Evidence presented in this thesis, using calphostin C (an specific inhibitor of PKC) and PMA, 
indicates that PKC is also involved in the NGF-dependent transcriptional activation of the 
NPY-Yl receptor gene in PC12 cells (Chapter 4). In addition, the PACAP-38 mediated 
transcriptional activation of the NPY-Yl gene also appears to be dependent on PKC activity 
(See Chapter 5). Therefore it is possible that the AP-1 site present in the promoter of this 
neuropeptide receptor gene may be involved in mediating this PKC-dependent response in 
PC 12 cells. In order to evaluate the importance of the AP-1 site in the transcriptional activation 
of the NPY-Yl receptor gene by NGF and pharmacological agents known to increase AP-1 
activity in PC 12 cells, such as phorbol esters, the construct pY l-A Pl in which the API 
consensus site was deleted from the promoter region of the NPY-Yl receptor gene was made. 
Transfection experiments using this deletion clone and also the clones with the progressive 
deletions of the promoter will be used to provide an understanding of the transcriptional control 
mechanisms of this neuropeptide receptor gene.
6.3.3 PUTATIVE ROLE OF THE GRE SITES
Nuclear receptors consists of proteins that mediate the actions of many important cell 
regulators. These includes the steroid hormones (oestrogens, progestins, androgens, 
glucocorticoids, mineralocorticoids, ecdysteroids, vitamin D), thyroid hormones and retinoids 
(Evans, 1988). In contrast to receptors for peptide hormones, which are located in the cell 
membrane, nuclear receptors are present within the cell. Each of these intracellular receptors 
contains a DNA binding domain, which shows a high degree of homology with other members 
of the family, a ligand-binding region showing some homology, and different variable regions. 
The DNA-binding domain contains two "zinc fingers" (looped structures involving chelated 
metal ions) that are responsible for reaction with DNA in the hormone responsive element 
(HRE) of target genes. Receptors for thyroid hormones and retinoic acid, appear- to exist only 
in a DNA-binding state in the nucleus, but those for steroid hormones are present in an inactive 
form in the cytoplasm. Thus, ligand binding converts the native receptor to a biochemically 
functional state that can bind in the DNA and enhance gene transcription (Evans, 1988).
Glucocorticoid receptor (GR), like other members of the steroid receptor superfamily consists 
of three structural domains, the amino-terminal domain, the DNA-binding domain and the 
hormone binding-domain (Beato, 1989). The amino-terminal domain is essential for full 
transcriptional activity and contains an acidic region that acts as transcriptional activator. The 
DNA binding domain, comprising approximately 75 amino acids, contains two zinc-fingers 
that confer DNA binding specificity on the receptor. It also contains a basic region involved in 
nuclear localization and possible interactions with DNA. The hormone-binding domain, upon 
binding of hormone promotes DNA binding and transcriptional activation. In the absence of the 
hormone, this domain supresses receptor activity (Beato, 1989).
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The action of nuclear hormone receptors can be modulated through "cross-talk" with signal 
transduction cascades activated by external signals with other transcription factors (Lopes da 
Silva and Burbach, 1995). Heterodimerization with other promiscuous nuclear receptors such 
as retinoid-X-receptor (RXR) and non-nuclear receptor such as Jun/Fos (AP-1) proteins can 
activate or inhibit transcription. For example, the GR has been found to repress AP-1 
stimulated transcription, through a segment of the amino-terminus region of this receptor. At 
the DNA level further interaction can result from shai'ing or overlapping of responsive elements 
with other nuclear hormone receptors or non-receptor factors. The NPY-Yl promoter region 
has two overlapping consensus sequences, an API and non-palindromic GRE (Figure 3-1). 
These interactions may affect the NPY-Yl gene transcription positively or negatively.
The regulatory DNA sequences require for hormone-dependent activation of transcription have 
been termed hormone responsive elements (HREs) and are the specific high affinity DNA 
binding sites for the activated hormone-receptor complexes. GRE is a consensus 15 bp 
imperfect palindromic DNA sequence: 5'-AG(A/G)ACANNNTGTTCT-3' (Beato, 1989). The 
fact of GRE are palindromic structure is in agreement with the finding that GR bind as dimers 
to their respective response elements. In some genes, like the NPY-Yl receptor, GREs are 
often clustered, forming hormone responsive units (HRUs) that behave as strong inducible 
enhancers and in some cases are formed by a combination of several imperfect HREs that are 
poorly activated separately but act synergistic fashion. The promoter region of the NPY-Yl 
receptor gene contains four non-palindromic GRE sites. In order to study the relevance of these 
GREs in the dexamethasone-mediated activation of the NPY-Yl gene, progressive deletions of 
this promoter were created. Further experiments will be necesary to understand the steroid 
receptor control of this neuropeptide receptor gene in PC I2 cells.
6.4 SUMMARY
6.1 A specific deletion of a CRE site of the promoter of the NPY-Yl gene was 
created using restriction enzymes.
The NPY-Yl receptor gene is under the transcriptional control of the PKA signalling pathway 
in PC 12 cells (Chapter 5). The promoter region of this gene has two CRE elements which are 
known to mediate the cAMP-PKA-dependent transcriptional control of other genes. In order to 
evaluate the role of one of these CRE sites, the construct pY 1 -CRE was created using 
restriction enzymes.
6.2 A specific deletion of a APl-G R E site of the promoter N PY -Y l gene was 
create using PCR.
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NPY-Yl receptor gene is under the transcriptional control of the PKC signalling pathway in 
PC 12 cells (Chapter 4). The promoter region of this gene has an API site which is known to 
mediate the PKC-dependent transcriptional control of other genes. Thus, in order to evaluate 
the role of this sequence in the NGF and PMA-dependent response of this gene, the construct 
pY l-A Pl was made using PCR. This clone has the luciferase gene under the control of a API- 
deleted version of the promoter region of this neuropeptide receptor gene.
6.3 Progressive deletions o f a putative DNA binding sequences of the 
promoter of the NPY-Yl gene were created using PCR.
NPY-Yl receptor gene is under the transcriptional control of the glucocorticoid receptor 
signalling pathway in PC I2 cells (Chapter 3). The promoter region of this gene has several 
non-palindromic sequences which are known to mediate the glucocorticoid-dependent 
transcriptional control of other genes. In order to evaluate the role of this consensus sequences 
in the dexamethasone-dependent response of this gene, five different deletion clones were 
made using PCR. These clones have the luciferase gene under the control of progressive 
deleted version of the promoter region of this neuropeptide gene.
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CHAPTER 7
REGULATION OF THE mRNA LEVELS OF THE NPY-Yl RECEPTOR GENE
7.1 INTRODUCTION
7.1.1 QUANTIFICATION OF mRNA LEVELS
Cells respond to environment changes and development processes by regulation of their genes. 
Gene regulation occurs at several levels: (i) transcription of a gene to a primary heteronuclear 
RNA (hRNA), (ii) processing of the primary transcript to messenger RNA (mRNA), (iii) 
stabilisation of the mRNA in the nucleus or cytoplasm, (iv) translation of the mRNA into a 
protein and (v) post-translational modifications of the protein, such as acylation, glycosylation 
and/or phosphorylation (Watson et al., 1992).
Control of gene transcription, the process in which gene DNA sequence serves as template for 
mRNA synthesis, plays a critical role in the multistep process that regulates gene expression. 
Gene transcription levels change in response to a wide variety of signals that occur during cell 
development, differentiation and physiological function. Changes in transcription levels may 
also occur in response to disease and other pathological factors. In turn, these changes in gene 
transcription levels cause variations in the steady-state levels of individual mRNAs.
One of the most studied gene regulation mechanism is the transcriptional control by which the 
level of transcription of the activated genes is modified or the transcription of the inactivated 
genes is induced. Although, the phenotypic changes involved in the transcriptional control can 
be considerable, alterations in the gene expression are in general moderate. Therefore, for the 
study of the changes in gene expression are necessary sensitive methods that permit the 
detection and/or quantitative analysis of specific mRNAs (Becker-Andre, 1991).
There are two principal approaches for detection and/or quantification of absolute or relative 
levels of the specific mRNAs in different cell, tissues or organs (Becker-Andre, 1991):
(i) Quantification by hybridisation with specific probe.
(ii) Quantification by PCR.
7.1.2 QUANTIFICATION BY HYBRIDISATION WITH A
SPECIFIC PROBE
Traditionally, levels of individual mRNAs have been analysed by procedures such as, RNA 
dot/slot blots. Northern blots and Nuclease Protection Assays. The several methods that used 
this approach are based on moleculai* hybridisation using labelled probes. In these methods the 
mRNAs amount is proportional to the hybridisation signal intensity; the specificity is obtained
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by the hybridisation condition and the sensitivity is consequence of the increase in the specific 
signal detection and the reduction of the background as a consequence of the non-specific 
binding of the labelled probes.
There aie two principal hybridisation strategies:
(i) Hybridisation in mixture phase (e.g. RNA dot/slot blots, Northern blots), in which the 
mRNA in a pool ai'e fixed irreversibly to a solid phase (nitrocellulose or nylon membranes) and 
a solution that contains labelled probe of nucleic acid (DNA or RNA) is hybridised to the 
immobilised mRNA. By using autoradiography or non-radioactive methods is possible detect 
and/or quantify the amounts of probe specifically hybridised, and these amounts are directly 
proportional to the amount of mRNA immobilised in the solid phase (membrane).
(ii) Hybridisation in solution (e.g. Nuclease protection assays). In these techniques the 
mRNAs are hybridised with a excess probe of DNA or RNA in the same phase (solution). The 
non-hybridised probe is specifically removed by digestion with nuclease S 1 (probes of DNA) 
or RNAse A-RNAse T1 (probes of RNA). In this method the absolute concentration of the 
sequence of interest is calculated from the rate of hybridization of a small amount of a specific 
radioactive probe with a known quantity of purified cellular RNA. Thus, the concentration of 
the mRNA of interest can be estimated by autoradiography or scintillation counting from the 
amount of radioactivity that becomes resistant to nuclease treatment. This method offers the 
advantage of higher sensitivity than hybridisation in mixture phase and results less 
background.
7 .1 .2.1 QUA NTIFIC ATIO N  BY H Y BRIDISATIO N IN M IXTURE PH ASE
7.1 .2 .1 .1  N orthern  B lots
Northern hybridizations is a method in which the size and amount of specific mRNA molecules 
in preparations of total or poly(dA) RNA are determined. RNA is separated according to size 
by electrophoresis through a denaturing (formaldehyde) agarose gel and is then transferred to 
activated cellulose, nitrocellulose or nylon membranes. RNA of interest is then located by 
hybridization with radiolabelled DNA (double stranded, single stranded or oligonucleotides) or 
RNA probes followed by autoradiography. The sensitivity with which RNA bound to the 
membranes can be detected is such that species of mRNA comprising no more than 0.001% of 
the mRNA can be rapidly identified and easily quantified.
236
7.1.2.2 QUANTIFICATION BY HYBRIDISATION IN SOLUTION
7.1 .2 .2 .1  R ibonuclease Protection  A ssay
Ribonuclease protection assay (RPA) is an sensitive technique for the detection and quantitation 
of mRNA species in a complex sample mixture of total cellular RNA. For the RPA, a labelled 
RNA probe is synthesised that is complementary to the target RNA to be analysed. This is 
done by inserting the probe fragment into one of the common transcription vectors under the 
control of a bacteriophage promoter (either the T3, T7 or SP6 promoter) and using the 
corresponding T3, T7 or SP6 RNA polymerase to generate an antisense RNA transcript of 
high specific activity.
The labelled probe is then mixed with the sample RNA and incubated under conditions that 
favor hybridisation of complementary transcripts. After hybridisation, the mixture is treated 
with ribonuclease to degrade single-stranded, unhybridised probe. Labelled probe that 
hybridised to complementai'y RNA in the sample mixture will be protected from ribonuclease 
digestion, and can be separated by polyacrylamide gel electrophoresis (PAGE) and visualised 
by autoradiography. When the probe is present in molar excess over the target fragment, the 
intensity of the protected fragment will be directly proportional to the amount of complementaiy 
RNA in the sample mixture.
7.1.3 QUANTIFICATION BY PCR
One of the most used applications of PCR is RT-PCR that permit the qualitative and 
quantitative analysis of the levels of the expression of specific genes using both reverse 
transcription (conversion of mRNA to cDNA) and PCR (selective amplification of DNA). This 
PCR-based method has been termed as RT-PCR (Rappolee et al., 1991), RNA-PCR 
(Kawasaki, 1991), RNA phenotyping (Chelly et al., 1988) or message amplification 
phenotyping (MAPPing) (Brenner et al., 1989).
RT-PCR it is 1,000 to 10,000 times more sensitive than traditional techniques of RNA blotting 
(Byrne et al., 1988; Wang et al., 1989). This extraordinary sensitivity of RT-PCR has been 
used to amplify, clone and characterise mRNAs of short life and/or present in very little 
amounts and detection mRNAs of specific cells in a heterogeneous mixture of cells. For these 
reasons it can be used for diagnosis of genetic diseases, cancer and the study of the 
susceptibility of diseases (Gilliland et al., 1990; Wang et al., 1990; Siebert et al., 1992; Ferre 
et al., 1994). In the RT-PCR process the RNA is first isolated from cells or tissues and then 
used as a template for reverse transcription to complementaiy DNA (cDNA). The cDNA in turn 
is used as template for PCR, using primers designed to amplify a selected cDNA region. The
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PCR product is analysed by agarose gel electrophoresis. The amplified cDNA is identified by 
size of the PCR product and this product can be further validated by restriction digestion, 
hybridization or nucleotide sequencing.
PCR is an exponential reaction in which small variations in amplification efficiency can yield 
large changes in the amount of products. In addition, later cycles of PCR exhibit the plateau 
effect, in which the rate of amplification slows and eventually levels off. These characteristics 
of PCR can make it difficult to obtain quantitative data. However, if specific conditions and 
proper controls are used, quantitative information about mRNA levels can be obtained. Careful 
kinetic analyses can be used to determine initial concentrations of mRNAs by linear regression 
analysis without internal controls (Singer-Sam et al., 1989). Nonetheless, it necessary to 
include internal controls to address the problem of tube-to-tube variation in amplification 
efficiency. Internal controls can be a endogenous mRNA or exogenous cRNA. In addition, 
exogenous standards can be designed with the same or different primer annealing sequences as 
their target molecules.
One advantage of using endogenous internal mRNA controls is that the yield of RNA and the 
efficiency of the reverse transcription can vary to some extent without loss of accuracy. 
However, preliminary studies must be performed to ensure that the levels of the endogenous 
control mRNA does not change during the experiment. This must be tested because many 
housekeeping genes whose expression may seen unrelated to the experimental conditions, are 
transcriptionally regulated by many different phaimacological agents. In addition, the data must 
be collected before the amplification reaction reaches the plateau phase. This can be difficult if 
the endogenous control gene is expressed at a different level than the target gene or if their 
relative amplification efficiencies differ greatly.
Exogenous internal standards that share the same primer annealing sequences with the target 
allow calculation of the absolute amount of target mRNA. A similar method, termed 
competitive PCR, circumvents many of the disadvantage of the other quantitative methods. 
Competitive PCR is accurate enough to discern differences in mRNA levels as small as 2- to 3- 
fold or smaller. This is comparable to the accuracy of quantitative methods that used either 
endogenous or exogenous internal standards in non-competitive experiments. Competitive 
PCR can be used to measure relative changes in mRNA levels as well, for example, in gene 
regulation studies. However two conditions must be met to use competitive PCR. First, the 
molar quantity of the competitor RNA or DNA must be known (usually this is not a problem 
beeause it can be measured by UV spectrophotometry). Second, the amplification efficiency of 
the competitor and target must be identical. This is often true because the standard and target 
possess the same primer binding sequences. If the standard is a RNA fragment, the efficiency 
of the reverse transcription must also be considered.
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Perhaps the most important advantage of competitive PCR is that useful data can be obtained 
during the entire course of amplifieation, even after the reaction has reached the plateau phase. 
This is not the case for methods using internal standards. Homologous competitor fragments 
have the same amplification efficiency as their corresponding target but can form 
heteroduplexes which can complicate the measurement of PCR products. Heterologous 
competitor fragments, on the other hand, cannot form heteroduplexes, but their amplification 
efficiencies must be shown to be equal (or very similar to) that of the target.
7.2 RESULTS
7.2.1 TOTAL RNA ISOLATION
The use of high-quality RNA is critical for the success of gene expression analysis. To ensure 
optimal quantification of the mRNA levels of the NPY-Yl receptor gene in PC12 cells, the 
quality of the all the total RNA preparations were assessed by examining a number of factors. 
Firstly, the absorbance at 260 nm (indicating the amount of RNA) was compared to that 
absorbance at 280 nm (indicating the contamination with proteins). Routinely the ratio 260/280 
nm was about 1.8-2.0 indicating a high quality RNA (Chapter 2. Quantification of the nucleic 
acid). If the ratio fell outside this range, the RNA preparation was discarded. Secondly, the 
RNA was separated by size in a denaturing (formaldehyde) agarose gel electrophoresis to 
check that not be degraded by ribonucleases (See Chapter 2. Nucleic acid separation), by 
examining the intactness of the ribosomal (rRNA) bands 18 S and 28 S . If the RNA is intact, 
it will exhibit a sharp and distinct 28 S and 18 S rRNA bands, with the 28 S band about twice 
as intense as the 18 S band under UV light (Figure 7-3A).
The most common and successful methods for isolation pure, intact total RNA are 
modifications of the original guanidium thiocyanate method (Chirgwin et al, 1979). One 
method was used in the thesis (See Chapter 2. Total RNA isolation). This method was chosen 
because of its simplicity, speed, ability to handle many samples and consistent. In this method 
the eells were disrupted in high concentrations (4 M) of guanidium thiocyanate to rapidly 
inactivate ribonucleases. The resultating lysate was extracted with an acidic solution of 
chloroform: phenol: isoamyl alcohol (24 : 24 : 1) to remove proteins and DNA, and the total 
RNA was precipitated with isopropanol (Chomczynsky and Sacchi, 1987). The total RNA 
yield per 60 mm plate (containing approximately 1.8-2.0 x 10  ^ cells) obtained by the acid 
phenol method was about 80-100 p.g. This value was reproducible during the course of this 
thesis. Isolated total RNA was stored as an ethanol precipitate at -20°C for several months or in 
aqueous solution (DEPC-treated water) at -80°C for immediate use. Total RNA stored in 
ethanol remained in good conditions for several months as assessed by denaturing agarose gel 
electrophoresis. However, repeated freeze and thaw cycles of the RNA solution were avoid.
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7.2.2 NORTHERN BLOT ANALYSIS
In order to study the relative expression of the NPY-Yl receptor gene in PC 12 cells, Northern 
blot analysis was performed using total RNA and random-primer radioactive-labelled probes 
complementary to the mRNA of this neuropeptide receptor. As a positive control of the 
Northern blot analysis a full length double stranded cDNA for open reading frame of the rat 
NPY gene was used. The NPY cDNA was released from the pGEM-3 vector (Promega) by 
digestion with Eco RI of the construct NPY-5 supplied by Professor Janet M. Allen (Allen et 
al., 1987) (See Chapter 2. Nucleic acid labelling).
7.2.2.1 OLIGO NUCLEOTIDES FOR PROBE OF THE N P Y -Y l GENE
The oligonucleotides 2010-2011 (Appendix II) were used to amplify by PCR the ORE of the 
rat NPY-Y 1 gene from a cDNA plasmid library of RINm5f cells supplied by Professor Janet 
M. Allen (Figure 7.1). Forward primer (2010) was modified at the 5’-region to include a Hind 
III restriction enzyme site to be used for subcloning purposes. This primer anneals to the 5'- 
UT region (at the exon II) of the rat NPY-Yl gene, specifically at -54 to -30 bp from the first 
ATG. Reverse primer (2011) was modified at the 5'-region to include an Xba I restriction 
enzyme site to be used for subcloning purposes. This primer anneals to the 3’-UT region (at 
the exon III) of the rat NPY-Yl receptor gene, specifically at 1284 to 1260 bp from the first 
ATG (Appendix II). This cDNA clone containing the ORE of the rat NPY-Yl receptor (pBS- 
Y l) was further used as a probe by random-primer labelling for Northern blot assays.
7.2.2.2 CLONING OF THE ORF OF THE N P Y -Y l GENE
The ORF of the rat NPY-Yl gene was amplified by PCR using the Dynazyme DNA 
polymerase from a cDNA plasmid library of RINni5f cells (rat insulinoma pancreatic cell line 
expressing the NPY-Yl receptor) (Figure 7-2A). This PCR product (1.3 kb) (Figure 7-2B) 
containing the ORF of the rat NPY-Y 1 gene was first extracted with phenol/chloroform and the 
DNA precipitated by addition of 2 volume of ethanol. Following the PCR product (1.3 kb) 
generated with the Dynazyme polymerase was phosphorylated with T4 polynucleotide kinase 
or digested with the restriction enzymes Hind III and Xba I. This DNA was extracted again 
with phenol/ chloroform and ethanol precipitated.
In parallel, the pBluescribe SK+ (Stratagene) was digested with EcoR V and the enzyme was 
then inactivated by heating the reaction for 15 minutes at 65 °C. The free ends of the vector 
were dephosphorylated by treatment with SAP and the enzyme was also inactivated by heating 
for 15 minutes at 65 °C. As alternative method of cloning, the pBluescribe SK+ was digested
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Methodological strategy used for quantification of the NPY-Yl receptor gene in PC I2 cells
241
simultaneously with two restriction enzymes Hind lll-X ba  I (present in the 5'-end of the 
forward and reverse primers but not in the ORF of the NPY-Yl gene) and these enzymes were 
also inactivated by heating the reaction for 15 minutes at 65 °C.
The PCR product (1.3 Kb) containing the ORF of the NPY-Yl gene treated with T4 
polynucleotide kinase was bidirectionally ligated into the Eco R V (blunt-end) site of the 
polylinker region of the pBluescribe SK+ previously treated with SAP phosphatase (Figure 7- 
2C). In addition, PCR product previously digested with Hind Hl-Xba I was also ligated into 
the Hind ll\-Xba  I (sticky-end) sites of the pBluescribe SK'*' (Figure 7-1). Ligation of these 
PCR products into the EcoR V or Hind IH-Xba I sites of the pBluescribe SK+ was carried 
out by overnight incubation at 15 °C. A negative control ligation reaction was performed to test 
efficiency of the vector dephosphorylation (blunt-end cloning), using identical conditions but 
the PCR product was replaced by water. Positive control reaction was performed using 10-100 
ng of the Eco R V-digested pBluescribe SK+ to test the efficiency of the ligation reaction. 10 p.1 
of each ligation reaction were transformed into competent bacteria and transforming colonies 
selected on agai' plates containing 100 j-lg/ml ampicillin.
A NPY-Yl receptor clone (pBS-YI) was generated from the EcoR V (blunt-end) cloning 
procedure and this insert was used as a probe for Northern blot assays (Figure 7-2C). Insert 
was obtained for the pBS-Yl by digestion with Hind \H.-Xba I (Figure 7-2D) and purified in 
a 1% LMP agai'ose gel. 1.3 Kb insert was labelled by random-primer (See Chapter 2. Nucleic 
acid labelling). This clone was also used to generate cRNA antisense probes for RPA (See 
Chapter 2. Nucleic acid labelling). Orientation of the insert in the pBS-Yl was determined by 
digestion with several restriction enzymes, includind Pst I and Xho I (Figure 7-2D) 
confirming that the insert was cloned in the opposite direction of the T7 promoter. The clone 
was digested with the restriction enzyme Nde I which generates a 5'-protruding end and 
results in a "run-off" transcripts (600 bp) from the insert sequence (Figure 7-2E). Linearized 
pBS-Y 1 was extracted with phenol/chloroform before using the DNA for in vitro transcription 
(See Chapter 2. cRNA synthesis).
1 ,2 ,1 3  N O R T H E R N -B L O T S
For Northern blot analysis, equal amounts of the total RNA was loaded in each well of a 
denaturing (formaldehyde) agarose gel (See Chapter 2. Nucleic acid separation). This uniform 
loading was confirmed by compaiing the intensity of the rat ribosomal RNA bands, 18 S (4.8 
Kb) and 28 S (1.9 kb) from the different samples loaded side by side (Figure 7.3 A).
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FIGURE 7.2 CLONING NPY-Yl RECEPTOR GENE
Strategy used for cloning the open reading frame of the NPY-Yl receptor gene
A. RINm5f cDNA plasmid library was used to amplify by PCR a 1,3 Kb fragment of the ORF 
of the NPY-Yl receptor gene.
B. Agarose gel showing a 1.3 Kb PCR from the RINm5f cDNA library.
Lane 1; MWM (A, x Hmd lll-Eco RI) Lane 2; PCR product (1.3 Kb)
C. The PCR product was cloned in the Eco RV of pBS-SK+ (pBS-Y 1)
D. Agarose gel showing a restriction map of the PCR insert of the pBS-Yl. Inserts were 
obtained by Hind lll-Xba I restriction and used as a probe to Northern blot.
Lane 1; pBS-Yl x Xho I Lane 2: pBS-Yl x Pst I
Lane 3; pBS-Yl x Hind lll-Xba I Lane 4: MWM {XxHind III-Eco RI)
E. pBS-Y 1 was cut with Nde I and used to generated antisense cRNA probe to RPA. Agarose 
denaturing gel showing antisense cRNA of the NPY-Yl receptor.
Lane 1: MWM (A, x Hind lll-Eco RI) Lane 3: antisense cRNA mouse f3-actin.
Lane 5: antisense cRNA NPY-Yl receptor.
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For Northern-blot analysis, total RNA was electrophoresed in the presence of ethidium 
bromide (See Chapter 2. Nucleic acid separation). This did not interfere with the performance 
of the assay and provide additional advantages as it was possible to verify equal loading of total 
RNA into different lanes of the gel, and visualization of the transfer of the total RNA to the 
membrane. A photograph of the gel under UV light was taken routinely to confirm the quality 
of the total RNA prepai'ation (Figure 7-3 A).
Autoradiographic results of this experiment was illustrated in the figure 7.3B. Up to 50 pg of 
total RNA of PC 12 cells were loading in each lane and hybridised to a high-specificity cDNA 
probes for NPY-Yl receptor (Figure 7.3 A) and NPY (positive control) (Figure 7-3 B). The rat 
NPY-Yl receptor probe result in no signal after overnight incubation at high stringency 
conditions (Chapter 2. Nucleic acid hybridization). However, using the rat NPY probe the 
mRNA was detected in untreated PC12 cells and the treatment with NGF (100 ng/ml) for 48 
hours resulted in a approximately 10-fold increase in the amount of NPY mRNA over basal 
levels. Similar level of NGF-induced activation was previously reported to this neuropeptide 
gene in PC12 cells (Allen et al., 1987; Balbi and Allen, 1994). For this reason the hibridization 
conditions were made less stringet, reducing the temperature of the incubation (45 °C) and/or 
increasing the SDS (2X) in the washing buffer (See Chapter 2. Nucleic acid hybridization), but 
in this case the rat NPY-Yl receptor probe hybridised to the 28 S and 18 S ribosomal RNA 
(data not shown).
Since the dissociation temperatures of the NPY and NPY-Yl receptor probes were comparable 
and specific activities generated for these labelled probes were similar, as quantitated by liquid 
scintillation counting, the different hybridisation signal likely reflects inherent differences in the 
abundance of the both mRNAs in PC12 cells. For this reason a more sensitive approach, 
ribonuclease protection assay (RPA) was used.
7.2.3 RIBONUCLEASE PROTECTION ASSAY
7.2.3.1 LABELLING OF THE DNA M ARKERS
Dephosphorylated fragments of (j)X174 digested with H infl (250 ng) were used as a molecular 
weight markers (MWM) in the RPA. This DNA markers were 5'-end labelled with T4 
polynucleotide kinase (See Chapter 2. Nucleic acid labelling) and were stored in 200 pi of 
nuclease-free water (DEPC-treated) at -20 °C. For accurate sizing of single stranded denatured 
DNA or RNA it is important that the DNA markers be denatured before loading them on the gel 
(See Chapter 2). The dénaturation of the DNA markers for RPA was made as following: 1 pi 
of the phosphorylated mai'kers was added to the RNA loading dye (Appendix II), heated at 90 
°C for 10 minutes and immediately loaded on the denaturing PAGE (Figure 7.3C).
244
FIGURE 7.3 NORTHERN BLOT AND RIBONUCLEASE 
PROTECTION ASSAY
FIGURE 7.3A TOTAL RNA EXTRACTED FROM  PC12 CELLS
Equal amounts of total RNA (10 pg) were extracted from un stimulated and NGF (100 ng/ml) 
stimulated PC 12 cells for 48 hours. RNA samples were denatured and subsequently 
electrophoresed in a formaldehyde gel. Run 100 volts x 2 hours. 18S and 28S ribosomal 
RNAs (rRNA) aie marked with arrows.
Lane 1: Total RNA of untreated PC 12 cells.
Lane 2: Total RNA of NGF-treated cells.
FIGURE 7.3B NORTHERN BLOT ASSAY
Northern blot assay of the NPY mRNA in un stimulated and NGF (100 ng/ml) treated PC 12
cells for 48 hours. Gel described before (Figure 7.3A) was blotted to nylon membranes and
hybridization analysis with radioactively-labelled NPY cDNA probe was performed. 
Autoradiograph exposure time: overnight with intensifying screen (-70°C). Autoradiograph of 
the membrane was scanned using the phosphoimager scanning densitometer (Fuji, model 
BAS 1000 MacBas). 18S and 28S ribosomal RNAs (rRNA) are marked with arrows.
Lane 1: Total RNA of untreated PC 12 cells.
Lane 2; Total RNA of NGF-treated PC12 cells.
FIGURE 7.3C RIBO NUCLEASE PROTECTION ASSAY
Ribonuclease protection assay (RPA) of RNA 18S and NPY-Yl mRNAs in unstimulated 
PC 12 cells using the human RNA 18S probe (protected fragment of 80 bases). As a negative 
control yeast RNA (10 pg) (RPA II kit, Ambion) was used and as a positive control antisense 
human RNA 18S probe was used. Total RNA (10 pg) of unstimulated PC 12 cells was used. 
The samples were run at 250 Volts x 2 hours in a PAGE (4%) gel. Autoradiograph exposure 
time: overnight with intensifying screen (-70°C).
Lane 1: MWM ((|)X174 x Hinf I)
Lane 2: yeast total RNA (human RNA 18 S)
Lane 3: PC 12 total RNA (human RNA 18 S 4- NPY-Yl receptor probe)
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7.2.3.2 LABELLING OF THE RNA PROBE
A preliniinai'y requirement for a RPA is the synthesis of the labelled antisense RNA transcript 
which is used as hybridization probe for the detection of the mRNA of interest. For the 
synthesis of the cRNA antisense probe the pBS-Yl was linearized with Nde I restriction 
enzyme (See Chapter 2. Nucleic acid labelling). This Nde I restriction site is present at the 
position 749 of the first ATG (methionine) in the open reading frame of the NPY Y 1 receptor 
gene and results in a 5'-overhang ends. In vitro transcription reaction using T7 RNA 
polymerase generated a probe of approximately 600 nucleotides of full length transcript and 
540 base protected fragment (Figure 7.2E). This size helps to maximize synthesis of full length 
transcripts and increase the sensitivity of the RPA assay.
In vitro transcription reaction using the Riboprobe Assay System (Promega) generated a RNA 
probe with high-specific activity (data not shown). This RNA radiolabelled probe not was gel 
purified because most of the transcript is present as a single band of the expected size, as 
assessed on a 2 % agarose gel (Figure 7.2E). Unincorporated ribonucleotides were removed 
for ethanol precipitation before the proportion of radiolabel incorporated into transcript was 
determinated by tiichloroacetic acid (TCA) precipitation (See Chapter 2. Nucleic acid labelling). 
However, unincorporated nucleotides generally not cause problems, since they will not 
hybridize to the target mRNA and run off to the end of the gel when the protected fragments aie 
separated. The probe was usually stored at -20 °C in DEPC-treated water.
As a negative control for the RPA, a yeast tRNA (10 pg) supplied with the RPA II in vitro 
transcription kit (Ambion) was used. As a positive control of the RPA a human RNA 18S 
antisense probe supplied with the RPA II in vitro transcription kit (Ambion) was used. This 
human RNA 18S probe is under the control of T7 RNA promoter. In the case of this human 
RNA 18S probe a 1/500 dilution of the RNAse solution was used to assess total RNA of PC 12 
cells and the yeast tRNA control tube was digested with the same reduced amount of RNAse.
7.2.3.3 HYBRIDIZATION, RNAse DIGESTION AND SEPARATION OF
PROTECTED FRAGMENTS
As a negative control for the RPA one tube of yeast tRNA (10 pg) with the radiolabelled 
human RNA 18S antisense probe was set up (Figure 7-4). This tube was incubated overnight 
at 45°C with a diluted amount of RNase (1/500 dilution of the RNase solution). This reaction 
showed the expected result as no specific signal can be seen on the lane, although some 
smaller, smeared, heterogeneous material can be seen, which is presumably due to radiolytic 
decay of the human probe.
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As a positive control for the RPA one tube of PC 12 cells RNA (10 pg) with the radiolabelled 
human RNA 18S antisense probe and the NPY-Yl receptor antisense probe was set up (See 
Chapter 2. Ribonuclease protection assay). This tube was incubated overnight a 45 °C and then 
treated with a diluted amount of RNAse (1/500 dilution of the RNAse solution). This lane 
showed the expected result as a band of 80 nucleotides can be seen corresponding to the human 
RNA 18S protected fragment (Figure 7.3C). Differences observed with the DNA mai'kers were 
a consequence of the different relative mobilities of DNA and RNA fragments in 7M urea 
polyacrylamide gels, with RNA fragments running somewhat slower (approximately 10 %) 
than their DNA counterparts. This result confirms that the RNA is in optimal conditions and the 
human RNA 18S probe is over molar excess over the 18S mRNA.
The NPY-Yl receptor antisense probe was also mixed with PC12 total RNA (10 pg). 
However, the expected fragment of approximately 540 nucleotides corresponding to the NPY- 
Y 1 receptor mRNA was not observed. As an assessment of the probe quality, the yeast tRNA 
was mixed with the NPY-Yl receptor antisense probe and incubated without RNAse. This 
result showed a band representing mainly the full-length probe (data not shown). Moreover, 
increasing the sensitivity of the assay, by increasing the concentrations of total RNA of the 
PC 12 cells (up to 50 pg) or increasing the dilution of the RNAse solution (up to 1/50) did not 
result in the expected specific signal corresponding to the NPY-Yl receptor mRNA (data not 
shown).
The results of the ribonuclease protection assay (RPA) experiments studies suggest that the 
expression of the NPY-Y 1 receptor gene is very low in the PCI2 cells. For this reason a more 
sensitive approach, reverse transcription-polymerase chain reaction (RT-PCR) was used.
7.2.4 RT-PCR DETECTION OF THE NPY-Yl GENE
7.2.4.1 OLIGONUCLEOTIDES FOR QUANTITATIVE RT-PCR
7.2.4.1.1 Oligonucleotides for Positive Control
Oligonucleotides 2486-2487 (Appendix II) were used to amplify by RT-PCR a small fragment 
(approximately 400 bp) of the 3'-flanking region of the NPY-Yl receptor gene (Figure 7-4A). 
Forward primer (2486) was designed to anneal to 3'-flanking region of the NPY-Yl receptor 
gene, specifically to the nucleotides 871 to 888 from the first ATG. Reverse primer (2487) was 
designed to anneal to the 3'-UT region of the NPY-Yl receptor gene, specifically to the 
nucleotides 1281 to 1260 from the first ATG.
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PCR fragment of the NPY-Yl receptor (approximately 400 bp) was amplified using PC 12 cells 
total RNA (1 pg) and the Tag DNA polymerase (Figure 7-4A) and was subsequently cloned in 
the pTAg vector (R&D Systems). One positive clone (pRT-PCR) was further used to create a 
antisense cRNAs by in vitro transcription for use as positive control of the RT-PCR 
amplification of the mRNA of the NPY-Yl receptor gene (Figure 7-4B). This small PCR 
fragment was also used for create by PCR a specific deletion of 100 nucleotides for be used as 
exogenous internal control for a competitive RT-PCR.
7 .2.4.1.2 Oligonucleotides For Exogenous Control
Oligonucleotides (T7507-T7508) (Appendix II) were used to create a PCR deletion of 
approximately 100 bp in the small PCR fragment (400 bp) of the 3’-flanking region of the 
NPY-Yl receptor cloned in the pTAg vector (pRT-PCR clone) for use as exogenous control in 
a competitive RT-PCR. The internal reverse primer (T7507) was modified to include at the 5'- 
flanking region a Sac II restriction site not present in the pTAg cloning vector or the PCR 
fragment (to be used for cloning purposes). This primer anneals to the nucleotides 941 to 923 
(from the first ATG of the NPY-Yl receptor gene). The internal forward primer (T7508) was 
also modified at the 5'-flanking region to include a Sac II restriction site. This primer anneals 
to the nucleotides 1151 to 1169 of the NPY-Y 1 gene.
Forward primer (2486) and the "internal" reverse primer (T5707) were used to generate a PCR 
fragment of approximately 170 bp (product I) (Figure 7-6). The "internal" forward (T5708) 
and the reverse primer (2487) were used to synthesise another PCR fragment of approximately 
130 bp (product II) (Figure 7-6). These two PCR fragments were ligated and re-amplified to 
generated a DNA fragment of approximately 300 bp containing a specific deletion of 100 bp of 
the 3'-flanking region of the NPY-Yl gene (Figure 7-6). This PCR fragment (300 bp) was 
subsequently cloned into the pTAg vector (R&D Systems). One positive clone (pTA/ART- 
PCR) was further used to make antisense cRNAs by in vitro transcription using the Riboprobe 
System kit (Figure 7-4E). This cRNAs were used to develop a competitive RT-PCR to study 
the NPY-Y 1 receptor gene expression in PC 12 cells.
7.2.4.1.3 Oligonucleotides For Endogenous Control (RT-PCR)
Oligonucleotides (Y7462-Y7463) (Appendix II) were used to detected by RT-PCR a small 
fragment (approximately 300 bp) of the open reading frame of the rat cyclophilin gene 
(Appendix III) for be used as endogenous control for a quantitative RT-PCR. The rat 
cyclophylin gene is constitutively expressed in several eukaryotic cell lines and expression is 
not altered by NGF (Fanger et al., 1993) which is known to increase the transcriptional 
activity of the NPY-Yl receptor gene in PC 12 cells .
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Forward primer (Y7462) anneals to the nucleotides 232 to 256 from the first ATG of the rat 
cyclophilin gene. The reverse primer (Y7463) anneals to the nucleotides 534 to 513 from the 
first ATG of this gene. The RT-PCR reaction of total RNA of PC 12 cells using these primers 
generated a DNA fragment of 300 bp (Figure 7-7). Thus, this DNA will be used as internal 
control in a quantitative RT-PCR (multiplex RT-PCR) of the NPY-Y 1 gene in PC 12 cells.
7.2.5 CLONING PCR PRODUCTS
7.2.5.1 CLONING A FRAGM ENT OF ORF OF THE N P Y -Y l GENE
Oligonucleotides 2486-2487 (Appendix II) were used to amplify by RT-PCR a small fragment 
(approximately 400 bp) of the 3'-flanking region of the NPY-Yl receptor gene (Figure 7-3A). 
This PCR fragment of the NPY-Yl gene was amplified using PC 12 cells total RNA as a 
template and the Taq DNA polymerase (Figure 7-4A). The PCR fragment generated was 
subsequently cloned into the pTAg vector (R&D Systems) using the manufacturer instructions. 
Positive colonies were obtained, plasmid was isolated from these colonies and digested with 
the restriction enzymes Hind III- Bam HI present in the polylinker region of the pTAg-cloning 
vector, at both sides of the cloning site. Positive clones were obtained with a insert of the 
expected size (approximately 400 bp) and digested with Hinc II to determine the orientation of 
the insert (data not shown). One positive clone (pRT-PCR) with the insert cloned in the 
opposite direction to the T7 RNA polymerase was used to large scale plasmid purification 
using the Wizard Maxipreps kit (Figure 7-4B). This clone was deleted in 100 bp to create 
antisense cRNAs by in vitro transcription for be use as internal control of the RT-PCR 
amplification of the NPY-Yl receptor gene.
7.2.S.2 CLONING A DELETION FRAGMENT OF THE pRT-PCR
In order to delete 100 bp of the 3'-flanking region of the rat NPY-Y 1 receptor gene present in 
the pTA/RT-PCR, the PCR reaction was used (Figure 7-4C). The pRT-PCR was amplified 
using the "original" forward primer (2486) and the "internal" reverse primer (T5707). This pair 
of primers generates a PCR fragment of 170 bp (product I) which is similar to the molecular 
weight of a band seen in the 2% agarose gel (Figure 7-4C). The "internal" forward (T5708) 
and the "original" reverse primer (2487) were used to create other PCR fragment of 130 bp 
(product II) which is similar to the moleculai' weight of a band seen in the same gel (Figure 7- 
4C).
249
FIGURE 7.4 CLONING OF A 3 -FRAGMENT OF THE NPY-Yl 
GENE AND ITS DELETION
Cloning a PCR fragment (400 bp) of the 3'-flanking region of the NPY-Y 1 gene.
A. A small fragment (400 bp) of the 3'-region of the NPY-Yl receptor gene was amplified by 
RT-PCR using total RNA of unstimulated PC12 cells. As a negative control total RNA (1 pg) 
of COS-7 cells was used and cRNA IL -la  (GeneAmp kit, Perkin Elmer) was used as a 
positive control. Agaiose gel showing a PCR product of the expected size (400 bp).
Lane 1: MWM {X x Hind III- Eco RI). Lane 2: RT-PCR COS-cells 
Lane 3: RT-PCR cRNA IL -la  (300 bp) Lane 4: RT-PCR PC12 cells (400 bp)
B. PCR fragment was ligated into the pTAg-cloning vector (pTA/RT-PCR). This clone was 
used to generate a cRNA external control for a quantitative RT-PCR.
Strategy used for the generation of a exogenous internal control for a quantification of NPY-Yl 
mRNA in PC 12 cells by competitive RT-PCR.
C. Two fragments of the 3'-region of the NPY-Yl receptor gene were amplified by PCR using 
the pRT-PCR as template.
Agarose gel showing two PCR products with the expected size.
Lane 1: MWM (XxHind lll-Eco RI).
Lane 2: PCR product I (170 bp).
Lane 3: PCR product II (130 bp).
D. PCR products were ligated and reamplified using the Taq DNA polymerase. Agarose gel 
showing a PCR product of the expected size (300 bp).
Lane 1: MWM {X xHind lll-Eco RI). Lane 3: PCR product (300 bp).
E. PCR product was ligated into the pTAg cloning vector (pTA/RT-APCR).
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These two PCR fragments were digested by overnight incubation with the Sac II and ligated 
using T4 DNA ligase. The ligation reaction was reamplified using PCR and the "original" 
forward (2486) and reverse (2487) primers. In theory, only the correct ligated products can be 
re-amplified to generated a DNA fragment of approximately 300 bp containing a specific 
deletion of the 3'-flanking region of the NPY-Yl gene present in the pRT-PCR clone (Figure 
7-4D). This PCR fragment (300 bp) was subsequently cloned into the pTAg cloning vector 
(R&D Systems), Positive colonies were obtained, plasmid was isolated from these colonies 
and digested with Sac II. This restriction enzyme is not present in the pTAg cloning vector and 
only plasmids with the correct ligated product can be linearised. In addition, the orientation of 
the clone was verified using the Hinc II restriction enzyme, only present in the 5'-flanking 
region of the insert but not in the pTAg-cloning vector (data not shown). One positive clone 
(pTA/ART-PCR), with the insert cloned in the opposite orientation of the T7 RNA polymerase 
was obtained and amplified by large scale plasmid purification using the Wizard Maxipreps kit 
(Figure 7-4E).
The deletion in this clone was further confirmed using one restriction site {Acc I) present in the 
100 bp deleted region of the NPY-Yl gene of the pRT-PCR but not in the pTAg-cloning 
vector. This restriction enzyme {Acc I) can cut once the pTA/RT-PCR but cannot cut the 
pTA/ART-PCR (data not shown). However, the restriction enzyme Sac II cannot cut the pRT- 
PCR but cut once the pTA/ART-PCR (data not shown). This clone was further used to 
synthesise antisense cRNAs by in vitro transcription using the Riboprobe System kit 
(Promega). This antisense cRNAs were used as internal control in a competitive RT-PCR to 
study the NPY-Yl receptor gene expression in PC 12 cells.
7.2.6 QUANTITATIVE RT-PCR OF THE NPY-Yl GENE
7.2.6.1 cRNA SYNTHESIS ( I N  V I T R O  TRANSCRIPTION)
Antisense cRNAs for be used as internal control of the competitive RT-PCR were synthesized 
from the clone pTA/ART-PCR using T7 RNA polymerase and the Riboprobe kit (Promega). 
This clone was linearized with the Hind III enzyme present in poly linker region of the pTAg 
vector, opposite to the T7 RNA polymerase. This DNA fragment was used as a template for a 
"in vitro " transcription reaction in order to synthesize a "run-off" transcripts of 300 bp to be 
used as internal control in a competitive RT-PCR reaction.
7.2.6.2 cDNA SYNTHESIS (REVERSE TRANSCRIPTION)
cDNA template was synthesized from a cRNA or total RNA of PC 12 cells by reverse 
transcription (RT) using the random primers present in the GeneAmp RNA PCR kit (Perkin
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Elmer-Cetus) following the manufacturer instructions (See Chapter 2. cDNA synthesis). As a 
positive control IL -la cRNA was amplified by two specific primers DM151-DM 152 which 
generated a 308-bp product. As negative control total RNA of COS-7 cells which do not 
express the NPY-Yl gene was used.
7.2.6.3 DNA AMPLIFICATION (PCR)
In order to define the linear range of amplification of the NPY-Yl gene in PC 12 cells, a RT- 
PCR reaction was set-up. Total RNA (1 pg) of unstimulated PC 12 cells was amplified using 
the "original" forward (2486) and reverse (2487) primers and different PCR cycles (10-40 
cycles) (Figure 7-5A). These primers amplify a PCR product of 400 bp of the 3'-flanking 
region of the NPY-Yl receptor gene. However this product can be detected only after 40 cycles 
of PCR amplification (Figure 7-5A). This result indicates that the mRNA for the NPY-Yl gene 
is expressed at very low levels in PC12 cells, consistent with the previous negative results 
obtained with other less sensitive techniques, such as Northern blots and RPA. Thus, the next 
RT-PCR reactions were made using 35-40 cycles of amplification.
In the following experiment, the NPY-Yl gene was amplified using total RNA of PC 12 cells, 
as well as of other cells lines which express this neuropeptide receptor gene, RINm5f cells (a 
rat pancreatic cell line) (Polak et al., 1993). Preliminary results show that PC12 cells and 
RINm5f have similar levels of NPY-Yl receptor expression (Figure 7-5B).
In the next experiment, the mRNA of the NPY-Yl receptor gene was amplified from PC 12 
cells treated with different pharmacological agents which are known to increase the levels of 
transcription of this gene, such as dexamethasone, NGF, PACAP, forskolin and PM A (See 
Chapter 3). This showed that in comparison with the basal mRNA levels, the different aggents 
increased the NPY-Yl receptor gene expression (Figure 7-5C). However, these relative results 
are difficult to quantitate without internal control, because PCR is an exponential reaction in 
which small differences in the efficiency of the amplification results in significant differences in 
the amount of the product. They are two approaches to be used as internal control for a 
quantitative RT-PCR: (i) endogenous control and (ii) exogenous (homogenous or 
heterogeneous) control.
7.2.6.3.1 RT-PCR with Endogenous Control
Endogenous control are in generally housekeeping genes whose expression is not altered under 
the different treatments and for this reason can be used as internal control of the RT-PCR 
reactions. In the case of PC 12 cells several housekeeping genes can be used, such as tubulin 
and cyclophilin genes. Cyclophilin gene has the advantage that expression is known to be not
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FIGURE 7.5 QUANTITATIVE RT-PCR OF THE NPY-Yl GENE 
7.5A LINEAR RANGE OF RT-PCR AMPLIFICATION
Agarose gel of RT-PCR products of NPY-Yl receptor mRNA using different PCR cycles 
(kinetic analysis). Total RNA (1 |ag) from unstimulated PC 12 cells was used to amplified a 400 
bp of the 3'“flanking region of the NPY-Yl mRNA by RT-PCR with the indicated number of 
cycles. As a positive control a IL-lacRN A  (300 bp) was used.
Lane 1: MWM (A, x Hind lll-Eco RI) Lane 2: RT-PCR IL -la  cRNA (40 cycles)
Lane 3: RT-PCR PC 12 cells (10 cycles) Lane 4: RT-PCR PC 12 cells (20 cycles)
Lane 5: RT-PCR PC12 cells (30 cycles) Lane 6: RT-PCR PC12 cells (40 cycles)
FIGURE 7.5B RT-PCR AMPLIFICATION NPY-Yl mRNA FROM PC12 AND 
RINniSf CELLS
Agarose gel of RT-PCR products of NPY-Yl receptor mRNA from RINm5f and PC12 cells. 
Total RNA (1 pg) from unstimulated RINm5f and PC12 cells was used to amplified a 400 bp 
fragment of the 3'-region of the NPY-Yl mRNA by RT-PCR (40 cycles).Antisense NPY-Yl 
cRNA (300 bp) and antisense NPY-Yl cRNA (400 bp) were used as external control of the 
NPY-Yl gene RT-PCR amplification.
Lane 1: MWM {X xHind lU-Eco RI) Lane 2: NPY-Yl cRNA (300 bp) (1 pg)
Lane 3: NPY-Yl cRNA (400 bp) (1 pg) Lane 4: Total RNA RINm5f cells (1 pg)
Lane 5: Total RNA PC 12 cells (1 pg)
FIGURE 7.5C RT-PCR AMPLIFICATION OF NPY-Yl mRNA OF PC12 
CELLS TREATED WITH DIFFERENT AGENTS
Agarose gel of RT-PCR amplification of a 400 bp fragment of the 3'-flanking region of the 
NPY-Yl mRNA. Total RNA (1 pg) of unstimulated (basal) and PC 12 cells treated with 
different agents : DEX (dexamethasone 1 pM), NGF (nerve growth factor 100 ng/ml), 
PACAP (PACAP-38, 5 nM), FORSK (forskolin, 10 pM), PMA (phorbol-12-myristate-13- 
acetate, 1 nM) for 48 hours was used for RT-PCR reaction (40 cycles). As a positive control a 
IL -lacR N A  (300 bp) was used. Total RNA (Ipg) of unstimulated COS-7 cells was used as 
negative control. NPY-Yl cRNA (400 bp) was used as external control.
Lane 1: MWM {XxHind lll-Eco RI) Lane 2: IL-lacR N A  (10^ copies)
Lane 3: RT-PCR COS-7 (1 pg) Lane 4: antisense NPY-Yl cRNA (1 pg)
Lane 5: PC12 basal (1 pg) Lane 6: PC12 DEX (Ipg)
Lane 7: PC12 NGF (1 pg) Lane 8: PC12 PACAP (1 pg)
Lane 9: PC12 FORSK (1 pg) Lane 10: PC12 PMA (Ipg)
253
1 2 3 4 5 6
1 2 3 4 5
1 2 3 4 5 6 7 8 9  10
affected by NGF treatment of the PC 12 cells (Fanger et al., 1993) and for this reason was 
choice as internal control for a quantitative RT-PCR. In order to obtain the relative levels of 
amplification of this gene under the different treatments, total RNA of untreated PCI2 cells and 
cells treated for 48 hours with different agents, such as NGF, PACAP, forskolin and PMA 
were amplified using the forward (Y7462) and reverse (Y7463) primers of the rat cyclophilin 
gene. These primers synthesise a RT-PCR product of 300 bp after 40 cycles of amplification 
(Figure 7-6A). This result showed that the mRNA levels of this gene are not altered by these 
agents. For this reason this gene can be used as internal control for a quantitative RT-PCR.
The next step was try to define the conditions for co-amplification of the two mRNAs 
(cyclophilin and NPY-Yl genes) in a one tube of RT-PCR reaction. This was difficult due to 
intrinsic differences in the levels of the expression of both genes in PC 12 cells. Several 
attempts were made using constant amounts (20 pmol) of the primers for the NPY-Y1 receptor 
gene and different dilutions of the primers for the cyclophilin gene. However, after several 
attempts optimal conditions were defined for a narrow margin (between 1 to 5 pmoles) of the 
primers for the cyclophilin gene after 35 cycles of amplification (Figure 7-6B). Further co­
experiments, including a analysis of the linear range of co-amplification of both messages 
under these conditions will be necessary to obtain valid results of this quantitative RT-PCR.
7.2.6.3.2 RT-PCR with Exogenous Control
Exogenous controls are genes that are added to the RT-PCR reaction and can be used as 
internal standard. The theory behind the use of exogenous gene sequences is similar to that 
described before for endogenous reference sequences. However, there is a significant 
advantage, as the amount of added standai'd is precisely known, it is possible to calculate the 
absolute amount of tai’get mRNA present in the sample.
In order to design a competitive RT-PCR of the NPY-Yl receptor gene in PC 12 cells a 
exogenous internal standard was prepared. This exogenous control is a small cRNA fragment 
(300 bp) of the NPY-Yl gene which can be amplified using the same forward (2486) and 
reverse (2487) primers used to detect of a 400 bp fragment of NPY-Yl gene. The theory 
behind this indicates that the amplification occurs in a truly competitive fashion because the 
standard and the target sequences actually compete for the same primers and therefore, for 
amplification. Moreover, the two products can be distinguished by size in a agarose gel. 
Initially, optimal conditions for the amplification of the cRNA (internal standard) were defined 
(Figure 7-12). This result indicated that 1 jig of cRNA (internal control) results in a similar 
levels of amplification for 1 fig of total RNA of PC 12 cells. However, further experiments will 
be necessary for generating a standard curve using dilution of the cRNA standard containing 
the same amount of sample mRNA (or total RNA), to quantitate the initial amount of taiget.
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FIGURE 7.6 RT-PCR AMPLIFICATION OF THE RAT 
CYCLOPHILIN GENE
FIGURE 7.6A RT-PCR AMPLIFICATION OF RAT CYCLOPHILIN mRNA OF 
PC12 CELLS TREATED WITH DIFFERENT AGENTS
Agarose gel of RT-PCR amplification of a 300 bp fragment of the open reading frame of rat 
cyclophilin mRNA. Total RNA (1 (ig) of unstimulated (basal) and PC 12 cells treated with 
different agents : DEX (dexamethasone 1 |iM), NGF (nerve growth factor 100 ng/ml), PMA 
(phorbol-12-m yristate-13-acetate, 1 nM), PACAP (PACAP-38, 5 nM) and FO R SK  
(forskolin, 10 jiM) for 48 hours was used for the RT-PCR reaction (40 cycles).
Lane 1: MWM (X xHind III-Eco RI) Lane 2: PC12-Basal (Ip^)
Lane 3: PC12-NGF (1 pg) Lane 4: PC12-PACAP (Ipg)
Lane 5: PC12-FORSK (Ipg) Lane 6: PC12-PMA (1 pg)
FIGURE 7.6B RT-PCR CO-AMPLIFICATION OF CYCLOPHILIN AND NPY- 
Y l mRNA OF PC12 CELLS TREATED WITH DIFFERENT AGENTS
Agarose gel of RT-PCR amplification of a 300 bp fragment of the open reading frame of rat 
cyclophilin mRNA and a 400 bp fragment of the 3'-flanking region of the NPY-Yl mRNA. 
Total RNA (1 pg) of unstimulated (basal) and PC12 cells treated with different agents : NGF 
(nerve growth factor 100 ng/ml), PMA (phorbol-12-myristate-13-acetate, 1 nM), PACAP 
(PACAP-38, 5 nM) and FORSK (forskolin, 10 pM) for 48 hours was used for the RT-PCR 
reaction (40 cycles).
Lane 1; MWM (1 Kb ladder) Lane 2: PC12-BASAL (Ipg)
Lane 3: PC12-NGF (1 pg) Lane 4: PC12-PMA (Ipg)
Lane 5: PC12-PACAP (Ipg) Lane 6: PC12-FORSK (1 pg)
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7.3 DISCUSSION
Previous results (Chapters 3, 4 and 5) have shown that pharmacological agents, such as 
dexamethasone, NGF, PACAP, forskolin and PMA among others, known to alter the levels of 
the expression of several genes in PC 12 cells, also increase the transcriptional activity of the 
NPY-Yl receptor gene (Figure 3-10). However, it is important to remember that the amount of 
mRNA measured at any time is influenced not only by the rate of transcription of the gene but 
also by other post-transcriptional mechanisms, such as mRNA stability. Moreover, many 
factors that alter transcription of genes, also alter the stability of its mRNA, in turn increasing 
the pool of measurable RNA.
7.3.1 NORTHERN BLOT ANALYSIS
In this chapter an attempt was made to quantify the mRNA levels of the NPY-Y 1 gene in PC 12 
cells. There are a number of different techniques for measuring mRNAs levels. The initial 
approach used was that of Northern blot analysis which is least sensitive technique but most 
robust. The general principle is that the total RNA is extracted from the cells or tissues, 
electrophoresed through denaturing agarose gel and transferred onto a blot. Specific mRNA is 
visualized by probing the blot with an antisense version of the mRNA radioactive or non­
radioactive labelled to allow visualisation. Total RNA was extracted from the different cells 
used in this thesis. The quality of the total RNA was assayed by two different ways: first, the 
relative ratio 260/280 was generally 1.8-2.0 indicating that the levels of contamination with 
proteins are very low; second, the RNA was separated by size in a denaturing agarose gel and 
the presence of sharp and distinctive ribosomal 28 S and 18 S bands was regar ded as an index 
of high quality non-degraded RNA (Figure 7-3 A). Moreover, consistent yields of total RNA 
were obtained using this acid-phenol extraction method (Chomczynski et ah, 1989) indicating 
that this is a reliable method of total RNA extraction. Northern were probed until radio labelled 
cDNA or cRNA probes derived from the cDNA of the NPY-Yl.
However, no signal was identified. As a consequence of this negative result, the same blot was 
probed for the NPY mRNA, which is known to be present in PC12 cells (Allen et ah, 1987b). 
Using this neuropeptide cDNA probe a specific signal was obtained corresponding to the NPY 
mRNA (Figure 7-3B). This results indicated that the RNA was in good condition. The 
different hybridisation signal likely reflects inherent differences in the abundance of both 
mRNAs in PC I2 cells.
256
7.3.2 RIBONUCLEASE PROTECTION ASSAY ANALYSIS
The RPA is a sensitive technique in which a synthetic RNA probe is hybridized in a complex 
sample mixture of RNA to the specific mRNA. After hybridization, the mixture is treated with 
ribonuclease to degrade single-stranded unhybridized probe. However, the labelled probe that 
hybridises to the mRNA is protected from ribonuclease digestion and can be separated by 
PAGE and visualized by autoradiography. For the RPA assay, the NPY-Yl cDNA in pBS-Yl 
was digested with Nde I to allow the synthesis of a cRNA antisense transcript by "in vitro " 
transcription. As a positive control in the RPA assay, the human RNA 18S probe was used. 
The expected site band for the protected fragment (80 nucleotides) of human RNA 18S probe 
was identified (Figure 7-3C). However, the expected protected fragment (540 nucleotides) for 
the NPY-Yl probe was not observed. Increasing the sensitivity of the assay did not alter this 
negative result, indicating that the message of the NPY-Yl receptor is veiy rare in PC I2 cells.
7.3.3 RT-PCR ANALYSIS
RT-PCR permits the qualitative and quantitative analysis of the levels of the expression of 
specific genes. RT-PCR is 1,000 to 10,000 times more sensitive than traditional techniques of 
RNA blotting (Byrne et ah, 1988; Wang et ah, 1989). The extraordinary sensitivity of RT- 
PCR has been used to amplify, clone and characterise mRNAs of short life and/or present in 
very little amounts and detection mRNAs of specific cells in a heterogeneous mixture of cells 
(Gilliland et ah, 1990). In the RT-PCR process, RNA is first isolated from cells or tissues and 
then used as a template for reverse transcription to cDNA. The cDNA in turn is used as 
template for PCR, using primers designed to amplify a selected cDNA region. The PCR 
product is analysed by agarose gel electrophoresis and identified by size. It can be further 
validated by restriction digestion, hybridization or nucleotide sequencing.
The extent of the expression of the genes under study can be estimated by knowing the amount 
of RNA used for the synthesis of cDNA, the amount of cDNA used for PCR and the number 
of PCR cycles needed to generate a visible band on an agarose gel. However, while RT-PCR 
is an extremely sensitive method of mRNA analysis, obtaining quantitative information with 
this technique can be difficult. This is due primarily to the fact that there are two sequential 
enzymatic reactions involved: the synthesis of DNA from the RNA template by reverse 
transcriptase and the specific amplification of the DNA by polymerase chain reaction (PCR). 
Both steps must be considered for quantification of mRNA levels.
The cDNA synthesis step will reflect the relative amount of mRNA in the cells or tissue only if 
two conditions are met: (i) a high proportion of the RNA is intact and (ii) cDNA synthesis is 
efficient for the mRNA under study. PCR products can be measured with 32p-iabelled or non-
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isotopically dNTPs, primers or probes by blot hybridization or by densitometry of fluorescent- 
stained gels, biotin-streptavidin binding and antibody detection of digoxigenin.
The goal of quantitative PCR is to deduce, from the final amount of PCR product, either the 
initial number of taiget molecules (Nq) or the relative starting levels of target molecules among 
several samples. Thus, the first step in this process is to measure the amount of PCR product. 
Several methods are commonly used to quantify PCR products. The most straightforward 
approach is to measure the incorporation of labelled nucleotides or primers into PCR products 
resolved by gel electrophoresis. Other strategies for quantifying PCR products are based on 
hybridisation. The most common of these methods is to probe a Southern blot of the PCR 
product using a radio actively labelled probe designed to hybridise to specific, amplified 
sequences. Because the nucleic acid probes only hybridise to the corresponding amplified DNA 
sequences, this method offers the advantage of detecting only the correct PCR product. Non­
specific products should not produce a signal. In this thesis the measurement of the ethidium 
bromide luminescence emanating from PCR products resolved by gel electrophoresis was the 
method of choice (Nakayama et al., 1992),
7.3.3.1 The exponential nature of the PCR
The PCR amplification step is a complex, exponential process and for this reason small 
variations in amplification efficiency of the reaction can drastically affect the yield of products. 
In addition, the efficiency of PCR decreases at the latter stages of amplification due to depletion 
of reaction components, diminished enzymatic activity and accumulation of products. Although 
PCR is an efficient technique, exponential amplification is not a limitless process. Kinetic 
analysis of PCR show two reaction phases: one exponential and other linear' (Figure 7-15). The 
following factors may account for any observed plateau effect: the product accumulates to a 
concentration at which reassociation competes with primer annealing and extension, the molar 
ratio of polymerase to template falls below a critical value, inhibitors of polymerase activity, 
such as pyrophosphates, may accumulate, and one or more of the components (generally the 
DNA polymerase) necessary for the reaction become limiting .
The number of cycles needed to reach the plateau phase varies and this variability makes it 
difficult to predict precisely the time course of the reaction or the amount of product 
synthesised before plateau phase is reached. The uncertainties inherent in the plateau effect, as 
well as the exponential nature of PCR, contribute to the difficulty of performing quantitative 
PCR. Therefore any attempt to quantitate mRNA levels by RT-PCR must be limited to the 
analysis of products generated only during the exponential phase of the amplification. Under 
these conditions, RT-PCR can yield precise information about changes in mRNA levels.
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In order to define the exponential phase of amplification of the NPY-Y 1 gene in PC 12 cells, 1 
jig of total RNA of untreated PC 12 cells was amplified using the forward (2486) and reverse 
(2487) primers and different PCR cycles (10-40 cycles) (Figure 7-7). This RT-PCR reaction 
generates a PCR product of 400 bp which can be detected only after 40 cycles of RT-PCR 
amplification (Figure 7-5A). This result indicates that the mRNA for the NPY-Yl gene is 
expressed at very low levels in PC 12 cells, which are consistent with the previous negative 
results obtained with other less sensitive techniques, such as Northern blots and ribonuclease 
protection assay (RPA). However more detailed RT-PCR studies, including the use of 
radiolabelled primers or hybridization probes will be necessaiy to know the exponential phase 
of amplification of the NPY-Yl gene under these RT-PCR conditions.
In addition, the mRNA of the NPY-Yl gene was amplified by RT-PCR from different cells 
lines which ai'e known to express this neuropeptide receptor gene, such as RINni5f cells. This 
result showed that the levels of the NPY-Y 1 mRNA expression ai'e similar between the two cell 
lines:(Figure 7-5B). This preliminary results needs to be confirmed using an internal control to 
validate this differences. The mRNA levels of the NPY-Yl receptor gene were analysed for 
PC 12 cells treated with different agents which are known to increase the levels of transcription 
of this gene (See Chapter 3). This preliminary result showed that mRNA levels increased in 
compai'ison with basal levels of NPY-Yl expression (Figure 7-5C).
By definition, PCR process is a chain reaction. The products from one cycle of amplification 
serve as substrates for the next. Therefore, the amount of product increases exponentially and 
not linearly, as in most enzymatic processes. Under ideal or theoretical conditions, the amount 
of product doubles during each cycle of the PCR reaction according to equation (1) : N = N q 
2", where N is the number of amplified molecules, No is the number of molecules and n is the 
number of amplification cycles. This equation indicates a linear relationship between the 
number of amplified target molecules and the initial number of target molecules. The principal 
problem is that the amplification efficiency, that is, the fraction of the template replicated during 
each reaction cycle, is a crucial factor and experimentally is less than perfect. Thus, a PCR 
process is described by equation (2) : N=No (1+E)", where E is the amplification efficiency. 
Because of the exponential nature of PCR, a very small change in amplification efficiency, E, 
can yield dramatic differences in the amount of product, N, even if the initial number of target 
molecules, N q, is the same. Several experimental factors may affect the efficiency of 
amplification, including: the sequence and length of the DNA being amplified, the sequence of 
the primers and impurities in the sample, among others.
Although these factors can be controlled, there are variations between tubes that can make 
precise quantification of the PCR products difficult such as small variations in the temperature 
of the thermal cycling apparatus. Unfortunately, tube-to-tube variation in amplification
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efficiency can be both significant and unpredictable. They are two approaches to be used as 
internal control for a quantitative RT-PCR: (i) RT-PCR with endogenous control and (ii) RT- 
PCR with exogenous control.
7.3.3.2 Quantitative RT-PCR with Endogenous Control
Relative quantification of specific mRNA can be obtained comparing the relation between 
mRNA and a calibration curve using series dilutions of a synthetic cRNA, a cDNA or standard 
cells that contain a know number of copies of a tai’get DNA (Michael et al., 1992; Winters et 
al., 1992). The kinetic analyses of PCR reactions using a target mRNA and a cRNA standard 
curve can reveal differences in the efficiency of amplification, due to vai’iations in the efficiency 
of hybridisation of the primers, and, for this reason, is not possible to directly correlate the 
amount of target mRNA and the amount of the cRNA standard. For more accurate quantitation 
of mRNA levels, corrections for tube to tube vaiiation in amplification efficiency aie necessai-y. 
This is most coimnonly performed by inclusion of a internal standard.
An endogenous sequence or gene transcript that is normally present in the sample and is known 
to be present at constant levels throughout the series of samples to be compared, can be used as 
an internal standard in quantitative RT-PCR reactions (Chelly et al., 1988; Noonan et al., 1990; 
Abe et al., 1992; Kellog et al., 1992; Singer-Sam et al., 1992). Endogenous mRNA standards, 
typically house keeping genes or genes that are stmcturally or functionally related to the target 
mRNA, have been used to determine relative levels of specific mRNAs (Noonan et al., 1990; 
Murphy et al., 1990; Kinoshita et al., 1992). Ribosomal RNA genes are also used as an 
endogenous internal control for quantitation of mRNAs (Khan et ah, 1992). These techniques 
avoid an absolute quantification of specific mRNA.
In this approach, the endogenous standard sequence is amplified using a second pair of gene- 
specific primers, either in two separate PCR reactions, or in the same reaction as the target 
sequence. This method is sometimes referred as "multiplex PCR" (Gaudette et ah, 1991) or 
"differential PCR" (Frye et ah, 1989). The ratio of the amount of PCR products generated by 
target and endogenous sequences in the samples is then determined and compared. The data 
from this type of experiment must be obtained before the amplification reactions reach the 
plateau phase. Moreover, the data must be collected either by a titration of the sequences to be 
amplified, or by kinetic analysis, to ensure that signals are derived only from the exponential 
phase of the amplification.
The relative initial amounts of a target sequence (Not) and the endogenous standard ( N Q s)  (i.e., 
the ratio Not/Nos) can be determined from equation (4) : Not/Nos = Nt (1-t-Eg)" / N& (l+ E J"  
(The subscripts "t" and "s" refer to the tai’get and standard sequences, respectively) where: Nqi
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= initial number of target molecules, Nqs = initial number of standard molecules, Nl = number 
of amplified target molecules, N s = number of amplified standard molecules. Et = amplification 
efficiency of the target, Es = amplification efficiency of the standard and n = number of 
amplification cycles. Values for E for the target and standard may be calculated from the slope 
of a graph of Log N  as a function of cycle number (n). When the amplification efficiencies of 
the two reactions, target and standard, are identical, i.e.. Et = Eg, the analysis is greatly 
simplified (Santagatti et ah, 1993).
However, even without a full mathematical analysis, and even in case where Es does not equal 
Et, it has been shown empirically that endogenous mRNAs can be used to normalise target 
mRNA levels between samples to be compared. Thus, instead of determining the ratio of the 
initial absolute amounts of target and standard using linear regression, the relative amounts of 
PCR products generated by the target and standard templates in different samples is simply 
compared. Although it has not been shown theoretically, it has been suggested that if the 
internal standard mRNA is expressed at the same level in two samples, the ratio of PCR 
products generated from the target and standard should indicate the relative level of expression 
of the target mRNA in those samples (Horikoshi et ah, 1992; Neubauer et ah, 1991). 
Furthermore, it may be true that if the target and standard are amplified in the same tube, tube 
to tube variations in amplification efficiency (due, for example, to pippeting error, sample 
impurities, or partially degraded RNA) may be minimised as well.
Perhaps the greatest advantage of using the expression of an endogenous sequence as an 
integral standard is that the reference mRNA and the target mRNA are usually processed 
together for the entire duration of the experiment, from RNA extraction through PCR 
amplification. This tends to minimise differences in RNA yield between samples, an important 
advantage, particularly for analysis of small tissue samples where the quantities of RNA are too 
small to measure by UV spectrophotometry. In addition, if the entire population of mRNA is 
converted to cDNA by the use of oligo(dT) primers or random hexamers, the overall efficiency 
of the cDNA synthesis also is somewhat normalised.
Not withstanding the advantages to this approach, several complications may arise when 
amplification of endogenous mRNAs is used for semi-quantitative analysis. For this method to 
be reliable, the level of expression of the reference standai'd must be the same in each sample to 
be compared and must not change as a result of the experimental treatment. Unfortunately, few 
if any genes are expressed strictly in this manner. This is even the case for many housekeeping 
genes, including b-actin. Therefore, the level of the mRNA used as the endogenous standard 
must be examined very carefully to ensure its constancy among all of the experimental 
conditions studied. In order to obtain the relative levels of amplification by RT-PCR of the rat 
cyclophilin gene (a housekeeping gene) in PC 12 cells under the different treatments (NGF,
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PACAP, forskolin and PMA), total RNA was amplified using the forward (Y7462) and 
reverse (Y7463) primers generating a product of 300 bp after 40 cycles of amplification (Figure 
7-6A). Results showed that the mRNA levels of this gene was not altered by the agents known 
to increase the transcriptional activation of the NPY-Y 1 gene. For this reason this gene can be 
used as internal control for a quantitative RT-PCR in PC 12 cells using the above mentioned 
pharmacological agents.
Another challenge of this approach is to obtain values of Nt and Ng before the amplification 
reactions reach the plateau phase, especially when the relative levels of expression of the 
standard and target sequences differ greatly. In addition, the cyclophilin mRNA (internal 
control) may be present at a much higher level than the target transcript, and amplification of 
this control may approach plateau phase well in the advance of that of the target sequence. One 
solution to this problem involves simply waiting until later stages of the amplification before 
adding the primers for the endogenous standard. Other researchers used gene-specific primers 
to synthesise cDNA from the control and target mRNAs in separate tubes and then mixed 
dilutions of the control and target cDNAs before performing multiplex PCR. Interference is a 
frequently observed problem when more than one set of primers is used in the same PCR 
reaction. In general the amount of product generated (from either the target, the standard, or 
both) is often dramatically reduced when both sequences aie amplified in a single reaction. In 
fact, primer pairs that function truly independently seem to be the exception rather than the rule.
For this reason, the next series of experiments were performed to try to define the conditions 
for a C O -amplification of the two messages (cyclophilin and NPY-Yl genes) in one tube of RT- 
PCR reaction. Different experiments were made using constant amounts (20 pmol) of the 
primers for the NPY-Yl gene and several dilutions of the primers for the rat cyclophilin gene. 
After several failed experiments the optimal conditions were set-up for a narrow margin of 
dilution (between 1 to 5 pmoles) of the primers for the cyclophilin gene after 35 cycles of 
amplification (Figure 7-11). However, further co-amplification RT-PCR experiments, 
including an analysis of the exponential phase of co-amplification of both mRNAs using 
radiolabelled primers will be necessaiy to obtain valid results of this quantitative RT-PCR.
7.3.3.2 Quantitative RT-PCR With Exogenous Control
Exogenous sequence can also be used as internal RT-PCR control. In this approach, a 
synthetic cRNA control containing the same primer template sequences as the experimental 
target is added to the target sample and amplified simultaneously with the target transcript in a 
single RT-PCR reaction mixture. The theory behind use of exogenously added gene sequences 
as internal controls is similai' to that described above for endogenous reference sequences. With 
both types of internal controls, the amount of amplified control can be quantified after the
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experiment, and the change in the amount of control is proportional to the change in the amount 
of the target. However, there is a significant advantage in using an exogenously added 
sequence as the internal control; namely, the initial amount of control used in the RT-PCR 
reaction is precisely known. This makes it possible to calculate the absolute level of target 
mRNA present in the original sample.
Competitive PCR uses an exogenous template as an internal control and the amplification takes 
place in a competitive fashion because the control and target sequences compete for the same 
primers and, therefore, for amplification. A critically important requirement of this type of 
experiment is that the value of efficiency (E) be the same for both the target and control 
mRNAs. This can be accomplished by designing the control to contain the same primer binding 
sequence as the corresponding target mRNA. In many cases this is sufficient to make Eg equal 
to Et (Becker-André and Hahlbrock, 1989; Gilliland et al., 1990).
As the control cRNA molecules and the target mRNA molecules are co-amplified in the same 
tube, changes in any of the variants that affect the efficiency of the RT-PCR reaction are 
identified and affect in equal proportion the amounts of amplified products of both RNA. For 
this reason it is not necessaiy to do kinetic studies of the efficiency of the reaction for each both 
of the RNA molecules by separated. In addition, in the competitive RT-PCR reaction the initial 
proportion of target mRNA molecules and control cRNA molecules stay constant during the 
amplification, and the quantification can be done in the linear phase (saturation) of the RT- 
PCR. The amounts produced by RT-PCR of both RNAs can be obtained using densitometric 
analysis in gels stained with ethidium bromide (Clementi et al., 1993; Ferre et al., 1994).
Although the variables that affect the efficiency of a RT-PCR reaction are carefully controlled, 
small differences in the rate of amplification of a target mRNA and cRNA control are magnified 
during the exponential phase of the PCR, and can underestimate or overestimate the amount of 
unknown mRNA. To avoid these, it is necessary use as internal control a cRNA molecule that 
has the same nucleotide sequence as the target mRNA and, the same set of primers should be 
used to amplify both RNAs in a same tube. Unfortunately, the products of the PCR can not be 
distinguished because they have the same sequence and size. For this reason, it is necessary to 
use a cRNA control, whose product can be distinguished from the target mRNA by size, 
hybridisation with a specific probe or use restriction enzymes (Becker-Andre et ah, 1989; 
Gilliland et ah, 1990). The cRNA standard can be made by an allelic variant (for example, a 
gene with a small deletion or insertion, as a fragment of genomic DNA that contain a small 
intron) (Becker-Andre et ah, 1989) or a mutant cDNA (prepared by a change in a pair of bases 
by direct mutagenesis) which contain or lose a restriction enzyme site (Gilliland et ah, 1990).
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A exogenous internal control for a competitive RT-PCR of the NPY-Y 1 receptor gene in PC 12 
cells was prepared. This exogenous control is a internal control cRNA of the 3'-flanking region 
of the NPY-Yl receptor gene which can be amplified to generate a fragment of approximately 
300 bp. This fragment was amplified using the same pair of primers (2486-2487) which were 
used to amplify a 400 bp fragment of the mRNA of this neuropeptide receptor gene. The two 
products can be separated by size in a 2% agarose gel. Initially, the optimal conditions for the 
amplification of the cRNA (internal standard) were obtained (Figure 7-5B). However, further 
experiments in which a dilution series of the cRNA control sequence and a constant amount of 
the total RNA of the PC 12 cells are co-amplified will be necessary to determin the absolute 
amounts of this NPY-Yl receptor gene in these cells. Quantification will be performed after 
competitive amplification of the entire series of reactions and is achieved by distinguishing the 
two PCR products from each tube by differences in size. An advantage of this method is that, 
because the ratio of target to standard is constant during the amplification, it is not necessary to 
obtain data before the plateau phase of the reaction.
Finally, in a competitive PCR, the competitor fragment takes the place of the standard. When 
the amplification efficiencies of the tai'get and standai'd molecules aie the same, equation (4) can 
be simplified to equation (5): NOt/NOg = Nt /Ng = At /Ag where: Not = initial number of tai'get 
molecules, Nqs = initial number of standard molecules, N t = number of amplified target 
molecules, Ns = number of amplified standard molecules. At = amount of amplified target (in 
cpm or OD260 units), As = amount of amplified standai'd (in cpm or OD26O units). Thus, for 
any value of n, the initial ratio of target to standard is equal to the ratio of their amplification 
products (i.e., Nt /Ng or At /Ag). This has been demonstrated both theoretically (Nedelman et 
ah, 1992) and empirically (Bouaboula et ah, 1992). Therefore, if the standard and target 
sequences amplify with the same efficiency, the absolute initial amount of tai'get mRNA, can be 
determined by allowing known amounts of internal cRNA molecules to compete with the target 
for primer binding.
7.4 SUMMARY
7.4 .1  The complete open reading frame of the N PY -Y l receptor gene was 
obtained by PCR from a RINmSf cDNA library.
A 1.3 kb fragment containing the ORF of the NPY-Yl gene was cloned opposite to the T7 
RNA polymerase of the pBluescribe SK+ vector. This clone was verified by specific restriction 
enzyme digestion and was used to synthesize cDNA probes for Northern blots or cRNA 
probes for RPA.
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7.4.2 Northern blot assays fail to detect the signal of the N PY -Y l receptor 
gene in PC12 cells.
7.4.2.1 High quality RNA was purified and quantified from PC12 cells. This total RNA was 
separated by size, blotted in nylon membranes and hybridized with two specific DNA probes.
7.4.2.2 A NPY probe results in detectable signal of this neuropeptide mRNA in unstimulated 
PC 12 cells. Moreover, this signal was increased in PC I2 cells treated with NGF consistent 
with previous results (Allen et ah, 1987; Balbi and Allen, 1994). This result indicates that the 
total RNA extracted from the PC I2 cells is in good conditions and the labelling reaction results 
in a probe with high specific activity.
7.4.2.3 A NPY-Yl receptor probe fails to produce a detectable signal of this neuropeptide 
receptor mRNA in untreated PC I2 cells under the same hybridization conditions used for the 
NPY probe. Moreover, increasing the amount of RNA or decreasing the stringency of the 
hybridization did not increase the specific signal. This results indicate that in comparison with 
the NPY, the NPY-Yl receptor is expressed at very low levels in PC12 cells.
7.4.3 Ribonuclease protection assays (RPA) also fail to detect tbe signal of tbe 
N PY-Yl receptor gene in PC12 cells
7.4.3.1 A human RNA 18S antisense probe results in a protected fragment of approximately 
80 nucleotides in untreated PC 12 cells. This result indicates that the total RNA extracted from 
the PC 12 cells is in good conditions and the "in vitro " labelling reaction results in a probe with 
high specific activity.
7.4.3.2 A NPY-Yl receptor antisense probe fails to protect a fragment of approximately 540 
nucleotides in untreated PC 12 cells. Moreover, increasing the sensitivity of the RPA did not 
increase the specific signal. This result confirms the previous Nor then blot results that the 
PC 12 cells express very low levels of the NPY-Yl receptor mRNA.
7.4.4 RT-PCR detect tbe mRNA of tbe NPY -Y l receptor gene in PC12 cells 
but only after 40 cycles of amplification.
7.4.4.1 mRNA of the NPY-Yl receptor gene was detected after 40 cycles of RT-PCR 
amplification in PC 12 cells. Moreover, similai' results were obtained using RINiii5f cells. This 
results indicate a very low levels of expression of the mRNA in theses cells.
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7.4.4.2 Preliniinai'y results indicate that different pharmacological agents known to increase the 
levels of transcription of this gene in PC12 cells also increase levels of NPY-Yl gene 
expression. However, an internal control need to be used to confirm this results
7.4.5 A small fragment (300 bp) of tbe rat eyclopbilin gene was amplified by 
RT-PCR to be used as endogenous control in a quantitative RT-PCR.
7.4.5.1 The levels of amplification of a fragment of 300 bp of a rat cyclophilin gene were not 
altered by different pharmacological agents known to increase the levels of the NPY-Yl gene in 
PC 12 cells. This result indicates that this mRNA is a good internal control for the RT-PCR 
quantification of NPY-Yl receptor mRNA.
7.4.5.2 Preliminary results indicate that the co-amplification of both mRNAs, the NPY-Yl 
receptor gene and the rat cyclophilin gene, were obtained but in a narrow range of primer 
concentrations, NPY-Y 1 gene (20 pmoles) and rat cyclophilin (3-5 picomoles) after 40 cycles 
of RT-PCR amplification.
7.4.6 A small fragment (300 bp) of tbe 3 '-flanking region of tbe N PY -Y l 
receptor gene was amplified by RT-PCR to be used as exogenous control in a 
com petitive RT-PCR.
7.4.6.1 Preliminary results indicated that a exogenous cRNA fragment (300 bp) synthesized by 
"in vitro " transcription can be amplified by the same primers used to amplified the mRNA of 
the NPY-Y 1 receptor gene (Figure 7-12). This results indicate that this cRNA is a good internal 
control for a competitive RT-PCR.
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CHAPTER 8 
GENERAL DISCUSSION
8.1 RELEVANCE OF THE NPY-Yl RECEPTOR
The role of neuropeptide receptors in the functional organisation of the nervous system is 
continuously expanding. Neuropeptide receptors are widely distributed throughout the central 
and peripheral nervous system and they have been found to play a major role in almost all 
systems where they have been identified. NPY receptors, in particular, are among the most 
abundant neuropeptide receptors in the nervous system (Lai'hammai' et ah, 1997).
In the CNS, the NPY-Yl receptor has been linked with different physiological process, 
including anxyolitic-sedative effects, cardiovascular effects, inflammation and nociception and 
release of pituitary hormones, among others (Wahlestedt et ah, 1990; Grundemar and 
Hakanson, 1994). In the PNS, the NPY-Yl receptor is found at the sympathetic postsynaptic 
sites where it mediates the vascular smooth muscle contractile response to NPY (Wahlestedt et 
ah, 1990; Grundemar and Hakanson, 1994). Understanding the molecular mechanisms 
controlling NPY-Yl receptor gene expression will provide clues not only about the numerous 
systems where this receptor plays a regulatory role but also about the role of NPY receptors in 
general on the overall organisation of the nervous system.
The nervous system contains diverse populations of cells which interconnect in precise 
manners. The identity of these cells is determined by their ability to transcribe a par ticular set of 
genes. The factors participating in NPY-Yl receptor gene expression have to satisfy unique 
criteria since this receptor is distributed in specific cell populations throughout the nervous 
system (Eva et ah, 1990).
The PC I2 cell line is a clonal cell line established from a rat adrenal medullary tumour. These 
cells have been widely used as an important model system to examine the process of neuronal 
differentiation induced by NGF (Greene and Tischler, 1976). P C I2 cells have high 
concentrations of NPY (Allen et ah, 1984) and also express NPY-Yl receptors (Schwartz et 
ah, 1990). Moreover, PC12 cells differentiated to a neuronal-like phenotype by NGF or to 
adrenal chi'omaffin-like cells with dexamethasone aie responsive to selective NPY-Yl agonists 
with inhibition of evoked cAMP and induced catecholamine overflow (DiMaggio et ah, 1994). 
For this reason this cell line was used as a sympatho-adrenal (SA) model system to study the 
molecular mechanisms controlling expression of the NPY-Yl receptor gene.
8.2 THE LUCIFERASE REPORTER SYSTEM
The experiments presented in this thesis represent the first characterisation of the molecular 
mechanisms involved in the transcriptional control of the NPY-Yl receptor gene in PC 12 cells.
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Approximately 600 bp of the promoter region of the rat NPY-Yl receptor gene that lies 
upstream to the open reading frame have been attached to the reporter function, luciferase, so 
the expression of this enzyme has been placed under the transcriptional control of the promoter 
of this neuropeptide receptor gene.
Optimal conditions for several parameters which improve the transfection efficiency and can 
affect levels of luciferase activity in PC 12 cells were found empirically. These parameters 
include the amount and quality of the DNA added to the cells, the time that the cells were 
incubated with the DNA and general conditions of the luciferase assay, such as the time point 
of har vesting, among others. In addition, luciferase activity was found to be: (i) linear over the 
range of dilution (1 : 5 to 1 : 20) used in the assay, (ii) highly reproducible and (iii) resistant to 
repeat cycles of freeze-thawing. Finally, it was found that cell extracts of non-transformed 
PC 12 cells showed no detectable luciferase activity indicating that the only source of luciferase 
activity was derived from the DNA (pYl-LUC) transfected into the cells.
The luciferase assay was found to be a good reporter system for PC 12 cells. Very low levels of 
luciferase activity were achieved with the promoterless plasmid (pGL3-Basic) indicating that 
the vector itself contained no sequences that could activate gene expression in PC 12 cells. 
Maximum levels were achieved with the control vector (pGL3-Control) in which the luciferase 
is under the control of a SV40 early enhancer/promoter, indicating that PC 12 cells were able to 
produce high levels of active luciferase enzyme. Slightly higher levels of luciferase activity 
were measured in cells transfected with the fusion gene pYl-LUC compared to the 
promoterless vector. These results indicate that the luciferase assay was able to report factors 
that increase or decrease transcriptional activity in PC 12 cells. These results also demonstrate a 
low constitutive basal level of transcription of this gene in PC 12 cells in keeping with previous 
results that showed that these cells express NPY-Yl receptors on their cell surface (DiMaggio 
et al., 1994).
Different agents known to cause the differentiation of PC 12 cells, such as dexamethasone (to 
adrenal chromaffin cells) and NGF (to post-ganglionic sympathetic neurons) also increase the 
transcriptional activity of the NPY-Yl receptor gene. However, it is important to confirm that 
the differences observed in the levels of luciferase activity using these different treatments, 
reflect differences in the transcriptional activity of the NPY-Yl receptor gene and are not the 
result fn post-transcriptional effects, such as mRNA stability or non-specific effects of 
sequences present in the promoterless vector (pGL3-Basic). Luciferase activity was unaffected 
by these treatments when expressed from the promoterless plasmid (pGL3-Basic) or from 
SV40 promoter (pGL3-control).
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This result indicates that the differences in the luciferase activity obtained with the 
pharmacological agents resulted from effects on the transcriptional activity of the NPY-Yl 
receptor gene. However, further measurements of luciferase mRNA using specific inhibitors of 
the RNA polymerase, such as actinomycin D, will be necessary to determine that the 
expression of the luciferase enzyme is not affected by post-trancriptional mechanisms, such as 
mRNA stability, induced for these different treatments in PC 12 cells.
Thus, this region of the NPY-Y 1 receptor gene contains a functional promoter that is active and 
responsive to transcriptional activation in a neural crest-derived (sympathoadrenal) cell line: 
PC I2 cells. Moreover, this promoter region is also active in other cells lines such as GTl-7, a 
mouse hypothalamic neurosecretory (GnRH) cell line (Mellon et al., 1990) and RINm5f, a rat 
b-pancreatic insulinomic cell line (Gazdar et al., 1980) which also express this neuropeptide 
receptor. In these cell lines, the pYl-LUC results in slightly higher levels of luciferase activity 
compared to the promoterless vector (pGL3-Basic) but considerable less than the activity 
obtained with the control vector (pGL3-Control), indicating that the luciferase is a also a good 
reporter assay system to study mechanisms of transcriptional control of the NPY-Yl receptor 
gene in these cells. This promoter is inactive in COS-7 cells, a monkey kidney-derived SV-40 
transformed cell line. NGF and PACAP did not increase the transcriptional activity of the 
NPY-Yl receptor gene in these cells. Taken together, these results indicate that NPY-Yl gene 
contains a cell-type specific core promoter consistent with its known distribution in rats (Eva et 
ah, 1990).
A control reporter vector (pRL) and the Dual-Luciferase'^’^  reporter assay system were used in 
order to normalize for transfection efficiencies. Sources of variation in transfection efficiency 
include: quality of the DNA preparations, small changes in the pH of the transfection solutions 
or differences in the density or healthy of the cells, among others. Typically, pRL-CMV or 
pRL-SV40 were used as control reporter genes in co-transfected experiments with the pY l- 
LUC vector. These control vectors were used because they are linked to a different reporter 
gene (Renilla luciferase) and were under the control of constitutive active promoters in PC 12 
cells. However, the CMV immediate early enhancer/promoter present in pRL-CMV was 
responsive to all the activator compounds tested: dexamethasone (IjllM), NGF (100 ng/ml), 
PACAP (5  nM) and forskolin (10 |LlM )  which precluded its use as internal control. The SV40 
early enhancer/promoter region present in pRL-SV40 was responsive only to dexamethasone 
(1 |iM) and NGF (100 ng/ml), but was unresponsive to PACAP (5  nM) and forskolin (10 
|iM). For this reason pRL-SV40 was used as internal control in PC I2 cells treated with 
PACAP and other PKA activators, such as forskolin and DBC.
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8.3 PROMOTER REGION OF THE RAT NPY-Yl GENE
The promoter region of the rat NPY-Yl receptor gene contains several consensus sequences 
that constitute putative binding sites for different transcription factors including : (i) an AT-rich 
"TATA-like" box (AAATA), (ii) a putative "CCAAT" box (TCAAT), (iii) a GC rich Spl 
binding site (GGGGCG), (iv) an AP-1 binding site (TGAGTCA), (v) two ORE binding sites 
(CGTCA), (vi) one ERE binding site (TGACC), (vii) three GRE binding sites (AGGACT) and 
(viii) one GRE binding site (TGTTCT).
8.3.1 BASAL REGION OF THE PROMOTER OF THE NPY-Y l GENE
A sequence comparison between the promoter of the mouse, rat and human NPY-Yl genes 
showed a high degree of homology in the region close to the putative start site, including a 
highly conserved "TATA-like" box (AAATA) and "CAAT-like" box (TCAAT). These elements 
are likely to be involved in the control of the basal levels of transcriptional activity of this gene 
in PC 12 cells. However, preliminary results in this thesis using RT-PCR suggest that the 
transcription initiation site in the rat NPY-Yl gene is upstream of the putative cap site. These 
results are similar to primer extension analysis which revealed several closely spaced sites for 
transcription initiation in the promoter of the mouse (Eva et al., 1992) and human (Ball et ah, 
1995) NPY-Yl receptor genes. Further RT-PCR studies using upstream primers will be 
necessaiy to obtain a more precise location of the start transcription site of this gene.
The GC-box (GGGGCG) constitutes a putative Spl binding site. This site is conserved in the 
mouse and rat NPY-Yl promoters and constitutes another element that may contribute to the 
basal transcriptional activity of this gene in PC 12 cells. Spl is a ubiquitous transcription factor 
that may recruit TATA-box binding proteins or initiation complexes to the initiation site in 
promoters lacking consensus TATA-boxes. Spl has been reported to be non-inducible but is 
an enhancer of constitutive expression of several genes, specially housekeeping genes 
(Radon aga et ah, 1987). However, Spl-like proteins has also been reported to be involved in 
the NGF-mediated transcriptional activation of the NPY gene (Minth and Dixon, 1990). 
Further deletions of this site will be important to know the relevance of Spl in the 
transcriptional activation of the NPY-Y 1 receptor gene in PC 12 cells.
8.3.2 AP-1 SITE OF THE PROMOTER OF THE NPY-Y l GENE
The promoter of the rat NPY-Yl gene has a complete AP-1 site (TGAGTCA). This element is 
also present in the promoter of mouse NPY-Yl gene (Eva et ah, 1992). Moreover, the 
promoter of human NPY-Y 1 gene have another AP-1 site located upstream of this binding site
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(Ball et al., 1995) shared with the mouse NPY-Yl gene (Musso et ah, 1997) and the mouse 
NPY-Yl promoter also have another AP-1 site downstream of this binding site. This element 
constitutes a consensus DNA binding site for the transcriptional factor AP-1, comprising 
dimers of the c-fos and c-jun families of proteins (Curran and Franza, 1988). Expression of 
c-fos is known to be activated in PC 12 cells by growth factors, such as NGF and by phorbol 
esters, such as PMA and this activation is at least partially dependent on PKC activity in this 
cells (Sigmund et al., 1990). c-fos activation via the PKC-dependent pathway has been shown 
to be regulated by a serum responsive element (SRE) (Treisman, 1995). SRE is the specific 
binding site for a nuclear protein, serum responsive factor (SRF), present in nuclear extracts of 
PC 12 cells (Sheng and Greenberg, 1990). In addition, the PKC-mediated induction of c-jun 
transcriptional activity is thought to result from a positive autoregulatory mechanism and to 
involve dephosphorylation for an PRC-activated phosphatase at inhibitoiy phosphorylation site 
next to a carboxy-terminal DNA-binding domain of c-jun . Thus, transcriptional activation of c- 
fos and post-translational regulation of pre-existing of c-jun can induce AP-1 transcriptional 
activity, in turn increasing the expression of late responsive genes in PC 12 cells.
The AP-1 site is the most like element to mediate the NGF- and PMA-dependent transcriptional 
activation of the NPY-Yl receptor gene in PC 12 cells. AP-1 consensus sites are present in 
several late responsive genes (ERG) regulated by NGF and PMA in PC 12 cells, such as the 
gene for transin/stromelysin (Machida et a l, 1989), neurotensin/neuromedin N (Kislauskis and 
Dobner, 1990), tyrosine hydroxylase (Gizan-Ginsberg and Ziff, 1990) and NPY (Balbi and 
Allen, 1994).
Previous results, have shown that the NGF and PMA mediated transcriptional activation of the 
NPY gene is dependent on PKC activity and a specific deletion of the AP-1 site significantly 
reduced the NGF response whereas the response to PMA was completely abolished (Balbi, 
1994; Balbi and Allen, 1994). Moreover, in the neurotensin/neuromedin N gene, mutation of 
the AP-1 site reduced the transcriptional response to NGF (Kislauskis and Dobner, 1990). AP- 
1 sites are also involved in mediating NGF inducibility of the tyrosine hydroxylase (Gizan- 
Ginsberg and Ziff, 1990) and transin genes (Machida et a l, 1989) in PC12 cells.
In order to evaluate the role of this AP-1 site in the control of the expression of the NPY-Yl 
receptor gene in PC 12 cells, a specific mutation of this site was obtained by PCR and cloned in 
the luciferase reporter vector (pY 1-APl). Thus the luciferase activity is under the control of this 
AP-1 deleted version of the promoter of the NPY-Yl receptor gene. Further luciferase reporter 
assay experiments using this deletion fusion gene will be necessai'y to determine the relevance 
of this AP-1 mutation in the control of the basal- and NGF-dependent transcriptional activation 
of the NPY-Yl receptor gene in PC 12 cells.
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8.3.2.1 NGF EFFECTS ON THE TRANSCRIPTION OF THE NPY-Y l GENE
The mechanisms underlying the transcriptional effects of NGF have been the subject of intense 
research (Halegoua et ah, 1991). While there has been a continuous input of information about 
the intracellular mechanisms activated during the early stages of NGF-induced differentiation, 
including transcription of immediate early genes (lEGs), such as c-fos , c-myc , NGFl-A, 
NGFl-B and NGFl-C (Halegoua et ah, 1991) relatively little is known about the effect of 
NGF on late response genes (ERG). This group of late responsive genes include peripherin 
(Leonard et ah, 1988), neurotrensin/neuromedin N (Kislauskis and Dobner, 1990), tyrosine 
hydroxylase (Gizan-Ginsberg and Ziff, 1990), transin/stromelysin (Machida et ah, 1991), 
voltage-dependent sodium channel (Ginty et ah, 1992), GAP-43 (Perrone-Bizzozero et ah, 
1993) and NPY (Balbi and Allen, 1994).
It is becoming apparent that the mechanisms of the regulation of this ERG by NGF are 
different from those of the regulation of lEG. The transcriptional induction of lEGs is transient 
and independent of protein synthesis while that of ERGs is usually long lasting (> 6 hours) and 
requires ongoing protein synthesis (Sheng and Greenberg, 1990), lEGs can regulate the 
expression of ERGs by virtue of their transcriptional regulatory activity and thereby act as 
mediators of long term changes in gene expression induced by external stimuli such as NGF 
(Morgan and Curran, 1991). Further experiments using cyclohexamide, a potent inhibitor of 
protein synthesis that interferes with mRNA translation at the ribosomes will be necessary to 
understand the role of the translation machinary and the synthesis de novo of transcription 
factors which are not normally present in non-differentiated cells in the activation of NPY-Yl 
gene in PC I2 cells.
Binding of NGF to its high affinity receptor, trk A , results in dimerization and trans-auto- 
phosphorylation of tyrosine residues in the cytoplasmic domain (Kaplan and Stephens, 1994). 
Four intracellular' proteins ai'e activated by the phosphorylated trk A receptor: PECg-1 (Vetter et 
ah, 1991), PI-3 kinase (Raffioni and Bradshaw, 1992), she (Obermeir et ah, 1993) and 
MAPK-1 (Eoeb et al, 1994). This initial tyrosine phosphorylation events are followed by the 
activation of several protein kinases, that include members of the PKC, raf-1 , MEKs, MAPKs 
and S6 kinases, which are involved in mediating the NGF effects in PC 12 cells (Halegoua et 
ah, 1991). Stimulation with NGF causes translocation of these kinases from the cytosol to the 
nucleus, which results in the activation of specific nuclear targets, such as the transcription 
factors c-fos , c-jun and c-myc , there by initiating specific gene transcription events required 
for mediating the NGF response in PC 12 cells.
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8.3.2.1.1 Role of Tyrosine Kinase Pathway
In chapter 4, the results from experiments aimed at characterising mechanisms involved in the 
NGF-induced transcriptional activation of the NPY-Yl receptor gene were detailed. NGF 
results in a concentration-dependent increase in the transcriptional activation of this gene in 
PC12 cells. The concentration range (10-100 iiM) of the NGF is consistent with the known 
biological potency of this neurotrophic factor in PC I2 cells. The increase in transcriptional 
activity of the NPY-Yl receptor gene is consistent with previous studies which have shown 
that NGF differentiated PC 12 cells are responsive to the NPY-Yl receptor selective agonists 
(DiMaggio et ah, 1994).
This NGF-induced response of the NPY-Yl receptor gene is dependent in trk A receptor 
activation. Pretreatment of PC 12 cells with K-252a (200 nM), a specific inhibitor of the 
tyrosine kinase activity of the trk A receptor (Berg et al., 1992) completely blocked the NGF 
transcriptional activation of the NPY-Yl gene but had no effect on basal levels in PC12 cells. It 
will be useful establish weather other neurotrophins such as BDNF, NT-3 and NT-4/5 affect 
the transcriptional activity of this promoter to understand the role of the low affinity P7 5 NTR 
receptor in this response.
Basal- and NGF-dependent activation of transcriptional of NPY-Yl receptor gene in PC12 
cells appear to be negatively regulated by an intrinsic and NGF-induced tyrosine kinase. 
Genistein (50 (iM) increased both the basal- and NGF-dependent transcriptional activity of the 
NPY-Yl gene. Previous results have been shown that genistein (50 jiM) inhibits p60‘^--^ '^‘^ 
kinase activity (Akiyama et ah, 1987). Moreover, genistein also inhibits the increase of ras 
-GTP induced by NGF in PCI2 cells (Nakafuku et ah, 1992). activation appear occurs
upstream of p2F ’^-^ , and this activation is required for the p60‘^‘‘^ '^‘^ induced neurite outgrowth in 
PC I2 cells (Ki'emer et ah, 1991). These possibly suggest that genistein inhibition of an 
intrinsic tyrosine kinase (possible p 6 0 ^ k i n a s e )  by the inhibition of p2F''^‘^ activation, results 
in the basal- and NGF-dependent transcriptional activation of the NPY-Yl receptor gene in 
PC 12 cells. These results are consistent with the role of the ras -MAP kinase pathway in the 
transcriptional activation of this neuropeptide receptor gene in PC 12 cells. However, further 
experiments will be necessary to confirm this hypothesis, including the use of specific 
antibodies against or expression of a dominant negative mutant of this kinase to mimic
the inhibitory effect of genistein. In addition, constitutive active mutants of this tyrosine kinase, 
will be useful to demonstrate the negative role of the in the transcriptional activation of
the NPY-Yl gene in PC 12 cells. Moreover, the effect of the p21™-^ ' activity in this genistein 
effect could be confirmed in a PC12-ra.s' negative cell line (Buensuceso, 1995). Finally, the 
use of an inactive analogue of genistein, such as daidzein (Akiyama et al., 1987) will be
important to confirm the specificity of this result.
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The role of sodium orthovanadate in the reduction of basal- and NGF-dependent transcriptional 
activation of the NPY-Yl gene could be more complex. Sodium orthovanadate induces 
differentiation and neurite outgrowth of PC12 cells by increasing tyrosine kinase activity. 
Sodium ortho vanadate also increases tyrosine kinase activity in PC 12 cells
(Buensuceso, 1995). Moreover, MAPK activity also can be induced by sodium orthovanadate 
(Tsao et ah, 1990). This MAPK activation is independent of trk A tyrosine kinase activity, as 
it cannot be blocked by K-252a, it is dependent on p2F' '^^ activity, as a PC12-rai’ negative cell 
line did not exhibit MAPK activity or neurite outgrowth upon exposure to sodium 
orthovanadate (Buensuceso, 1995). Taken together, this results suggest that the negative effect 
of sodium orthovanadate on the transcription of the NPY-Yl receptor gene involves the 
sequential activation of src-ras- MAPK in PC 12 cells, following a model of sequential src-ras 
activation as proposed by NGF in PC12 cells (Ki’emer et ah, 1991). However, will be 
important to demonstrate the role of the MAPK pathway in this sodium ortho vanadate effect 
using a VC\2-ras negative cell line or specific inhibitors of this pathway, such as PD98059.
8.3.2.1.2 Role of the ras-MAPK pathway
Previous results have been shown that p2F'<^  ^is central to the NGF-induced signalling pathway 
in PC 12 cells. NGF induces an accumulation of the GTP-bound active form of p2F'^‘^ in PC 12 
cells (Qui and Green, 1991). Moreover, introduction of constitutively active oncogenic form of 
p2 ira j PC 12 cells can mimic the NGF-mediated differentiation, including neurite 
outgrowth. In addition, microinjection of anti-ra^" antibodies or transfection with a dominant 
negative mutant of p2F'‘^ ‘^ blocks NGF-dependent effects in PC 12 cells (Ki’emer et ah, 1991). 
Furthermore, expression of a dominant negative mutant p2H<^ '^  also blocks the NGF-dependent 
activation of raf-1 , MAPKs and RSKs in PC 12 cells (Thomas et ah, 1992; Wood et ah, 
1992).
However, the NGF-dependent transcriptional activation of the NPY-Yl receptor gene is
independent of the ras -MAPK pathway. NGF induced a similar activation of NPY-Yl gene
transcription in a PC12-ra.s’ negative cell line compared with a PC 12-wild type cell line. This
result indicates that the p2F'<^ -^  protein is not involved in this NGF-dependent effect and is
consistent with previous results which have been shown that some of the NGF-dependent
effects in PC 12 cells are ras -independent. In particular, the NGF-dependent induction of the
differentiation-associated gene Thy-1 (D'arcangelo and Halegoua, 1993) or a voltage-gated
sodium channel, a late responsive gene (Fanger et ah, 1993), are ras -independent in PC 12
cells. Further experiments will be necessary to understand the role of the p2F‘^ ‘^ protein in the
NGF-dependent transcriptional activation of the NPY-Yl receptor gene in PC12 cells. For
example, it will be useful to know if NGF can increase PKC activity and c-fos expression in
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this VCl2-ras negative cell line in similar way to that observed for the PC 12-wild type. 
Moreover, it will be important to know the effect of block specific signalling pathways, such as 
PKC (using calphostin C), PI-3-K (using wortmannin) and ras -MAPK kinase (using PD 
98059) in the transcriptional activation of the NPY-Yl gene in this cell line. Finally, this PC12- 
ras negative cell line will be a useful model to understand the role of the src-ras activation in 
the transcription of this neuropeptide receptor gene, using genistein and sodium ortho vanadate 
as mentioned before.
Pretreatment of the PC12-wild type cells with PD 98059 (20 jlM), a MEK-1 kinase inhibitor 
blocks NGF-induced neuronal differentiation of PC 12 cells (Alessi et ah, 1995), this inhibitor 
paradoxically increased the basal transcriptional activation of the NPY-Yl gene, indicating that 
intrinsic MEK-1 kinase activity may inhibit the transcription of this neuropeptide receptor gene 
in PC 12 cells. It is tempting to speculate that the NGF activation of the MAPK pathway has a 
negative effect on the transcriptional activation of NPY-Y 1 receptor gene in PC 12 cells.
8.3.2.1.3 Role of the PKC pathway
There is evidence that PKC activation is an early and important event following NGF treatment 
of PC 12 cells. NGF induces rapid hydrolysis of phosphoinositides and increases PKC activity 
in this cell line (Hama et ah, 1986; Heasley and Johson, 1989: Balbi and Allen, 1994). PI- 
turnover has been implicated in the action of NGF in PC12 cells (Contreras and Guroff, 1987). 
This effect is likely mediated through phosphorylation and activation of PLC-yl by the 
tyrosine kinase activity of trk A (Vetter et ah, 1991). Specific mutation of the site in the trk A 
receptor responsible for the activation of PLC-yl results in a selective loss of the NGF- 
mediated increase of a late responsive gene peripherin (Loeb et al., 1994).
NGF causes an increase in DAG production in PC 12 cells, which peaks by about 2-3 minutes 
and declines to basal levels by 5 minutes (Chan et ah, 1989). There is a second wave of slow 
and long lasting DAG production 5 minutes after NGF treatment which suggests activation of 
another phospholipids PLD (Chan et ah, 1989). PLD hydrolyses PC to generate PA and 
choline. This PA is hydrolysed to DAG by the action of PAH enzyme, and this DAG may 
activate PKC. However, pretreatment of PC 12 cells with butan-l-ol (0.3 % v/v), which diverts 
the production of PA to phosphatydilbutanol, and so blocks DAG production did not affect the 
NGF-induced transcriptional activation of the NPY-Yl gene. These results indicate that PLD 
activity is not responsible for the NGF-mediated response in PC 12 cells. Further experiments, 
including the use of inhibitors of phospholipases will be useful to understand the role of this 
enzymes in these NGF-mediated response.
275
PKC activation seems to be a necessary step for the transcriptional activation of the NPY-Yl 
gene by NGF in PC 12 cells as suggested by the complete inhibition following pretreatment of 
PC12 cells with calphostin C (1 |iM), a specific inhibitor of PKC. This result is consisting 
with the calphostin C-mediated inhibition of the transcription of the NPY gene in PC 12 cells 
(Balbi and Allen, 1994).
PMA have a similar structure to DAG and is able to activate PKC both in vivo and in vitro by 
increasing the affinity of the enzyme for Ca++ (Nishizuka, 1988). In PC 12 cells, activation of 
PKC with PMA induces tyrosine phosphorylation. Moreover, PMA can mimic the NGF- 
induced phosphoiylation of MAPKs and this strong and long-lasting activation is dependent on 
p2F'^^' activity in PC 12 cells and is completed inhibited by PKC down-regulation by long-term 
incubation with PMA (Thomas et ah, 1992). However, phorbol esters do not promote neurite 
outgrowth in PC 12 cells (Young et ah, 1994), indicating perhaps PMA affect component(s) of 
the differentiation machinery.
DH-1 (1 nM) an synthetic activator of PKC which binds PKC at the same site as phorbol esters 
(Mastro and Grove, 1989) induces a similar increase in the transcriptional activation of the 
NPY-Yl gene in comparison with that for NGF. DH-1 activation is completely block by 
calphostin C (1 flM), indicating that this response is dependent on PKC activation, PMA 
results in a relatively small but consistent increase in transcription of the NPY-Yl receptor gene 
in PC 12 cells. This effect was not altered by increasing intracellular Ca++ using the ionophore 
ionomycin, which is known to act synergistically with phorbol esters in the activation of PKC 
in some biological systems (Wilkimson and Hallan, 1994). However, this PMA-dependent 
response is completely blocked by calphostin C (1 jiM).
PC 12 cells treated with PMA (1 nM) for 1 hour resulted in an increase of PKC activity which
was considerably higher than obtained using PMA (1 |LiM). The levels of PKC activity obtained
with PMA (1 jtlM) are very similar to the basal levels of PKC activity. This result is consistent
with previous experiments indicating that PKC activity is lower than basal levels after 3 hours
of treatment with PMA (0.4 |iM) (Hama et ah, 1986; Balbi and Allen, 1994). PKC is down-
regulated by long-term treatment with phorbol esters, which is mostly due to degradation of
membrane-bound activated PKC by the proteolytic enzymes as calpain (Nishizuka, 1988). The
extent of downregulation is dependent on the cell type, isoform of the enzyme, the time of
treatment and phorbol ester concentration (Nishizuka, 1988). PKC activation after NGF
showed a different time course. Thus 1 hour after NGF treatment, PKC activity was equivalent
to PMA (1 nM). However, PKC levels returned to basal values 3 hours after NGF treatment
(Balbi, 1994).Taken together, these results suggests that the PMA-dependent fail to mimic the
NGF-induced transcriptional activation of NPY-Yl receptor gene in PC 12 cells will be a
consequence of a downregulation of PKC by long term incubation with PMA.
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Thus, results obtained with PMA should be used carefully when attempting to understand the 
role of PKC in mediating the effects of NGF in PC12 cells. Together, this information raises 
the possibility that the effect of phorbol esters may be a complex response to both short and 
long term effect of PMA on the PKC activity on PC12 cells. Further experiments, including a 
time course of PKC activation upon DHl (1 nM) and PMA (1 iiM) treatment will be necessary 
to understand the differences observed with these two specific activators of PKC in the 
transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. In addition, it will be 
important to know a time course of the transcriptional activation of this neuropeptide receptor 
gene with PMA (1 nM) and PMA (1 p,M) in PC 12 cells.
PC 12 cells can be depleted of several PKC isoenzymes by treatment with high concentrations 
of phorbol esters for several hours (Roivainen et ah, 1995). Previous studies have been shown 
that pretreatment of the PC I2 cells with 100 nM PMA for 24 hours downregulates the (3, 6 and 
£ PKC isoforms. The conventional PKC-a is downregulated after treatment with 1 p.M PMA 
for 24 hours, whereas the atypical PKC-Ç is resistant to downregulation by PMA (Rovainen et 
ah, 1995). The role of PMA sensitive-PKC activity in the NGF-dependent increase in 
transcriptional activation of this gene in PC 12 cells can be studied by depletion of these specific 
PKC isoforms by long term incubation with PMA (1 p,M). Finally, it will be important to 
understand the role of the specific inhibitors, such as K-252a, calphostin C, genistein and 
sodium orthovanadate which are known to affect the NGF-dependent transcriptional activation 
of the NPY-Y1 receptor gene in the PKC activity and other PKC-dependent responses such as 
c~fos expression in both FC12~ras negative and PC 12-wild-type cells.
Post-transcriptional mechanisms may be also involved in the effect of PMA in the luciferase 
activity in PC 12 cells. Phorbol esters have been shown to desestabilise specific mRNAs. It has 
been suggested that the mechanisms involved in the selective elimination of mRNAs in eaidy 
thymocytes involve PKC-mediated synthesis of sequence-specific proteins that degrade these 
mRNAs (Takahama and Singer, 1992). For this reason, time course experiments of luciferase 
niRNA levels, using specific inhibitors of RNA synthesis, such as actinomycin D will be 
necessary to understand the role of PMA in the stability of the luciferase niRNA in PC 12 cells. 
Moreover, the use of the luciferase under the control of other known PMA-responsive 
promoter, such as NPY (Balbi and Allen, 1994), will be useful to understand the effect of 
post-transcriptional mechanisms in this PMA-dependent response. However, preliminary 
results using the pGL3-Basic and the pGL3-Control vector indicates that PMA (1 nM) after 48 
hours of incubation had no effect in the levels of luciferase activity in PC 12 cells, indicating 
that the increase of luciferase activity is dependent in the transcriptional activation of the NPY- 
Y l gene, and is independent of non-specific sequences present in the vector or post- 
transcriptional effects such as luciferase mRNA stability.
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8.3.2.1.4 Role of the PI-3-K pathway
NGF is able to activate PI-3-K and this in turn stimulates an increase in levels of PI-3,4-P2 and 
PI-3,4,5-P3 in PC12 cells, which reach a maximum after 3 minutes and decline after 10 
minutes (Kimura et al., 1994). Pretreatment of PC12 cells with wortmannin (ICO nM) for 30 
minutes abolished the elevation of PI-3,4-P2 levels after NGF stimulation and completely 
inhibited PI-3-K activity (Kimura et al., 1994). These 3-inositol phosphorylated phospholipids 
are potent and selective activators of Ca++ independent PKC and phorbol ester insensitive PKC 
(Nakanishi et ah, 1993). PC 12 express multiple PKC isoforms, including conventional PKCs 
( a , (3, y), novel PKCs ( 6 , 8 )  and atypical PKC ( Ç ) (Wooten et al., 1992). NGF treatment 
of the PC 12 cells result in translocation of the PKC-Ô and Ç isoforms (Wooten et ah, 1994).
However, neither wortmannin (10 jiiM) or LY 294002 (10 fiM), another specific inhibitor of 
the PI-3-K inhibited the basal- or NGF-dependent transcriptional activation of the NPY-Yl 
gene in PC 12 cells, indicating that the NGF-induced PI-3-K activity has no role in mediating 
this response. Further experiments using constitutive active or dominant negative mutants of 
the different PKC isoforms, will be important to understand the role of these enzymes in the 
NGF-mediated response in the transcription of this neuropeptide receptor gene in PC 12 cells.
8.3.2.1.5 Role of the PKA pathway
The role of PKA in mediating NGF effects on P C I2 cells is controversial. Early reports 
proposed that cAMP mediates the neurotrophic actions of NGF. It has been suggested that 
NGF is able to affect cAMP metabolism, but by mechanisms independent of activation of 
adenylyl cyclase activity as measured by conversion of [2-^H] adenine to [^H] cAMP (Race 
and Wagner et al., 1985). NGF has been described to produce a transient increase in PKA 
activity in PC 12 cells (Kniper et ah, 1993) and this activity seems to be necessary for the NGF 
induced phosphorylation of tyrosine hydroxylase, at least at some of the potential 
phosphorylation sites (Cremins et ah, 1986). PKA has also been shown to be necessary for the 
post-translational modification of sodium channels by NGF in PC12 cells (Ginty et ah, 1992). 
Thus, it is generally believed that PKA may play a role in some but not all of the NGF actions 
in PC12 cells (Halegoua et ah, 1991). However, many other reports have refuted claims that 
NGF signals through cAMP (Halegoua et ah, 1991; Balbi and Allen, 1994). PC 12 cells 
containing a mutated regulatory subunit of PKA showed comparable responses to parental cells 
in several aspects of the NGF induced differentiation such as neurite outgrowth and protein 
phosphorylation (Ginty et ah, 1991). For example, the NGF induced expression of GAP-43, 
transcriptional activation of erg-1 and induction of ornitine decarboxylase activity are all 
unaffected in these PKA-deficient cells suggesting that NGF is able to produce all these
responses via PKA-independent mechanisms (Ginty et ah, 1991).
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Previous experiments have shown that the NGF-induced priming of PC 12 cells is different to 
the priming induced by DEC, an analogue of cAMP (Greene, 1978). When PC 12 cells are 
treated for several days with NGF and then replated in the presence of NGF, the rapid 
regeneration of neurites was not observed within 24 hours. Instead, when PC 12 cells were 
pre-treated with DEC and then replated in the presence of NGF, the rapid regeneration of their 
neurites was not observed. H-89, dihydrochloride a synthetic isoquinolinesulfonamide, is a 
potent and selective inhibitor of PKA activity (Cliijiwa et ah, 1990). Pretreatment of PC 12 cells 
with H-89 (30 p,M) led to a dose-dependent inhibition of the forskolin-induced protein 
phosphorylation and neurite outgrowth but the NGF-induced protein phosphorylation and 
neuronal differentiation were not inhibited (Chijiwa et ah, 1990). Pretreatment of PC 12 cells 
with H-89 (30 fxM) had no effect on the NGF-stimulated transcriptional activation of the NPY- 
Y l receptor gene in PC 12 cells, indicating that this NGF effect is not dependent in PKA 
activation. However, H-89 (30 fxM) reduced basal levels of transcriptional activity of the NPY- 
Y l receptor gene in PC 12 cells, indicating that PKA activity is involved in the basal 
transcription of this gene. Moreover, the NPY-Yl promoter has two CRE elements and is 
under transcriptional control of phaimacological agents that increase cAMP, such as PACAP (5 
nM), forskolin (10 |iM) and DEC (1 mM) in PC12 cells.For this reason its important to know 
the role of these CRE sites site in the NGF-mediated transcriptional activation of the NPY-Yl 
gene.Further experiments, including the use of the luciferase enzyme under the control of 
CRE-deleted versions of the NPY-Yl promoter will be useful to understand the role of this 
transcription factor in the NGF-mediated transcriptional activity of this neuropeptide receptor 
gene in PC 12 cells.
Previous studies have suggested that NGF may activate CREE independently of PKA 
activation (Hawley et ah, 1992). In addition, this transcription factor can be phosphorylated 
and activated by cross-talk with other signalling pathways, such as PKC (Xie and Rohstein, 
1995) and CaM-K II (Sheng et al., 1991). However, CaM-K II appears not involved in the 
NGF-mediated response, as KN-62 (1 pM) a specific inhibitor of the CaM kinase II activity in 
PC 12 cells (Tokomitsu et al., 1990) failed to block NGF-induced transcriptional activation of 
the NPY-Y I receptor in these cells. It will be important to know the role of the Ca++ signalling 
pathway in the transcriptional activation of this neuropeptide receptor gene; specifically the role 
of membrane depolarisation, induced either by potassium chloride or by neurotransmitters, 
which are known to increase the expression of c-fos (Sheng and Greenberg, 1990) and the 
phosphorylation and activation of CREE (Sheng et al., 1991). Further studies, including 
luciferase reporter assays using the AP-1 and CRE-deleted versions of the promoter of the 
NPY-Yl receptor gene or transient expression of CREE will be necessary to understand the 
role of this Ca++ signalling pathway and cross-talk with other signalling pathways, such as the 
PKA and PKC in the transcriptional activation of this neuropeptide receptor gene in PC 12 
cells.
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8.3.3 CRE SITES OF THE PROMOTER OF THE NPY-Y l GENE
The promoter region of the rat NPY-Yl receptor gene has two partial CRE sites (CGTCA). 
These sequences are the most likely elements to mediate the basal- and PACAP-dependent 
transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. CRE sites are found in a 
group of rat neuropeptide genes, exemplified by somatostatin, proenkephalin and vasoactive 
intestinal peptide (VIP) whose expression is regulated by cAMP (Roesler et ah, 1988). 
Different cAMP-regulated genes are expressed in PC 12 cells, including the dopamine beta- 
hydroxylase and tyrosine hydroxylase genes, which are regulated in a co-ordinate fashion by 
PKA pathway in PC12 cells via CRE elements (Roesler et ah, 1988).
The available evidence supports a dual role for the CRE site as both a basal and an inducible 
transcriptional enhancer element (Roesler et ah, 1988). CREB appears to bind the CRE site in 
a cAMP-independent manner, and thus resembling a basal transcription factor. Moreover, 
unlike transcription factors whose activity is regulated, at least in part, by subcelluiar 
localisation, nuclear expression of CREB is constitutive in PC 12 cells. Rapid changes in the 
intracellular levels of cAMP leads to PKA-mediated phosphorylation of the transcriptional 
activation domains of CREB, already bound to their respective CRE elements in the promoter- 
regulatory region of the gene. This phosphorylation is thought to be necessary and sufficient 
for the activation of transcription by cAMP (Roessler et ah, 1988).
The activation domain of CREB is serine rich and includes consensus phosphorylation sites for 
different protein kinases, such as PKC, casein kinase II and CaM-K II (Fiol et ah, 1994). 
Thus, CREB is involved in the cross-talk between different signalling pathways (Dash et ah, 
1991; Sheng et ah, 1991). Both Ca++ and cAMP stimulation of PC12 cells results in the rapid 
phosphorylation of transcription factor CREB at Ser-133 (Sheng et ah, 1991). These findings 
suggest that CREB is a convergence point for synaptic activity acting through PKA and 
impulse activity acting through CaM-K in PC 12 cells. Together the two kinases are able to 
activate transcription in a synergistic fashion in PC 12 cells. Further experiments will be 
necessary to understand the role of this cross-talk in the transcriptional activation of the NPY- 
Y l gene.
The experiments described in the chapter 5 were designed to understand the role of trans-
synaptic activity and in particulai' the relevance of peptides co-released from pre-synaptic nerve
terminals in the control of the NPY-Yl receptor gene expression in a model of post-synaptic
cells, PC 12 cell line. PACAP and YIP are present in pre-synaptic fibres of the sympathetic
nervous system, including fibres innervating adrenal chromaffin cells (Yoshikawa et ah, 1990)
and are released after electrical stimulation (Malhotra et ah, 1989). In PC12 cells, they exert a
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regulatory effect on the synthesis of tyrosine hydroxylase (TH) (Wessels-Reiker et al, 1991) 
and NPY (Colbert et ah, 1994). The fact that neuropeptides induce gene expression in PC 12 
cells constitutes evidence that neuromodulators other that classical neurotransmitters such as 
ACh may participate in trans-synaptic control of gene regulation. For this reason, it will be 
important to know the role of these peptides in the trans-synaptic control of the expression of a 
neuropeptide receptor, NPY - Y 1. The activity-dependent release of peptide neurotransmitters 
begins a cascade of events which culminates in post-synaptic changes in gene expression. 
Trans-synaptic activation requires, as its initial step, the binding of the peptide to its receptor. It 
is well established that interaction of PACAP with their specific receptors leads to activation of 
two major intracellular signalling pathways: the PKA and the PLC pathways (Arimura, 
1992b). These receptor system mediate post-synaptic changes in gene transcription through 
these second messenger pathways, which are activated upon ligand binding. They link the 
neurotransmitter receptors to molecular regulators of gene transcription (Armstrong and 
Montminy, 1993).
Diverse agents which increase the levels of intracellular cAMP in PC 12 cells increased the 
transcriptional activity of the NPY-Yl receptor gene in PCI2 cells. These include PACAP-38, 
an activator of adenylyl cyclase via GPCRs, forskolin, and direct activator of adenylyl cyclase 
and DBC. In chapter 5, an attempt was made to further study the molecular mechanisms 
involved in the role of different signalling pathways activated by PACAP-38 in PC 12 cells, 
such as the PKA, PKC and the ras -MAP kinase pathways (Deutsch and Sun, 1992; Colbert et 
ah, 1994; Hernandez et al., 1995) in the transcriptional activation of NPY-Yl receptor gene by 
using the Dual-luciferase™ reporter system and pRL-SV40 as internal control of tiansfection.
In order to evaluate the role of one of these CRE sites in the transcriptional control of the NPY- 
Y l receptor gene in PC12 cells, a specific mutation was obtained by restriction enzyme 
digestion and cloned in the luciferase reporter vector (pYl-CRE). Further luciferase reporter 
assay experiments using this deletion clone will be necessai*y to determine the relevance of this 
mutation in the basal- and PACAP-dependent transcriptional activation of the NPY-Yl gene.
8.3.3.1 PACAP EFFECT ON THE TRANSCRIPTION OF THE NPY-Y l GENE
PACAP-38 stimulates adenylyl cyclase activity and elevates cAMP, and is a potent activator of 
the PI cascade at nanomolar concentrations in PC 12 cells by specific binding to a type I 
receptor in PC 12 cells (Deutsch and Sun, 1992). PACAP-38 has previously been shown to 
cause PC12 cells to adopt a neuronal morphology (Colbert et al., 1994; Deutsch and Sun, 
1992; Hernandez et ah, 1995). This PACAP-38 effect is mediated by the rapid but long lasting 
activation of MAPK through a ras -independent but PKC-dependent mechanism (Barrie and 
Allen, 1994).
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PACAP-38 induced a concentration-dependent increase in the transcriptional activity of the 
NPY-Yl receptor gene in PC12 cells. The concentration range (0.5-5 nM) of the PACAP-38 
effect on the promoter region of the NPY-Yl receptor gene is consistent with the binding 
affinity of the PACAP type I receptor and the biological potency of PACAP-38 in PC 12 cells 
(Deutsch and Sun, 1992). However it will be important to know the effect of another related 
neuropeptide VIP on the transcriptional activity of the NPY-Yl receptor gene, because its 
known that these two peptides have a similar distribution in rats (Arimura, 1992b)
The PACAP-38 transcriptional activation of the NPY-Yl gene is not dependent in differences 
in transfection efficiency because PC 12 cells were co-transfected with a control reporter vector, 
pRL-SV40, in which the activity of the Renilla luciferase enzyme is under the control of SV40 
early enhancer/promoter. The levels of Renilla luciferase activity of PACAP-38 treated cells 
were similar to the basal levels (untreated cells), indicating that differences in luciferase activity 
upon PACAP-38 treatment are not related to variations in transfection efficiency. In addition, 
PACAP-38 (5 nM) did not increase the levels of luciferase activity of the promoterless vector 
(pGL3-Basic) and the control vector (pGL3-Control). These results indicate that non-specific 
sequences of the reporter vector or post-transcriptional mechanisms, such as mRNA stability 
are not involved in this PACAP-38 response.
8.3.3.1.1 Role of the PKA pathway
PACAP-38 is a potent activator of adenylyl cyclase and increase cAMP in PC 12 cells with an 
EC50 of 1 nM (Deutsch and Sun, 1992). PACAP-38 (5 nM) also increased the transcriptional 
activity of NPY-Yl receptor gene in PC 12 cells. This transcriptional activation was mimicked 
by different pharmacological compounds known to increase intracellular cAMP, such as 
forskolin (10 |lM), by direct binding and activation of adenylyl cyclase (Laurenza, 1989) and 
DBC (1 mM), a compound which permeates the cell membrane and is metabolised to generate 
cAMP (Posternak and Weiman, 1974). Both forskolin- and DBC-mediated transcriptional 
activation of the NPY-Yl receptor gene were also found to be independent of transfection 
efficiency, because these agents did not increase the Renilla luciferase activity of the pRL- 
SV40 in co-transfection experiments in PC 12 cells.
H-89 a potent and selective inhibitor of PKA in PC12 cells (Chijiwa et ah, 1990; Balbi and
Allen, 1994) led to a concentration-dependent reduction of the basal- and PACAP-38 induced
transcriptional activation of the NPY-Yl gene in P C I2 cells. Moreover, H-89 (30 jiM)
completely blocked the forskolin (10 p.M) and DBC (1 mM) dependent transcriptional
activation of NPY-Yl gene. This result is consistent with previous experiments which showed
that PACAP-38 activates transcription of the NPY gene in PC 12 cells, and that this activation is
completely block by pretreatment with PI-89 (Colbert et ah, 1994). Taken together, this results
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indicates that the PKA signalling pathway is mediating the transcriptional response of the NPY- 
Yl receptor gene to PACAP-38, forskolin and DBC. H-89 (30 p,M) also reduced the basal 
levels of transcriptional activity of the NPY-Y 1 receptor gene in PC 12 cells.
Taken together, these results indicate that the activation of the PKA pathway is involved in the 
basal- and PACAP-38 induced transcriptional activity of the NPY-Yl receptor gene in PC 12 
cells. Further experiments will be necessary to confirm this results, such as the expression of a 
constitutively active catalytic PKA subunit or expression of the protein kinase inhibitor peptide 
(PKI). In addition, the role of the PKA pathway can be confirmed with the use of a clonal cell 
line deficient in PKA (Ginty et ah, 1991).
8.3.3.1.2 Role of the PKC pathway
PACAP-38 is also a potent activator of the PI turnover in PC 12 cells with a EC50 of 7 X lO'^ 
M (Deutscht and Sun, 1992; Hernandez et ah, 1995). This effect appeared to be mediated by 
direct activation of a specific phospholipase-coupled to a G-protein. There are several splice 
variants of the PACAP type I receptor that demonstrate different abilities to activate adenylyl 
cyclase and PLC in PC 12 cells (Sprengler et al., 1993).
Previous results has been shown that the PKC signalling pathway is involved in the basal- and 
NGE-dependent transcriptional activation of the NPY-Yl receptor gene in PC 12 cells. To 
evaluate the role of this pathway in the PACAP-38 response a specific inhibitor of PKC, 
calphostin C (Kobayashi et ah, 1989) was used. Calphostin C (1 pM) results in a reduction of 
the PACAP-38 (5 nM) mediated transcriptional activation of the NPY-Yl receptor gene in 
PC 12 cells. However, calphostin C (500 nM) did not affect the forskolin (10 pM) or DBC (1 
mM)-dependent transcriptional activation of this neuropeptide receptor gene, indicating that in 
these responses PKC activity was not involved.
Evidence for cross-talk between the cAMP system and PKC has been established in the 
literature. PKC-dependent phosphorylation and activation of adenylyl cyclase is well 
documented (Kawabe et ah, 1994). Increases in intracellular cAMP levels have been shown to 
regulate PKC activity (Anderson and Breckon, 1991; Houslay, 1991). This interaction has 
been described as a monodirectional mode of signalling transduction whereby PKA may 
influence PKC in a positive fashion. Evidence is accumulating that phosphorylation of PKC 
may likely play a key role in regulation of PKC activity. Phosphorylation of PKC appears to 
influence positively the activity of the enzyme, resulting in a molecule that is constitutively 
active and independent of the regulation exerted by second messengers. For example, PKC-Ç 
is phosphorylated and activated by PKA in PC 12 cells (Wooten et ah, 1996).
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PC 12 cells are neuroendocrine cells in which several biological responses to extracellular 
stimuli are elicited via ion channel activation. Specifically other signalling pathways stimulated 
as part of the PI breakdown, such as the Ca++ signalling pathway may also play a role in the 
PACAP-38 response in PC 12 cells. PACAP-38 results in a increase in the intracellular levels 
of Ca++ in PC 12 cells (Hernandez et ah, 1995). However, KN-62 (1 p,M) a specific inhibitor 
of the CaM-K II (Tokumitsu et ah, 1990) had no effect in the PACAP-38 induced 
transcriptional activation of the NPY-Yl receptor gene, indicating that this kinase is not 
involved in this PACAP-38 response in PC 12 cells. However, it is possible that other related 
CaM-dependent proteins, such as calcineurin (PP2B phosphatase) and/or phosphodiesterases 
are involved in a Ca++-dependent signalling pathway. The type I phosphodiesterases, specific 
enzymes which hydrolyse cAMP leading to cessation of its biological effects, are CaM- 
dependent. The use of selective inhibitors of this phosphodiesterase, such as IB MX, may 
increase the PACAP-38 transcriptional activation of the NPY-Yl receptor gene in PC 12 cells.
8.3.3.1.3 Role of the ras -MAPK pathway
PACAP-38 has been shown to stimulate MAPK activity in PC 12 cells (Frodin et ah, 1994; 
Young et ah, 1994; Barrie et ah, 1997). This increase of MAPK activity is rapid (5 minutes) 
and long lasting (up to 60 minutes). Moreover, this MAPK stimulation is ras -independent and 
sensitive to PKC inhibition (Frodin et ah, 1994; Barrie et ah, 1997). In similar way, PACAP- 
38 (5 nM) has been shown to activate transcription of the NPY-Yl receptor gene in a FC\2-ras 
negative cell line. This result indicates that the ^2V^^ protein is not required to mediate the 
response to PACAP-38. However, it will be important to know the role of specific signalling 
pathways activated by PACAP-38 in PC 12 cells, such as the PKA and PKC pathways, in the 
transcriptional activation of the NPY-Yl receptor gene in this PC12-mj negative cell line.
PD98059, is a potent inhibitor of MEK-1 known to block the increase in MAPK activity and 
neuronal differentiation by PACAP-38 in PC12 cells (Barrie et ah, 1997). Pretreatment of the 
PC12 cells with PD98059 (20 p,M) increased basal levels of transcription the NPY-Yl gene. 
This paradoxical finding makes it difficult to interpret the role of MEK-kinase in mediating the 
response to PACAP.
8.3.4 GRE SITES OF THE PROMOTER OF THE NPY-Y l GENE
The regulatory DNA sequences required for nuclear hormone-dependent activation of
transcription have been termed hormone responsive elements (HREs) being the specific high
affinity DNA binding sites for the activated nuclear hormone-receptor complexes. The
glucocorticoid response element (GRE) is a consensus 15 bp imperfect palindromic DNA
sequence: 5'-AG(A/G)AC(A/T)NNNTGTTCT-3' (Beato, 1989). Surprisingly, the GREs
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always coincide with DNA sequences which are also required for androgen, progesterone and 
mineralocorticoid regulation of transcription. Thus, the nucleotide sequence for the 
progesterone responsive element (PRE), the androgen responsive element (ARE) and the 
mineralocorticoid responsive element (MRE) cannot be discriminated from the GRE consensus 
sequence.
Several reverse complement non-palindromic GRE sites (AGGACT) were found at -230 bp, 
-373 bp and -553 bp (conserved in mouse, rat and human NPY-Yl genes) and one (TGTTCT) 
at -540 bp (conserved only in rat NPY-Yl gene) of the putative transcriptional start site. 
Moreover, in the NPY-Yl human gene there are additional potential binding sites for the 
glucocorticoid receptor (GR) in promoters A, B and C (Ball et ah, 1995). These GRE sites in 
the promoter of the NPY-Yl receptor gene are the most likely elements to mediate the 
glucocorticoid (dexamethasone) hanscriptional activation of this gene in PC 12 cells.
It has been reported that the palindromic structure of GRE sequence is required for the binding 
of the dimerised receptor to potentiate fully transcriptional activity (Chalepakis et ah, 1990). 
Each of the four elements in the promoter of the NPY-Yl gene do not comprise a palindromic 
structure. However, the close location of GREs at -540 and -553 in the NPY-Yl gene, 
suggests that these sites may act co-operatively. Synergistic action of several imperfect GRE 
has been reported (Chalepakis et ah, 1990). In some cases, this type of synergy has been 
shown to result from co-operative DNA binding of the nuclear hormone receptors and to 
depend on the distance separating the adjacent HREs, suggesting that protein-protein 
interactions are involved. For example, GREs without palindromic structure can form a 
functional complex with monomeric GR in MMTV and activate gene transcription (Chalepakis 
et ah, 1990). In addition, dexamethasone increases the transcription of the rat NPY gene and 
three non-palindromic GRE are found far upstream of this gene (Misaki et ah, 1992).
The NPY-Yl promoter region also has two overlapping consensus sequences; the AP-1 and a 
non-palindromic GRE at -230 bp using as as reference the putative transcription start site. The 
putative interaction of these transcription factors by direct protein-protein association may affect 
the NPY-Yl gene expression positively (transcriptionally active complex) or negatively 
(complex unable to bind the hormone responsive element) in PC 12 cells (Lopes da Silva and 
Burbach, 1995). In order to understand the role of this API-GRE site, a specific deletion was 
made by PCR and cloned in the luciferase reporter vector (pYl-APl). Further experiments will 
be necessary to understand the role of this site in the dexamethasone response on this NPY-Y 1 
receptor gene in PC 12 cells. However, to understand the role of each DNA binding element in 
the transcriptional activation of this gene it will be necessary to make site-direct mutations of 
both the AP-1 and GRE site.
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In addition, in order to study the relevance of the others GREs elements in the dexamethasone 
induced activation of the NPY-Y 1 receptor gene, progressive deletions of the promoter were 
made by PCR and cloned in the luciferase reporter vector. Clone A lacks the two closer located 
GRE sites far upstream of the NPY-Yl promoter. Clones C and D also lacks one of the non- 
palindromic GRE and the API-GRE site, respectively. Further experiments will be necessary 
to understand the role of each specific non-palindromic GRE element in the basal- and 
dexamethasone-dependent transcriptional activation of the NPY-Yl receptor gene in PC 12 
cells.
8.3.4.1 DEXAMETHASONE EFFECTS ON THE TRANSCRIPTION OF THE
N PY -Y l GENE
Glucocorticoids positively regulate several genes governing neurotransmitter and neuropeptide 
biosynthesis, such as tyrosine hydroxylase, proenkephalin and NPY (Higuchi et ah, 1988). 
During rat development glucocorticoids can direct the differentiation of bipotential neural crest 
cells toward the chromaffin cell phenotype. It has been demonstrated that differentiation of 
adrenal progenitor cells into clnomaffin cells is dependent upon the presence of glucocorticoid 
hormones; indeed these cells are exposed to high levels of such hormones upon migration to 
the adrenal gland since the adrenal cortex synthesises high levels of glucocorticoids.
The majority of NPY-Yl neurons in the hypothalamus and the brain contains a high density of 
nuclear glucocorticoid receptors (Harfstrand et ah, 1989) and the NPY content of cultured rat 
hypothalamic neurons is increased with glucocorticoids (Corder et al., 1990). However, little 
is known about the transcriptional activation of the NPY-Yl receptor gene. Administration of 
glucocorticoids to rats causes an up-regulation of NPY-Yl receptor expression in the arcuate 
nucleus. Moreover, in the mouse adrenocortical cell line Y-1, dexamethasone increases the 
density of NPY-Yl receptors (Weng et ah, 1995). In keeping with these observations 
dexamethasone (1 p,M) increased the transcription of the NPY-Yl receptor gene in PC I2 cells 
grown in a chareoal/dextran treated serum to remove endogenous steroids in the DMEM 
medium. This result is consistent with previous findings that show that dexamethasone treated 
cells aie responsive to the NPY-Yl agonist (DiMaggio et ah, 1994).
Preliminary results indicated that sex steroids, such as estrogen (1 pM) and progesterone
(IpM) did not increase the transcription of this gene in PC 12, indicating that the glucocorticoid
specificity of this response reflects a GR-mediated response or that PC 12 cells lack estrogen
receptor (ER) or progesterone receptor (PR). However, estrogen (1 pM) and progesterone (1
pM) induced the transcriptional activation of the NPY-Yl receptor gene in a mouse
hypothalamic cell line, GTl-7 (Mellon et ah, 1990). The progesterone receptor (PR) can bind
the same GREs present in the promoter of the NPY-Y 1 gene, however, the estrogen receptor
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(ER) can bind a non-palindromic ERE (TGACC) present at -350 bp of the transcription start 
site. The role of this ERE element in the estrogen mediated activation of the NPY-Y 1 receptor 
gene in the GTl-7 cells can be analysed using the deletion clone C, will lacks this responsive 
element region. However, specific deletion of this element using site-direct mutagenesis will be 
important to understand the role of estrogen in the transcriptional activation of this 
neurosecretory (GnRH) cell line.
8.4 REGULATION OF THE NPY-Yl mRNA IN PC12
CELLS
In chapter 7 an attempt was made to quantify the NPY-Yl mRNA in PC 12 cells. The amount 
of mRNA measured at any time is dependent not only by the rate of transcription of the gene 
but also by post-transcriptional mechanisms such as the stability of the mRNA. mRNA 
stabilisation is a economical and energetically favourable way to increase protein synthesis by 
making use of pre-existing mRNA. Under conditions of intense neuronal activity, an increase 
in the half-life of the NPY-Yl mRNA would allow for increased production and subsequent 
replenishment of the NPY-Yl receptor stores. This increase the complexity of regulation, 
allows for more diverse responses to signals effecting the overall level of NPY-Yl receptor 
production in PC 12 cells.
There are several methods of measuring specific mRNAs, including Northern blot analysis, 
ribonuclease protection assay (RPA) and quantitative RT-PCR. These are listed in order of 
sensitivity and in degree of complexity. Northern blots and RPA failed to detect the NPY-Y 1 
mRNA in PC12 cells, indicating that this mRNA is expressed at very low levels in these cells. 
One alternative will be used polyA+ mRNA instead of total RNA, but this approach is time 
consuming. For this reason, selective amplification of the NPY-Yl mRNA by quantitative RT- 
PCR was the approach chosen.
Using 1 |lg of total RNA of PC 12 cells the NPY-Yl receptor mRNA was detected after 40 
cycles of RT-PCR amplification. This result is consistent with previous findings using 
Northern blots and RPA, indicating that the NPY-Y 1 mRNA is expressed at very low levels in 
PC 12 cells. Moreover, similar results results were obtained RINm5f cells. Taken together, this 
results indicates a very low levels of constitutive expression of this neuropeptide receptor gene 
in these cell lines.
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by treatment with agents known to increase the levels of transcription of the NPY-Y 1 gene in 
PC 12 cells, such as NGF, PACAP, forskolin and PMA. This result is consistent with previous 
findings which show that the cyclophylin gene is constitutively expressed in PC 12 cells and 
unaffected by NGF and forskolin and PMA treatment (Machida et al., 1989). Results indicate 
that co-amplification of both the NPY-Yl receptor gene and the cyclophilin gene is possible but 
that a narrow ratio of NPY-Yl primers (20 pmol) to cyclophilin primers (2-5 pmol) is required. 
Further experiments will be necessary to found the linear range of co-amplification of both 
messages in PC 12 cells. As exogenous control an homogeneus cRNA fragment (300 bp) was 
used to allow amplification using the same primers used to amplified the mRNA of the NPY- 
Y 1 receptor gene was used. However, further co-amplification experiments will be necessary 
to set-up the conditions for used this internal control in a competitive RT-PCR.
8.5 SUMMARY
The major achievement reported in this thesis was the subcloning of 600 bp of the promoter 
region of the rat NPY-Yl receptor gene in the luciferase reporter vector (pYl-LUC). This 
fusion gene was further transiently transfected in PC 12 cells and was shown to produce low 
levels of luciferase activity consistent with previous findings that indicate that PC 12 cells 
express constitutive levels of the NPY-Yl gene (DiMaggio et al. 1994). Further, the effect of 
different factors in the transcriptional control of this neuropeptide receptor gene was obtained. 
Dexamethasone, NGF and PACAP increased the transcriptional activity of this gene in PC 12 
cells, indicating that the NPY-Yl receptor expression is under tight regulation in this cell line.
The effect of NGF in the transcriptional activation of the NPY-Yl receptor gene in PC 12 cells 
was dependent in trk A receptor and PKC activation, but is independent in the activation of the 
ms -MAP kinase, PI-3-K and CaM-K II intracellular signalling pathways. Moreover, the effect 
of PACAP-38 was dependent in PKA and PKC activation but is also independent on the ras 
-MAP kinase pathway. In addition, activation of both pathways using DBC, forskolin (PKA) 
or D H l, PMA (PKC) also mimic the increase in the transcriptional activity of the NPY-Yl 
gene obtained with NGF and PACAP. In conclusion, both the PKA and PKC intracellular 
signalling pathways are involved in the transcriptional control of this neuropeptide receptor 
gene in PC 12 cells. For understanding the role of the putative transcription factor sites present 
in the promoter region of the NPY-Yl receptor gene, specific deletion of these sites were made 
using standard molecular biology techniqes. Further experiments using these specific mutants 
will be necessary to assess the role of the API, CRE and GRE sites in the dexamethasone, 
NGF and PACAP transcriptional activation of the NPY-Yl gene.Northern blots, RPA and RT- 
PCR experiments indicated that the NPY-Yl gene was expressed at very low levels in PC 12 
cells. Further experiments using competitive RT-PCR will be necessary to know the effect of 
dexamethasone, NGF and PACAP in the expression of NPY-Yl gene in PC 12 cells.
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APPENDIX I
MAMMALIAN CELL CULTURE
RAT TAIL COLLAGEN
25 mg rat type I collagen in 100 ml 0.5 M acetic acid (4.3 ml glacial acetic acid/120 ml water). 
Filter sterilise the acetic acid and dissolve the collagen in the sterile acetic acid solution. Aliquot 
in 10 ml fractions and store at 4°C.
POLY-D-LYSINE
5 mg poly-D-lysine (70,000-150,000 MW) in 30 ml sterile tissue culture water. Aliquot in 1ml 
fractions and store at -20°C.
DMEM
Dissolve powder in 1 litre deionized water. Add 3.7 g sodium bicarbonate/litre medium and 
110 mg sodium pyruvate/litre medium. Adjust pH to between 7.2-7.35 with HCl. Filter sterile 
in 400 ml aliquots and store 4°C. Test sterility by placing 3 ml of medium in the incubator for 
48 hours.
RPMI 1640
Dissolve powder in 1 litre deionized water. Add 2.0 g sodium bicarbonate/litre medium. Adjust 
pH to 6.8-7.0 with HCl. Filter sterile in 400 ml aliquots and store at 4°C. Test sterility by 
placing 3 ml of medium in the incubator for 48 hours.
GLUTAMINE (0.2 M)
Glutamine (200 mM) in 100 ml water. Stir and heat to 50°C to dissolve. Filter sterilise in 5 ml 
aliquots and freeze with the lids loose. Store at -20°C.
PENICILLIN/STREPTOMYCIN
Penicilin 10,000 units/ml (100 X), streptomycin 10,000 mg/ml (100 X). Aliquot in 10 ml 
fractions and store at -20°C.
TRYPSIN/EDTA (lOX)
Trypsin (0.05% ), EDTA (0.005 M) in PBS (IX). Filter sterilise in 10 ml aliquots. Store at -20 
°C. Dilute 1/10 trypsin/EDTA (IX) in sterile PBS (IX).
PBS (20X)
NaCl (137 mM), KCl (2.7 mM), Na2HP0 4 .2H2 0  (8 mM), KH2PO4 (147 mM) in distilled 
water. Sterilise by autoclave and store at room temperature in 500 ml aliquots.
HANK’S MODIFFIED BUFFER
CaCl2 (1.3 mM), KCl (5.4 mM) MgCl2 (0.5 mM), MgS04 (0.5 mM), NaCl (137 mM), 
NaCOs (4 mM), NaH2P04 (0.4 mM) in distilled water.
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DEXTRAN COATED CHARCOAL
Charcoal (0.25% w/v), Dextran (0.025% w/v) in PBS (IX). Store in 25 ml aliquots at 4°C.
MAMMALIAN CELL TRANSFECTION 
CaC l2 (2.5 M)
CaCl2 (2.5 M) in deionized water. Filter sterile and store in 10 ml aliquots at -20°C. Dilute 1/5 
(0.5 M) in sterile PBS (IX) before using for transfection.
HEPES BUFFER (2X)
NaCl (280 mM), HEPES (50 M), Na2HP04(1.5 mM) in deionized water. Adjust to pH 7.05-
7.1 with NaOH. Filter sterile and store in 50 ml aliquots at -20°C.
TE BUFFER (TRIS 10 mM/EDTA 0.1 mM)
Tris (lOmM) pH 7.4 and EDTA (0.1 mM) in sterile deionized water. Filter sterile and store in 
10 ml aliquots at room temperature.
DEAE-DEXTRAN (10 mg/ml)
DEAE-Dextran (10 mg/ml) in PBS (IX). Filter sterilise and store in 1ml aliquots at 4°C.
CHLOROQUINE (100 mM)
Chloroquine (100 niM) in 10 ml of PBS (IX).Filter sterilise and store in 10 ml aliquots at 4°C.
DMSO (10% v/v)
23.5 ml PBS (20X) plus 27 ml DMSO in 400 ml sterile water. Store in 500 ml aliquots at room 
temperature.
HEPES BUFFER (IX)
NaCl (150 mM), HEPES (20 mM) in deionized water. Adjust to pH 7.4 with NaOH. Filter 
sterile and store in 50 ml aliquots at -20°C.
BACTERIA CELL CULTURE 
LB MEDIUM
Bacto-tryptone (1% w/v), bacto-yeast extract (0.5% w/v) and NaCl (1% w/v) in distilled 
water. Sterilise by autoclaving and store in 500 ml aliquots at room temperature.
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M9 MINIMUM MEDIUM
M9 solution: NaCl (0.05% w/v), NH4C1 (0.1% w/v), KH2P04 (0.3% w/v), Na2HP04 (0.6% 
w/v) in distilled water. Sterilise by autoclaving. After cooling at 50°C addCaCl2 (1 M), MgS04 
(1 M) and glucose (20% v/v). Store in 500 ml aliquots at 4°C. thiamine-HCl solution (1 M) in 
distilled water. Filter sterile and store in 1 ml aliquots at -20°C.
To make M9 plates prepare 1.7 agar (1.7 % w/v) in 100 ml distiled water. Sterilise by 
autoclaving. After cooling at 50°C add 0.12 ml thiamine solution (IM) and 1.2 ml M9 
solution. Pour in the plastic plates.
TYM MEDIUM
Bacto-tryptone (2 w/v %), Bacto-yeast extract (0.5% w/ ), NaCl (0.1 M) and MgCl2 (0.01 M) 
in 100 ml of distilled water. Sterilise by autoclaving and store in 500 ml aliquots at room 
temperature
COMPETENT BACTERIA SOLUTION (Tfb I)
KG Ac (30 mM), MnCl2 (50 mM), KCl (100 mM), CaCl2 (10 mM), glycerol (15% v/v), 
EDTA (0.2 mM) in distilled water. Filter sterilise and store in 500 ml aliquots at 4^C.
COMPETENT BACTERIA SOLUTION (Tfb II)
Na-MOPS pH7 (10 mM), CaC12 (75 mM), KCl (10 mM), glycerol (15 % v/v) in distilled 
water. Filter sterilise and store in 500 iT il aliquots at 4 °C.
TOTAL RNA EXTRACTION
DEPC TREATED WATER
Add DEPC (0.1 % v/v) to distilled water and stirred for 1-2 hours. Autoclave the DEPC water 
and store in 1000 ml aliquots at room temperature.
GUANIDIUM THYOCIANATE BUFFER
Guanidinum thiocyanate (4M), sodium citrate pH 7.0 (25 mM), sarcosyl (0.5% w/v) in DEPC- 
treated water. Store in 50 ml aliquots at 4°C for up to six months. Just before use add 7.2 
jLtl/ml b-mercaptoethanol (100 mM). Store in 10 ml aliquots at 4®C for up to three months.
SODIUM ACETATE (2 M)
Sodium acetate (2 M) in 100 ml of DEPC treated water. Adjust the pH to 4.0 with acetic acid 
glacial. Store in 50 ml aliquots at 4°C.
PLASMID DNA EXTRACTION
SOLUTION I (Resuspension solution)
Tris (50mM) pH 7.4, EDTA (0.1 mM) (pH 8.0) in distilled water. Store in 100 ml aliquots at 
room temperature. Add RNAse A to 100 mg/ml final concentration.
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SOLUTION II (Lysis solution)
NaOH (0.2 M), SDS (1% w/v) in distilled water. Store in 100 ml aliquots at 4®C.
SOLUTION III (Neutralization solution)
potassium acetate (1.32 M) pH 4.8 in distilled water. Store in 100 ml aliquots at 4°C.
NUCLEIC ACID SOLUTIONS
AMMONIUM ACETATE (7.5 M)
Ammonium acetate (7.5 M) in distilled water. Adjust pH 7.0 with acetic acid glacial. Store in 
100 ml aliquots at 4°C.
SODIUM ACETATE (3 M)
Sodium acetate (3 M) in distilled water. Adjust pH 7.0 with acetic acid glacial. Store in 100 ml 
aliquots at 4°C.
M gCl2 (1 M)
MgCl2 (1 M) in distilled water. Store in 100 ml aliquots at 4°C.
ETHIDIUM BROMIDE (10 mg/ml)
Ethidium bromide (10 mg/ml) in TE buffer. Store away from light at room temperature.
lODOACETAMIDE (0.5M)
lodoacetamide (0.5 M) dissolved in ethanol. Store away of the light at 4°C.
DNA LOADING BUFFER
Glycerol (50% v/v), TAE buffer (IX) and bromophenol blue (1% v/v) in ditilled water. Store 
in 1 ml aliquots at -20°C.
cDNA LOADING BUFFER
Formamide (98% v/v), EDTA (10 mM), xylene cyanol (0.1% w/v) and bromophenol blue 
(0.1% w/v) in distilled water.Store in 1 ml aliquots at -20°C.
RNA LOADING BUFFER
Glycerol (50% v/v), EDTA (ImM) and bromophenol blue (0.4% w/v) in distilled water. Store 
in 1 ml aliquots at -20°C.
RNA SAMPLE BUFFER
Deionized formamide (10% v/v), formaldehyde (10% v/v) and MOPS IX in DEPC treated 
water. Store in 1 ml aliquots at -20°C.
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RESTRICTION ENZYME BUFFERS
LOW SALT BUFFER (10 X)
Tris-HCl (lOmM) pH 7.5, M gC^ (lOmM), DTT (ImM) in distilled water.
MEDIUM SALT BUFFER (10 X)
NaCl (50mM), Tris-Cl (lOmM) pH 7.5, MgCl2 (lOmM), DTT (ImM) in distilled water.
HIGH SALT BUFFER (10 X)
NaCl (lOOmM), Tris-Cl (lOmM) pH 7.5, MgCl2 (lOmM), DTT (ImM) in distilled water.
DNA MODIFYING ENZYME BUFFERS
T4 POLYNUCLEOTIDE KINASE BUFFER (10 X)
Tris-HCl (500 mM) pH 7.4, MgCl2 (100 mM), DTT (100 mM), glycerol (40% v/v) in distilled 
water. Store at -20®C.
SAP BUFFER (10 X)
Tris-HCl (200 mM) pH 8.0, MgCl2 (100 mM) in distilled water.Store in 1 ml aliquots at 
-20®C.
T4 DNA LIGASE BUFFER (10 X)
Tris-HCl (500 mM) pH 7.5, M gC^ (100 mM), DTT (200 mM), ATP (10 mM) in distilled 
water.Store in 1 ml aliquots at -20®C.
DNA POLYMERASE I BUFFER (10 X)
Tris-HCl (500 mM) pH 8.0, MgCU (100 mM), DTT (1 mM), BSA (500 flg/ml) in distilled 
water.Store 1 ml aliquots at -20®C.
AMY REVERSE TRANSCRIPTASE (5 X)
Tris-HCl (250 mM) pH 8.3, KCl (250 mM), MgCl2 (50 mM), DTT (50 mM) and spermidine 
(2.5 mM) in distilled water. Store in 1 ml aliquots at -20®C.
AMY PRIMER EXTENSION (2X)
Tris-HCl (100 mM) pH 8.3, KCl (100 mM), MgCl2 (20 mM), DTT (20 mM), dNTP (2 mM), 
spermidine (ImM) in distilled water. Store in 1 ml aliquots at -20®C.
DNAZYME DNA POLYMERASE (lOX)
Tris-HCl (100 mM) pH 8.3, KCl (100 mM), EGTA (7.5 mM)and Triton X-100 (0.1% w/v)in 
distilled water. Store in 1 ml aliquots at -20°C.
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TAQ DNA POLYMERASE (lOX)
Tris-HCl (10 mM) pH 8.3, KCl (50 mM) iii distilled water. Store in 1 ml aliquots at -20®C.
TRANSCRIPTION OPTIMIZED BUFFER (5X)
Tris-HCl (200 mM) pH 7.5, NaCl (50 mM), MgCl2 (30 mM) and spermidine (10 mM) in 
distilled water.Store in 1 ml aliquots at -20®C.
NUCLEIC ACID SEPARATION
TAE BUFFER (50X)
Tris base (2 M), sodium acetate.(1 M), EDTA (50 mM) in distilled water. Store at 4®C.
TBE BUFFER (20 X)
Tris base (1 M), borid acid (1 M), EDTA (20 mM) in distilled water. Store at 4®C.
MOPS BUFFER (lOX)
MOPS (0.2 M), 20 ml 0.5 M EDTA. 2 H2O (10 mM), 16.6 ml 3 M sodium acetate (in DEPC 
treated water. Adjust at pH 7.0 with NaOH. Store at 4®C.
GLYCEROL TOLERANT BUFFER (20X)
Tris base (216 gm). Taurine (gm), EDTA (4 gm) in 1000 ml of deionized water. Store at room 
temperature.
NORTHERN BLOT ASSAYS
FORMALDEHYDE (deionized)
Add 5 g Dowex XG8 to 100 ml formamide and stir at room temperature for 1 hour. Filter twice 
through Whatman N1 paper. Store in 1 ml aliquots at -70®C.
SSC BUFFER (20X)
NaCl (3 M) and Na3 citrate (0.3 M) in DEPC treated water. Adjust at pH 7.0 with NaOH ION. 
Store in 500 ml aliquots 4®C.
HYBRIDIZATION SOLUTION (DNA PROBES)
Buffer phoosphate (0.77 M) pH 7.2, SDS (6.6% w/v) and polyA DNA (100 fig/ml) in distilled 
water. Store in 100 ml aliquots at room temperature.
DENHARDT'S SOLUTION
Ficoll (Type 400) (2% w/v), polyvinyl polyrrolidone (2% w/v) and BSA (2% w/v) in DEPC 
treated water. Sterilize by filtration and store at -20®C.
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HYBRIDIZATION SOLUTION (RNA PROBES)
Formamide deionized (50% v/v), SSC (5X), dextran sulfate (10% w/v), Denhardt's solution 
(5X), DTT (1 mM), SDS (1% w/v) and salmon DNA (100 |L tg /m l)  in DEPC treated water. 
Store at room temperature.
RIBONUCLEASE PROTECTION ASSAYS 
SOLUTION A
Formamide deionized (80% v/v), sodium citrate (100 mM) pH 6.4, sodium acetate (300 mM) 
pH 6.4 and EDTA (1 mM). Store at -20®C.
SOLUT ION F
Ammonium acetate (0.5 MO, EDTA (1 mM) and SDS (0.2% w/v) in DEPC trated water. Store 
at room temperature. Store at -20°C.
SOLUTION R
RNAse A (250 units/ml) and RNAse T1 (10,000 unit/ml) DEPC treated water. Store at -20®C.
LUCIFERASE ASSAYS
LU C IFERA SE ASSAY REAGENT
Tricine (20 mM), (MgC03)4Mg(0H)2 (1.7 mM), MgS04 (2.67 mM), EDTA (0.1 mM), DTT 
(33.3 mM), coenzyme A (270 |LLM), ATP (530 pM) pH 7.8 in distilled water.
CELL CULTURE LYSIS BUFFER (IX)
Tris-phosphate (25 mM) pH 7.8, DTT (2 mM), glycerol (1% w/v) and Triton X-100 (1% w/v) 
in distilled water.
PKC ASSAY SYSTEM
BUFFER A (EXTRACTION BUFFER)
Tris-HCl (20 mM) pH 7.5, EDTA (0.5 mM), EGTA (0.5 mM), Triton X-100 ().5 % w/v). 
aprotinin (25 |ag/ml) and leupeptin (25 ftg/ml) in distilled water.
BU FFER B (DEAE W ASH BUFFER)
Tris-HCl (20 mM) pH 7.5, EDTA (0.5 mM), EGTA (0.5 mM) in distilled water.
BUFFER C (ELUTION BUFFER)
Tris-HCl (20 mM) pH 7.5, EDTA (0.5 mM), EGTA (0.5 mM), P-mercaptoethanol ( 10 mM), 
NaCl (0.2 M) in distilled water.
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APPENDIX II
SYNTHETIC OLIGONUCLEOTIDES
RAT NPY-Yl RECEPTOR (open reading frame)
Sequence 2010 (forward primer)
5'-TTC GGA GCT TCC TAA GAG TCC GTT-3'
Sequence 2011 (reverse primer)
5'~GGA TGT TCT AGA CTT TCC AAA CCT-3'
RAT NPY-Yl RECEPTOR (5'-promoter region)
Sequence 2024 (forward primer)
5 -GGC ACG AGG ATC CTT TGG CTT-3'
Sequence 2023 (reverse primer)
5 -CTG TTA GGA TCC TTC GAA ATG G-3'
RAT NPY-Yl RECEPTOR (3'-flanking region)
Sequence 2486 (forward primer)
5-ATC ATT GCC ACC TGC AAC-3'
Sequence 2487 (reverse primer)
5 -TGT CCT GGA CTT TCC AAA C-3'
RAT NPY-Yl RECEPTOR (deletion 3 -flanking region)
Sequence T7507 (internal reverse)
5'-GTC ACC GCG GTC GTC TCG AGA CCG GAA G-3'
Sequenee T7508 (internal forward)
5'~GTC ACC GCG GTC TGA AGC TGC TGA GAA C-3'
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RAT NPY-Yl RECEPTOR (deletion AP-1 site)
Sequence V5339 (internal forwaid)
5 -GTC ACC GCG GGT GAG AGC TCT GTG TGG-3'
Sequence V5340 (internal reverse)
5-GTC ACC GCG GGG AAG GCG CAT TTA CAA-3'
RAT NPY-Yl RECEPTOR (progressive promoter deletions)
Sequence V7613 (forward primer-clone A)
5'-AAC TTC TCG GAT CCG GCG TGC-3’
Sequence V7614 (forward primer-clone B)
5 -CTT GAG TAG GGA TCC AAG CTC-3’
Sequence V7615 (forward primer-clone C)
5 -CAG GAT CCT AAA TGC GCC TTC-3'
Sequence V7616 (forwai'd primer-clone D)
5'-TTC GGA TCC GAC AGT GTG GGC-3'
Sequence V7617 (forwai’d primer-clone E)
5'-CAT GAT CCT GGA TCC GGT GGA-3’
FIREFLY LUCIFERASE GENE (open reading frame)
Sequence T1886 (reverse primer RPA)
5'-TAT CTC TTC ATA GCC TTA TGC AGT T-3'
FIREFLY LUCIFERASE GENE (open reading frame)
Sequence Y7464 (reverse primer RT-PCR)
5 -TAG CCT TAT GCA GTT-3'
Sequence Y7465 (forward primer RT-PCR)
5'-GGA GAA ATA CCA ACA-3'
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Sequence Y7466 (forward primer RT-PCR)
5'-GAT CTT TCT TCC CTC-3'
Sequence Y7467 (forward primer RT-PCR)
5'-CAG TGA CAC TCG TCC-3'
RAT CYCLOPHILIN GENE (open reading frame)
Sequence Y7462 (forward primer)
5’-GGT GAC TTC ACA CGC CAT AAT G-3'
Sequence Y7463 (reverse primer)
5'-GAG TTG TCC ACA GTC GGA GAT G-3'
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